
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
        <meta name="author" content="YW Chen">
      
      
        <link rel="canonical" href="https://didiowen.github.io/notes-not-scandal/">
      
      
      
        <link rel="next" href="category/medicine/">
      
      
      <link rel="icon" href="assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.5.33">
    
    
      
        <title>Notes Not Scandal</title>
      
    
    
      <link rel="stylesheet" href="assets/stylesheets/main.3cba04c6.min.css">
      
        
        <link rel="stylesheet" href="assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="css/timeago.css">
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
    
    <script>__md_scope=new URL(".",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="pink" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="." title="Notes Not Scandal" class="md-header__button md-logo" aria-label="Notes Not Scandal" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54Z"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Notes Not Scandal
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Home
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="(prefers-color-scheme: light)" data-md-color-scheme="default" data-md-color-primary="pink" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="(prefers-color-scheme: dark)" data-md-color-scheme="slate" data-md-color-primary="pink" data-md-color-accent="blue"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="." title="Notes Not Scandal" class="md-nav__button md-logo" aria-label="Notes Not Scandal" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54Z"/></svg>

    </a>
    Notes Not Scandal
  </label>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
    
  
  
    
      
    
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="." class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_2" >
        
          
          <label class="md-nav__link" for="__nav_2" id="__nav_2_label" tabindex="0">
            
  
  <span class="md-ellipsis">
    Archive
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_2">
            <span class="md-nav__icon md-icon"></span>
            Archive
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="archive/2024/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    2024
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="archive/2023/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    2023
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" >
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="0">
            
  
  <span class="md-ellipsis">
    Categories
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            Categories
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/medicine/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    medicine
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/medicineabx/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    medicine/abx
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/medicinefungi/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    medicine/fungi
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/medicinehiv/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    medicine/hiv
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/medicinetb/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    medicine/tb
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/reading/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    reading
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="category/writingtaiwanese/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    writing/taiwanese
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

  

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
  <div class="md-content" data-md-component="content">
    <div class="md-content__inner">
      <header class="md-typeset">
        <p>Ditched Notion for Obsidian for some time, as Notion takes forever to open a big, fat note. However, Obsidian isnâ€™t very sharable without the paid Publish feature.</p>
<p>Finally set up this site so I can look something up in my notes while Iâ€™m seeing patients in the out-patient department or in jail!</p>
<p>My Notion site is still functioning, although a bit out-dated:<br />
- <a href="https://didiowen.notion.site/336e4bf161d347f1a4ef74a78c55aade?v=1c01c8b26b084d9d92605f5ded2f27ce&amp;pvs=74">Infectious Disease</a><br />
- <a href="https://didiowen.notion.site/Hematology-b1a003097226464d9b6e861560fe7dc7?pvs=74">Hematology</a></p>
<p>BTW, the site name is inspired by Cate Blanchettâ€™s <a href="https://www.rottentomatoes.com/m/notes_on_a_scandal">Notes on a Scandal</a></p>
      </header>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-09-02 00:00:00">September 2, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/reading/" class="md-meta__link">reading</a></li>
        
        
          
          <li class="md-meta__item">
            
              1 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="_1"><a class="toclink" href="reading/Yeh-Shyr-Tau/">è‡ºç£ç”·å­è‘‰çŸ³æ¿¤çš„æµªæ¼«èˆ‡é„‰æ„</a></h2>
<h3 id="_2"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_2">èµ°è®€å¸¶å°ï¼š<a href="https://www.facebook.com/chuck158207/posts/pfbid0qxE6an3MRpryvga8acfv84QNdRj8Zji8CLxgutj13sEqfJTrZ8JjAQKDUJDwYAewl">æœ±å®¥å‹³</a></a></h3>
<h3 id="_3"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_3">ğŸ“ åœ‹èŠ±å¤§æ¨“</a></h3>
<ul>
<li>å‡ºç”Ÿåœ°ï¼šæ‰“éŠ€è¡—  </li>
<li>æˆ°çˆ­ä¸­è¢«è½Ÿç‚¸æ‹†é™¤ â†’ æ¬åˆ°å‚€å„¡å··ç§Ÿå±‹  </li>
</ul>
<h3 id="_4"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_4">ğŸ“è¬ç¦åºµç…§ç‰†</a></h3>
<ul>
<li>ã€ˆå‚€å„¡å··èˆ‡è§€ä¸‰å§‘ã€‰  <ul>
<li>è‘‰è€å–œæ„›çš„å¯«ä½œå…ƒç´ ï¼šå°å—å··å¼„ã€æ°‘ä¿—ã€å¤–åœ‹äºº  </li>
</ul>
</li>
<li>é™³ä¸–èˆˆå¤å®…ï¼šã€ˆè¬ç¦åºµã€‰ä¸­çš„æ–½å®¶  </li>
</ul>
<h3 id="_5"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_5">ğŸ“ç¥€å…¸æ­¦å»Ÿ</a></h3>
<ul>
<li>ã€Šè‘«è˜†å··æ˜¥å¤¢ã€‹  </li>
</ul>
<h3 id="_6"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_6">ğŸ“çŸ³ç²¾è‡¼</a></h3>
<ul>
<li>è‘‰è€æœ€å–œæ­¡ç±³ç³•+é­šä¸¸æ¹¯  </li>
<li>ã€ˆè„±èµ°å…µã€‰ï¼ˆé€ƒå…µï¼‰ï¼šæ—¥æœ¬äººæ¥å—å°ç£å°åƒ â†’ å¥½äºº  </li>
<li>ã€ˆå·§å…‹åŠ›èˆ‡ç«ç‘°èŠ±ã€‰ï¼šåŠªåŠ›çš‡æ°‘åŒ–å½è£æˆæ—¥æœ¬äººçš„å°ç£äºº  </li>
</ul>
<h3 id="_7"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_7">ğŸ“ç±³è¡—</a></h3>
<ul>
<li>å¿ æ¾¤å ‚ï¼šä»¥å‰æ˜¯æ£ºæåº—  </li>
<li>è‘‰è€åœ¨é€™è£¡çš„äºŒæ‰‹æ›¸æ”¤è²·æ¯›æ¾¤æ±è‘—ä½œï¼Œä½†ç•¶æ™‚é‚„ä¸æ˜¯ç¦æ›¸ï¼Œ1951æ‰é–‹å§‹ç™½è‰²æä½ˆ  </li>
</ul>
<h3 id="_8"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_8">ğŸ“è¸ç‰›å··</a></h3>
<ul>
<li>
<p>è‘‰è€åœ¨å°å—æœ€å¾Œå±…ä½è™•  </p>
</li>
<li>
<p>1951-1954 ç™½è‰²æä½ˆã€Œé€²ä¿®ã€  </p>
</li>
<li>1954-1965 æ‰¾ä¸åˆ°å¥½å·¥ä½œï¼Œå¾æ–‡å£‡æ¶ˆå¤±  </li>
<li>
<p>1965å¾Œåˆ°å·¦ç‡Ÿæ•™æ›¸ï¼Œå¾©å‡ºæ–‡å£‡  </p>
</li>
<li>
<p>è€•è€…æœ‰å…¶ç”°ï¼šæ¶ˆæ»…å°åœ°ä¸»ï¼ˆçŸ¥è­˜ä»½å­ä¸»åŠ›ï¼‰  </p>
</li>
</ul>
<h3 id="_9"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_9">ğŸ“è¥¿é–€å¸‚å ´</a></h3>
<ul>
<li>è‘‰è€åœ¨é€™è£¡çœ‹åˆ°é¾è‚‡æ”¿ç·¨çš„åˆŠç‰©ã€Šå°ç£æ–‡è—ã€‹ â†’ é–‹å§‹æŠ•ç¨¿é€šä¿¡ â†’Â Â å—è‘‰åŒ—é˜  </li>
</ul>
<h3 id="_10"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_10">ğŸ“æ—ç™¾è²¨</a></h3>
<ul>
<li>æ¯è¦ªè³¼ç‰©è™•  </li>
<li>ã€ˆæˆ°é¬¥å¤©ä½¿ã€‰ï¼šæå¯«æ¯è¦ª  </li>
<li>åƒè‹¦è€å‹ï¼Œå°å­©å·¥ä½œç©©å®šå¾Œä»å·¥ä½œåˆ°è€ï¼ŒéŒ¢è‡ªå·±èŠ±æ‰æ¢³å¦æ‰“æ‰®ç”¨  </li>
</ul>
<h3 id="_11"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_11">ğŸ“æ„›åœ‹å©¦äººæœƒé¤¨</a></h3>
<ul>
<li>1940å¹´ä»£å°ç£æ–‡å£‡æœ€å¤§åˆŠç‰©ï¼š  <ul>
<li>ã€Šå°ç£æ–‡å­¸ã€‹ï¼šå¼µæ–‡ç’°ï¼Œæœ¬åœŸæ´¾ï¼Œå¯«å¯¦  </li>
<li>ã€Šæ–‡è—å°ç£ã€‹ï¼šè¥¿å·æ»¿ï¼Œæµªæ¼«æ´¾  </li>
</ul>
</li>
<li>
<p>å…©æ´¾æ°´ç«ä¸å®¹  </p>
</li>
<li>
<p>17æ­²è¢«ã€Šå°ç£æ–‡å­¸ã€‹é€€ç¨¿ä½†æŠ•ä¸Šã€Šæ–‡è—å°ç£ã€‹  </p>
</li>
<li>
<p>åœ¨æ­¤åƒåŠ è¥¿å·æ»¿åº§è«‡ â†’ é«˜ä¸­ç•¢æ¥­å¾Œå»ç•¶åŠ©ç†ç·¨è¼¯ï¼ˆå‚¬ç¨¿ï¼‰ï¼Œæ’°æ–‡æ‰¹è©•å¼µæ–‡ç’°ï¼Œä½†è¥¿å·æ»¿æ­»å¾Œè‘‰è€èªªé‚£ç¯‡æ˜¯è¥¿å·æ»¿å¯«äº†ç”¨ä»–åå­—ç™¼è¡¨çš„  </p>
</li>
</ul>
<h3 id="_12"><a class="toclink" href="reading/Yeh-Shyr-Tau/#_12">ğŸ“è‘‰çŸ³æ¿¤æ–‡å­¸ç´€å¿µé¤¨</a></h3>
<ul>
<li>
<p>æ—©æœŸä½œå“ï¼šé’æ˜¥ã€ä¸‰æœˆçš„åª½ç¥–  </p>
<ul>
<li>ä¸‰æœˆæŒ‡äºŒäºŒå…«  </li>
</ul>
</li>
<li>
<p>æå¯«ç™½è‰²æä½ˆï¼š  </p>
<ul>
<li>ã€Šä¸€å€‹å°ç£è€æœ½ä½œå®¶çš„äº”é›¶å¹´ä»£ã€‹  </li>
<li>ã€Šå°ç£ç”·å­ç°¡é˜¿æ·˜ã€‹  </li>
</ul>
</li>
<li>
<p>è§£åš´å¾Œï¼šæ½˜éŠ€èŠ±ç³»åˆ—ï¼ˆè±”æƒ…ï¼‰  </p>
</li>
<li>
<p>ã€Šå°ç£æ–‡å­¸å²ç¶±ã€‹ï¼šæœ€å¥½è²·è¨»è§£ç‰ˆ  </p>
</li>
</ul>
<p>æœ€å¾Œé¤¨å…§è®€äº†ã€ˆè¬ç¦åºµã€‰ã€ã€ˆå¤œè¥²ã€‰å…©ç¯‡çŸ­ç¯‡å°èªªæŠ½å°æœ¬ï¼Œå¾ˆå¥½çœ‹ã€‚çœŸå¸Œæœ›å°å­¸çš„æ™‚å€™å°±æœ‰é€™å€‹ç´€å¿µé¤¨å’Œå°ç£æ–‡å­¸é¤¨ï¼Œé€™æ¨£æˆ‘å°±æœƒæ˜¯å¾å°è®€å°ç£æ–‡å­¸é•·å¤§è€Œä¸æ˜¯åœ¨é‚£é‚Šè®€ç„¡ä¸‰å°éŒ„ç”¨çš„ä¸­åœ‹æ­·å²äº†â‹¯</p>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-22 00:00:00">August 22, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicinefungi/" class="md-meta__link">medicine/fungi</a></li>
        
        
          
          <li class="md-meta__item">
            
              4 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="invasive-mold-disease"><a class="toclink" href="medicinefungi/invasive-mold-disease/">Invasive Mold Disease</a></h2>
<p>Source: [@Donnell2020RevisionUpdate]<br />
- Proven IFD can apply to any patient, regardless of whether the patient is immunocompromised<br />
- Probable invasive fungal diseases (IFD) requires the presence of at least 1 host factor, a clinical feature and mycologic evidence and is proposed for <strong>immunocompromised patients</strong> <strong>only</strong><br />
- Cases that meet the criteria for a host factor and a clinical feature but for which mycological evidence has not been found are considered possible IFD<br />
- (1,3)-beta-D glucan was not considered to provide mycological evidence of any invasive mold disease  </p>
<h3 id="proven"><a class="toclink" href="medicinefungi/invasive-mold-disease/#proven">Proven</a></h3>
<ul>
<li>Microscopic (Sterile Material): Histopathologic, cytopathologic, or direct microscopic examinationb of a specimen obtained by needle aspiration or biopsy in which hyphae or melanized yeast-like forms are seen  accompanied by evidence of associated tissue damage  </li>
<li>Culture (Sterile Material): Recovery of a hyaline or pigmented mold by culture of a specimen obtained by a sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with an infectious disease process, excluding BAL fluid, a paranasal or mastoid sinus cavity specimen, and urine  </li>
<li>Blood: Blood culture that yields a moldc (eg, Fusarium species) in the context of a compatible infectious disease process  </li>
<li>Tissue Nucleic Acid Diagnosis: Amplification of fungal DNA by PCR combined with DNA sequencing when molds are seen in formalin-fixed paraffin-embedded tissue  </li>
</ul>
<h3 id="probable"><a class="toclink" href="medicinefungi/invasive-mold-disease/#probable">Probable</a></h3>
<h4 id="host-factors"><a class="toclink" href="medicinefungi/invasive-mold-disease/#host-factors">Host factors</a></h4>
<ul>
<li>Recent history of neutropenia (&lt;0.5 Ã— 10<sup>9</sup> neutrophils/L [&lt;500 neutrophils/mm<sup>3</sup>] for &gt;10 days) temporally related to the onset of invasive fungal disease  </li>
<li>Hematologic malignancy<sup id="fnref:a"><a class="footnote-ref" href="medicinefungi/invasive-mold-disease/#fn:a">1</a></sup>  </li>
<li>Receipt of an allogeneic stem cell transplant  </li>
<li>Receipt of a solid organ transplant  </li>
<li>Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a therapeutic dose of <strong>â‰¥0.3 mg/kg</strong> corticosteroids for <strong>â‰¥3 weeks</strong> in the past 60 days  </li>
<li>Treatment with other recognized T-cell immunosuppressants, such as calcineurin inhibitors, tumor necrosis factor-a blockers, lymphocytespecific monoclonal antibodies, immunosuppressive nucleoside analogues during the past 90 days  </li>
<li>Treatment with recognized B-cell immunosuppressants, such as Brutonâ€™s tyrosine kinase inhibitors, eg, ibrutinib  </li>
<li>Inherited severe immunodeficiency (such as chronic granulomatous disease, STAT 3 deficiency, or severe combined immunodeficiency)  </li>
<li>Acute graft-versus-host disease grade III or IV involving the gut, lungs, or liver that is refractory to first-line treatment with steroids  </li>
</ul>
<h5 id="icu-patients"><a class="toclink" href="medicinefungi/invasive-mold-disease/#icu-patients">ICU patients</a></h5>
<ul>
<li>Glucocorticoid treatment with prednisone equivalent of 20 mg or more per day  </li>
<li>Qualitative or quantitative neutrophil abnormality (inherited neutrophil deficiency, absolute neutrophil count of â‰¤500 cells/mm<sup>3</sup>)  </li>
<li>Chronic respiratory airway abnormality (chronic obstructive lung disease, bronchiectasis)  </li>
<li>Decompensated cirrhosis  </li>
<li>Treatment with recognized immunosuppressants (eg, calcineurin or mammalian target of rapamycin [mTOR] inhibitors, blockers of tumor necrosis factor [TNF] and similar antifungal immunity pathways, alemtuzumab, ibrutinib, nucleoside analogues) during the past 90 days  </li>
<li>Hematological malignancies/HSCT  </li>
<li>SOT  </li>
<li>Human immunodeficiency virus infection  </li>
<li>Severe influenza (or other severe viral pneumonia, such as coronavirus disease 2019 [COVID-19])  </li>
</ul>
<h4 id="clinical-features"><a class="toclink" href="medicinefungi/invasive-mold-disease/#clinical-features">Clinical features</a></h4>
<h5 id="pulmonary-aspergillosis"><a class="toclink" href="medicinefungi/invasive-mold-disease/#pulmonary-aspergillosis">Pulmonary aspergillosis:</a></h5>
<ul>
<li>The presence of 1 of the following 4 patterns on CT:   <ul>
<li>Dense, well-circumscribed lesions(s) with or without a halo sign  </li>
<li>Air crescent sign  </li>
<li>Cavity  </li>
<li>Wedge-shaped and segmental or lobar consolidation  </li>
</ul>
</li>
</ul>
<h5 id="other-pulmonary-mold-diseases"><a class="toclink" href="medicinefungi/invasive-mold-disease/#other-pulmonary-mold-diseases">Other pulmonary mold diseases:</a></h5>
<ul>
<li>As for pulmonary aspergillosis but also including a reverse halo sign  </li>
</ul>
<h5 id="tracheobronchitis"><a class="toclink" href="medicinefungi/invasive-mold-disease/#tracheobronchitis">Tracheobronchitis:</a></h5>
<ul>
<li>Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis  </li>
</ul>
<h5 id="sino-nasal-diseases"><a class="toclink" href="medicinefungi/invasive-mold-disease/#sino-nasal-diseases">Sino-nasal diseases:</a></h5>
<ul>
<li>Acute localized pain (including pain radiating to the eye)  </li>
<li>Nasal ulcer with black eschar  </li>
<li>Extension from the paranasal sinus across bony barriers, including into the orbit  </li>
</ul>
<h5 id="central-nervous-system-infection"><a class="toclink" href="medicinefungi/invasive-mold-disease/#central-nervous-system-infection">Central nervous system infection</a></h5>
<p>1 of the following 2 signs<br />
- Focal lesions on imaging<br />
- Meningeal enhancement on magnetic resonance imaging or CT  </p>
<h4 id="mycology-evidences"><a class="toclink" href="medicinefungi/invasive-mold-disease/#mycology-evidences">Mycology evidences</a></h4>
<ul>
<li>Any mold, for example, Aspergillus, Fusarium, Scedosporium species or Mucorales recovered by culture from sputum, BAL, bronchial brush, or aspirate  </li>
<li>Microscopical detection of fungal elements in sputum, BAL, bronchial brush, or aspirate indicating a mold  </li>
</ul>
<h5 id="tracheobronchitis_1"><a class="toclink" href="medicinefungi/invasive-mold-disease/#tracheobronchitis_1">Tracheobronchitis</a></h5>
<ul>
<li>Aspergillus recovered by culture of BAL or bronchial brush  </li>
<li>Microscopic detection of fungal elements in BAL or bronchial brush indicating a mold  </li>
</ul>
<h5 id="sino-nasal-diseases_1"><a class="toclink" href="medicinefungi/invasive-mold-disease/#sino-nasal-diseases_1">Sino-nasal diseases</a></h5>
<ul>
<li>Mold recovered by culture of sinus aspirate samples  </li>
<li>Microscopic detection of fungal elements in sinus aspirate samples indicating a mold  </li>
</ul>
<h5 id="aspergillosis-only"><a class="toclink" href="medicinefungi/invasive-mold-disease/#aspergillosis-only">Aspergillosis only</a></h5>
<ul>
<li>Galactomannan antigen detected in plasma, serum, BAL, or CSF  <ul>
<li>Any 1 of the following:  <ul>
<li>Single serum or plasma: â‰¥1.0 <mark>(0.5 for ICU or COVID patients)</mark> [@Bassett2021EORTCMSGERC, @Koehler2021Definingmanaging]  </li>
<li>BAL fluid: â‰¥1.0 <mark>(0.8 for ICU patients)</mark>  </li>
<li>Single serum or plasma: â‰¥0.7 <strong>and</strong> BAL fluid â‰¥0.8  </li>
<li>CSF: â‰¥1.0  </li>
</ul>
</li>
</ul>
</li>
<li>Aspergillus PCR  <ul>
<li>Any 1 of the following:  <ul>
<li>Plasma, serum, or whole blood 2 or more consecutive PCR tests positive <sup id="fnref:b"><a class="footnote-ref" href="medicinefungi/invasive-mold-disease/#fn:b">2</a></sup>  </li>
<li>BAL fluid 2 or more duplicate PCR tests positive (or single with Ct &lt; 36) <sup id="fnref2:b"><a class="footnote-ref" href="medicinefungi/invasive-mold-disease/#fn:b">2</a></sup>  </li>
<li>At least 1 PCR test positive in plasma, serum, or whole blood and 1 PCR test positive in BAL fluid   </li>
</ul>
</li>
</ul>
</li>
<li><em>Aspergillus</em> species recovered by culture from <strong>sputum, BAL, bronchial brush, or aspirate</strong> (+  cytology or direct microscopy for ICU patients)  </li>
</ul>
<h3 id="possible"><a class="toclink" href="medicinefungi/invasive-mold-disease/#possible">Possible</a></h3>
<ul>
<li>Host factors + clinical features (for immunocompromised patients only)  </li>
</ul>
<div class="footnote">
<hr />
<ol>
<li id="fn:a">
<p>Hematologic malignancy refers to active malignancy, in receipt of treatment for this malignancy, and those in remission in the recent past. These patients would comprise largely acute leukemias and lymphomas, as well as multiple myeloma, whereas patients with aplastic anemia represent a more heterogeneous group of individuals and are not included.&#160;<a class="footnote-backref" href="medicinefungi/invasive-mold-disease/#fnref:a" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
<li id="fn:b">
<p>For CAPA: In case of patients with chronic obstructive pulmonary disease or chronic respiratory disease, the PCR or culture results should be confirmed by galactomannan testing to rule out colonisation or chronic aspergillosis.&#160;<a class="footnote-backref" href="medicinefungi/invasive-mold-disease/#fnref:b" title="Jump back to footnote 2 in the text">&#8617;</a><a class="footnote-backref" href="medicinefungi/invasive-mold-disease/#fnref2:b" title="Jump back to footnote 2 in the text">&#8617;</a></p>
</li>
</ol>
</div>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-14 00:00:00">August 14, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              2 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="fever"><a class="toclink" href="medicine/fever/">Fever</a></h2>
<p>source: Harrison's Principles of Internal Medicine, 21e  </p>
<h3 id="_1"><a class="toclink" href="medicine/fever/#_1">æ­£å¸¸é«”æº«</a></h3>
<ul>
<li>é«”æº«ç”±ä¸‹è¦–ä¸˜æ§åˆ¶  </li>
<li>æ ¹æ“šä¸€é …å°35,000å¤šåå¹´é½¡â‰¥18æ­²çš„å€‹é«”é€²è¡Œçš„ä¾‹è¡Œé†«ç™‚è¨ªå•ç ”ç©¶ï¼Œå¹³å‡å£è…”æº«åº¦ç‚º36.6Â°Cï¼ˆ95%ç½®ä¿¡å€é–“ç‚º35.7-37.3Â°Cï¼‰ã€‚æ ¹æ“šé€™é …ç ”ç©¶ï¼Œå¥åº·å€‹é«”99%ç™¾åˆ†ä½æ•¸çš„é«”æº«å®šç¾©ç‚ºç™¼ç‡’ï¼Œå³è¶…é<strong>37.7Â°C</strong>ï¼ˆ99.9Â°Fï¼‰  </li>
<li>é«”æº«å…·æœ‰æ™å¤œå’Œå­£ç¯€è®ŠåŒ–ï¼Œæ—©ä¸Š8é»å’Œå¤å­£æ™‚æœ€ä½ï¼Œè€Œä¸‹åˆ4é»å’Œå†¬å­£æ™‚æœ€é«˜  </li>
<li>è‚›æº«é€šå¸¸æ¯”å£è…”æº«åº¦é«˜0.4Â°Cï¼ˆ0.7Â°Fï¼‰  </li>
<li>åœ¨è‚²é½¡å¥³æ€§ä¸­ï¼Œæ’åµå‰å…©é€±çš„æ—©æ™¨é«”æº«é€šå¸¸è¼ƒä½ï¼›æ’åµæ™‚é«”æº«ä¸Šå‡ç´„0.6Â°Cï¼ˆ1Â°Fï¼‰ï¼Œä¸¦ä¿æŒè‡³æœˆç¶“ä¾†  </li>
</ul>
<h3 id="_2"><a class="toclink" href="medicine/fever/#_2">ç™¼ç‡’</a></h3>
<ul>
<li>ç™¼ç‡’æ˜¯é«”æº«è¶…éæ­£å¸¸æ—¥å¸¸è®ŠåŒ–ç¯„åœï¼Œä¸¦ä¼´éš¨ä¸‹è¦–ä¸˜è¨­å®šé»ä¸Šå‡ï¼ˆä¾‹å¦‚ï¼Œå¾37Â°Cä¸Šå‡åˆ°39Â°Cï¼‰è€Œç™¼ç”Ÿçš„ç¾è±¡  </li>
<li>è¶…é41.5Â°Cï¼ˆ106.7Â°Fï¼‰çš„ç™¼ç‡’ç¨±ç‚ºé«˜ç†±ï¼ˆhyperpyrexiaï¼‰ã€‚é€™ç¨®æ¥µé«˜çš„ç™¼ç‡’å¯èƒ½å‡ºç¾åœ¨æ‚£æœ‰åš´é‡æ„ŸæŸ“çš„æ‚£è€…ä¸­ï¼Œä½†æœ€å¸¸è¦‹æ–¼ä¸­æ¨ç¥ç¶“ç³»çµ±ï¼ˆCNSï¼‰å‡ºè¡€çš„æ‚£è€…  </li>
</ul>
<h3 id="_3"><a class="toclink" href="medicine/fever/#_3">ç†±è¡°ç«­</a></h3>
<ul>
<li>é›–ç„¶å¤§å¤šæ•¸é«”æº«å‡é«˜çš„æ‚£è€…æ˜¯ç™¼ç‡’ï¼Œä½†æœ‰äº›æƒ…æ³ä¸‹ï¼Œé«”æº«å‡é«˜ä¸¦éç”±æ–¼ç™¼ç‡’ï¼Œè€Œæ˜¯ç”±æ–¼ç†±è¡°ç«­ï¼ˆç†±ä¸­æš‘ï¼‰ã€‚ç†±è¡°ç«­çš„ç‰¹å¾µæ˜¯é«”æº«ä¸å—æ§åˆ¶åœ°ä¸Šå‡ï¼Œè¶…éäº†èº«é«”æ•£ç†±çš„èƒ½åŠ›ã€‚æ­¤æ™‚ï¼Œä¸‹è¦–ä¸˜é«”æº«èª¿ç¯€ä¸­å¿ƒçš„è¨­å®šæœªè®ŠåŒ–ã€‚  </li>
<li>ç†±è¡°ç«­é€šå¸¸æ ¹æ“šæ ¸å¿ƒé«”æº«å‡é«˜å‰çš„äº‹ä»¶ä¾†è¨ºæ–·â€”â€”ä¾‹å¦‚ï¼Œç†±æš´éœ²æˆ–ä½¿ç”¨å¹²æ“¾é«”æº«èª¿ç¯€çš„è—¥ç‰©ã€‚åœ¨ç†±ä¸­æš‘ç¶œåˆç—‡æ‚£è€…å’Œé‚£äº›æœç”¨é˜»æ­¢å‡ºæ±—è—¥ç‰©çš„æ‚£è€…ä¸­ï¼Œçš®è†šæœƒè®Šç†±ä½†ä¹¾ç‡¥ï¼Œè€Œåœ¨ç™¼ç‡’æ™‚ï¼Œç”±æ–¼è¡€ç®¡æ”¶ç¸®ï¼Œçš®è†šå¯èƒ½æœƒæ„Ÿåˆ°å¯’å†·ã€‚é€€ç‡’è—¥ä¸æœƒé™ä½ç†±è¡°ç«­å¼•èµ·çš„é«”æº«ï¼Œè€Œåœ¨ç™¼ç‡’â€”â€”ç”šè‡³é«˜ç†±ä¸­ï¼Œé©é‡çš„é˜¿å¸åŒ¹æ—æˆ–acetaminophené€šå¸¸æœƒå°è‡´é«”æº«æœ‰æ‰€ä¸‹é™ã€‚  </li>
</ul>
<h3 id="_4"><a class="toclink" href="medicine/fever/#_4">è™•ç½®</a></h3>
<ul>
<li>ä½¿ç”¨é›»å­è¨­å‚™æ¸¬é‡å£è…”ã€é¼“è†œæˆ–ç›´è…¸æº«åº¦æ˜¯å¯é çš„ï¼Œä½†æ‡‰è©²æŒçºŒä½¿ç”¨åŒä¸€å€‹éƒ¨ä½ä¾†ç›£æ¸¬ç™¼ç†±ç‹€æ³  </li>
<li>å°æ–¼ä½åº¦ç™¼ç‡’æˆ–æ‡·ç–‘éš±åŒ¿æ€§ç–¾ç—…çš„æ‚£è€…ï¼Œæœ€æœ‰åƒ¹å€¼çš„æ¸¬é‡æ˜¯Cåæ‡‰è›‹ç™½ï¼ˆCRPï¼‰å’Œç´…è¡€çƒæ²‰é™ç‡ï¼ˆESRï¼‰  </li>
</ul>
<h3 id="_5"><a class="toclink" href="medicine/fever/#_5">æ²»ç™‚æ–¹æ¡ˆ</a></h3>
<ul>
<li>ç”¨å¸¸è¦çš„é€€ç‡’è—¥æ²»ç™‚ç™¼ç‡’åŠå…¶ç—‡ç‹€æ—¢ç„¡å®³ï¼Œä¹Ÿä¸æœƒå»¶ç·©å¸¸è¦‹ç—…æ¯’å’Œç´°èŒæ„ŸæŸ“çš„ç—Šç™’  </li>
<li>åœ¨ç´°èŒæ„ŸæŸ“ä¸­ï¼Œåœæ­¢ä½¿ç”¨é€€ç‡’è—¥å¯ä»¥å¹«åŠ©è©•ä¼°ç‰¹å®šæŠ—ç”Ÿç´ çš„æœ‰æ•ˆæ€§ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ²’æœ‰è‡´ç—…èŒçš„é™½æ€§åŸ¹é¤Šçµæœçš„æƒ…æ³ä¸‹ï¼Œå¸¸è¦ä½¿ç”¨é€€ç‡’è—¥å¯èƒ½æœƒæ©è“‹æ²»ç™‚ä¸è¶³çš„ç´°èŒæ„ŸæŸ“  </li>
<li>æ²»ç™‚ç™¼ç‡’çš„ç›®æ¨™æ˜¯é¦–å…ˆé™ä½å‡é«˜çš„ä¸‹è¦–ä¸˜è¨­å®šé»ï¼Œå…¶æ¬¡ä¿ƒé€²æ•£ç†±ã€‚ç”¨é€€ç‡’è—¥é™ä½ç™¼ç‡’é‚„èƒ½æ¸›å°‘é ­ç—›ã€è‚Œè‚‰ç–¼ç—›å’Œé—œç¯€ç–¼ç—›ç­‰å…¨èº«ç—‡ç‹€ã€‚  </li>
<li>å£æœaspirinå’ŒNSAIDsæœ‰æ•ˆåœ°é™ä½ç™¼ç‡’ï¼Œä½†å¯èƒ½å°è¡€å°æ¿å’Œæ¶ˆåŒ–é“ç”¢ç”Ÿä¸è‰¯å½±éŸ¿ã€‚å› æ­¤ï¼Œacetaminophenä½œç‚ºé€€ç‡’è—¥æ›´å—æ¨è–¦ã€‚  </li>
<li>åœ¨å…’ç«¥ä¸­ï¼Œå¿…é ˆä½¿ç”¨acetaminophenæˆ–å£æœibuprofenï¼Œå› ç‚ºaspirinæœƒå¢åŠ Reyeç¶œåˆç—‡çš„é¢¨éšªã€‚å¦‚æœæ‚£è€…ç„¡æ³•æœç”¨å£æœé€€ç‡’è—¥ï¼Œå¯ä»¥ä½¿ç”¨éœè„ˆæ³¨å°„çš„NSAIDså’Œå„ç¨®é€€ç‡’è—¥çš„ç›´è…¸æ “åŠ‘ã€‚  </li>
<li>åœ¨æŸäº›æ‚£è€…ä¸­ï¼Œç™¼ç‡’çš„æ²»ç™‚æ˜¯é«˜åº¦å»ºè­°çš„ã€‚ç™¼ç‡’å¢åŠ äº†æ°§æ°£éœ€æ±‚ï¼ˆå³æ¯å‡é«˜1Â°Cï¼Œæ°§æ°£æ¶ˆè€—å¢åŠ 13%ï¼‰ï¼Œä¸¦å¯èƒ½åŠ åŠ‡å·²æœ‰==<strong>å¿ƒè‡Ÿã€è‚ºéƒ¨æˆ–ä¸­æ¨ç¥ç¶“ç³»çµ±åŠŸèƒ½æå®³</strong><mark>çš„æ‚£è€…çš„ç—…æƒ…ã€‚å°æ–¼</mark><strong>æœ‰ç™¼ç‡’æˆ–éç™¼ç‡’æ€§ç™²ç™‡ç—…å²çš„å…’ç«¥</strong>==æ‡‰ç©æ¥µæ²»ç™‚ä»¥é™ä½ç™¼ç‡’ã€‚ç„¶è€Œï¼Œç›®å‰å°šä¸æ¸…æ¥šå¼•ç™¼ç™¼ç‡’æ€§ç™²ç™‡çš„å…·é«”åŸå› ï¼Œä¸”åœ¨æ˜“æ„Ÿå…’ç«¥ä¸­ï¼Œç™¼ç‡’æ€§ç™²ç™‡çš„ç™¼ä½œèˆ‡é«”æº«çš„çµ•å°å‡é«˜ä¹‹é–“æ²’æœ‰ç›¸é—œæ€§ã€‚  </li>
<li>åœ¨é«˜ç†±ç—‡ä¸­ï¼Œä½¿ç”¨é™æº«æ¯¯æœ‰åŠ©æ–¼é™ä½é«”æº«ï¼›ç„¶è€Œï¼Œä¸æ‡‰åœ¨æ²’æœ‰å£æœé€€ç‡’è—¥çš„æƒ…æ³ä¸‹ä½¿ç”¨é™æº«æ¯¯ã€‚åœ¨æœ‰ä¸­æ¨ç¥ç¶“ç³»çµ±ç–¾ç—…æˆ–å‰µå‚·ï¼ˆä¸­æ¨ç¥ç¶“ç³»çµ±å‡ºè¡€ï¼‰çš„é«˜ç†±æ‚£è€…ä¸­ï¼Œé™ä½æ ¸å¿ƒé«”æº«å¯ä»¥æ¸›å°‘é«˜æº«å°å¤§è…¦çš„æœ‰å®³å½±éŸ¿ã€‚  </li>
</ul>
<h3 id="relative-bradycardia"><a class="toclink" href="medicine/fever/#relative-bradycardia">Relative Bradycardia</a></h3>
<ul>
<li>Definition: For every 1Â°C (1.8Â°F) increase in core temperature, the heart rate typically rises by 15â€“20 beats/min.  </li>
</ul>
<table>
<thead>
<tr>
<th>Causes of Relative Bradycardia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gram-negative bacteria</td>
<td><strong><em>Salmonella typhi</em></strong><br><em>Francisella tularensis</em><br><em>Brucella</em> spp.<br><strong><em>Coxiella burnetii</em> (Q fever)</strong><br><strong><em>Leptospira interrogans</em></strong><br><strong><em>Legionella pneumophila</em><br><em>Mycoplasma pneumoniae</em></strong></td>
</tr>
<tr>
<td>Tick-borne organisms</td>
<td><strong><em>Rickettsia</em> spp.</strong><br><strong><em>Orientia tsutsugamushi</em> (scrub typhus)</strong><br><em>Babesia</em> spp.</td>
</tr>
<tr>
<td>Other intracellular organisms</td>
<td><em>Corynebacterium diphtheriae</em><br><em>Plasmodium</em> spp. (malaria)</td>
</tr>
<tr>
<td>Viruses/viral infections</td>
<td>Yellow fever virus<br><strong>Dengue virus</strong><br>Viral hemorrhagic feversa<br>Viral myocarditis</td>
</tr>
<tr>
<td><strong>Noninfectious Causes</strong></td>
<td>Drug fever<br>Beta blocker use<br>Central nervous system lesions<br>Malignant lymphoma<br>Factitious fever</td>
</tr>
<tr>
<td>## ç‰¹æ®Šæ¨¡å¼çš„ç™¼ç‡’</td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li>æŸäº›æ„ŸæŸ“æœ‰ç‰¹æ®Šæ¨¡å¼ï¼Œå…¶ä¸­ç™¼ç‡’æœŸèˆ‡æ­£å¸¸é«”æº«æœŸäº¤æ›¿ã€‚ä¾‹å¦‚ï¼Œæƒ¡æ€§ç˜§ç–¾ï¼ˆ<em>Plasmodium vivax</em>ï¼‰æ¯ä¸‰å¤©ç™¼ç‡’ä¸€æ¬¡ï¼Œè€Œå››æ—¥ç˜§ç–¾ï¼ˆ<em>Plasmodium malariae</em>ï¼‰æ¯å››å¤©ç™¼ç‡’ä¸€æ¬¡ã€‚  </li>
<li>å¦ä¸€ç¨®å¾©ç™¼æ€§ç™¼ç‡’èˆ‡ä¼¯æ°ç–èºæ—‹é«”æ„ŸæŸ“ç›¸é—œï¼Œç™¼ç‡’å¹¾å¤©å¾Œä¼´æœ‰å¹¾å¤©çš„ç„¡ç™¼ç‡’æœŸï¼Œéš¨å¾Œå†æ¬¡ç™¼ç‡’ã€‚  </li>
<li>åœ¨Pel-Ebsteinæ¨¡å¼ä¸­ï¼Œç™¼ç‡’æŒçºŒ3-10å¤©ï¼Œéš¨å¾Œç„¡ç™¼ç‡’æœŸç‚º3-10å¤©ï¼›é€™ç¨®æ¨¡å¼å¯ä»¥æ˜¯ä½•æ°é‡‘æ·‹å·´ç˜¤å’Œå…¶ä»–æ·‹å·´ç˜¤çš„å…¸å‹ç‰¹å¾µã€‚  </li>
<li>åœ¨å¾ªç’°æ€§å—œä¸­æ€§çƒä½ä¸‹ç—‡ä¸­ï¼Œç™¼ç‡’æ¯21å¤©ç™¼ä½œä¸€æ¬¡ï¼Œä¸¦ä¼´æœ‰å—œä¸­æ€§çƒä½ä¸‹ã€‚  </li>
<li>é‚„æœ‰ä¸€äº›å‘¨æœŸæ€§ç™¼ç‡’ç—‡å€™ç¾¤ï¼ˆä¾‹å¦‚å®¶æ—æ€§åœ°ä¸­æµ·ç†±ã€TNFå—é«”ç›¸é—œå‘¨æœŸæ€§ç¶œåˆç—‡[TRAPS]ï¼‰ï¼Œé€™äº›ç—‡å€™ç¾¤åœ¨å‘¨æœŸæ€§ã€ç™¼ä½œæŒçºŒæ™‚é–“ã€è‡¨åºŠç‰¹å¾µçµ„åˆã€éºå‚³åŸå› å’Œæ²»ç™‚ä¸Šæœ‰æ‰€ä¸åŒ  </li>
</ul>
<h2 id="fuo"><a class="toclink" href="medicine/fever/#fuo">FUO</a></h2>
<p>1961å¹´ï¼ŒPetersdorf å’Œ Beeson æœ€åˆå°‡ä¸æ˜åŸå› ç™¼ç†±ï¼ˆFUOï¼‰å®šç¾©ç‚ºç—…ç¨‹è¶…é3é€±ã€è‡³å°‘å…©æ¬¡ç™¼ç‡’ï¼ˆâ‰¥38.3Â°Cæˆ–â‰¥101Â°Fï¼‰ï¼Œä¸¦ä¸”åœ¨ä½é™¢1é€±çš„è©•ä¼°å¾Œä»æœªç¢ºè¨ºã€‚å¦‚ä»Šï¼Œå¤§å¤šæ•¸ FUO æ‚£è€…åªæœ‰åœ¨è‡¨åºŠæƒ…æ³éœ€è¦æ™‚æ‰æœƒä½é™¢ï¼Œè€Œéåƒ…ç‚ºäº†è¨ºæ–·ç›®çš„ï¼›å› æ­¤ï¼Œä½é™¢è©•ä¼°è¦æ±‚å·²å¾å®šç¾©ä¸­å–æ¶ˆã€‚æ­¤å¤–ï¼ŒFUO çš„å®šç¾©é€²ä¸€æ­¥æ’é™¤äº†å…ç–«ä¸å…¨æ‚£è€…ï¼Œå› ç‚ºé€™äº›æ‚£è€…çš„è¨ºæ–·å’Œæ²»ç™‚æ–¹æ³•å®Œå…¨ä¸åŒã€‚ç‚ºäº†æœ€ä½³åœ°æ¯”è¼ƒä¸åŒåœ°å€çš„ FUO æ‚£è€…ï¼Œæœ‰äººå»ºè­°å°‡å®šé‡æ¨™æº–ï¼ˆç¶“é1é€±è©•ä¼°å¾Œè¨ºæ–·ä»ä¸ç¢ºå®šï¼‰æ›´æ”¹ç‚ºéœ€è¦é€²è¡Œç‰¹å®šæª¢æŸ¥çš„å®šæ€§æ¨™æº–ã€‚å› æ­¤ï¼ŒFUO ç¾åœ¨çš„å®šç¾©å¦‚ä¸‹ï¼š  </p>
<ul>
<li>è‡³å°‘å…©æ¬¡é«”æº«é”åˆ°æˆ–è¶…é38.3Â°Cï¼ˆ101Â°Fï¼‰  </li>
<li>ç–¾ç—…æŒçºŒæ™‚é–“é”åˆ°æˆ–è¶…é3é€±  </li>
<li>ç„¡å·²çŸ¥çš„å…ç–«ä¸å…¨ç‹€æ…‹  </li>
<li>ç¶“éå¾¹åº•çš„ç—…å²è©¢å•ã€ç†å­¸æª¢æŸ¥ä»¥åŠä»¥ä¸‹å¿…éœ€æª¢æŸ¥å¾Œï¼Œè¨ºæ–·ä»ç„¶ä¸æ˜ï¼š<br />
  erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level; platelet count; leukocyte count and differential; measurement of levels of hemoglobin, electrolytes, creatinine, total protein, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, ferritin, antinuclear antibodies, and rheumatoid factor; protein electrophoresis; urinalysis; blood cultures (<em>n</em> = 3); urine culture; chest x-ray; abdominal ultrasonography; and tuberculin skin test (TST) or interferon Î³ release assay (IGRA)  </li>
</ul>
<h3 id="structured-approach-to-patients-with-fuo"><a class="toclink" href="medicine/fever/#structured-approach-to-patients-with-fuo">Structured approach to patients with FUO</a></h3>
<p><img alt="fuo_flowchart" src="../../assets/images/66855bcbe1aee21fd2f8a8bf99ca31dd_MD5.jpeg" />  </p>
<h3 id="_6"><a class="toclink" href="medicine/fever/#_6">è€ƒå¤é¡Œ</a></h3>
<h4 id="_7"><a class="toclink" href="medicine/fever/#_7">å°ˆå¸«</a></h4>
<h4 id="_8"><a class="toclink" href="medicine/fever/#_8">å…§ç§‘é†«å¸«</a></h4>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-14 00:00:00">August 14, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              15 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="_1"><a class="toclink" href="medicine/im-board-exam/">å…§å°ˆè€ƒå¤é¡Œæ„ŸæŸ“ç§‘è©¦é¡Œ</a></h2>
<ol>
<li>
<p>é£Ÿåª’æ€§ç–¾ç—…ï¼Œä»¥ä¸‹å“ªäº›é…å°æœ€ä¸æ­£ç¢ºï¼Ÿ<br />
A. Listeriosisèˆ‡ä¹³é…ª<br />
B. Campylobacter jejunièˆ‡æœªç…®ç†Ÿé›è‚‰<br />
C. Salmonellaèˆ‡ç”Ÿé›è›‹<br />
D. Norovirusèˆ‡ç”Ÿè ”æˆ–æ±¡æŸ“çš„æ°´<br />
<mark>E. Q feverèˆ‡ç”Ÿç‰›è‚‰</mark>  </p>
</li>
<li>
<p>ä¸€ä½30æ­²çš„å¥³æ€§ï¼Œåƒäº†ç”Ÿè±¬è‚‰ä¹‹å¾Œç™¼ç”Ÿæ˜é¡¯çš„è…¸èƒƒç‚ç—‡ç‹€ï¼Œä¸”æœ‰ç™¼ç‡’ã€å³ä¸‹è…¹ç—›åŠè…¹ç€‰ï¼Œæ€¥è¨ºå®¤è¨ºæŸ¥ç™¼ç¾terminal ileuméƒ¨ä½ç™¼ç‚(ileitis)ï¼Œä¸¦æœ‰å³ä¸‹è…¹éƒ¨åå½ˆç—›ç–‘ä¼¼ç›²è…¸ç‚ï¼Œè«‹å•æœ€æœ‰å¯èƒ½æ˜¯ä¸‹åˆ—å“ªä¸€ç¨®è…¸é“è‡´ç—…åŸ? <br />
A. Vibrio cholera<br />
B. Salmonella typhi<br />
<mark>C. Yersinia enterocolitica</mark><br />
D. E. coli O157<br />
E. Enterovirus 71 (EV71)  </p>
</li>
<li>
<p>ä¸€ä½30æ­²å¥³æ€§ï¼Œé–‹å¿ƒæ­ä¹˜éƒµè¼ªå‡ºéŠï¼Œä½†åœ¨èˆ¹ä¸Šé€²é£Ÿå¾Œ24å°æ™‚å·¦å³é–‹å§‹å‡ºç¾ç™¼ç‡’ã€è…¹ç—›ã€è…¹ç€‰ä¹‹ç—‡ç‹€ï¼Œå…¶ä»–åŒè¡Œè€…ä¹Ÿæœ‰å¤šäººå‡ºç¾è…¸èƒƒä¸é©ï¼Œè«‹å•ä¸‹åˆ—ä½•è€…æ˜¯æœ€å¯èƒ½çš„è‡´ç—…åŸ?<br />
<mark>A. Norovirus</mark><br />
B. Giardia lamblia<br />
C. Cryptosporidium<br />
D. Entameoba histolytica<br />
E. Escherichia coli  </p>
</li>
<li>
<p>æ²™é–€æ°èŒå¸¸æºè‡ªè›‹ã€ç”Ÿè‚‰ã€ç‰›å¥¶ç”¢å“ã€èŠ±ç”Ÿé†¬ã€æ–°é®®è”¬èœæˆ–æ¥è§¸çˆ¬èŸ²é¡å‹•ç‰©,å¯ä»¥é€ æˆè…¸é“æ„ŸæŸ“ç—‡ç‹€æˆ–èŒè¡€ç—‡, ä»¥ä¸‹æœ‰é—œæ²»ç™‚ä¹‹æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ<br />
    (1). å¹´ç´€å°æ–¼50æ­²ä¹‹å¥åº·æˆäººè‹¥æœ‰è¼•å¾®è‡³ä¸­ç­‰åº¦è…¸èƒƒç—‡ç‹€,å¯ä¸éœ€ç”¨æŠ—ç”Ÿç´  (2). æˆäººå¹´ç´€å¤§æ–¼50æ­², ç—‡ç‹€è¼•å¾®å‰‡ä¸éœ€ä½¿ç”¨æŠ—ç”Ÿç´  (3). æœ‰äººå·¥è¡€ç®¡æ¤å…¥ç‰©ã€äººå·¥é—œç¯€è€…, ç—‡ç‹€è¼•å¾®äº¦æ‡‰ä½¿ç”¨æŠ—ç”Ÿç´  (4). æ¥å—åŒ–å­¸æ²»ç™‚è—¥æ²»ç™‚ç™Œç—…æˆ–å…ç–«æŠ‘åˆ¶åŠ‘è€…, ç—‡ç‹€è¼•å¾®äº¦æ‡‰ä½¿ç”¨æŠ—ç”Ÿç´  #medicine/Salmonella <br />
A. (1)+(2)+(3)+(4)<br />
<mark>B. (1)+(3)+(4)</mark><br />
C. (2)+(3)+(4)<br />
D. (3)+(4)<br />
E. (4)  </p>
</li>
<li>
<p>ä¸€ä½50æ­²ä½é™¢æ¥å—åŒ–å­¸æ²»ç™‚ç—…æ‚£ï¼Œå› ä¸­æ€§çƒä½ä¸‹ç™¼ç‡’ä½¿ç”¨æŠ—ç”Ÿç´ ï¼Œæ²»ç™‚æœŸé–“ç™¼ç”Ÿè…¹ç€‰ï¼Œè‡¨åºŠé†«å¸«æ‡·ç–‘ç‚ºå›°é›£æ¢­ç‹€æ¡¿èŒ(Clostridium difficile)è…¸ç‚ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…ç‚ºéï¼Ÿ #medicine/CDI <br />
A. è‡¨åºŠä¸Šè¨ºæ–·æ„ŸæŸ“æ€§è…¹ç€‰ï¼Œéœ€åŒ…æ‹¬é€£çºŒ2 å¤©ä»¥ä¸Šæ¯å¤©æœ‰3æ¬¡ä¸æˆå½¢ç³ä¾¿<br />
B. å¯ä»¥ç”¨æ ¸é…¸æª¢å®štoxin Aæˆ–toxin Bä¾†ç¢ºèªæ„ŸæŸ“<br />
<mark>C. è¨ºæ–·éœ€ä¾è³´å…§è¦–é¡æª¢æŸ¥åŠç³ä¾¿åŸ¹é¤Š</mark><br />
D. åˆ¤å®šæ²»ç™‚æ˜¯å¦å¤±æ•—ï¼Œæ‡‰è‡³å°‘ä½¿ç”¨6å¤©è—¥ç‰©æª¢è¦–æ²»ç™‚æ•ˆæœæ±ºå®š<br />
E. å°è¼ƒåš´é‡æ„ŸæŸ“ç—…æ‚£ï¼Œå¦‚è¡€æ¶²ç™½è¡€çƒæ•¸&gt;15000/Î¼Lï¼Œé¦–é¸ä½¿ç”¨å£æœVancomycin  </p>
</li>
<li>
<p>æœ‰é—œå›°é›£æ¢­ç‹€æ¡¿èŒ NAPI/BI/027èŒæ ªï¼Œä¸‹åˆ—ä½•è€…ç‚ºé? <br />
A. NAPI/BI/027èŒæ ªæ˜¯è¿‘å¹´ä¾†é€ æˆå…¨çƒæµè¡Œï¼Œæ­ç¾åœ°å€é†«é™¢ç¾¤çªç™¼çš„ä¸»è¦èŒæ ª<br />
<mark>B. æ­¤èŒæ ªå°æ–¼fluoroquinolonesé¡æŠ—ç”Ÿç´ å…·æœ‰é«˜åº¦æ„Ÿå—æ€§(susceptible)</mark><br />
C. èˆ‡ä¸€èˆ¬èŒæ ªç›¸æ¯”ï¼ŒNAPI/BI/027èŒæ ªå¯ç”¢ç”Ÿ16è‡³23å€çš„toxin Aèˆ‡toxin B<br />
D. æ­¤èŒäº¦å·²è¢«ç™¼ç¾é™¤toxin AåŠtoxin Bå¤–ï¼Œå¦å¯ç”¢ç”Ÿç¬¬3ç¨®æ¯’ç´ (binary toxin CDT)<br />
E. æ­¤èŒæ ªå¯ä½¿ç”¨metronidazoleæˆ–vancomycinä¾†ä½œç¬¬ä¸€ç·šå£æœæ²»ç™‚  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œç¤¾å€æ€§è‚ºç‚è‡´ç—…åŸèˆ‡ç›¸é—œå®¿ä¸»å› ç´ çš„é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/pneumonia <br />
A. Streptococcus pneumoniae -é…’ç™® (alcoholism)<br />
B. Klebsiella pneumoniae â€“ ç³–å°¿ç—… (diabetes)<br />
C. Haemophilus influenzae â€“ æ…¢æ€§é˜»å¡æ€§è‚ºç—… (COPD)<br />
D. Pseudomonas aeruginosa â€“ æ”¯æ°£ç®¡æ“´å¼µ(bronchiectasis)<br />
<mark>E. Coxiella burnetiiâ€“èˆ‡é³¥é¡æ¥è§¸</mark>  </p>
</li>
<li>
<p>ä¸‹åˆ—ç¤¾å€æ€§è‚ºç‚è‡´ç—…åŸèˆ‡å®¿ä¸»å› å­ä¹‹é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶? #medicine/pneumonia <br />
A. Alcoholism - Streptococcus pneumoniae<br />
B. Bronchiectasis - Pseudomonas aeruginosa<br />
C. Post-Influenza illness - Stapylococcus aureus<br />
<mark>D. Exposure to bird - ChlamydiaÂ trochomatis</mark> Â <code>Chlamydia psittaci</code><br />
E. Exposure to sheep - Coxiella burnetii  </p>
</li>
<li>
<p>æœ‰é—œé€€ä¼è»äººç—‡(Legionella Infection)ä¹‹æ²»ç™‚è—¥ç‰©ï¼Œä¸‹åˆ—ä½•è€…æ˜¯æœ€å®Œæ•´çš„å¯é¸æ“‡è—¥ç‰©çµ„åˆ?  #medicine/Legionella <br />
   (1) Macrolides (2) Quinolones (3) Tetracyclines (4) CephalosporinsÂ (5) Trimethoprim/ Sulfamethoxazle<br />
A. (1)+(2)<br />
B. (1)+(2)+(3)<br />
C. (2)+(3)+(4)<br />
<mark>D. (1)+(2)+(3)+(5)</mark><br />
E. (3)+(4)+(5)  </p>
</li>
<li>
<p>æœ‰é—œæ¢…æ¯’çš„æª¢é©—, ä»¥ä¸‹ä½•è€…æ­£ç¢º?<br />
    (1) ç•¶ç—…äººæ˜¯HIV(+)æ™‚, è‹¥RPR (æˆ–VDRL)â‰§1:32æˆ–CD4&lt;=350/cumm, å‰‡æ‡‰åšCSFæª¢æŸ¥RPR (2) primary/secondaryæ¢…æ¯’, åŸRPRç‚º1:32, æ–¼æ²»ç™‚å¾Œ6è‡³12å€‹æœˆè¿½è¹¤, å†é©—RPRç‚º1:8, ä¹ƒè¡¨ç¤ºæ²»ç™‚åæ‡‰è‰¯å¥½ (3) Latent/late syphilis æ–¼æ²»ç™‚å¾Œ6ã€12ã€24å€‹æœˆçš†æ‡‰å†é€²è¡Œè¿½è¹¤æª¢æŸ¥ (4) åŒæ™‚æœ‰HIV(+)è€…, æ²»ç™‚å¾Œ3ã€6ã€9ã€12åŠ24å€‹æœˆçš†è¦è¿½è¹¤æª¢é©— #medicine/syphilis  #medicine/STD <br />
A. (1)+(2)+(3)<br />
B. (2)+(3)+(4)<br />
C. (1)+(2)+(4)<br />
D. (1)+(3)+(4)<br />
<mark>E. (1)+(2)+(3)+(4)</mark>  </p>
</li>
<li>
<p>ä¸€ä½20æ­²å¹´è¼•å¥³æ€§ï¼Œé ­ç—›ç™¼ç‡’åŠé ¸éƒ¨åƒµç¡¬è‡³æ€¥è¨ºå°±é†«ï¼Œæ€¥è¨ºé†«å¸«åŸ·è¡Œè…¦è„Šé«“æ¶²æª¢æŸ¥ï¼Œè¨ºæ–·ç‚ºç´°èŒæ€§è…¦è†œç‚ï¼Œè«‹å•ä¸‹åˆ—æœ‰é—œè…¦è„Šé«“æ¶²æª¢æŸ¥çµæœæ•˜è¿°ï¼Œä½•è€…ç‚ºé? #medicine/CNS <br />
A. å¤šå‹æ ¸ç™½è¡€çƒ(PMN)æ•¸ &gt;100 cells/uL<br />
B. è‘¡è„ç³–æ¿ƒåº¦ &lt; 40 mg/dL<br />
C. è›‹ç™½è³ª(protein) &gt; 45 mg/dL<br />
D. è…¦è„Šé«“æ¶²ç´°èŒåŸ¹é¤Šé™½æ€§ç‡é«˜ï¼Œç´„ç‚º80%<br />
<mark>E. è…¦è„Šé«“æ¶²é©è˜­æ°æŸ“è‰²é™½æ€§ç‡ä½ï¼Œç´„ç‚º40%</mark> <code>60%</code>  </p>
</li>
<li>
<p>28æ­²ç”·æ€§å› é«˜ç‡’ä¸‰æ—¥å°±é†«,åˆä½µæœ‰é ­ç—›ã€å™å¿ƒã€å˜”åã€é ¸éƒ¨åƒµç›´ã€å‡ºè¡€æ€§çš®ç–¹åœ¨æ€¥è¨ºæ¥å—è…¦è„Šé«“æ¶²æŠ¹ç‰‡æª¢æŸ¥å¦‚åœ–ï¼Œé—œæ–¼æ­¤ç—…ç—‡ä¹‹æ²»ç™‚åŠæ„ŸæŸ“ç®¡åˆ¶æªæ–½ä½•è€…ç‚ºéŒ¯èª¤çš„?  #medicine/meningococcus  #medicine/CNS <br />
A. æ‡‰æ–¼24å°æ™‚å…§é€šå ±,ä¸¦å¼·åˆ¶éš”é›¢æ²»ç™‚<br />
B. ç—…äººé ˆæ¡å–é£›æ²«éš”é›¢è‡³æŠ—ç”Ÿç´ æœ‰æ•ˆæ²»ç™‚24å°æ™‚å¾Œæ‰èƒ½è§£é™¤éš”é›¢<br />
C. è¦ªå¯†æ¥è§¸è€…é ˆæŠ•ä»¥é é˜²æ€§ç”¨è—¥<br />
<mark>D. å¸¸ç”¨ä¹‹é é˜²æ€§ç”¨è—¥ä»¥Erythomycinç‚ºä¸»</mark>  <code>rifampin</code><br />
E. ä¸€èˆ¬ç’°å¢ƒä½¿ç”¨0.06%æ¼‚ç™½æ°´æ“¦æ‹­  </p>
</li>
<li>
<p>ä¸€ä½34æ­²é•·æœŸä½¿ç”¨éœè„ˆæ³¨å°„æµ·æ´›è‹±çš„ç”·æ€§ï¼Œå› ç™¼ç‡’ã€å–˜ã€å‘¼å¸å›°é›£ä¸€é€±ä¾†æ€¥è¨ºå°±è¨ºï¼Œèº«é«”è¨ºå¯Ÿæœ‰ç™¼ç¾æ”¶ç¸®æœŸå¿ƒé›œéŸ³ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…ç‚ºéï¼Ÿ #medicine/IE <br />
    (1) æ„ŸæŸ“åŸæœ€å¸¸è¦‹ç‚ºé‡‘é»ƒè‰²è‘¡è„çƒèŒ(Staphylococcus aureus)<br />
    (2) æ­¤S. aureus æ¥µå°‘ç‚ºmethicillinæŠ—è—¥(MRSA)æ€§èŒæ ª<br />
    (3) æ­¤å³å¿ƒå¿ƒå…§è†œç‚ï¼Œä»¥ä¸‰å°–ç“£(tricuspid valve)ç‚ºä¸»è¦ä¾µçŠ¯ä½ç½®<br />
    (4) ç›¸å°æ–¼ééœè„ˆè—¥ç™®å¿ƒå…§è†œç‚ï¼Œæ­¤ç—…äººè‡´ç—…åŸæ›´å¸¸æœ‰ç¶ è†¿æ¡¿èŒ(Pseudomonas aeruginosa)æˆ–å¿µç èŒ(Candida)æ„ŸæŸ“çš„æ©Ÿæœƒ<br />
    (5) è‹¥ç‚ºHIVæ„ŸæŸ“è€…ï¼Œè‡´ç—…åŸå‡ºç¾HACEK groupçš„æ©Ÿæœƒè¼ƒé«˜<br />
A. (1)+(2)+(3)<br />
B. (1)+(3)+(5)<br />
C. (4)+(5)<br />
<mark>D. (2)+(5)</mark><br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>ä¸€ä½53æ­²å¥³æ€§, 8æœˆ15æ—¥å› ç‚ºé«˜ç‡’ã€ç•å¯’ã€é ­ç—›ã€è‚Œè‚‰ç— ç—›è€Œåˆ°æ€¥è¨ºå®¤æ±‚æ²»,æŠ½è¡€æª¢é©—ç™½è¡€çƒ13500/cummã€ä¸­æ€§ç™½è¡€çƒ86%ã€è¡€å°æ¿56000/cummã€AST 176 U/Lã€ALT 152 U/Lã€Cr 1.4 mg/dLã€CRP 10mg/dLã€è¡€æ¶²åŸ¹é¤Šé™°æ€§, å¥¹å’Œä¸€ç¾¤åŒä¼´å–œå¥½æ²³å·æ¸¸æ³³ã€‚è«‹å•ä¸‹åˆ—å“ªé …è·æ¥­æœ€ä¸å®¹æ˜“å¾—åˆ°é€™å€‹ç–¾ç—…?  #medicine/Leptospira <br />
A. ç¸é†«<br />
B. è¾²å¤«<br />
C. å± å®°å ´å·¥äºº<br />
<mark>D. å…¬è»Šå¸æ©Ÿ</mark><br />
E. æ±™æ°´é“å·¥äºº  </p>
</li>
<li>
<p>ä¸€ä½å»šå¸«ï¼Œåœ¨æ¸…ç†å»šé¤˜æ™‚ä¸æ…è¢«è€é¼ (Rodent)å’¬å‚·è…³è¶¾ï¼Œå¹¾å¤©å¾Œé–‹å§‹å‡ºç¾é«˜ç‡’ã€ç•å¯’ã€é ­ç—›ã€å››è‚¢ç–¼ç—›ã€æ·‹å·´è…«è„¹ã€è¡€æ¶²ç´°èŒåŸ¹é¤Šæœ‰å ±å‘Šé•·èŒï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…ç‚ºéï¼Ÿ  #medicine/SSTI <br />
A. è‡´ç—…åŸç‚ºStreptobacillus moniliformisæˆ–Pasteurella multocida<br />
<mark>B. æ­¤æ„ŸæŸ“è‡´ç—…èŒå±¬æ–¼é©è˜­æ°é™½æ€§æ¡¿èŒ(Gram positive bacilli)</mark><br />
C. æ­¤èŒç”Ÿé•·ç·©æ…¢ï¼Œå¯èƒ½éœ€è¦3è‡³7å¤©åŸ¹é¤Šæ‰æœƒé¤Šå‡º<br />
D. è‹¥å°æ–¼Penicillinæœ‰éæ•ï¼Œå¯ä»¥ä½¿ç”¨doxycycline<br />
E. è‡´ç—…åŸäº¦å¯ç‚ºLeptospiraï¼Œå¯åˆ©ç”¨è¡€æ¸…æŠ—é«”åŠ›åƒ¹è¨ºæ–·  </p>
</li>
<li>
<p>ä¸€ä½20 æ­²ç”·æ€§ç—…æ‚£ï¼Œç™¼ç‡’æ•¸å¤©ä½é™¢æ²»ç™‚ï¼Œæœªä½¿ç”¨beta-blockerï¼Œä½é™¢ç”Ÿå‘½å¾µè±¡ç‚ºé«”æº«38.5è‡³39.5åº¦Cã€å¿ƒè·³æ¯åˆ†é˜70è‡³80ä¸‹ï¼Œè«‹å•ä¸Šè¿°ç´€éŒ„ç‚ºä¸‹åˆ—å“ªäº›ç–¾ç—…ä¹‹è‡¨åºŠè¡¨å¾µ? (1). æ²™é–€æ°èŒ(Salmonella typhi) (2). é€€ä¼è»äººèŒ(Legionella) (3). ç«‹å…‹æ¬¡é«”(Rickettsia) (4). æµæ„Ÿç—…æ¯’(Influenza) #medicine/fever <br />
A. (1)+(3)<br />
B. (2)+(3)<br />
C. (3)+(4)<br />
<mark>D. (1)+(2)+(3)</mark><br />
E. (1)+(2)+(3)+(4)  </p>
</li>
<li>
<p>æœ‰é—œä¸­æ±å‘¼å¸ç—‡ç‹€ç¾¤å† ç‹€ç—…æ¯’æ„ŸæŸ“ç—‡(MERS-CoV)ï¼Œä¸‹åˆ—ä½•è€…æ•˜è¿°ç‚ºéï¼Ÿ #medicine/EID <br />
A. å‚³æŸ“é€”å¾‘ç‚ºé£›æ²«åŠæ¥è§¸å‚³æŸ“ï¼Œæ½›ä¼æœŸç´„ç‚º7è‡³14å¤©ï¼Œå·²æœ‰å‡ºç¾å±€é™æ€§äººå‚³äººçš„ç¾¤èšæ„ŸæŸ“äº‹ä»¶<br />
B. ä¸­æ±å‘¼å¸ç—‡ç‹€ç¾¤å† ç‹€ç—…æ¯’æ„ŸæŸ“ç—‡è‡¨åºŠè¡¨ç¾åŒ…æ‹¬ç™¼ç‡’ã€å’³å—½ã€å‘¼å¸æ€¥ä¿ƒèˆ‡å‘¼å¸å›°é›£ã€é€šå¸¸æœƒæœ‰è‚ºç‚ï¼Œéƒ¨åˆ†ç—…äººæœƒå‡ºç¾è…è¡°ç«­ã€å¿ƒåŒ…è†œç‚ã€è¡€ç®¡å…§ç€°æ¼«æ€§å‡è¡€(DIC)æˆ–æ­»äº¡<br />
<mark>C. ç—…æ‚£å°±é†«æˆ–é€²è¡Œæª¢æŸ¥æ™‚ï¼Œç—…æ‚£éœ€å¼·åˆ¶é…æˆ´N95å£ç½©ï¼Œä½é™¢é‡ç—‡æ’ç®¡ç—…æ‚£æ­»äº¡ç‡ç´„ç‚º10%è‡³12%</mark><br />
D. ç—…æ‚£æ‡‰å…¥ä½è² å£“éš”é›¢ç—…å®¤ï¼Œè‹¥ç„¡è² å£“éš”é›¢ç—…å®¤å¯æš«æ™‚å®‰ç½®æœ‰è¡›æµ´è¨­å‚™çš„å–®äººç—…å®¤ï¼Œä¸”ç—…å®¤æˆ¿é–€æ‡‰ç¶­æŒé—œé–‰<br />
E. ç›®å‰ä»ç„¡æœ‰æ•ˆæ²»ç™‚è—¥ç‰©ï¼Œä¸»è¦ä»¥æ”¯æŒæ€§ç™‚æ³•ç‚ºä¸»  </p>
</li>
<li>
<p>æœ‰é—œç™¼ç‡’ã€çš®ç–¹(skin rashes)ä¹‹ç–¾ç—…èˆ‡è‡´ç—…åŸä¹‹é…å°ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…ç‚ºéï¼Ÿ<br />
A. Measles (éº»ç–¹) - Paramyxovirus<br />
B. Rubella (å¾·åœ‹éº»ç–¹) - Togavirus<br />
<mark>C. Erythema infectiosum (ç¬¬äº”ç—…)-Â Coxsackievirues A9</mark>Â  <code>Parvo B19</code><br />
D. Roseola (ç«ç‘°ç†±ã€ç¬¬å…­ç—…) - Human herpesvirus 6<br />
E. Dengue fever (ç™»é©ç†±) â€“ Flaviviruses  </p>
</li>
<li>
<p>è¿‘å¹´åˆèˆˆèµ·éº»ç–¹ç¾¤èšç–«æƒ…ï¼Œç›¸é—œæ•˜è¿°è«‹é¸å‡ºæœ€æ­£ç¢ºä¹‹çµ„åˆã€‚Â  #medicine/measles  #medicine/EID <br />
    (1) å‚³çµ±åˆæ¬¡æ„ŸæŸ“éº»ç–¹çš„è‡¨åºŠè¡¨ç¾åŒ…æ‹¬å…¨èº«æ€§çš®è†šæ–‘ä¸˜ç–¹ï¼Œç™¼ç‡’38.3Â°Cä»¥ä¸Šï¼Œä»¥åŠcoryzaï¼Œcoughæˆ–conjunctivitisï¼Œè€Œæ›¾æ–½æ‰“éç–«è‹—è€…å¾—åˆ°éº»ç–¹å‰‡ç—‡ç‹€å¸¸å‘ˆç¾ä¸å…¸å‹Â <br />
    (2) éº»ç–¹è¿„ä»Šä¸¦ç„¡æŠ—ç—…æ¯’è—¥ç‰©å¯æ²»ç™‚ï¼Œè‡¨åºŠè™•ç†æ¡æ”¯æŒæ€§æ²»ç™‚å¦‚æ°´ä»½å’Œé€€ç‡’è—¥ã€‚è€Œvitamin Aæ²»ç™‚å¯é™ä½éº»ç–¹morbidityå’ŒmortalityÂ <br />
    (3) éº»ç–¹åš´é‡åˆä½µç—‡åŒ…æ‹¬ç—…æ¯’ç›´æ¥ä¾µçŠ¯å‘¼å¸é“åŠçºŒç™¼æ€§ç´°èŒæ„ŸæŸ“é€ æˆè‚ºç‚æˆ–ä¸­è€³ç‚ã€‚æ¥µåš´é‡çš„è…¦è„Šé«“ç‚ç™¼ç”Ÿç‡ç´„ç‚ºåƒåˆ†ä¹‹ä¸€Â <br />
    (4) é†«è­·äººå“¡è‹¥10è‡³15å¹´å…§æœ‰æ‰“éMMRç–«è‹—ï¼Œåœ¨æœªé˜²è­·æƒ…æ³æš´éœ²åˆ°å¸¶ç—…æ¯’é‡è¼ƒé«˜çš„å…ç–«æŠ‘åˆ¶æ‚£è€…ï¼Œä¸å¿…æ“”å¿ƒé­å—æ„ŸæŸ“Â <br />
    (5) æ€¥æ€§IgMè‹¥å‘ˆé™°æ€§ï¼Œä¹Ÿä¸å¯æ’é™¤æ„ŸæŸ“ï¼Œè€Œé¼»å’½æ‹­å­PCRæª¢æ¸¬ä¹‹é™½æ€§ç‡æœƒæ›´é«˜ã€‚<br />
A. (1)+(3)+(5)<br />
B. (1)+(2)+(3)<br />
C. (1)+(2)+(3)+(4)<br />
<mark>D. (1)+(2)+(3)+(5)</mark><br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>æœ‰é—œç™»é©ç†±çš„æè¿°ï¼Œæœ€æ­£ç¢ºçš„çµ„åˆç‚ºä¸‹åˆ—ä½•è€…?Â  #medicine/dengue  #medicine/EID <br />
    (1) ç™¼ç–¹ç´„åœ¨é ­ç—›ã€ç™¼ç‡’ç¬¬4è‡³ç¬¬7æ—¥ï¼Œå¾è»€å¹¹æ•£è‡³é ­éƒ¨åŠå››è‚¢ã€‚Â <br />
    (2) ç™¼ç–¹æ¬¡åºå’Œéº»ç–¹é¡ä¼¼ã€‚Â <br />
    (3) çš®ç–¹å‡ºç¾æ™‚ï¼Œè¡€å°æ¿ã€ç™½è¡€çƒæ•¸ç›®ç´„é™è‡³æœ€ä½é»ï¼Œè€Œå¾Œå†é€æ¼¸å›å‡ã€‚Â <br />
    (4) çš®ç–¹åˆç™¼é¡è‰²è¼ƒæ½®ç´…ï¼Œè€Œå¾Œæ¼¸æš—æ¶ˆé€€ï¼Œç´„4-7å¤©æ‰æ¶ˆå¤±ã€‚Â <br />
    (5) ç´„æœ‰50%è‡³90%çš„ç—…äººæ„ŸæŸ“ç—‡ç‹€ä¸æ˜é¡¯ã€‚<br />
A. (1)+(2)+(3)+(4)<br />
<mark>B. (1)+(3)+(4)+(5)</mark><br />
C. (1)+(2)+(3)+(4)+(5)<br />
D. (3)+(4)+(5)<br />
E. (1)+(2)+(3)  </p>
</li>
<li>
<p>æš´éœ²å¾Œé é˜²å»ºè­°ä½¿ç”¨æŠ—å¾®ç”Ÿç‰©è£½åŠ‘è€…ï¼Œè«‹é¸å‡ºæœ€é©ç•¶çš„ç­”æ¡ˆï¼Ÿ #medicine/HIV #medicine/influenza #medicine/meningococcus #medicine/CNS <br />
    (1) HIV<br />
    (2) éº»ç–¹<br />
    (3) COVID-19<br />
    (4) Influenza<br />
    (5) Meningococcus<br />
A. (1)+(2)+(4)<br />
B. (1)+(3)+(4)<br />
<mark>C. (1)+(4)+(5)</mark><br />
D. (1)+(3)+(4)+(5)<br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>æœ‰ä¸€ä½30æ­²å­•å©¦ï¼Œæƒ³ä¾†é–€è¨ºæ–½æ‰“ç–«è‹—é é˜²æ„ŸæŸ“ï¼Œä¸‹åˆ—é‚£äº›ç–«è‹—æ˜¯å­•å©¦ä¸å»ºè­°æ³¨å°„çš„ï¼Ÿ #medicine/vaccine <br />
    (1) Influenza vaccine æµæ„Ÿç–«è‹—<br />
    (2) MMR vaccine (Measles â€“ Mump â€“ Rubella vaccine) éº»ç–¹-è…®è…ºç‚-å¾·åœ‹éº»ç–¹ç–«è‹—<br />
    (3) Varicella vaccine æ°´ç—˜ç–«è‹—<br />
    (4) Pneumococcal vaccine è‚ºç‚éˆçƒèŒç–«è‹—<br />
A. (1)+(3)<br />
<mark>B. (2)+(3)</mark><br />
C. (1)+(4)<br />
D. (1)+(2)+(3)<br />
E. (2)+(3)+(4)  </p>
</li>
<li>
<p>é—œæ–¼çµæ ¸ç—…è—¥ç‰©å‰¯ä½œç”¨çš„è™•ç†åŸå‰‡ï¼Œä¸‹åˆ—å“ªäº›æ•˜è¿°æ˜¯æ­£ç¢ºçš„ï¼Ÿ #medicine/TB <br />
    (1) è¡€ä¸­å°¿é…¸å¢é«˜æ™‚ï¼ŒåŒæ™‚æœç”¨allopurinolï¼Œé™å°¿é…¸æ•ˆæœé€šå¸¸å¾ˆé¡¯è‘—<br />
    (2) å› åš´é‡çš®è†šå‰¯ä½œç”¨è€Œä¸­æ–·æ²»ç™‚è€…ï¼Œå¾…å‰¯ä½œç”¨æ¶ˆå¤±å¾Œï¼Œæ‡‰è€ƒæ…®ç”±ä½åŠ‘é‡è‡³é«˜åŠ‘é‡é€ä¸€åŠ å…¥æŠ—çµæ ¸è—¥ç‰©<br />
    (3) åš´é‡å‰¯ä½œç”¨æ™‚ï¼Œä¾‹å¦‚è‚ç‚ã€åš´é‡è¦–åŠ›æ¨¡ç³Šã€åš´é‡è¡€çƒé™ä½ã€åš´é‡çš®è†šå‰¯ä½œç”¨æ™‚ï¼Œæ‡‰åŒæ™‚åœæ­¢æ‰€æœ‰æŠ—çµæ ¸è—¥ç‰©æ²»ç™‚Â <br />
    (4) è…¸èƒƒä¸é©ã€çš®ç–¹ã€æ”ç™¢ã€é—œç¯€ç— ç—›ç­‰å‰¯ä½œç”¨ï¼Œé€šå¸¸åœ¨æœç”¨æŠ—çµæ ¸è—¥ç‰©å…©å‘¨å¾Œæœƒè‡ªç„¶æ¸›è¼•ã€‚å› æ­¤ï¼Œè‹¥ç—‡ç‹€ä¸åš´é‡ï¼Œæ‡‰çµ¦äºˆç—…äººé©ç•¶è¡›æ•™ã€å¿ƒç†æ²»ç™‚ï¼Œå¿…è¦æ™‚çµ¦äºˆè—¥ç‰©ç—‡ç‹€æ²»ç™‚å³å¯<br />
A. (1)+(2)+(3)+(4)<br />
B. (1)+(2)+(3)<br />
C. (1)+(2)+(4)<br />
D. (1)+(3)+(4)<br />
<mark>E. (2)+(3)+(4)</mark>  </p>
</li>
<li>
<p>ä¸€ä½60æ­²å¥³æ€§å› ç‚ºå‘¼å¸æ€¥ä¿ƒå’Œè…³è…«æ–¼1å¤©å‰è¢«é€åˆ°æ€¥è¨ºå®¤ï¼Œè‡¨åºŠåˆ¤æ–·ç‚ºå¤±å„Ÿæ€§(decompensated)å¿ƒè¡°ç«­ï¼Œå¥¹æ¥å—å°å°¿ç®¡ç½®æ”¾ï¼Œéœè„ˆæ³¨å°„çµ¦äºˆåˆ©å°¿åŠ‘å¹¶ä½é™¢ã€‚å¥¹æœ‰é«˜è¡€å£“ã€ç³–å°¿ç—…å’Œæ…¢æ€§è…ç—…ç­‰æ½›åœ¨ç–¾ç—…ã€‚å¥¹æ‰€ä½¿ç”¨çš„è—¥ç‰©åŒ…æ‹¬aspirinï¼Œcarvedilolï¼Œinsulinï¼Œlisinoprilï¼Œrosuvastatinï¼Œspironolactoneå’Œè¦–éœ€è¦ç”¨furosemideã€‚èº«é«”è¨ºå¯Ÿé«”æº«36.5Â°Cï¼Œè¡€å£“128/72 mmHgï¼Œå¿ƒè·³96/minï¼Œå‘¼å¸18/minï¼Œè½è¨ºè‚ºéƒ¨é›™å´åŸºåº•æœ‰å›‰éŸ³ï¼Œå¿ƒéŸ³æœ‰S3ï¼ŒäºŒå´ä¸‹è‚¢æœ‰ç¬¬äºŒåº¦æ°´è…«ï¼Œç”±å°¿ç®¡æµå‡ºçš„å°¿æ¶²æ˜¯æ¸…æ¾ˆçš„ï¼Œå¯¦é©—å®¤æª¢æŸ¥è¡€æ¸…Creatinine 2.8 mg/dLã€‚ è«‹å•æ­¤æ™‚å°ç—…äººå°å°¿ç®¡æœ€æ°ç•¶çš„è™•ç†ç‚ºä½•? #medicine/IC <br />
A. ä¸‰å¤©å¾Œæ‹”å°å°¿ç®¡<br />
B. æ›ä¸€æ”¯å°å°¿ç®¡<br />
<mark>C. æ‹”æ‰å°å°¿ç®¡</mark><br />
D. ç•¶è…åŠŸèƒ½å›å¾©åˆ°ç—…äººåŸºç¤å€¼æ™‚æ‹”å°å°¿ç®¡<br />
E. ç­‰å‡ºé™¢å†æ‹”å°å°¿ç®¡  </p>
</li>
<li>
<p>ç‚ºé™ä½é†«ç™‚æ©Ÿæ§‹å…§å¤šé‡æŠ—è—¥æ€§ç—…åŸä¹‹äº¤å‰æ„ŸæŸ“ï¼Œå€¡å°é†«è­·äººå“¡æ‰‹éƒ¨è¡›ç”Ÿï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢º?Â  #medicine/IC <br />
    (1) ä½¿ç”¨é…’ç²¾æ€§ä¹¾æ´—æ‰‹æ¶²é€²è¡Œæ‰‹éƒ¨è¡›ç”Ÿï¼Œåœ¨æ¸…æ½”æ•ˆæœã€ä½¿ç”¨æ™‚æ©Ÿã€èŠ±è²»æ™‚é–“ã€å°çš®è†šçš„å½±éŸ¿ã€ å®‰å…¨è€ƒé‡åŠæ´—æ‰‹éµå¾æ€§ç­‰æ–¹é¢ï¼Œå‡æ¯”ä½¿ç”¨è‚¥çš‚æˆ–æ¶²æ…‹çš‚é€²è¡Œæ¿•æ´—æ‰‹çš„æ•ˆæœç‚ºä½³Â <br />
    (2) é†«è­·äººå“¡åœ¨æ‰‹éƒ¨ç„¡æ˜é¡¯é«’æ±™æ™‚ï¼Œå„ªå…ˆä½¿ç”¨é…’ç²¾æ€§ä¹¾æ´—æ‰‹æ¶²æ¸…æ½”æ‰‹éƒ¨Â <br />
    (3) æ‰‹éƒ¨æœ‰æ˜é¡¯é«’æ±™æˆ–æ²¾æœ‰è¡€æ¶²/é«”æ¶²æ™‚ï¼Œä½¿ç”¨è‚¥çš‚å’Œæ¸…æ°´ä¹‹æ¿•æ´—æ‰‹15ç§’Â <br />
    (4) åœ¨ç…§è­·é»æ™®éè¨­ç½®æˆ–éš¨èº«æ”œå¸¶é…’ç²¾æ€§ä¹¾æ´—æ‰‹æ¶²Â <br />
    (5) é…’ç²¾æ€§ä¹¾æ´—æ‰‹æ¶²å°è«¾ç¾…ç—…æ¯’(norovirus)ã€è…¸ç—…æ¯’å’ŒClostridium difficileçš†æœ‰å¾ˆå¥½ä¹‹æ¶ˆæ¯’æ•ˆæœ<br />
A. (1)+(2)+(3)+(4)+(5)<br />
<mark>B. (1)+(2)+(4)</mark><br />
C. (2)+(4)+(5)<br />
D. (2)+(3)+(4)<br />
E. (1)+(3)+(4)  </p>
</li>
<li>
<p>æœ‰é—œæŠ—ç”Ÿç´ ä¹‹æè¿°ï¼Œä¸‹åˆ—å“ªä¸€é …ä¸æ­£ç¢º? #medicine/antibiotics <br />
A. Fluoroquinoloneé¡æŠ—ç”Ÿç´ åœ¨QTc prolongationçš„ç—…äººç”¢ç”Ÿå¿ƒå¾‹ä¸æ•´çš„é¢¨éšªå¢åŠ <br />
B. è€å¹´äººå’ŒåŒæ™‚ç”¨steroidçš„äººä½¿ç”¨fluoroquinoloneæœƒå¢åŠ tendinitiså‰¯ä½œç”¨ä¹‹é¢¨éšª<br />
C. æ‡·å­•å©¦äººä¸å»ºè­°ä½¿ç”¨streptomycinï¼Œtetracyclineæˆ–tigecycline (category D)<br />
D. ä½¿ç”¨ceftriaxoneä¸å¯åŠ å…¥å«éˆ£ä¹‹é»æ»´æ³¨å°„æ¶²<br />
==E. Fluoroquinoloneå°MRSAåŠVREæ²»ç™‚æ•ˆæœè‰¯å¥½ ==  </p>
</li>
<li>
<p>æœ‰é—œæ„ŸæŸ“æ€§ä¸»å‹•è„ˆç‚(infective aortitis)çš„æè¿°,ä¸‹åˆ—ä½•è€…éŒ¯èª¤ï¼Ÿ #medicine/syphilis  #medicine/STD <br />
(1) ç´°èŒæ„ŸæŸ“æ€§ä¸»å‹•è„ˆç‚é€ æˆæ„ŸæŸ“æ€§å‹•è„ˆç˜¤(mycotic aneurysm)å¥½ç™¼éƒ¨ç‚ºåœ¨infrarenal abdominal aorta<br />
(2) ç´°èŒæ„ŸæŸ“æ€§ä¸»å‹•è„ˆç‚é€ æˆæ„ŸæŸ“æ€§å‹•è„ˆç˜¤å¥½ç™¼æ–¼å¹´è¼•äºº<br />
(3) ç´°èŒæ„ŸæŸ“æ€§ä¸»å‹•è„ˆç‚é€ æˆæ„ŸæŸ“æ€§å‹•è„ˆç˜¤å¥½ç™¼æ–¼ç”·æ€§<br />
(4) æ¢…æ¯’æ€§ä¸»å‹•è„ˆç‚(syphilitic aortitis) å¥½ç™¼æ–¼å‡ä¸»å‹•è„ˆ(ascending aorta)ï¼Œå°¤å…¶æ˜¯ä¸»å‹•è„ˆæ ¹éƒ¨(aortic root)<br />
(5) æ¢…æ¯’æ€§ä¸»å‹•è„ˆç‚æœƒé€ æˆè¡€ç®¡æ»‹é¤Šç®¡ (vasa vasorum) çš„é–‰å¡æ€§å‹•è„ˆå…§è†œç‚( obliterative endarteritis)<br />
<mark>A. (1)+(2)</mark><br />
B. (2)+(3)<br />
C. (2)+(4)<br />
D. (1)+(4)<br />
E. (3)+(5)  </p>
</li>
</ol>
<p>%%<br />
28. ä¸€ä½50æ­²ä¹‹å¥³æ€§ç—…æ‚£ï¼Œ10å¤©å‰åˆ°æ±å—äºæ—…éŠæ›¾ç”Ÿé£Ÿæµ·é®®ï¼Œè¿”åœ‹å¾Œç™¼ç”Ÿè…¹ç€‰è…¹ç—›ï¼ŒæŠ½è¡€æª¢æŸ¥ç™¼ç¾è¡€æ¶²å—œä¼Šç´…æ€§ç™½çƒç•°å¸¸å¢åŠ (WBC 7800/mm3ã€eosinophil 38%)ï¼Œè«‹å•æœ€å¯èƒ½æ˜¯ä¸‹åˆ—ä½•ç¨®ç—…åŸ?<br />
<mark>A. Capillaria (é­æ¯›èŸ²)</mark><br />
B. Ascaris (è›”èŸ²)<br />
C. Strongyloides (ç³å°æ¡¿ç·šèŸ²)<br />
D. Hookworm (é‰¤èŸ²)<br />
E. Cryptosporidium (éš±å­¢å­èŸ²)  <br />
%%  </p>
<ol>
<li>
<p>ä¸‹åˆ—é—œæ–¼HIVæ„ŸæŸ“èˆ‡è…«ç˜¤çš„é—œä¿‚ä½•è€…éŒ¯èª¤ï¼Ÿ #medicine/HIV <br />
A. Kaposiâ€™s sarcomaèˆ‡Human Herpes virus â€“ 8 (HHV-8) çš„æ„ŸæŸ“æœ‰é—œ<br />
B. Anogenital carcinomaèˆ‡Human papilloma virus (HPV) çš„æ„ŸæŸ“æœ‰é—œ<br />
C. Primary CNS lymphoma (åŸç™¼æ€§ä¸­æ¨ç¥ç¶“æ·‹å·´ç˜¤) èˆ‡Epstein-Barr virus ( EBV )çš„æ„ŸæŸ“æœ‰é—œ<br />
<mark>D. Burkittâ€™s lymphomaèˆ‡Cytomegalovirus ( CMV ) çš„æ„ŸæŸ“æœ‰é—œä¿‚</mark>  <code>EBV</code><br />
E. HIVæ„ŸæŸ“ç›¸é—œä¹‹lymphomaä¸»è¦æ˜¯B cell lymphoma  </p>
</li>
<li>
<p>é–€è¨ºä¾†äº†ä¸€ä½70æ­²å¥³æ€§ï¼Œå¥¹å…ˆç”Ÿ3å€‹æœˆå‰ç¢ºè¨ºé–‹æ”¾æ€§è‚ºçµæ ¸ï¼Œå¥¹æ–¼2å€‹æœˆå‰ç…§ä¸€å¼µèƒ¸éƒ¨Xå…‰ç„¡ç•°å¸¸ç‹€æ³ï¼Œå¥¹ç¾åœ¨æ²’ä»»ä½•ç—‡ç‹€ã€‚ä»¥ä¸‹ä½•è€…æ­£ç¢ºï¼Ÿ #medicine/TB <br />
A. å¹«å¥¹å®‰æ’èƒ¸éƒ¨Xå…‰æª¢æŸ¥ï¼Œè‹¥æ­£å¸¸ï¼Œå‰‡ç¹¼çºŒå®šæœŸè¿½è¹¤<br />
B. å¹«å¥¹å®‰æ’èƒ¸éƒ¨Xå…‰æª¢æŸ¥ï¼Œç™¼ç¾å³ä¸‹è‚ºæœ‰æµ¸æ½¤ç¾è±¡ï¼Œçµ¦äºˆè™•æ–¹levofloxacinæ²»ç™‚7-10å¤©<br />
<mark>C. å¹«å¥¹å®‰æ’èƒ¸éƒ¨Xå…‰æª¢æŸ¥ï¼Œç„¡ç•°å¸¸ç™¼ç¾ï¼Œå¯å†å®‰æ’ä¸™å‹å¹²æ“¾ç´ é‡‹å‡ºåˆ†æ(inferferon-Î³ release assay)æª¢æ¸¬ï¼Œä»¥åšç‚ºæ½›ä¼çµæ ¸æ²»ç™‚æ±ºç­–ä¹‹åƒè€ƒ</mark><br />
D. ç›´æ¥å®‰æ’ä¸™å‹å¹²æ“¾ç´ é‡‹å‡ºåˆ†ææª¢æ¸¬ï¼Œè‹¥ç‚ºé™½æ€§çµæœï¼Œç¶“ç—…äººåŒæ„å¯ç›´æ¥çµ¦äºˆæ½›ä¼çµæ ¸æ²»ç™‚è™•æ–¹<br />
E. å¹«å¥¹å®‰æ’èƒ¸éƒ¨Xå…‰æª¢æŸ¥ï¼Œç™¼ç¾å³ä¸‹è‚ºæœ‰æµ¸æ½¤ç¾è±¡ï¼Œè’é›†ç—°æ¶²acid fast stainé™°æ€§ï¼Œç¹¼çºŒå®šæœŸè¿½è¹¤å³å¯  </p>
</li>
<li>
<p>ä½ æ”¶ç™‚çš„ç™»é©ç†±æ‚£è€…å³å°‡å‡ºé™¢ï¼Œé—œæ–¼å‡ºé™¢è¡›æ•™ï¼Œä»¥ä¸‹ä½•è€…æ­£ç¢ºï¼Ÿ #medicine/dengue  #medicine/EID <br />
A. ç™»é©ç†±å¸¸ç™¼ç”Ÿåœ¨ç†±å¸¶åŠäºç†±å¸¶åœ°å€ï¼Œåœ¨å°ç£ä¸»è¦ç—…åª’èšŠç‚ºç˜§èšŠå’Œç™½ç·šæ–‘èšŠ<br />
B. å¾—éç™»é©ç†±ä¹‹å¾Œå³æœƒå‡ºç¾ä¿è­·æ€§æŠ—é«”ï¼Œå°ç™»é©ç†±çµ‚ç”Ÿå…ç–«<br />
<mark>C. ç™»é©ç†±ä¸€å…±æœ‰4å‹ï¼Œç›®å‰èªç‚ºç¬¬ä¸€æ¬¡æ„ŸæŸ“ç™»é©ç†±ç—…æ¯’å¾Œé«”å…§è‡ªç„¶ç”¢ç”Ÿçš„æŠ—é«”ï¼Œå¯èƒ½æœƒåœ¨æ„ŸæŸ“å…¶ä»–å‹åˆ¥ç™»é©ç†±æ™‚é€ æˆã€ŒæŠ—é«”ä¾è³´æ€§å…ç–«åŠ å¼·åæ‡‰ã€(antibody dependent enhancement; ADE)ï¼Œé€ æˆåš´é‡çš„ä½µç™¼ç—‡</mark><br />
D. ç™»é©å‡ºè¡€ç†± (dengue hemorrhagic fever) èˆ‡ç™»é©ç†±ä¼‘å…‹ç—‡å€™ç¾¤ (dengue shock syndrome) åƒ…æœƒå‡ºç¾åœ¨ç¬¬ä¸€å‹ç™»é©ç†±ï¼Œæ‰€ä»¥è‹¥æ›¾å¾—éç™»é©å‡ºè¡€ç†±ï¼Œå°±æœƒçµ‚ç”Ÿå…ç–«äº†<br />
E.Â ç™»é©ç†±4æ•ˆåƒ¹æ¸›æ¯’æ´»ç–«è‹—Â (Sanofi)Â å»ºè­°ä½¿ç”¨æ–¼æœªæ›¾æ„ŸæŸ“éç™»é©ç†±çš„äºº  </p>
</li>
<li>
<p>æœ‰é—œè…¸çƒèŒèˆ‡æŠ—ç”Ÿç´ ä¹‹æ•˜è¿°ï¼Œè«‹é¸å‡ºæœ€æ­£ç¢ºçš„ç­”æ¡ˆ #medicine/antibiotics <br />
    (1) VancomycinæŠ—è—¥æ€§è…¸çƒèŒ (VRE) æœ€å¸¸è¦‹çš„èŒç¨®æ˜¯Enterococcus faecium<br />
    (2) Enterococcus faecalisèŒè¡€ç—‡é€šå¸¸ä»¥ vancomycinæ²»ç™‚<br />
    (3) Enterococcus faecailsæ„ŸæŸ“çš„é¦–é¸æ²»ç™‚é€šå¸¸æ˜¯ ampicillin<br />
    (4) VREçš„åš´é‡æ„ŸæŸ“å¸¸éœ€ä½¿ç”¨linezolidæˆ–daptomycinæ²»ç™‚<br />
    (5) å°¿æ¶²åŸ¹é¤Šæˆ–ç—°æ¶²åŸ¹é¤Šæœ‰VREï¼Œéœ€ä½¿ç”¨linezolidæ²»ç™‚<br />
A. (1)+(2)<br />
B. (1)+(3)<br />
C. (2)+(4)<br />
<mark>D. (1)+(3)+(4)</mark><br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>åŠ è­·ç—…æˆ¿æ´—æ°´æ§½åŒæ™‚ä½¿ç”¨æ–¼æ±™æŸ“ç‰©æ¸…æ´—å’Œæ´—æ‰‹ç­‰è¡Œç‚ºï¼Œå®¹æ˜“é€ æˆé™¢å…§æ„ŸæŸ“ï¼Œå› æ­¤å»ºè­°æ±™æ°´èˆ‡æ¸…æ½”æ°´æ§½éœ€å€åˆ†æ¸…æ¥šï¼Œç”šè‡³å°‡æ±™æ°´æ§½ç§»å‡ºåŠ è­·ç—…æˆ¿ï¼Œå¸¸è¦‹ä¹‹ç—…åŸèŒä¸‹åˆ—ä½•è€…ç‚ºéï¼Ÿ  #medicine/IC <br />
A. Pseudomonas aeruginosa<br />
B. Nontuberculous Mycobacterium<br />
C. Chryseobacterium<br />
D. Stenotrophomonas maltophilia<br />
<mark>E. Aspergillus fumigatus</mark>  </p>
</li>
<li>
<p>ä¸‹åˆ—ç”¨æ–¼æ²»ç™‚methicillin-resistant Staphylococcus aureus (MRSA)ä¹‹æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ #medicine/antibiotics <br />
A. MRSAèˆ‡ methicillin-susceptible Staphylococcus aureus (MSSA) å¿ƒå…§è†œç‚æ­»äº¡ç‡ç›¸è¿‘<br />
B. åªæœ‰é™¢å…§æ„ŸæŸ“æ‰æœ‰MRSAçš„é¢¨éšªï¼Œä¸€èˆ¬ç¤¾å€å‹è‚ºç‚ä¸æ‡‰å°‡MRSAåˆ—å…¥è€ƒé‡<br />
C. Tigecyclineå±¬æ–¼æ®ºèŒå‹è—¥ç‰©ï¼Œå¯ç”¨æ–¼å¿ƒå…§è†œç‚åŠèŒè¡€ç—‡ä¹‹æ²»ç™‚ï¼Œé«˜åŠ‘é‡ä½¿ç”¨é ˆæ³¨æ„è…¸èƒƒé“ç—‡ç‹€<br />
<mark>D. Linezolidé•·æ™‚é–“ä½¿ç”¨å¯èƒ½æœƒé€ æˆè¡€å°æ¿æ•¸é‡é™ä½ï¼Œä¹Ÿå¯èƒ½å¼•ç™¼è¦–ç¥ç¶“ç—…è®Šï¼Œé ˆæ³¨æ„çœ¼åº•æª¢æŸ¥</mark><br />
E. Vancomycinä½¿ç”¨æ™‚åªé ˆç›£æ¸¬è¡€ä¸­ trough æ¿ƒåº¦ï¼Œä»¥è©•ä¼°å…¶ç™‚æ•ˆåŠå‰¯ä½œç”¨  </p>
</li>
<li>
<p>è«‹å•ç´°èŒæ€§è…¦è†œç‚çš„è¨ºæ–·ã€æ²»ç™‚ä»¥ä¸‹ä½•è€…éŒ¯èª¤ï¼Ÿ #medicine/CNS <br />
A. é ˆç›¡å¿«ä½¿ç”¨æŠ—ç”Ÿç´ <br />
B. ç—…äººå¯èƒ½æœƒé ­ç—›ã€ç•å…‰<br />
C. ç¢ºå®šè¨ºæ–·éœ€è…°æ¤ç©¿åˆºï¼Œå°‡è…¦è„Šé«“æ¶²é€åŸ¹é¤Š<br />
D. è…°æ¤ç©¿åˆºå‰é ˆè€ƒæ…®åšé›»è…¦æ–·å±¤é¿å…åŠ é‡å¯èƒ½å·²å‡é«˜ä¹‹è…¦å£“<br />
<mark>E. ä½¿ç”¨è¼ƒå¾Œç·šä¹‹carbapenemé¡æŠ—ç”Ÿç´ å¯é¿å…æ²»ç™‚å¤±æ•—</mark>  </p>
</li>
<li>
<p>æœ‰é—œé é˜²ä¸­å¿ƒéœè„ˆå°ç®¡ç›¸é—œè¡€æµæ„ŸæŸ“ä¹‹å¯¦è­‰ï¼Œä¸‹åˆ—ä½•è€…çµ„åˆç‚ºæ­£ç¢ºï¼Ÿ #medicine/CRBSI <br />
    (1) ä½¿ç”¨æœ€å¤§ç„¡èŒé¢(maximal barrier precautions)åšé˜²è­·<br />
    (2) çš®è†šæ¶ˆæ¯’æ•ˆæœä½¿ç”¨Î²-iodineå„ªæ–¼chlorhexidineÂ <br />
    (3) ç½®æ”¾å°ç®¡å‰å¾Œéœ€åŸ·è¡Œæ‰‹éƒ¨è¡›ç”Ÿ(hand hygiene)<br />
    (4) ä¸­å¿ƒéœè„ˆå°ç®¡ç½®æ”¾æ™‚é–“ä»¥14å¤©ç‚ºåŸå‰‡ï¼Œæ¯14å¤©éœ€å¸¸è¦æ›´æ›ä¸€æ¬¡ï¼Œä»¥é¿å…æ„ŸæŸ“<br />
A. (1)+(2)+(3)+(4)<br />
B. (1)+(2)+(3)<br />
C. (2)+(4)<br />
<mark>D. (1)+(3)</mark><br />
E. (1)+(3)+(4)  </p>
</li>
<li>
<p>æœ‰é—œæŠ—ç”Ÿç´ æ²»ç™‚èˆ‡æ•—è¡€ç—‡è‡´ç—…åŸçš„é…å°,ä¸‹åˆ—å“ªäº›çµ„åˆæ˜¯æ­£ç¢ºçš„ï¼Ÿ #medicine/antibiotics <br />
    (1) Ceftriaxone - Neisseria meningitidisÂ <br />
    (2) Penicillin - Group A StreptococcusÂ <br />
    (3) Clindamycin - RickettsiaÂ <br />
    (4) Ceftazidime- Enterococcus<br />
<mark>A. (1)+(2)</mark><br />
B. (2)+(3)<br />
C. (1)+(3)<br />
D. (2)+(4)<br />
E. (1)+(4)  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œè…«ç˜¤èˆ‡æ„ŸæŸ“è‡´ç—…åŸçš„é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/virus<br />
A. å­å®®é ¸ç™Œ-äººé¡ä¹³çªç—…æ¯’(HPV)<br />
B. å¡æ³¢è¥¿æ°ç˜¤(Kaposiâ€™s sarcoma) â€“äººé¡ç¬¬8å‹çš°ç–¹ç—…æ¯’(HHV-8)<br />
C. Tç´°èƒè¡€ç™Œ(T-cell leukemia) â€“ HTLV-1<br />
D. è‚ç´°èƒç™Œ-Bå‹è‚ç‚(HBV)<br />
<mark>E. è‚›é–€é±—ç‹€ä¸Šçš®ç™Œ(squamous cell carcinoma) â€“ æ„›æ»‹ç—…æ¯’(HIV)</mark>  </p>
</li>
<li>
<p>ä¸€ä½76æ­²å©¦å¥³å› ç¤¾å€æ„ŸæŸ“è‚ºç‚ä½é™¢ï¼Œæ¥å—æ°§æ°£è£œå……ï¼Œæ³¨å°„ceftriaxoneå’Œazithromycinå…±3å¤©ï¼Œè¡€æ¶²åŠç—°æ¶²åŸ¹é¤Šå‡ç„¡ç´°èŒé•·å‡ºã€‚å¥¹æ„Ÿè¦ºæ¯”è¼ƒèˆ’æœï¼Œé£Ÿæ…¾è‰¯å¥½ï¼Œå’³å—½åŠå‘¼å¸æ€¥ä¿ƒéƒ½æ”¹å–„äº†ï¼Œåœ¨ä½é™¢ç¬¬2å¤©å°±é€€ç‡’äº†ã€‚å¥¹æ²’æœ‰å…¶ä»–å…±ç—…ã€‚èº«é«”è¨ºå¯Ÿé«”æº«37.8Â°Cï¼Œè¡€å£“120/74 mmHgï¼Œå¿ƒè·³90/minï¼Œå‘¼å¸18/minï¼Œæœªé¡å¤–çµ¦æ°§æ°£æ™‚æ°§é£½å’Œåº¦ç‚º94%ã€‚å¥¹å‘¼å¸å¹³ç©©ï¼Œè½è¨ºå…©å´è‚ºåŸºåº•å‘¼å¸è²é™ä½ï¼Œå©è¨ºç„¡æ¿éŸ³(dullness)ï¼Œå¿ƒè‡Ÿè¨ºå¯Ÿç„¡ç‰¹æ®Šç™¼ç¾ï¼Œé›™ä¸‹è‚¢ç„¡æ°´è…«ï¼Œå¯¦é©—å®¤æª¢æŸ¥å‘¨é‚Šè¡€ç™½è¡€çƒ13000/cumm(å…¥é™¢æ™‚18000/cumm)ï¼Œç”ŸåŒ–å€¼æ­£å¸¸ã€‚ è«‹å•ä¸‹åˆ—æœ€åˆé©ä¹‹æŠ—ç”Ÿç´ æ²»ç™‚ç‚ºä½•è€…? #medicine/pneumonia <br />
A. æŒçºŒceftriaxoneæ³¨å°„æ²»ç™‚<br />
<mark>B. æ”¹æˆå£æœæŠ—ç”Ÿç´ ä¸¦å‡ºé™¢</mark><br />
C. æ”¹æˆå£æœæŠ—ç”Ÿç´ ä¸¦è§€å¯Ÿ24å°æ™‚<br />
D. æ”¹æˆå£æœæŠ—ç”Ÿç´ ä¸¦èˆ‡æ³¨å°„æŠ—ç”Ÿç´ é‡ç–Š24å°æ™‚<br />
E. åœç”¨æŠ—ç”Ÿç´ ä¸¦å‡ºé™¢  </p>
</li>
<li>
<p>ä¸€ä½83æ­²ç”·æ€§ï¼Œå› ç‚ºå°¿è·¯æ„ŸæŸ“ä½µèŒè¡€ç—‡è€Œä½é€²åŠ è­·ç—…æˆ¿ã€‚ä¸‰å¤©å‰ä»–å› ç‚ºé–“æ–·æ€§ç¥æ™ºæ··äº‚ã€è™›å¼±ï¼Œè§£å°¿ç–¼ç—›å’Œè¡€å°¿è¢«é€åˆ°æ€¥è¨ºï¼Œå› ç‚ºè¡€æµå‹•åŠ›æƒ…æ³ä¸ç©©è€Œå…¥ä½åŠ è­·ç—…æˆ¿ï¼Œå‰›é–‹å§‹æ¥å—éœè„ˆè¼¸æ¶²ï¼Œç¶“é©—æ€§meropenemã€‚ä¸‰å¤©å¾Œä½è¡€å£“å’Œç™¼ç‡’éƒ½ç·©è§£ï¼Œèº«é«”è¨ºå¯Ÿé«”æº«37.6Â°Cï¼Œè¡€å£“120/80 mmHgï¼Œå¿ƒè·³94/minï¼Œå‘¼å¸18/minï¼Œå¿ƒè‡Ÿè¨ºå¯Ÿæ­£å¸¸ï¼Œè…°å´å’Œè…¹éƒ¨ç„¡å£“ç—›ï¼Œå°¿æ¶²åŸ¹é¤ŠEnterococcus faecaliså¤§æ–¼100000èŒè½ï¼Œè€Œè¡€æ¶²åŸ¹é¤Šä¹Ÿæ˜¯E. faecalisï¼ŒæŠ—ç”Ÿç´ æ„ŸæŸ“æ€§è©¦é©—å°ampicillinï¼Œvancomycinå’Œgentamicinå…·æ•æ„Ÿæ€§ã€‚ è«‹å•æ­¤æ™‚ä¸‹åˆ—å“ªä¸€é …æŠ—ç”Ÿç´ æ²»ç™‚æ˜¯é©ç•¶çš„? #medicine/antibiotics <br />
<mark>A. æ”¹æˆampicillin</mark><br />
B. æ”¹æˆampicillinå’Œgentamicin<br />
C. æ”¹æˆvancomycin<br />
D. æ”¹æˆvancomycinå’Œgentamicin<br />
E. ç¹¼çºŒä½¿ç”¨meropenem  </p>
</li>
<li>
<p>ä¸€ä½60æ­²ç”·æ€§å› è…¹ç€‰å’Œç™¼ç‡’3å¤©è€Œä¾†å°±è¨ºï¼Œä»–æ²’æœ‰è…¹ç—›æˆ–å˜”åï¼Œç³ä¾¿æ··æœ‰é»æ¶²ï¼Œä½†æ²’æœ‰çœ‹åˆ°è¡€ä¾¿ï¼Œä»–æ„Ÿè¦ºç–²å‹å’Œé£Ÿæ…¾è®Šå·®ï¼Œä»–å¾äº‹å¸‚å ´å·¥ä½œã€‚èº«é«”è¨ºå¯Ÿé«”æº«38Â°Cï¼Œè¡€å£“146/68 mmHgï¼Œå¿ƒè·³82/minï¼Œå‘¼å¸22/minï¼Œè…¹éƒ¨è¨ºå¯Ÿè…¸éŸ³å¢å¼·ï¼Œæ•´å€‹è…¹éƒ¨æœ‰è¼•å¾®å£“ç—›ã€‚å¯¦é©—å®¤æª¢æŸ¥å‘¨é‚Šè¡€ç™½è¡€çƒ11400/mm^3ï¼Œç³ä¾¿æœ‰æ½›è¡€åæ‡‰ã€‚ä»–æ¥å—ç³ä¾¿åŸ¹é¤ŠåŠç¶“é©—æ€§æŠ—ç”Ÿç´ levofloxacin 3å¤©å¾Œï¼Œç³ä¾¿åŸ¹é¤Šå‘ˆç¾Campylobacter jejuniï¼Œå°levofloxacinæœ‰æŠ—è—¥æ€§ã€‚ä»–ä¾†é–€è¨ºè¤‡æŸ¥æ™‚ï¼Œæ„Ÿè¦ºç—…å·²å¥½ï¼Œè…¹ç€‰åŠç™¼ç‡’éƒ½å·²ç·©è§£ã€‚ è«‹å•é€™æ™‚æœ€é©ç•¶çš„è™•ç†æ˜¯? #medicine/GI <br />
<mark>A. åœlevofloxacin</mark><br />
B. æ¡è¡€æ¶²åŸ¹é¤Š<br />
C. å†æ¡é›†ç³ä¾¿åŸ¹é¤Š<br />
D. æ”¹æˆazithromycin<br />
E. æ”¹æˆciprofloxacin  </p>
</li>
<li>
<p>æœ‰æ•ˆé™ä½ä¸­å¿ƒéœè„ˆå°ç®¡æ„ŸæŸ“çš„çµ„åˆå¼æ–¹æ³•å·²ç¶“åœ¨å…ˆé€²åœ‹å®¶å¾—åˆ°é©—è­‰ï¼Œå…¶ä¸­åŒ…æ‹¬: (1)æ‰‹éƒ¨è¡›ç”Ÿï¼Œé¸æ“‡é©ç•¶ç½®å…¥éƒ¨ä½ (2) ä½¿ç”¨2% chlorhexidineæ¶ˆæ¯’åŠ‘æ¶ˆæ¯’çš®è†š (3) æœ€å¤§ç„¡èŒé¢é˜²è­· (4) æ¯æ—¥è©•ä¼°å„˜æ—©æ‹”é™¤ä¸éœ€è¦ä¹‹å°ç®¡ (5) çµ„å¥—å¼çš„ä¾›æ‡‰åŒ…æˆ–ç½®æ”¾è»Šï¼Œæ¡checklistä»¥ç¢ºå®šæ¯ä¸€æ­¥é©Ÿä¹‹éµå¾ã€‚ #medicine/CRBSI <br />
A. (1)+(2)+(4)<br />
B. (1)+(3)+(4)<br />
C. (1)+(3)+(4)+(5)<br />
<mark>D. (1)+(2)+(3)+(4)+(5)</mark><br />
E. (1)+(2)+(3)+(4)  </p>
</li>
<li>
<p>æ‰‹éƒ¨è¡›ç”Ÿæ˜¯é é˜²é™¢å…§äº¤å‰æ„ŸæŸ“æœ€æœ‰æ•ˆä¹‹æ–¹æ³•ï¼Œæœ‰é—œé…’ç²¾æ€§ä¹¾æ´—æ‰‹ä¹‹æè¿°ï¼Œä¸‹åˆ—ä½•è€…æ­£ç¢º? (1) æ‰‹éƒ¨æœ‰æ˜é¡¯å¼„é«’æˆ–è¡€æ¶²æ±™æŸ“ä¸å¯ä½¿ç”¨ï¼Œæ‡‰æ¡æ´—æ‰‹ä¹³æ¿•æ´—æ‰‹ (2) åœ¨æ¥è§¸ç—…äººæˆ–æ—é‚Šç’°å¢ƒå‰å¾Œä½¿ç”¨ (3) ç—…æˆ¿æœ‰Clostridium difficileç¾¤èšæ„ŸæŸ“æ™‚ä½¿ç”¨ (4) è…¸ç—…æ¯’æµè¡Œæ™‚ä½¿ç”¨ (5) å¤§éƒ¨åˆ†çš„æƒ…æ³çš†å¯ä½¿ç”¨ã€‚ #medicine/IC <br />
<mark>A. (1)+(2)+(5)</mark><br />
B. (1)+(2)+(3)+(5)<br />
C. (1)+(2)+(4)+(5)<br />
D. (1)+(2)+(3)+(4)+(5)<br />
E. (2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>å°ç£åœ°å€65æ­²ä»¥ä¸Šè€äººï¼Œå»ºè­°æ¥ç¨®ç–«è‹—ç‚ºä½•? (1) è‚ºç‚çƒèŒç–«è‹— (2) æ—¥æœ¬è…¦ç‚ç–«è‹— (3) æµæ„Ÿç–«è‹— (4) Bå‹å—œè¡€æ¡¿èŒç–«è‹—(Hib vaccine) (5) ç ´å‚·é¢¨åŠæ¸›æ¯’ç™½å–‰æ··åˆç–«è‹—(Td) #medicine/vaccine <br />
A. (2)+(3)+(4)<br />
B. (2)+(3)+(5)<br />
C. (1)+(2)+(3)<br />
<mark>D. (1)+(3)+(5)</mark><br />
E. (1)+(3)  </p>
</li>
<li>
<p>ç¤¾å€æ€§æŠ—è—¥æ€§é‡‘é»ƒè‰²è‘¡è„çƒèŒ (Community-acquired MRSA) è‚ºç‚æ„ŸæŸ“ï¼Œè¿‘å¹´ä¾†æœ‰æµè¡Œç‡ä¸Šå‡çš„è¶¨å‹¢ï¼Œä¸‹åˆ—ç›¸é—œçš„æ•˜è¿°ï¼Œä½•è€…æœ€ä¸é©ç•¶? #medicine/pneumonia <br />
A. è‚ºéƒ¨æ„ŸæŸ“è¼ƒæ˜“å‡ºç¾é–‹æ´æ€§ç—…ç¶(Cavitation)æˆ–å£æ­»<br />
<mark>B. ç—…äººå¤§å¤šç‚ºæ…¢æ€§è…åŠŸèƒ½ä¸å…¨æ¥å—è¡€æ¶²é€ææ‚£è€…(Chronic dialysis)</mark><br />
C. æ‚£è€…è¼ƒç‚ºå¹´è¼•ï¼Œä¸”å¤šåŠä¹‹å‰å¥åº·ç‹€æ³è‰¯å¥½<br />
D. åˆä½µå’³è¡€ã€è‚Œè‚‰ç— ç—›åŠçš®ç–¹<br />
E. é™¤oxacillinæŠ—è—¥ä¹‹å¤–ï¼Œå…¶ä»–å¤šæ•¸æŠ—ç”Ÿç´ å…·æœ‰æ„Ÿå—æ€§(susceptible)  </p>
</li>
<li>
<p>æœ‰é—œå…¸å‹é€€ä¼è»äººç—‡(Legionnaires' disease)ä¹‹ç—…å²ï¼Œè‡¨åºŠè¡¨å¾µèˆ‡æª¢é©—çµæœä¹‹æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…æœ€ä¸é©ç•¶? #medicine/Legionella <br />
A. ä½µæœ‰ç™¼é«˜ç‡’(&gt;40â„ƒ)ã€è…¹ç€‰(Diarrhea)ç­‰<br />
B. å°¿æ¶²æŠ—åŸåæ‡‰ä¹‹æ•æ„Ÿåº¦(Sensitivity)ç´„ç‚º70%<br />
<mark>C. ä½µæœ‰é«˜è¡€éˆ‰ç—‡(hypernatremia)åŠä½è¡€é‰€ç—‡(hypokalemia)</mark> <code>ä½è¡€éˆ‰</code><br />
D. å…¸å‹ç—°æ¶²å¯è¦‹ä¸­æ€§çƒ(neutrophils)æµ¸æ½¤å¢åŠ ä½†é©è˜­æ°æŸ“è‰²æ‰¾ä¸åˆ°ç´°èŒ<br />
E. èˆ‡æœ‰æ±™æŸ“çš„æ°´æºç’°å¢ƒæ¥è§¸æœ‰é—œ  </p>
</li>
<li>
<p>æœ‰é—œè‡´ç—…åŸæ„ŸæŸ“èˆ‡æŠ—ç”Ÿç´ æ²»ç™‚çš„é…å°,ä¸‹åˆ—å“ªäº›çµ„åˆæ˜¯æ­£ç¢ºçš„? (1) Bacteroides - metronidazole (2) Meningococcus - ceftriaxone (3) Staphylococcus - vancomycin or oxacillin (4) Enterococcus - cefazolin  #medicine/antibiotics <br />
<mark>A. (1)+(2)+(3)</mark><br />
B. (2)+(3)+(4)<br />
C. (1)+(3)+(4)<br />
D. (1)+(2)+(4)<br />
E. (1)+(2)+(3)+(4)  </p>
</li>
<li>
<p>æœ‰é—œAæ—éˆçƒèŒé€ æˆçš„æ€¥æ€§å’½å–‰ç‚(pharyngitis)ä¹‹æ•˜è¿°ï¼Œä»¥ä¸‹æœ‰é—œæ²»ç™‚ä¹‹æ•˜è¿°ä½•è€…ä¸æ­£ç¢ºï¼Ÿ #medicine/antibiotics <br />
A. æ²»ç™‚å¯é™ä½é¢¨æ¿•ç†±ä¹‹é¢¨éšª<br />
B. æ²»ç™‚å¯ç¸®çŸ­ç–¾ç—…ç—‡ç‹€<br />
C. å¯é™ä½å°å¯†åˆ‡æ¥è§¸è€…æˆ–åœ¨æ“æ“ ç’°å¢ƒä¸­ä¹‹å‚³æ’­<br />
D. æ²»ç™‚å¯æ¡10å¤©ä¹‹å£æœAmoxicillin<br />
<mark>E. æ²»ç™‚æ¡moxifloxacin 7å¤©</mark>  </p>
</li>
<li>
<p>ä¸€èˆ¬å°ç¶ è†¿æ¡¿èŒæ„ŸæŸ“çš„æ²»ç™‚å¯é¸ä¸‹åˆ—å“ªäº›æŠ—ç”Ÿç´ ? (1) Moxifloxacin (2) Cefepime (3) Cefoxitin (4) Ertapenem (5) Ceftazidime  #medicine/antibiotics <br />
A. (1)+(2)+(4)<br />
B. (1)+(4)+(5)<br />
C. (2)+(4)+(5)<br />
D. (1)+(4)<br />
<mark>E. (2)+(5)</mark>  </p>
</li>
<li>
<p>ä»¥ä¸‹å“ªäº›æŠ—è—¥æ€§ç´°èŒæ„ŸæŸ“å¯è¢«é…å°æŠ—ç”Ÿç´ æ‰€æ²»ç™‚? (1) Extended spectrum beta-lactamase (ESBL)-producing E. coli: Ertapenem (2) KPC carbapenemase-producing K. pneumoniae: Meropenem (3) VRE: Linezolid (4) MRSA: Daptomycin (5). Carbapenem-resistant Pseudomonas aeruginosa: Tigecycline  #medicine/antibiotics <br />
A. (1)+(2)+(3)<br />
<mark>B. (1)+(3)+(4)</mark><br />
C. (3)+(4)+(5)<br />
D. (1)+(3)+(4)+(5)<br />
E. (1)+(3)  </p>
</li>
<li>
<p>èœ‚çª©çµ„ç¹”ç‚åœ¨ä»¥ä¸‹ä½•ç¨®æƒ…æ³å®œä½¿ç”¨amoxicillin/clavulanic acidæ²»ç™‚? (1) ç•¶æœ‰æ…¢æ€§æ·‹å·´è…«ä½µç™¼æ€¥æ€§èœ‚çª©çµ„ç¹”ç‚ (2) ç•¶æœ‰å‹•ç‰©(è²“ã€ç‹—)æˆ–äººå’¬å‚· (3) ç•¶åœ¨æ²³å·å·¥ä½œæœ‰å—å‚·ä¸”æµ¸æ³¡éæ²³å·æ°´æ™‚ (4) ç•¶æœ‰é‡˜å­åˆºå‚·æ·±éƒ¨çµ„ç¹”æ™‚ (5) ç•¶æœ‰è¢«é­šåˆºå‚·æ™‚  #medicine/SSTI <br />
A. (2)+(4)<br />
B. (3)+(5)<br />
<mark>C. (1)+(2)</mark><br />
D. (2)+(5)<br />
E. (1)+(2)+(3)+(4)  </p>
</li>
<li>
<p>ä¸€ä½75æ­²ç”·æ€§å› ç™¼ç‡’äºŒå¤©ï¼Œå‘¼å¸æ€¥ä¿ƒåŠå’³å—½åŠ åŠ‡è€Œä½é™¢ã€‚ä»–æ›¾æ–¼ä¸‰å‘¨å‰ç½¹æ‚£æµæ„Ÿè‚ºç‚ï¼Œä½†å‘¼å¸é“ç—‡ç‹€å·²ç¶“åœ¨äº”å¤©å‰æ¢å¾©äº†ã€‚ç„¶è€Œé€™äºŒå¤©å’³å—½åŠå‘¼å¸æ€¥ä¿ƒåˆç”¢ç”Ÿï¼Œæœ‰ç°é»ƒè‰²çš„ç—°æ¶²ã€‚ä»–å¹³æ™‚æœ‰é«˜è¡€å£“ï¼Œä½é™¢é«”æº«38.3Â°Cï¼Œè¡€å£“140/86mmHg,å¿ƒè·³90/minï¼Œå‘¼å¸26/min, è¡€æ°§æ¿ƒåº¦90% (åœ¨room air)ï¼Œèƒ¸éƒ¨å‘¼å¸éŸ³äºŒå´çš†æœ‰å›‰éŸ³ï¼Œ è€Œèƒ¸éƒ¨Xå…‰å…©å´çš†æœ‰ç©ºæ´æ€§æµ¸æ½¤ç¾è±¡ï¼Œè«‹å•é€™ä½ç—…äººæœ€å¯èƒ½çš„è‡´ç—…åŸæ˜¯ç”šéº¼ï¼Ÿ #medicine/pneumonia <br />
A. Legionella species<br />
<mark>B. Staphylococcus aureus</mark><br />
C. Pseudomonas aeruginosa<br />
D. Pneumocystis jirovecii<br />
E. Streptococcus pneumoniae  </p>
</li>
<li>
<p>Klebsiella pneumoniae æ¼¸æ¼¸æˆç‚ºæœ€é‡è¦çš„è…¸åŸæ€§è‡´ç—…èŒ, ä»¥ä¸‹æ•˜è¿°ä½•è€…æ­£ç¢º?  #medicine/antibiotics <br />
    (1) æ‰€æœ‰çš„è‡¨åºŠ Klebsiella pneumoniaeèŒæ ªçš†å° Ampicillinå’Œ Ticarcillinå…·æŠ—è—¥æ€§ <br />
    (2) Extended spectrum beta-lactamase (ESBL)-producing K. pneumoniaeå°ceftriaxoneå’Œ ceftazidimeå…·æœ‰æŠ—è—¥æ€§ï¼Œä½†å° Ertapenemå’Œ Fluoroquinolones å‰‡çš†å…·æœ‰æ„Ÿå—æ€§ (3) å¯ç”¢ç”ŸNDM-1 carbapenemase çš„ K. pneumoniae èŒå¯ç”¨Tigecyclineå’ŒPolymycinsæ²»ç™‚ <br />
    (4) å°ç£å¯ç”¢ç”ŸKPC carbapenemase çš„ K. pneumoniae èŒæ ªæ˜¯é€éè³ªé«”ç”¢ç”ŸæŠ—è—¥æ€§ï¼Œä¸¦é€éé†«ç™‚ç…§è­·æ©Ÿæ§‹å‚³æ’­ <br />
    (5) åœ¨å°ç£é€ æˆè‚è†¿ç˜æˆ–çœ¼å…§ç‚ä¸»è¦æ˜¯ ESBL-producing K. pneumoniae<br />
A. (1)+(2)+(3)<br />
B. (1)+(2)+(4)<br />
<mark>C. (1)+(3)+(4)</mark><br />
D. (1)+(3)+(5)<br />
E. (1)+(2)+(3)+(4)  </p>
</li>
<li>
<p>æœ‰é—œå£æ­»æ€§ç­‹è†œç‚(necrotizing fasciitis)ä¹‹æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…ç‚ºé? #medicine/SSTI <br />
A. å¯èƒ½æºè‡ªæ–¼å‰µå‚·ã€æ°´ç—˜æ„ŸæŸ“çš®ç—‚ã€æ‰‹è¡“æˆ–ç”Ÿç”¢å¾Œå‚·å£<br />
B. ç³–å°¿ç—…ã€éœè„ˆè—¥ç™®ã€æ…¢æ€§è‚è…ç–¾ç—…æ˜¯ç›¸é—œçš„å®¿ä¸»å› ç´ <br />
C. ç™¼ç—…å¾Œç´„3è‡³5å¤©è¡¨çš®å‡ºç¾æ°´æ³¡(bullae)åŠçš®è†šå£æ­»(necrosis)<br />
D. è‹¥åˆä½µæœ‰æ¯’æ€§ä¼‘å…‹ç—‡å€™ç¾¤(toxic shock syndrome)ï¼Œæ­»äº¡ç‡å¯é«˜é”70%<br />
<mark>E. Clostridium peringens å¼•èµ·ä¹‹å£æ­»æ€§ç­‹è†œç‚ç—…ç¨‹æ…¢ï¼Œè‡¨åºŠç—‡ç‹€ç·©å’Œï¼Œæ­»äº¡ç‡ä½</mark>  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œç¤¾å€æ€§è‚ºç‚è‡´ç—…åŸèˆ‡ç›¸é—œå®¿ä¸»å› ç´ çš„é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶? #medicine/pneumonia <br />
A. Acinetobacter - é…’ç™® (alcoholism)<br />
B. Klebsiella pneumoniae - ç³–å°¿ç—… (diabetes)<br />
C. Haemophilus influenza - æ…¢æ€§é˜»å¡æ€§è‚ºç—… (COPD)<br />
D. Pseudomonas aeruginosa - æ”¯æ°£ç®¡æ“´å¼µ(bronchiectasis)<br />
==E. Legionella - æµæ„Ÿæ„ŸæŸ“å¾Œ (post - flu)  ==  </p>
</li>
<li>
<p>ä¸€ä½30æ­²å¥³æ€§ï¼Œåœ¨åƒå®Œè›‹æ²™æ‹‰3å°æ™‚å¾Œå‡ºç¾æ€¥æ€§è…¹ç—›ã€å™å¿ƒå˜”ååŠè…¹ç€‰ï¼Œ è«‹å•æœ€å¯èƒ½æ˜¯ä¸‹åˆ—å“ªä¸€è‡´ç—…èŒæ‰€å¼•èµ·?  #medicine/GI <br />
<mark>A. Staphylococcus aureus</mark><br />
B. Enterotoxigenic E.coli<br />
C. Campylobacter jejuni<br />
D. Vibrio parahaemolyticus<br />
E. Ameoba histolytica  </p>
</li>
<li>
<p>æ„ŸæŸ“SARS-CoV-2çš„ç—…äººæ­»äº¡ç‡åé«˜ï¼Œå°æ–¼COVID-19é‡ç—‡çš„ç—…äººä¸‹åˆ—æ•˜è¿°ä½•è€…ç‚ºæ˜¯? #medicine/COVID <br />
    (1)æ²‰é»˜ç¼ºæ°§(silent hypoxia)ä¸»è¦æ˜¯è‚ºæ “å¡é€ æˆï¼Œå»ºè­°å¸¸è¦ç”¨æŠ—å‡è¡€åŠ‘æ²»ç™‚<br />
    (2)HFNC (high flow nasal cannula)ï¼Œè¢«ç¨±ç‚ºæ•‘å‘½ç¥å™¨ï¼Œä¸»è¦ç”¨ä¾†é™ä½å‘¼å¸è‚Œåšå·¥<br />
    (3)ä½¿ç”¨é¡å›ºé†‡å¯ä»¥é™ä½æ­»äº¡ç‡<br />
    (4)éä¾µè¥²æ€§æ­£å£“å‘¼å¸å™¨å¯ä»¥å¸¸è¦ç”¨ä¾†æ²»ç™‚COVID-19é€ æˆçš„å‘¼å¸è¡°ç«­<br />
    (5)ä¿¯è‡¥é€šæ°£(Prone Positioning)å¯ä»¥é™ä½æ°§æ°£éœ€æ±‚é‡<br />
A. (1)+(2)+(3)+(5)ã€‚<br />
B. (3)+(4)+(5)ã€‚<br />
<mark>C. (3)+(5)ã€‚</mark><br />
D. (1)+(3)+(5)ã€‚<br />
E. (2)+(3)+(5)ã€‚  </p>
</li>
<li>
<p>Clostridium difficileæ„ŸæŸ“ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ #medicine/CDI <br />
A. C. difficileæ˜¯ä¸æœƒç”¢ç”Ÿå­¢å­çš„é©è˜­æ°é™½æ€§æ¡¿èŒï¼Œæ•…70%é…’ç²¾å…·æœ‰æ­¤èŒè‰¯å¥½ä¹‹æ®ºèŒåŠ›ã€‚<br />
B. ä»¥å¤§è…¸é¡æª¢æŸ¥å½è†œæ€§è…¸ç‚(Pseudomembranous colitis)ä¹‹æ•æ„Ÿæ€§å¾ˆé«˜ï¼Œå› æ­¤è…¸é¡æª¢æŸ¥è‹¥ç„¡å‡ºç¾ç—…ç¶å‰‡<br />
å¯æ’é™¤æ­¤è¨ºæ–·ã€‚<br />
C. è‡´ç—…åŠ›å¯èƒ½å’Œtoxin Aå’Œtoxin Bç›¸é—œï¼Œtoxin Aæ˜¯cytotoxin, toxin Bæ˜¯enterotoxinã€‚<br />
<mark>D. å°æ–¼é¦–æ¬¡è¼•åº¦C. difficileè…¸ç‚ï¼Œé¦–é¸æ²»ç™‚è—¥ç‰©ç‚ºå£æœmetronidaozleæ²»ç™‚10åˆ°14å¤©ã€‚</mark><br />
E. å°æ–¼é¦–æ¬¡C. difficileè…¸ç‚é‡åº¦æ‚£è€…ï¼Œé¦–é¸æ²»ç™‚è—¥ç‰©ç‚ºé‡åŠ‘vancomycinæ²»ç™‚10åˆ°14å¤©ã€‚  </p>
</li>
<li>
<p>æœ‰é—œCOVID-19çš„æ²»ç™‚ï¼Œä»¥ä¸‹ä½•è€…æ­£ç¢ºï¼Œè«‹é¸å‡ºæœ€é©ç•¶çš„ç­”æ¡ˆ #medicine/COVID <br />
    (1) å–®ç¨ä½¿ç”¨æŠ—ç—…æ¯’è—¥Remdesivirå°ç–¾ç—…è¼•ã€é‡ç—‡æ‚£è€…ä¹‹é å¾Œéƒ½æœ‰æ¥µç‚ºé¡¯è‘—ä¹‹æ•ˆæœã€‚<br />
    (2) å–®æ ªæŠ—é«”Bamlanivimab + Etesevimabä¸»è¦ä½œç”¨æ–¼ç—…æ¯’spike glycoproteinï¼Œå°æ–¼ç–¾ç—…è¼•å¾®æˆ–ä¸­åº¦è€Œæœ‰é‡ç—‡å±éšªå› ç´ å¦‚å¹´ç´€â‰¥65æ­²ã€è‚¥èƒ–(BMI â‰¥35)ï¼Œæœ‰æ…¢æ€§è…ç—…ã€æ…¢æ€§è‚ºç—…ã€å¿ƒè¡€ç®¡ç–¾ç—…ã€é«˜è¡€å£“ã€ç³–å°¿ç—…ã€å…ç–«æŠ‘åˆ¶æ‚£è€…ï¼Œæ–¼ç™¼ç—…è¨ºæ–·3å¤©å…§ä½¿ç”¨ï¼Œå¯é™ä½ä½é™¢å’Œæ­»äº¡ä¹‹é¢¨éšªã€‚<br />
    (3) å–®æ ªæŠ—é«”Bamlanivimab + Etesevimabå°å—éè®Šç•°æ ª(B.1.351, Î²)å’Œå·´è¥¿è®Šç•°æ ª(P.1, Î³)åœ¨é«”å¤–ä¸­å’Œè©¦é©—æ•ˆæœè®Šå·®ï¼Œè€Œå–®æ ªæŠ—é«”Casirivimab + Imdevimabå‰‡å°å‰è¿°ç—…æ¯’è®Šç•°æ ªä¹‹é«”å¤–ä¸­å’Œè©¦é©—æ•ˆæœæœªæ”¹è®Šã€‚<br />
    (4) IL-6 receptor blockerå¦‚Tocilizumabå»ºè­°èˆ‡dexamethasoneåˆä½µä½¿ç”¨æ–¼åš´é‡è‚ºç‚ã€‚<br />
    (5) JAKæŠ‘åˆ¶åŠ‘Baricitinibï¼Œä¸å¯èˆ‡dexamethasoneåˆä½µä½¿ç”¨ã€‚<br />
A. (1)+(2)+(3)<br />
<mark>B. (2)+(3)+(4)</mark><br />
C. (1)+(2)+(4)<br />
D. (2)+(3)+(5)<br />
E. (2)+(4)  </p>
</li>
<li>
<p>æ¥ç¨®è…ºç—…æ¯’è¼‰é«”SARS-COV-2ç–«è‹—å¶ç™¼è¡€æ “æ€§è¡€å°æ¿ä½ä¸‹(thrombotic thrombocytopenia)ï¼Œä»¥ä¸‹æè¿°ä½•è€…éŒ¯èª¤? #medicine/COVID <br />
A. å¤§å¤šç™¼ç”Ÿæ–¼æ¥ç¨®ç–«è‹—å¾Œ5è‡³30å¤©<br />
B. å¸¸è¦‹è…¦éœè„ˆè¡€æ “ã€è…¹è…”å…§éœè„ˆè¡€æ “æˆ–è‚ºæ “å¡<br />
<mark>C. è¡¨ç¾èˆ‡heparin-induced thrombocytopeniaå¾ˆåƒï¼Œèˆ‡ç—…äººæœ€è¿‘æœ‰ä½¿ç”¨heparinæœ‰é—œ</mark><br />
D. ç—…äººè¡€æ¸…ä¸­å¯æ¸¬åˆ°å°æŠ—è¡€å°æ¿ç¬¬4å› å­(platelet factor 4)çš„è¡€å°æ¿æ´»åŒ–æŠ—é«”ï¼Œè©²æŠ—é«”å¯ç¶“ç”±èˆ‡è¡€å°æ¿FcÎ³æ¥å—å™¨è€Œæ´»åŒ–è¡€å°æ¿<br />
E. æ²»ç™‚å»ºè­°ä»¥nonheparinæŠ—å‡è¡€åŠ‘æˆ–IVIG  </p>
</li>
<li>
<p>ä¸€ä½58æ­²ç”·æ€§å› ç‚ºé«–éª¨éª¨æŠ˜æ¥å—æ‰‹è¡“ï¼Œæ‰‹è¡“å¾Œç™¼ç”ŸMRSAæ„ŸæŸ“ï¼Œæ–¼ä½é™¢å¾Œæ¥å—æ¸…å‰µæ‰‹è¡“åŠvancomycinæ³¨å°„ï¼Œæ²»ç™‚ä¸‰é€±é€²æ­¥å¾Œå‡ºé™¢ã€‚å‡ºé™¢æ™‚ä½¿ç”¨å£æœlinezolidæ²»ç™‚ï¼Œè«‹å•åœ¨é–€è¨ºè¿½è¹¤ä¸‹åˆ—å“ªä¸€é …è¼ƒä¸é‡è¦ï¼Ÿ #medicine/antibiotics <br />
A. Linezolidä¸å¯èˆ‡å–®èƒºæ°§åŒ–é…¶æŠ‘åˆ¶åŠ‘(monoamine oxidase inhibitor)æˆ–selective serotonin re-uptake inhibitorå…±åŒä½¿ç”¨<br />
B. è¦æ³¨æ„æ˜¯å¦æœ‰ä¹³é…¸ä¸­æ¯’ç¾è±¡<br />
<mark>C. æœƒé€ æˆQTc prolongation</mark><br />
D. ä½¿ç”¨è¶…é2é€±æœ‰éª¨é«“æŠ‘åˆ¶é¢¨éšª<br />
E. ä½¿ç”¨è¶…é4é€±æœ‰è¦–ç¥ç¶“å’Œå‘¨é‚Šç¥ç¶“ç—…è®Šä¹‹é¢¨éšªã€‚  </p>
</li>
<li>
<p>ä¸€ä½35æ­²ç”·æ€§åˆ°æ€¥è¨ºå°±é†«ï¼Œä¸»è¨´è…¹éƒ¨ä¸é©ã€å˜”åå’Œç¨€å¤§ä¾¿5å¤©ï¼Œç™¼ç‡’ä¹Ÿè¶Šä¾†è¶Šåš´é‡ï¼Œä¹Ÿæœ‰é ­ç—›å’Œçš®è†šç–¹ã€‚èº«é«”è¨ºå¯Ÿé«”æº«40Â°Cï¼Œè¡€å£“100/70mmHgï¼Œå¿ƒæ62/åˆ†ï¼Œå¸å‘¼20/åˆ†ï¼ŒBMI 26ï¼Œæ˜é¡¯ç”Ÿç—…æ¨£ã€‚åœ¨ä¸‹èƒ¸å’Œä¸Šè…¹éƒ¨æœ‰è®Šæ·¡çš„ç´…æ–‘ç–¹ï¼Œä»–çš„éè†œè®Šé»ƒï¼Œçµè†œå……è¡€ï¼Œå’½éƒ¨è¼ƒç´…ï¼Œè€Œè§¸è¨ºæœ‰è‚è„¾è…«å¤§å’Œå£“ç—›ã€‚CBCè¡€è‰²ç´ 12 gm/dlï¼Œç™½è¡€çƒ4500/cummï¼Œå¤šå½¢æ ¸ç™½è¡€çƒ68%ï¼Œband form 10%ï¼Œæ·‹å·´çƒ16%ï¼Œå–®æ ¸çƒ6%ï¼Œè¡€å°æ¿90000/cummï¼ŒAST 120u/Lï¼ŒALT 240u/Lï¼ŒäºŒå¥—è¡€æ¶²åŸ¹é¤Šç‚ºæ ¼è˜­æ°é™°æ€§èŒã€‚æœ€å¯èƒ½çš„è¨ºæ–·åŠå…¶æ²»ç™‚? #medicine/Salmonella <br />
A. éˆç«¯èºæ—‹é«”æ„ŸæŸ“ï¼Œciprofloxacin<br />
<mark>B. å‚·å¯’ï¼Œceftriaxone</mark><br />
C. é€€ä¼è»äººç—…ï¼Œciprofloxacin<br />
D. ææ–¯ç‰¹èŒæ„ŸæŸ“ï¼Œampicillin<br />
E. å¸ƒæ°æ¡¿èŒç—… (brucellosis)ï¼Œdoxycycline  </p>
</li>
<li>
<p>è¢«å‹•ç‰©å’¬å‚·æ™‚æœ‰æ‰€è,ç•¶ç—…æ‚£è¢«å’¬å‚·å¾Œåˆ°é†«é™¢å°±é†«,ä½ é™¤äº†è™•ç†å‚·å£å¤–,ä¸‹åˆ—æ•˜è¿°ä½•è€…ä¸æ­£ç¢º? #medicine/SSTI <br />
A. ç‹—å’¬å’Œè²“å’¬çš„è‡´ç—…èŒåŒ…æ‹¬é‡‘é»ƒè‰²è‘¡è„çƒèŒã€å·´å£«å¾·æ¡¿èŒ(Pasteurella multocida)å’Œå­æ°§èŒ<br />
B. å„ªå…ˆè€ƒæ…®çš„æŠ—ç”Ÿç´ æ˜¯amoxicillin/clavulanateæˆ–ampicillin/sulbactam<br />
C. å¦‚ç—…äººæœ‰penicillinéæ•å²ï¼Œå¯ç”¨clindamycin + trimethoprim-sulfamethoxazoleæˆ– fluoroquinolone<br />
D. éœ€è€ƒæ…®ç‹‚çŠ¬ç—…é é˜²<br />
<mark>E. è¢«çŒ´å­å’¬å‚·ä¹Ÿæ˜¯é¸æ“‡amoxicillin/clavulanateæ²»ç™‚ï¼Œç„¡éœ€è€ƒæ…®æŠ—ç—…æ¯’è—¥çš„ä½¿ç”¨</mark>  </p>
</li>
<li>
<p>ç—…å²è©¢å•å¯æä¾›æ•—è¡€ç—‡ç—…åŸé‡è¦ç·šç´¢, ä»¥ä¸‹å“ªäº›ç‹€æ³è¦æƒ³åˆ°é‰¤ç«¯èºæ—‹é«”ç—…ä¹‹é¢¨éšª? #medicine/Leptospira <br />
    (1)æ´ªæ°´æ°¾æ¿«å¾Œ<br />
    (2)åœ¨æºªæµæ²³å·æ´»å‹•<br />
    (3)å»šå¸«<br />
    (4)å¾äº‹è¾²ç”°ã€ç¸é†«æˆ–ç•œç‰§å·¥ä½œ<br />
    (5)åˆ°ä¸‰æº«æš–æ³¡è¶³éƒ¨æº«æ³‰<br />
A. (1)+(2)+(4)<br />
B. (3)+(4)+(5)<br />
C. (1)+(3)+(4)<br />
<mark>D. (1)+(2)+(3)+(4)</mark><br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>è€ƒé‡æŠ—ç”Ÿç´ çš„ç‰¹æ€§åŠæŠ—è—¥æ€§å•é¡Œ, åœ¨å°ç£ç›®å‰ç¶“é©—æ€§æŠ—ç”Ÿç´ åœ¨ä¸‹åˆ—å“ªäº›æƒ…æ³ä¸å»ºè­°ä»¥ fluoroquinolone ç•¶ä½œç¬¬ä¸€ç·šæ²»ç™‚?(1)æ€¥æ€§åŒ–è†¿æ€§æ‰æ¡ƒç‚(2)æ€¥æ€§è†€èƒ±ç‚(3)è¶³ç™¬åˆä½µä¸‹è‚¢èœ‚çª©çµ„ç¹”ç‚(4)æ€¥æ€§è…¦è†œç‚(5)æ€¥æ€§è…¹ç€‰ #medicine/antibiotics <br />
A. (1)+(4)+(5)<br />
B. (1)+(2)+(5)<br />
C. (2)+(3)+(5)<br />
<mark>D. (1)+(2)+(3)+(4)+(5)</mark><br />
E. (1)+(2)+(3)+(4)  </p>
</li>
<li>
<p>æœ‰ä¸€ä½23æ­²ç”·æ€§å› é«˜ç‡’ä¸é€€ä¸€é€±è€Œä¾†ä½é™¢ï¼Œä»–æ–¼ä¸‰é€±å‰å…¨èº«é•·æ»¿æ°´ç—˜ï¼Œæ–¼äºŒé€±å‰æ°´ç—˜å·²æ¼¸çµç—‚ã€‚ä½é™¢èº«é«”è¨ºå¯Ÿé«”æº«40Â°Cï¼Œè¡€å£“140/50mmHgï¼Œå¿ƒè·³136/minï¼Œå‘¼å¸22/minï¼Œçµè†œç™¼ç´…ï¼Œèƒ¸éƒ¨Xå…‰æª¢æŸ¥æ²’æœ‰æ˜é¡¯è‚ºæµ¸æ½¤ç¾è±¡ï¼ŒCBCå‘ˆç¾Hgb 12 gm/dLï¼ŒWBC 18000/cumm, neutrophil 82%, band form 6%, lymphocyte 10%, monocyte 2%ï¼Œå°¿æ¶²æª¢æŸ¥å‘ˆç¾RBC10-20, WBC5-10ï¼Œè›‹ç™½(-)ï¼Œä»¥ä¸‹å“ªä¸€é …ä¸æ­£ç¢ºï¼Ÿ #medicine/IE <br />
A. æ‡‰è¡Œå®Œæ•´çš„èº«é«”è¨ºå¯Ÿ<br />
B. å¯èƒ½æœƒæœ‰å¿ƒé›œéŸ³<br />
C. æ‡‰è¡Œè‡³å°‘å…©å¥—è¡€æ¶²åŸ¹é¤Š<br />
D. æ‡‰è¡Œå¿ƒè‡Ÿè¶…éŸ³æ³¢æª¢æŸ¥<br />
<mark>E. ç—…äººæœ€å¯èƒ½æœ‰è…¦è†œç‚</mark>  </p>
</li>
<li>
<p>ä¸€ä½65æ­²ç—…äººä½é™¢é€²è¡Œè†½çµçŸ³æ‰‹è¡“ï¼Œè¡“å¾Œ3å¤©ç™¼ç”Ÿé™¢å…§æ„ŸæŸ“è‚ºç‚ï¼Œè«‹å•ä¸‹åˆ—æ•˜è¿°ä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/OP <br />
A. é€ æˆç—…äººç™¼ç”Ÿé™¢å…§è‚ºç‚ä¸»è¦ä¾†è‡ªæ–¼å£å’½å—†å’³(oropharyngeal aspiration)<br />
B. é€²è¡Œä¸Šè…¹éƒ¨æ‰‹è¡“(upper abdominal surgery)å¢åŠ æ­¤ç—…äººç™¼ç”Ÿé™¢å…§è‚ºç‚çš„é¢¨éšª<br />
C. æ­¤ç—…äººç‚ºç™¼ç”Ÿæ—©ç™¼æ€§ï¼ˆearly onsetï¼‰è‚ºç‚ï¼Œè‡´ç—…åŸä¸»è¦ç‚ºå‘¼å¸é“å¸¸åœ¨èŒï¼Œå¦‚è‚ºç‚çƒèŒæˆ–æ„Ÿå†’æ¡¿èŒ<br />
D. è‹¥æ­¤ç—…äººæ’ç®¡ä½¿ç”¨å‘¼å¸å™¨ï¼Œåœ¨åŸ¹é¤Šæœªç™¼ç¾ç‰¹å®šæŠ—è—¥è‡´ç—…åŸä¸”ç—…äººè‡¨åºŠæ”¹å–„ï¼Œå»ºè­°æŠ—ç”Ÿç´ çŸ­æœŸæ²»ç™‚ï¼ˆ8å¤©ï¼‰ä»¥æ¸›å°‘å¾ŒçºŒæŠ—è—¥æ€§èŒç§»ç”Ÿ<br />
<mark>E. è¡“å‰ä½¿ç”¨é é˜²æ€§æŠ—ç”Ÿç´ 72å°æ™‚å¯ä»¥é™ä½æ‰‹è¡“ç—…äººç™¼ç”Ÿé™¢å…§æ„ŸæŸ“çš„æ©Ÿæœƒ</mark>  </p>
</li>
<li>
<p>æ ¹æ“šç¾åœ‹ç–¾ç—…ç®¡åˆ¶å±€çš„å»ºè­°ï¼Œå°æ–¼æ‡·å­•è€…ï¼ŒåŒ…æ‹¬é«˜é¢¨éšªæ„ŸæŸ“ä¹‹æ‡·å­•å©¦å¥³ï¼Œä¸‹åˆ—ä½•è€…æ˜¯ä¸å»ºè­°æ¥ç¨®çš„ç–«è‹—çµ„åˆï¼Ÿ(1)Bå‹è‚ç‚ç–«è‹—ï¼ˆHBV vaccineï¼‰(2)å¸¶ç‹€çš°ç–¹ç–«è‹—ï¼ˆVaricella-zoster vaccineï¼‰(3)éº»ç–¹ã€å¾·åœ‹éº»ç–¹ã€è…®è…ºç‚ç–«è‹—ï¼ˆMMR vaccineï¼‰(4)æµæ„Ÿç–«è‹—ï¼ˆInfluenzaï¼‰(5)ç™½å–‰ã€ç™¾æ—¥å’³ã€ç ´å‚·é¢¨ï¼ˆTd/Tdapvaccineï¼‰ #medicine/vaccine <br />
A. (1)+(2)<br />
<mark>B. (2)+(3)</mark><br />
C. (3)+(4)<br />
D. (4)+(5)<br />
E. (3)+(5)  </p>
</li>
<li>
<p>ä¸€ä½æ¥å—è¡€æ¶²å¹¹ç´°èƒç§»æ¤(Hematopoietic Stem Cell Transplantation)çš„ç—…äººï¼Œåœ¨ç§»æ¤å¾Œ100å¤©ç™¼ç”Ÿæ„ŸæŸ“ï¼Œè«‹å•åœ¨æ­¤æ™‚æœŸä¹‹å¸¸è¦‹ä¹‹è‡´ç—…åŸçµ„åˆï¼Œä¸‹åˆ—ä½•è€…ç‚ºæœ€æ­£ç¢º?(1) Escherichia coli (2) Aspergillus (3) Cytomegalovirus (4) Clostridium difficile (5) Encapsulated bacteria (6) Toxoplasma (7) Varicella zoster virus #medicine/transplant <br />
<mark>A. (2)+(3)+(6)</mark><br />
B. (1)+(3)+(4)+(5)<br />
C. (2)+(4)+(5)<br />
D. (5)+(6)+(7)<br />
E. (1)+(4)+(7)  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œæ–¼Herpesvirusç”¢ç”Ÿä¹‹ç–¾ç—…é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶?<br />
<mark>A. Herpes simplex virus type 1ï¼šHerpangina</mark>  <code>è…¸ç—…æ¯’</code><br />
B. Varicella-zoster virus : Ramsay Hunt syndrome<br />
C. Epstein-Barr virus : B cell lymphoma<br />
D. Human herpesvirus type 8 : Kaposiâ€™s sarcoma<br />
E. Epstein-Barr virus : Oral hairy leukoplakia  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œæ–¼æŠ—ç”Ÿç´ èˆ‡å…¶ä»–è—¥ç‰©ç”¢ç”Ÿä¹‹äº¤äº’ä½œç”¨é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/antibiotics <br />
A. Metronidazoleä½µç”¨Ethanolç™¼ç”Ÿdisulfiram-like reaction<br />
B. Macrolidesä½µç”¨Fluoroquinolonesæœƒå¢åŠ å¿ƒå¾‹ä¸æ•´(arrhythmias)çš„é¢¨éšª<br />
C. Tetracyclinesä½µç”¨WarfarinæœƒåŠ å¼·WarfarinæŠ—å‡è¡€åŠŸèƒ½å¢åŠ å‡ºè¡€çš„é¢¨éšª<br />
<mark>D. RifampinæœƒåŠ å¼·è·çˆ¾è’™ä½œç”¨ï¼Œå£æœé¿å­•è—¥(oral contraceptive)æ‡‰æ¸›é‡ä½¿ç”¨</mark><br />
E. Linezolidæœƒå¢åŠ adrenergicå‡å£“è—¥çš„ä½œç”¨ï¼Œç™¼ç”Ÿä¸æ˜“æ§åˆ¶çš„é«˜è¡€å£“  </p>
</li>
<li>
<p>æœ‰é—œæ–°å† è‚ºç‚ (Coronavirus disease 2019, COVID-19)ä¹‹æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/COVID <br />
A. è‡´ç—…åŸSARS-CoV-2å±¬æ–¼RNAç—…æ¯’ï¼Œäººé¡æ„ŸæŸ“å† ç‹€ç—…æ¯’ä»¥å‘¼å¸é“ç—‡ç‹€ç‚ºä¸»<br />
B. SARS-CoV-2æ½›ä¼æœŸä¸€èˆ¬ä»‹æ–¼2è‡³14å¤©ï¼Œå¤§éƒ¨åˆ†ç‚º4åˆ°5å¤©<br />
<mark>C. è‡¨åºŠç—‡ç‹€ç™¼ç”Ÿå‰æ¥µå°‘å…·æœ‰å‚³æŸ“æ€§ï¼Œå¤§å¤šæ•¸æ„ŸæŸ“è€…æ˜¯æ¥è§¸åˆ°æœ‰ç—‡ç‹€è€…è€Œç™¼ç”Ÿå‚³æŸ“</mark><br />
D. ç´„æœ‰5%æ‚£è€…æœƒç™¼ç”Ÿå‘¼å¸è¡°ç«­æˆ–æ•—è¡€æ€§ä¼‘å…‹ç­‰æ¥µåš´é‡æ„ŸæŸ“ï¼Œéœ€åŠ è­·æ²»ç™‚<br />
E. å¯¦é©—å®¤æª¢æŸ¥æ·‹å·´çƒæ¸›å°‘(lymphopenia)åˆä½µD-dimerå‡é«˜èˆ‡æ­»äº¡ç‡å‘ˆæ­£ç›¸é—œ  </p>
</li>
<li>
<p>æœ‰é—œå‘¼å¸å™¨ç›¸é—œè‚ºç‚ä¹‹é é˜²æªæ–½ï¼Œä¸‹åˆ—ä½•è€…ç‚ºéï¼Ÿ #medicine/pneumonia <br />
A. åºŠé ­æŠ¬é«˜ï¼Œä»¥æ¸›å°‘å—†å…¥æ©Ÿæœƒ<br />
<mark>B. å¸¸è¦åˆ¶é…¸åŠ‘ä½¿ç”¨ï¼Œå¢åŠ èƒƒpHå€¼ä»¥æ¸›å°‘ä¸Šæ¶ˆåŒ–èŒå¢</mark><br />
C. é•·æœŸæ’ç®¡ç—…äººï¼Œè©•ä¼°é®éœåŠ‘æ¯æ—¥ä¸­æ–·<br />
D. äººå“¡è½å¯¦æ‰‹éƒ¨è¡›ç”ŸåŠç„¡èŒæ“ä½œ<br />
E. æ§åˆ¶è¡€ç³–ä»¥æ”¹å–„å®¿ä¸»å…ç–«  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œæŠ—ç”Ÿç´ çš„ä¸»è¦æŠ‘åˆ¶æ©Ÿè½‰é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/antibiotics <br />
A. Cephalosporinâ€“æŠ‘åˆ¶ç´°èƒå£ï¼ˆCell wallï¼‰åˆæˆ<br />
B. Clindamycinâ€“ æŠ‘åˆ¶è›‹ç™½è³ªï¼ˆProtein synthesisï¼‰åˆæˆ<br />
<mark>C. Macrolideâ€“ æŠ‘åˆ¶DNAåˆæˆ</mark><br />
D. Sulfonamideâ€“ æŠ‘åˆ¶è‘‰é…¸ï¼ˆFolateï¼‰åˆæˆ<br />
E. Rifampin - æŠ‘åˆ¶RNAåˆæˆ  </p>
</li>
<li>
<p>ä¸€ä½46æ­²ç”·æ€§æœ‰ç™¼ç‡’ã€ç•å¯’ã€å’³å—½å¸¶é»ƒç—°5å¤©ï¼Œå› å‘¼å¸å›°é›£åŠ åŠ‡1å¤©ç”±æ€¥è¨ºæ”¶å…¥é™¢ã€‚ç—…äººåœ¨æ€¥è¨ºå®¤å› å‘¼å¸çª˜è¿«è€Œè¢«æ’ç®¡ä¸”æ¥ä¸Šå‘¼å¸å™¨ï¼Œæ€¥è¨ºå·²æŠ½äºŒå¥—è¡€æ¶²åŸ¹é¤Šï¼Œä½¿ç”¨ç¶“é©—æ€§æŠ—ç”Ÿç´ æ²»ç™‚ã€‚å…¥é™¢é«”æº«39â„ƒï¼Œè¡€å£“86/50 mmHgï¼Œå¿ƒæ132/minï¼Œå‘¼å¸28/minï¼ŒBMI 28.5ï¼Œè½è¨ºåœ¨å·¦å³å…©å´ä¸‹è‚ºå¯è½åˆ°æ”¯æ°£ç®¡éŸ³ã€‚å¯¦é©—å®¤æª¢æŸ¥è¡€ç´…ç´ 11 g/dLï¼Œç™½è¡€çƒ4200/cummï¼Œè¡€å°æ¿95000/cummï¼Œèƒ¸éƒ¨Xå…‰æª¢æŸ¥å‘ˆç¾äºŒå´ä¸‹è‚ºå’Œå·¦è‚ºä¸­è‘‰æœ‰å¯¦è³ªåŒ–ç¾è±¡ã€‚é™¤äº†æ°£ç®¡å…§æŠ½å¸ç—°æ¶²é€Gram stainå’ŒåŸ¹é¤Šå¤–ï¼Œæ­¤æ™‚ä¸‹åˆ—é‚£ä¸€é …æª¢æŸ¥æ˜¯æœ€åˆé©è¦å†åšçš„ï¼Ÿ #medicine/pneumonia <br />
A. æ”¯æ°£ç®¡é¡æª¢æŸ¥åŠå®šé‡ç´°èŒåŸ¹é¤Š<br />
<mark>B. Legionellaå’Œpneumococcuså°¿æŠ—åŸ</mark><br />
C. Legionellaè¡€æ¸…æŠ—é«”<br />
D. è‚ºåˆ‡ç‰‡æª¢æŸ¥<br />
E. ä¸éœ€è¦å†æª¢æŸ¥  </p>
</li>
<li>
<p>æˆ‘åœ‹2022å¹´5æœˆé–‹å§‹é¢å°å¤§é‡COVID-19ç¤¾å€æ„ŸæŸ“è€…ï¼Œé˜²æ²»ç­–ç•¥æ¼¸æ¬¡é€²å…¥èˆ‡ç—…æ¯’å…±å­˜çš„éšæ®µï¼Œæ­¤æ™‚æœ‰é—œCOVID-19çš„æ²»ç™‚ï¼Œä¸‹åˆ—ä½•è€…æ­£ç¢ºï¼Œè«‹é¸å‡ºæœ€é©ç•¶çš„ç­”æ¡ˆ #medicine/COVID <br />
    (1) Remdesiviræ˜¯RNA-dependent RNA polymeraseæŠ‘åˆ¶åŠ‘ï¼Œå°ç–¾ç—…è¼•ã€é‡ç—‡æ‚£è€…å–®ç¨ä½¿ç”¨ä¹‹é å¾Œçš†æœ‰é¡¯è‘—ä¹‹æ•ˆæœ<br />
    (2)Nirmatrelvir/ritonavir (Paxlovid)èƒ½é˜»æ­¢ç—…æ¯’è›‹ç™½é…¶è¤‡è£½ï¼Œritonaviræ˜¯cytochrome P450 3A4 (CYP3A4)çš„å¼·æŠ‘åˆ¶åŠ‘ï¼Œå¯æ¸›ç·©Nirmatrelvirè¢«è‚è‡Ÿcytochrome P450åˆ†è§£ä»£è¬çš„é€Ÿåº¦ï¼Œè€Œå¢å¼·å…¶æ•ˆæœ<br />
    (3) Molnupiravirå‰‡è—‰ç”±å…¶æˆä»½çš„æ ¸è‹·é¡ä¼¼ç‰©ï¼Œè®“ç—…æ¯’çš„è¤‡è£½é…¶åœ¨RNAè¤‡è£½æ™‚ç”¢ç”Ÿæœ‰ç¼ºé™·çš„RNAï¼Œå› æœ‰åŸºå› çªè®Šç­‰è€ƒé‡ï¼Œä¸å»ºè­°ä½¿ç”¨æ–¼å­•å©¦<br />
    (4) Paxlovidå’ŒMolnupiravirä¸»è¦æ–¼COVID-19ç™¼ç—…æ—©æœŸï¼Œç—‡ç‹€è¼•å¾®ä½†æœ‰ç™¼ç”Ÿé‡ç—‡æˆ–æ­»äº¡ä¹‹é«˜é¢¨éšªè€…<br />
    (5) Paxlovidæœ‰å¾ˆå¤šè—¥ç‰©äº¤äº’ä½œç”¨åŠç¦å¿Œç—‡ï¼ŒæƒŸè…åŠŸèƒ½åªè¦eGFR &gt;30å°±ä¸éœ€èª¿æ•´åŠ‘é‡<br />
A. (1)+(2)+(3)<br />
B. (1)+(2)+(3)+(4)<br />
<mark>C. (2)+(3)+(4)</mark><br />
D. (2)+(3)+(4)+(5)<br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>ä¸€ä½51æ­²å¥³æ€§æ–¼3å¤©å‰å› å™å¿ƒã€å˜”åã€å³å´è…°è‚‹ç–¼ç—›å’Œé«˜ç‡’ä½é™¢ï¼Œåœ¨æ€¥æ€§è…ç›‚è…ç‚çš„è¨ºæ–·ä¸‹å…¥é™¢å³é–‹å§‹æ¥å—Ceftriaxoneæ²»ç™‚ã€‚å› ç‚ºç—…äººé«˜ç‡’72å°æ™‚ä¸é€€ï¼Œä½ å€¼ç­è¢«å‘¼å«å»çœ‹ç—…äººï¼Œæ­¤æ™‚ç—…äººèº«é«”è¨ºå¯Ÿé«”æº«39â„ƒï¼Œè¡€å£“106/60 mmHgï¼Œè„ˆæ110/minï¼Œå‘¼å¸18/minï¼ŒBMI 27ï¼Œå³å´è‚‹è„Šè§’å£“ç—›ã€‚å…¥é™¢æ™‚å°¿æ¶²åŸ¹é¤Šç™¼ç¾å¤§æ–¼10âµèŒè½/mLçš„E. coliä¸”å°ceftriaxoneæœ‰æ•æ„Ÿæ€§ï¼Œè¡€æ¶²åŸ¹é¤Šé™°æ€§ã€‚è«‹å•ä¸‹åˆ—é‚£ä¸€é …æ˜¯æœ€é©ç•¶çš„è™•ç½®ï¼Ÿ #medicine/UTI <br />
<mark>A. è…è‡Ÿé›»è…¦æ–·å±¤æ”å½±æª¢æŸ¥</mark><br />
B. å°¿æ¶²åŸ¹é¤Š<br />
C. æŠ—ç”Ÿç´ æ”¹ç‚ºgentamicin<br />
D. æŠ—ç”Ÿç´ æ”¹ç‚ºamoxicillin/clavulanate<br />
E. çµ¦é€€ç‡’è—¥ï¼Œè§€å¯Ÿå³å¯  </p>
</li>
<li>
<p>ä¸€ä½50æ­²ç”·æ€§å› ç‚ºè‚ºçµæ ¸ç—…å·²ç¶“æ¥å—äºŒå€‹æœˆçš„æŠ—çµæ ¸æ²»ç™‚ï¼Œä»–ä½¿ç”¨çš„è—¥ç‰©åŒ…æ‹¬rifampinï¼Œisoniazidå’Œethambutolï¼Œé–‹å§‹æ™‚å°±å› ç—›é¢¨ç™¼ä½œè€Œæœªä½¿ç”¨pyrazinamideï¼Œç—°æ¶²çµæ ¸èŒåˆ†é›¢æ ªå°ç¬¬ä¸€ç·šæŠ—çµæ ¸è—¥ç‰©éƒ½å…·æ•æ„Ÿæ€§ã€‚ä»–çš„éå»ç—…å²åªæœ‰é«˜è¡€å£“ã€æ…¢æ€§ç—›é¢¨çŸ³é—œç¯€ç‚ä½µåè¦†æ€¥æ€§ç™¼ä½œï¼Œæœ‰ä½¿ç”¨lisinoprilå’Œallopurinolã€‚ä¾†é™¢èº«é«”è¨ºå¯Ÿç”Ÿå‘½å¾µè±¡éƒ½æ­£å¸¸ï¼Œè†å’Œæ‰‹è…³äºŒå´é—œç¯€æœ‰ç—›é¢¨è®ŠåŒ–ï¼Œåœ¨æ‰‹è‚˜æœ‰ç—›é¢¨çŸ³ã€‚èƒ¸éƒ¨Xå…‰æª¢æŸ¥ç„¡é–‹æ´ç—…ç¶ï¼Œæœ€è¿‘ç—°AFBæ˜¯é™°æ€§ã€‚è«‹å•ç—…äººè¦å†æ¥å—rifampinå’Œisoniazidæ²»ç™‚å¤šä¹…ï¼Ÿ #medicine/TB <br />
A. 4å€‹æœˆ<br />
<mark>B. 7å€‹æœˆ</mark><br />
C. 10å€‹æœˆ<br />
D. 12å€‹æœˆ<br />
E. å¯ä»¥åœè—¥äº†  </p>
</li>
<li>
<p>ä¸€ä½48æ­²ç”·æ€§äºŒå¤©å‰åœ¨æµ·é‚Šæ¶‰æ°´è¸©åˆ°é­šé‰¤è€Œè‡´å·¦è…³åº•å—å‚·ï¼Œå› ç™¼ç‡’åŠå·¦è…³ã€å·¦è¶³ç–¼ç—›åŠ åŠ‡è€Œç¶“ç”±æ€¥è¨ºå…¥é™¢ï¼Œä»–ç™¼ç¾ç´…è…«ç–¼ç—›å¾€ä¸Šæ“´æ•£è‡³å·¦è†ï¼Œä»–æœ‰Cå‹è‚ç‚ä½µè‚ç¡¬åŒ–ï¼Œå¹³æ™‚æœç”¨propranololå’Œ furosemideã€‚å…¥é™¢èº«é«”è¨ºå¯Ÿæº«åº¦39.5â„ƒï¼Œè¡€å£“90/60 mmHgï¼Œè„ˆæ72/minå‘¼å¸22/minï¼Œå·¦è¶³å’Œå·¦è…³è‡³è†éƒ¨æœ‰æ°´è…«ï¼Œåš´é‡å£“ç—›ï¼Œçš®è†šæœ‰å‡ºè¡€æ€§æ°´æ³¡ï¼Œå‘¨é‚Šç™½è¡€çƒ20000/cumm,ä¸­æ€§çƒ85ï¼…ï¼Œimmature band form 10ï¼…ï¼Œè€Œæ·‹å·´çƒ5ï¼…ï¼Œç·Šæ€¥å¤–ç§‘æ¸…å‰µæ‰‹è¡“é¡¯ç¤ºç‚ºå£æ­»æ€§è‚Œç­‹è†œç‚ï¼Œæ¸…å‰µçµ„ç¹”Gram stain é¡¯ç¤ºæœ‰å½æ›²çš„æ ¼è˜­æ°é™°æ€§èŒï¼Œä»¥ä¸‹å“ªä¸€é …æ˜¯æœ€å¯èƒ½çš„è‡´ç—…åŸ? #medicine/SSTI <br />
A. Erysipelothrix rhusiopathiae<br />
B. Listeria monocytogenes<br />
C. Mycobacterium marinum<br />
<mark>D. Vibrio vulnificus</mark><br />
E. Legionella pneumophila  </p>
</li>
<li>
<p>ä¸€ä½24æ­²ç”·æ€§å¤§å­¸ç”Ÿï¼Œå¹³å¸¸å¥åº·ï¼Œå› èšŠå­å®å’¬å¾Œï¼Œå·¦è…³ç´…è…«åˆ°é–€è¨ºä¾†ï¼Œèº«é«”è¨ºå¯Ÿé«”æº«37.3â„ƒ ï¼Œè¡€å£“120/72 mmHgï¼Œè„ˆæ72/minï¼Œå‘¼å¸14/minï¼Œåœ¨å·¦è…³æœ‰3Ã—5å…¬åˆ†ç´…è…«ï¼Œè§¸æ‘¸æœ‰æº«ç†±ï¼Œä½†ç„¡åŒ–è†¿ç¾è±¡ï¼Œä¹Ÿç„¡æ·‹å·´çµè…«ç—›ã€‚ä¸‹è¿°æœ€åˆé©çš„æŠ—ç”Ÿç´ : #medicine/SSTI <br />
A. moxifloxacin<br />
B. ciprofloxacin<br />
C. linezolid<br />
<mark>D. cephalexin</mark><br />
E. doxycycline  </p>
</li>
<li>
<p>çŒ´ç—˜ (monkeypox) 2022å¹´6æœˆè‡³å°‘åœ¨27å€‹éæ´²ä»¥å¤–åœ‹å®¶ç™¼ç¾ä¸¦é€šå ±ä¸–ç•Œè¡›ç”Ÿçµ„ç¹”(WHO)ã€‚ä¸‹åˆ—æ•˜è¿°ï¼Œä½•é …çµ„åˆæœ€æ­£ç¢º? #medicine #medicine/mpox<br />
    (1) çŒ´ç—˜ç”±DNAç—…æ¯’é€ æˆï¼Œç—‡ç‹€èˆ‡å¤©èŠ±é¡ä¼¼ï¼Œéå»ä¸»è¦ç™¼ç¾æ–¼é„°è¿‘ç†±å¸¶é›¨æ—çš„ä¸­éå’Œè¥¿éåœ‹å®¶ã€‚å¤©èŠ±ç–«è‹—å°çŒ´ç—˜æœ‰85%ä¿è­·åŠ›<br />
    (2) å‚³æ’­ä¸»è¦æ˜¯é€éå¯†åˆ‡æ¥è§¸åˆ°å‘¼å¸åˆ†æ³Œç‰©æ„ŸæŸ“çš„çš®è†šç—…ç¶æˆ–æ±™æŸ“çš„ç‰©é«”ã€‚æ½›ä¼æœŸå¯å¾5è‡³21å¤©ï¼Œä½†å¤§å¤š6è‡³13å¤©<br />
    (3) ç—‡ç‹€å¦‚ç™¼ç‡’ã€é ­ç—›ã€è‚Œè‚‰è…«è„¹å’Œé…¸ç—›ã€è™›è„«ï¼Œä¸€èˆ¬å…ˆå¾è‡‰éƒ¨å‡ºç–¹ï¼Œå†é€æ¼¸æ“´æ•£åˆ°æ‰‹ã€è¶³ç­‰èº«é«”å…¶ä»–éƒ¨ä½ã€‚çš®ç–¹å¾æ–‘ä¸˜ç–¹ã€å°æ°´çš°è½‰è®Šç‚ºè†¿çš°ï¼Œç´„10å¤©å¾Œçµç—‚ï¼Œ2è‡³3é€±æ¶ˆå¤±<br />
    (4) çŒ´ç—˜æ˜¯äººç•œå…±é€šå‚³æŸ“ç—…ï¼ŒæƒŸè¿‘æœŸå¾ˆå¤šæ–°å¢å€‹æ¡ˆæ˜¯ç¶“æ€§è¡Œç‚ºå‚³æ’­ï¼Œåœ¨æœƒé™°éƒ¨ç—…ç¶å¸¸éœ€èˆ‡æ¢…æ¯’ã€è»Ÿæ€§ä¸‹ç–³å’Œå¸¶ç‹€æ³¡ç–¹é‘‘åˆ¥<br />
    (5) çŒ´ç—˜ç—…äººåœ¨ç…§è­·ä¸Šï¼Œå°ç£CDCå»ºè­°æ”¶æ²»æ–¼å…·ç¨ç«‹è¡›æµ´ä¹‹å–®äººç—…æˆ¿ã€‚åœ¨é€²è¡Œæœƒå¼•èµ·æ°£æº¶è† çš„é†«ç™‚è™•ç½®(aerosal generating procedues)éœ€æœ‰ç©ºæ°£å‚³æŸ“é˜²è­·æªæ–½(airborne precaution)ï¼Œä¸”è¦ç©¿æˆ´é©ç•¶é˜²è­·è£å‚™<br />
A. (1)+(2)+(3)+(5)<br />
B. (1)+(2)+(3)<br />
C. (1)+(2)+(4)<br />
<mark>D. (1)+(2)+(3)+(4)+(5)</mark><br />
E. (1)+(3)+(4)+(5)  </p>
</li>
<li>
<p>æ¨å»£é…’ç²¾ä¹¾æ´—æ‰‹å¯ä»¥å¤§å¤§é™ä½é™¢å…§æ„ŸæŸ“çš„ç™¼ç”Ÿï¼Œä»¥ä¸‹æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ #medicine/IC <br />
A. é…’ç²¾ä¹¾æ´—æ‰‹æ¯æ¬¡ä½¿ç”¨é…’ç²¾é‡1æ¯«å‡å³å¯<br />
B. é…’ç²¾ä¹¾æ´—æ‰‹å¯æ¸…é™¤å¯„ç”ŸèŸ²èŸ²åµ<br />
C. é…’ç²¾ä¹¾æ´—æ‰‹å¯æ¸…é™¤è…¸ç—…æ¯’ã€è«¾ç¾…ç—…æ¯’<br />
<mark>D. é…’ç²¾ä¹¾æ´—æ‰‹å¯æ¸…é™¤æµæ„Ÿç—…æ¯’ã€æ–°å† ç—…æ¯’</mark><br />
E. ä»¥ä¸Šçš†æ­£ç¢º  </p>
</li>
<li>
<p>åœ¨å°ç£è¡€ç³–æ§åˆ¶ä¸è‰¯çš„æ‚£è€…ä¸­ï¼ŒKlebsiella pneumoniaeæ˜¯é‡è¦ä¸”å¸¸è¦‹çš„è…¸æºæ€§è‡´ç—…èŒï¼Œç¶“å¸¸é€ æˆè‚è†¿ç˜ã€æ³Œå°¿é“æ„ŸæŸ“ç­‰ç–¾ç—…ï¼Œä»¥ä¸‹ç›¸é—œæ•˜è¿°ï¼Œä½•è€…æ­£ç¢ºï¼Ÿ #medicine/antibiotics <br />
A. è‡¨åºŠä¸Šwild type K. pneumoniae å¯ç”¨Ampicillinæ²»ç™‚<br />
B. è‹¥æª¢é©—çµæœç‚ºExtended spectrum beta-lactamase (ESBL) -producing K. pneumoniae å› å°ç¬¬ä¸€ç·šæŠ—ç”Ÿç´ æœ‰æŠ—è—¥æ€§ï¼Œå»ºè­°ä½¿ç”¨Ceftriaxoneæ²»ç™‚<br />
<mark>C. è‡¨åºŠä¸Šå°æ–¼ESBL-producing K. pneumoniae æ„ŸæŸ“å»ºè­°ä½¿ç”¨imipenemæˆ–ertapenemæ²»ç™‚</mark><br />
D. å¯ç”¢ç”ŸNDM-1 carbapenemaseçš„K. pneumoniaeå¯ç”¨Tigecyclineå’ŒTrimethoprim /Sulfamethoxazole(TPM-SMX)æ²»ç™‚<br />
E. åœ¨å°ç£é€ æˆè‚è†¿ç˜æˆ–çœ¼å…§ç‚çš„è‡´ç—…èŒç›¸å°æŠ—è—¥æ€§è¼ƒé«˜ï¼Œå¤§å¤šæ˜¯å±¬æ–¼ESBL-producing K.<br />
pneumoniae  </p>
</li>
<li>
<p>ä¸‹åˆ—ç¤¾å€æ€§è‚ºç‚è‡´ç—…åŸèˆ‡å®¿ä¸»å› å­ä¹‹é…å°ï¼Œä½•è€…æœ€ä¸é©ç•¶?  #medicine/pneumonia <br />
A. Alcoholism â€“ Streptococcus pneumoniae<br />
B. Bronchiectasis â€“ Pseudomonas aeruginosa<br />
C. Post-Influenza illness â€“ Stapylococcus aureus<br />
<mark>D. Exposure to bird â€“ Chlamydia trochomatis</mark>   <code>Chlamydia psittaci</code><br />
E. Exposure to sheep â€“ Coxiella burnetii  </p>
</li>
<li>
<p>æœ‰é—œæŠ—ç”Ÿç´ æ²»ç™‚èˆ‡æ•—è¡€ç—‡è‡´ç—…åŸçš„é…å°,ä¸‹åˆ—å“ªäº›çµ„åˆæ˜¯æ­£ç¢ºçš„? #medicine/antibiotics <br />
    (1) Ceftriaxone - Neisseria meningitidis<br />
    (2) Penicillin - Group A Streptococcus<br />
    (3) Clindamycin - Rickettsia<br />
    (4) Ceftazidime- Enterococcus<br />
<mark>A. (1)+(2)</mark><br />
B. (2)+(3)<br />
C. (1)+(3)<br />
D. (2)+(4)<br />
E. (1)+(4)  </p>
</li>
</ol>
<p>%%<br />
86. æœ‰é—œFilariae(è¡€çµ²èŸ²)æ„ŸæŸ“äººé«”é€”å¾‘ï¼Œä¸‹åˆ—ä½•è€…ç‚ºæ˜¯?<br />
<mark>A. insect vector bite</mark><br />
B. larvae skin penetration<br />
C. ingest egg from mouth<br />
D. metacercaria in fish<br />
E. cercariae skin penetration from water<br />
%%  </p>
<ol>
<li>
<p>ä¸‹åˆ—æœ‰é—œéš±çƒèŒ(Cryptococcus)çš„æè¿°ï¼Œä½•è€…ç‚ºé? #medicine/CNS #medicine/Cryptococcus<br />
A. <em>C. gattii</em>åœ¨é³¥é¡ç³ä¾¿(å¦‚é´¿å­)ä¸å®¹æ˜“ç™¼ç¾<br />
B. åœ¨HIVæ„ŸæŸ“æ—ç¾¤ï¼Œmemory B cell IgMçš„ä¸‹é™ï¼Œå…·æœ‰è¼ƒé«˜çš„æ„ŸæŸ“é¢¨éšª<br />
<mark>C. Cryptococcal Agå¯ä»¥æœ‰æ•ˆçš„è¨ºæ–·è‚ºéƒ¨æ„ŸæŸ“(pulmonary cryptococcosis)ï¼Œå…·æœ‰å¾ˆå¥½çš„æ•æ„Ÿæ€§èˆ‡å°ˆä¸€æ€§</mark><br />
D. è‚ºéƒ¨éš±çƒèŒæ„ŸæŸ“çš„æ²»ç™‚ä»¥fluconazole 200-400mg/å¤©ç‚ºæœŸ3-6å€‹æœˆ<br />
E. è‚ºå¤–æ„ŸæŸ“(å¦‚è…¦è†œç‚)ä»¥amphotericin B deoxycholate 0.5-1 mg/kg/å¤©ï¼Œåšç‚ºèµ·å§‹æ²»ç™‚  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œCOVID-19æ²»ç™‚è—¥ç‰©èˆ‡å…¶æ©Ÿè½‰çš„é…å°ï¼Œä½•è€…ç‚ºé? #medicine/COVID <br />
A. Remdesivirï¼šInhibit viral RNA polymerase<br />
B. Tocilizumabï¼šIL-6 monoclonal Ab<br />
C. Molnupiravirï¼šRibonucleoside analog<br />
<mark>D. Baricitinibï¼šTNF-Î± inhibitor</mark><br />
E. Nirmatrelvir/Ritonavirï¼šprotease inhibitor  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œèˆ‡æ€§ç—…è¡¨å¾µ(syndrome)è‡´ç—…åŸ(pathogen)ä¹‹é…å°ï¼Œä½•é€™ç‚ºé? #medicine/STD <br />
A. Epididymitisï¼šChlamydia trachomatis<br />
B. Bartholinitis ï¼šTrichomonas vaginalis<br />
C. Infertility ï¼š Neisseria gonorrhoeae<br />
<mark>D. Genital wartsï¼šHuman herpes virus type 8</mark> <code>Human papillomavirus</code><br />
E. Genital ulcers ï¼š Haemophilus ducreyi  </p>
</li>
<li>
<p>ä¸€ä½30æ­²ç”·æ€§ï¼Œè·¯ä¸Šä¸æ…è¢«ç‹—å’¬å‚·ï¼Œè¢«é€è‡³æ€¥è¨ºè™•ç½®ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…ä¸æ­£ç¢º? #medicine/SSTI <br />
A. å¸¸è¦‹è‡´ç—…åŸç‚ºStaphylococcus aureusã€Pasteurella multocidaã€Anaerobeç­‰<br />
B. è‹¥è‡´ç—…åŸç‚ºCapnocytophaga canimorsuså¼•èµ·ä¹‹æ•—è¡€ç—‡ï¼Œè¡€æ¶²åŸ¹é¤Šéœ€è¦è‡³14å¤©<br />
C. é¦–é¸æ²»ç™‚ç‚ºamoxicillin/clavulanateæˆ–ampicillin/sulbactam<br />
<mark>D. è‹¥å°penicillinéæ•ï¼Œå¯ä½¿ç”¨macrolideæ²»ç™‚åšç‚ºæ›¿ä»£</mark><br />
E. éœ€è©•ä¼°æ˜¯å¦æœ‰Rabiesé é˜²è™•ç½®ä¹‹éœ€è¦  </p>
</li>
<li>
<p>åº«è³ˆæ°ç—…(Creutzfeldt-Jakob disease; CJD) åœ¨1920å¹´ä»£åˆæœŸé¦–å…ˆè¢«å ±å°ï¼Œç‚ºä¸€ç¨®ç›¸ç•¶ç½•è¦‹çš„ç–¾ç—…ã€‚ä¸‹åˆ—æ•˜è¿°ï¼Œä½•é …çµ„åˆæœ€æ­£ç¢º? #medicine/IC <br />
    (1) è‡´ç—…åŸPrionä¸æ˜¯å‚³çµ±çš„ç´°èŒæˆ–ç—…æ¯’ç­‰ç—…åŸï¼Œä¹Ÿä¸å…·æ ¸é…¸ï¼Œä½†å»æœ‰æ„ŸæŸ“åŠ›ï¼Œä½†åƒ…é™æ–¼åŒç¨®å‹•ç‰©é–“æ‰å¯å‚³æŸ“ã€‚<br />
    (2)è‡¨åºŠç—‡ç‹€åŒ…æ‹¬è¨˜æ†¶å–ªå¤±åŠæ··æ·†ã€æ…¢æ€§ç—´å‘†åŒ–ã€é‹å‹•ç¥ç¶“å¤±èª¿ã€åŠå–ªå¤±èªè¨€èƒ½åŠ›ã€‚<br />
    (3)äººçš„æ–°å‹åº«è³ˆæ°ç—…(new variant CJD, v-CJD)èˆ‡ç‰›æµ·ç¶¿ç‹€è…¦ç—…(Bovine spongiform encephalopathy; BSE)æœ‰é«˜åº¦ç›¸é—œã€‚æ­¤é¡æ‚£è€…ç™¼ç”Ÿå¹´é½¡è¼ƒæ•£ç™¼å‹åº«è³ˆæ°ç—…å¹´è¼•ã€‚<br />
    (4)ç…§é¡§ç—…æ‚£åŸºæœ¬ä¸Šä¸éœ€è¦ç‰¹åˆ¥éš”é›¢, åªéœ€ä»¥ä¸€èˆ¬é˜²è­·å†åŠ ä¸Šæ­£ç¢ºçš„æ¶ˆæ¯’ã€‚<br />
    (5)æ„ŸæŸ“æ€§çš„è®Šæ€§è›‹ç™½è³ªå°ä¸€èˆ¬å¸¸ç”¨çš„ç‰©ç†æˆ–åŒ–å­¸æ–¹æ³•æœ‰å¾ˆå¼·çš„æŠµæŠ—æ€§ï¼Œå¿…é ˆä½¿ç”¨ç´«å¤–ç·šã€è¼»å°„ç…§å°„åŠæ¶ˆæ¯’åŠ‘ä¾†æ¶ˆæ¯’ã€‚<br />
<mark>A. (2)+(3)+(4)</mark><br />
B. (2)+(3)+(5)<br />
C. (1)+(2)+(3)+(5)<br />
D. (2)+(3)+(4)+(5)<br />
E. (1)+(2)+(3)+(4)+(5)  </p>
</li>
<li>
<p>ä¸‹åˆ—æœ‰é—œAå‹è‚ç‚çš„æ•˜è¿°ï¼Œä½•è€…æ­£ç¢º? #medicine/HAV <br />
A. Aå‹è‚ç‚ç—…æ¯’æ˜¯ä¸€ç¨®ç„¡å¥—è†œã€å–®è‚¡å»æ°§æ ¸ç³–æ ¸é…¸(DNA)ç—…æ¯’ï¼Œé…’ç²¾å¯ä»¥æ¶ˆæ¯’Aå‹è‚ç‚ç—…æ¯’æ±¡æŸ“çš„è¡¨é¢<br />
<mark>B. ä¸»è¦æ˜¯ç¶“ç”±ç³å£é€”å¾‘å‚³æ’­ï¼Œå› æ­¤æœƒç¶“ç”±æ”å…¥å—æ±¡æŸ“çš„é£Ÿç‰©æˆ–æ°´è€Œæ„ŸæŸ“ï¼Œä¹Ÿæœƒç¶“ç”±æ€§æ¥è§¸å‚³æŸ“</mark><br />
C. è‡¨åºŠç—‡ç‹€åŒ…æ‹¬å…¨èº«å€¦æ€ ä¸é©ã€é£Ÿæ…¾ä¸æŒ¯ã€å˜”åã€å™å¿ƒã€é»ƒç–¸ç­‰ï¼Œä½†ä¸æœƒç™¼ç‡’ã€‚<br />
D. Aå‹è‚ç‚ä¸æœƒå°è‡´æ…¢æ€§è‚ç‚ï¼Œä½†æ˜¯å¤§å¤šæ•¸çš„ç—…æ‚£åœ¨ç—‡ç‹€æ¶ˆé€€æˆ–å‡ºç¾é»ƒç–¸1é€±å¾Œä»å…·é«˜å‚³æŸ“åŠ›<br />
E. Aå‹è‚ç‚ç–«è‹—çš„æ•ˆæœä½³ï¼Œåƒ…é ˆå®Œæˆä¸€åŠ‘ç–«è‹—æ¥ç¨®å³å¯æä¾›é•·æœŸçš„ä¿è­·åŠ›  </p>
</li>
<li>
<p>è¿‘å¹´ä¾†æŠ—è—¥æ€§ç´°èŒçš„å•é¡Œå¼•èµ·å„åœ‹æ”¿åºœé‡è¦–ï¼Œå°¤å…¶ä»¥ESKAPEé€™äº›èŒæœ€ç‚ºæ£˜æ‰‹ã€‚ä¸‹åˆ—æ•˜è¿°ï¼Œä½•é …çµ„åˆæœ€æ­£ç¢º? #medicine/antibiotics <br />
    (1) MRSAå¤šä»¥é™¢å…§æ„ŸæŸ“ç‚ºä¸»ï¼Œç¤¾å€å‹æ„ŸæŸ“ä¸éœ€è€ƒæ…®MRSAã€‚<br />
    (2) Linezolidç‚ºæŠ‘èŒå‹æŠ—ç”Ÿç´ ï¼Œæ‰€ä»¥ä¸é©åˆç”¨æ–¼æ²»ç™‚VRE (vancomycin-resistant Enterococcus)å¼•èµ·ä¹‹èŒè¡€ç—‡ã€‚<br />
    (3)ç”±æ–¼æŠ—è—¥æ€§ç´°èŒç››è¡Œç‡ç¯€ç¯€é«˜å‡ï¼Œå³ä¾¿ç¤¾å€å‹æ„ŸæŸ“é‚„æ˜¯å¾—ä½¿ç”¨å¾Œç·šæŠ—ç”Ÿç´ æ²»ç™‚ï¼Œä»¥å…æ²»ç™‚å¤±æ•—ã€‚<br />
    (4)ç•œç‰§æ¥­ä½¿ç”¨æŠ—ç”Ÿç´ ï¼Œèˆ‡äººé¡å¾—åˆ°æŠ—è—¥æ€§ç´°èŒæ„ŸæŸ“æœ‰é—œä¿‚ã€‚<br />
    (5)åœ¨å°ç£carbapenem-resistant Klebsiella pneumoniae (CRKP)ä¸»è¦èˆ‡ç¢³é’é»´çƒ¯é¡é…¶OXA-48æœ‰ç›¸é—œã€‚<br />
A. (1)+(3)<br />
B. (1)+(2)+(3) +(4)<br />
C. (2)+(4)<br />
D. (2)+(4)+(5)<br />
<mark>E. (4)+(5)</mark>  </p>
</li>
<li>
<p>æŸç‰¹æ®Šå–®ä½åœ¨å“¡å·¥å¹´åº¦é«”æª¢é ˆå°çµæ ¸æ„ŸæŸ“(æ½›ä¼æ€§)é€²è¡Œç¯©æª¢ï¼Œå…¶ä¸­ä¸€ä½62æ­²å“¡å·¥ä¸€å¹´å‰æ›¾æ‚£è†€èƒ±ç™Œä¸¦ä»¥BCG æ²»ç™‚ï¼Œæœ€è¿‘è†€èƒ±é¡æª¢æŸ¥ä¸¦ç„¡æ´»å‹•æ€§è†€èƒ±ç™Œä¹‹è­‰æ“šï¼Œä¹Ÿæ²’æœ‰å‘¼å¸é“æˆ–å…¨èº«æ€§ç—‡ç‹€ã€‚èº«é«”è¨ºå¯Ÿç”Ÿå‘½å¾µè±¡å’Œå¿ƒè‚ºéƒ½ç„¡ç•°å¸¸ã€‚è«‹å•æ­¤æ™‚é‚£ä¸€é …æª¢æŸ¥æœ€é©ç•¶? #medicine/TB <br />
A. CXR<br />
B. Tuberculin skin test<br />
<mark>C. Interferon-Î³ release assay</mark><br />
D. Two-step tuberculin skin testing<br />
E. ä»¥ä¸Šçš†æ˜¯  </p>
</li>
<li>
<p>æœ‰é—œpenicillinéæ•ï¼Œä»¥ä¸‹æ•˜è¿°ä½•è€…éŒ¯èª¤ï¼Ÿ #medicine/antibiotics <br />
A. è¶Šä¾†è¶Šå¤šç ”ç©¶èªç‚ºå¤šæ•¸è¨»è¨˜ç‚ºpenicillinéæ•åæ‡‰çš„ç—…äººä¸¦æ²’æœ‰çœŸæ­£éæ•ï¼Œè€Œä¸”penicillinéæ•åæ‡‰æœƒéš¨è‘—æ™‚é–“éå»è€Œé™ä½å…¶ç”¢ç”Ÿéæ•åæ‡‰çš„æ©Ÿæœƒï¼Œå› æ­¤ç—…å²è©¢å•ã€é‡æ–°è©•ä¼°å’Œæ­£ç¢ºè¨»è¨˜å¾ˆé‡è¦<br />
B. æ›¾è¢«è¨»è¨˜ç‚ºpenicillinéæ•çš„ç—…äººå› æ²»ç™‚æœƒæ¥å—æ›´å¤švancomycinã€fluoroquinoloneæˆ–clindamycinç­‰æŠ—ç”Ÿç´ ï¼Œè€Œå¢åŠ å¤šé‡æŠ—è—¥èŒæ„ŸæŸ“ç‡åŠæ‰‹è¡“å‚·å£æ„ŸæŸ“çš„æ©Ÿæœƒ<br />
C. å¤§å¤šæ•¸å°penicillinéæ•çš„ç—…äººä¸¦éå°å®Œæ•´è—¥ç‰©åˆ†å­éæ•ï¼Œè€Œæ˜¯å°é«”å…§penicilliné™è§£ç‰©èˆ‡ç™½è›‹ç™½å…±åƒ¹é€£æ¥ç”¢ç‰©éæ•ï¼Œä»¥è—¥ç‰©æº¶æ¶²é€²è¡Œçš®è†šæ¸¬è©¦ä¸è¶³ä»¥è­˜åˆ¥å¤§å¤šæ•¸ç—…äººçš„éæ•<br />
D. ç›®å‰åœ‹å…§è‡¨åºŠç—…äººè™•ç½®ä»¥ç—…å²ç‚ºä¸»ï¼Œè‹¥ç„¡penicillinéæ•ç—…å²ï¼Œæ–¼ç¬¦åˆé©æ‡‰ç—‡æ™‚å¯ä»¥ç›´æ¥ä½¿ç”¨penicillinï¼Œä¸¦ä¸é ˆä»¥è—¥ç‰©æº¶æ¶²é€²è¡Œçš®è†šæ¸¬è©¦;æƒŸå®Œå‚™æ€¥æ•‘è¨­å‚™è—¥ç‰©å’Œäººå“¡ç’°å¢ƒæ˜¯æ‰€æœ‰é†«ç™‚é™¢æ‰€ä¹‹åŸºæœ¬æ³•è¦è¦æ±‚<br />
<mark>E. è‹¥ç—…å²æœ‰ä¸­åº¦æˆ–é«˜åº¦penicillinéæ•åæ‡‰é¢¨éšªè€…ï¼Œå»ºè­°ä»¥è—¥ç‰©æº¶æ¶²é€•è¡Œé€²è¡Œçš®è†šæ¸¬è©¦</mark>  </p>
</li>
<li>
<p>SARS-CoV-2æ„ŸæŸ“åŠå…¶æ²»ç™‚ï¼Œä»¥ä¸‹æ•˜è¿°ä½•è€…éŒ¯èª¤ï¼Ÿ #medicine/COVID <br />
A. è‡ª2022å¹´1æœˆè‡³2023å¹´3æœˆï¼Œæˆ‘åœ‹å…¬å¸ƒ1010è¬æœ¬åœŸç¢ºè¨ºå€‹æ¡ˆä¸­ï¼Œç´„16%ç‚º60æ­²ä»¥ä¸Šã€‚ä¾WHOåš´é‡åº¦åˆ†é¡ç‚ºåš´é‡è‚ºç‚æˆ–ARDSå€‹æ¡ˆå 0.4%ï¼Œå…¶ä¸­58% ç‚ºå¤§æ–¼60æ­²<br />
B. å£æœæŠ—ç—…æ¯’Molnupiraviræ˜¯ä¸€ç¨®æ ¸è‹·é¡ä¼¼ç‰©ï¼Œä½¿ç—…æ¯’RNAè¤‡è£½æ™‚ä¸æ–·ç´¯ç©çªè®Šï¼Œå°è‡´ç„¡æ³•å®Œå…¨è¤‡è£½è€Œè‡ªè¡Œæ¶ˆå¤±<br />
C. Paxlovid (Nirmatrelvir/ritonavir)èƒ½é˜»æ­¢ç—…æ¯’è›‹ç™½é…¶è¤‡è£½ï¼Œritonaviræ˜¯è‚cytochrome P450 3A4çš„å¼·æŠ‘åˆ¶åŠ‘ï¼Œå¯æ¸›ç·©Nirmatrelvirè¢«cytochrome P450ä»£è¬ï¼Œè€Œå¢å¼·å…¶æŠ—ç—…æ¯’ä½œç”¨<br />
D. Paxlovidå’Œmolnupiravirå°ä¸é ˆç”¨æ°§æ°£ä¸”å…·é‡ç—‡é¢¨éšªå› å­ä¹‹SARS-CoV-2æ„ŸæŸ“è€…å¯é™ä½å…¶æ­»äº¡ç‡åŠå¾ŒçºŒä½é™¢ç‡<br />
<mark>E. é•·æ•ˆå–®æ ªæŠ—é«”è—¥Tixagevimab + cilgavimabå°SARS-CoV-2 Î±, Î², Î³, Î´åŠomicronæœ€è¿‘subvariant XBBå’ŒBQ.1.1 éƒ½ä¸€ç›´å…·æœ‰å¾ˆå¥½çš„ä¸­å’Œæ•ˆæœ</mark>  </p>
</li>
<li>
<p>æˆ‘åœ‹é˜²æ²»æ„›æ»‹ç—…å¼·èª¿æ­£ç¢ºä½¿ç”¨ä¿éšªå¥—ç­‰å®‰å…¨æ€§è¡Œç‚ºã€ç¯©æª¢åŠæš´éœ²æ„›æ»‹ç—…æ¯’å‰é é˜²æ€§æŠ•è—¥(PrEP) ã€‚æƒŸæ€§è¡Œç‚ºå‚³æŸ“çš„æ¢…æ¯’ã€æ·‹ç—…å’Œç ‚çœ¼æŠ«è¡£èŒæ„ŸæŸ“ä»é€æ¼¸å¢åŠ ã€‚é—œæ–¼æŠ«è¡£èŒå’Œæ·‹èŒï¼Œä¸‹åˆ—ä½•è€…éŒ¯èª¤? #medicine/STD<br />
A. æŠ«è¡£èŒæ„ŸæŸ“å¸¸ç„¡ç—‡ç‹€ï¼Œè€Œé€ æˆå­å®®å¤–å­•ã€ä¸å­•å’Œæ…¢æ€§éª¨ç›†è…”ç–¼ç—›ç—‡<br />
B. åœ¨ç¾åœ‹å»ºè­°æ‡·å­•æ™‚ã€å¹´è¼•å¥³æ€§æœ‰é¢¨éšªå› å­å’Œç”·ç”·æ€§è¡Œç‚ºè€…éœ€æ¯å¹´ç¯©æª¢æŠ«è¡£èŒå’Œæ·‹èŒ<br />
C. æ·‹èŒå¯é€ æˆå­å®®é ¸ç‚ã€éª¨ç›†è…”ç‚ã€å°¿é“ç‚å’Œå‰¯çªä¸¸ç‚ï¼Œä¹Ÿå¯é€ æˆå’½ç‚å’Œè…”é–€ç›´è…¸æ„ŸæŸ“<br />
D. ç€°æ¼«æ€§æ·‹èŒæ„ŸæŸ“ä¸»è¦ä»¥é—œç¯€ç‚å’Œçš®è†šç‚æˆ–åŒ–è†¿æ€§é—œç¯€ç‚è¡¨ç¾<br />
<mark>E. æ ¸é…¸æª¢é©— (NAAT)å°æŠ«è¡£èŒå’Œæ·‹èŒçš„æª¢é©—æ•æ„Ÿæ€§ä¸å¦‚åŸ¹é¤Šå’Œæ ¼è˜­æ°æŸ“è‰²</mark>  </p>
</li>
<li>
<p>å›°é›£æ¢­ç‹€æ¡¿èŒ(Clostridium difficile)æ„ŸæŸ“æ˜¯é†«ç™‚ç…§è­·æ©Ÿæ§‹ç›¸é—œå¤§è…¸ç‚æœ€é‡è¦çš„åŸå› ã€‚ä»¥ä¸‹æ•˜è¿°ä½•è€…éŒ¯èª¤? #medicine/CDI <br />
A. ç„¡ç—‡ç‹€å¸¶èŒè€…å¯ç¶“ç”±å£ç³å‚³æ’­é€”å¾‘æ•£æ’­ç´°èŒæˆ–å­¢å­<br />
B. å¸¶æ‰‹å¥—ã€ä¸ä½¿ç”¨æ±¡æŸ“çš„æº«åº¦è¨ˆåŠä»¥æ¼‚ç™½æ°´æ¸…æ½”æ¶ˆæ¯’ç—…äººä½æˆ¿ç’°å¢ƒå¯é é˜²å›°é›£æ¢­ç‹€æ¡¿èŒå‚³æ’­<br />
<mark>C. ä»¥é…’ç²¾æ€§ä¹¾æ´—æ‰‹æˆ–æ¿•æ´—æ‰‹éƒ½å¯ä»¥æœ‰æ•ˆé é˜²å‚³æ’­</mark><br />
D. æŠ—ç”Ÿç´ ä½¿ç”¨æ˜¯å¢åŠ å›°é›£æ¢­ç‹€æ¡¿èŒæ„ŸæŸ“é¢¨éšªé‡è¦çš„å› ç´ ï¼Œå°¤å…¶æ˜¯å°è…¸é“å­æ°§èŒå¾ˆæœ‰æ•ˆä½†å°å›°é›£æ¢­ç‹€æ¡¿èŒç„¡æ•ˆè€…å¦‚clindamycin<br />
E. æ¸›å°‘ç¬¬äºŒã€ä¸‰ä»£é ­å­¢å­ç´ ä½¿ç”¨ä¹Ÿé™ä½å›°é›£æ¢­ç‹€æ¡¿èŒæ„ŸæŸ“é¢¨éšª  </p>
</li>
<li>
<p>ä¸‹åˆ—ç–«è‹—çµ„åˆé¸é …ï¼Œä½•è€…çš†ç‚ºæ´»æ€§ç–«è‹—ï¼Œä¸å»ºè­°æ¥ç¨®æ–¼åš´é‡å…ç–«ä¸å…¨ç—…äºº?<br />
(1)TdaP(ç ´å‚·é¢¨ã€ç™½å–‰ã€ç™¾æ—¥å’³æ··åˆç–«è‹—) (2)MMR(éº»ç–¹ã€è…®è…ºç‚ã€å¾·åœ‹éº»ç–¹æ··åˆç–«è‹—) (3)HPV(äººé¡ä¹³çªç—…æ¯’ç–«è‹—) (4)Varicella-Zoster(å¸¶ç‹€çš°ç–¹ç–«è‹—ï¼ŒZostavaxÂ®)  (5)Meningococcal vaccine(è…¦è†œç‚é›™çƒèŒç–«è‹—) #medicine/vaccine <br />
A. (1)+(3)+(5)<br />
<mark>B. (2)+(4)</mark><br />
C. (1)+(2)+(3)<br />
D. (2)+(3)+(5)<br />
E. (4)+(5)  </p>
</li>
<li>
<p>æœ‰é—œç¤¾å€æ€§é‡‘é»ƒè‰²è‘¡è„çƒèŒè‚ºç‚(Community-acquired MRSA pneumonia)ä¹‹è‡¨åºŠè¡¨å¾µåŠå¾®ç”Ÿç‰©ç‰¹æ€§ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æœ€ä¸é©ç•¶? #medicine/pneumonia <br />
A. èƒ¸éƒ¨Xå…‰é¡¯ç¤ºé–‹æ´æµ¸æ½¤(cavitary infiltrate)æˆ–å£æ­»(necrosis)<br />
B. å¯èƒ½åŒæ™‚åˆä½µæµæ„Ÿ(concurrent influenza)<br />
C. å‡ºç¾å’³è¡€(gross hemoptysis)ã€çš®ç–¹(erythematous rash)<br />
<mark>D. æ˜“ç™¼ç”Ÿæ–¼å¹´é•·è€… (elderly)ï¼Œå¹´è¼•å¥åº·(young, previously healthy)æ—ç¾¤ååˆ†å°‘è¦‹</mark><br />
E. Oxacillinå‘ˆç¾æŠ—è—¥æ€§ï¼Œclindamycinå¯åšç‚ºè¼”åŠ©æ²»ç™‚è—¥ç‰©  </p>
</li>
<li>
<p>æœ‰é—œç¤¾å€æ€§è‚ºç‚æ„ŸæŸ“è‡´ç—…åŸèˆ‡å®¿ä¸»å› ç´ ä¹‹é—œè¯ï¼Œä¸‹åˆ—ä½•è€…æœ€ä¸é©ç•¶? #medicine/pneumonia <br />
A. é…’ç™®(alcoholism)- Klebsiella pneumoniae<br />
B. æ…¢æ€§è‚ºç—…(COPD) â€“ Pseudomonas aeruginosa<br />
C. æ”¯æ°£ç®¡æ“´å¼µç—‡(bronchiectasis) â€“ Staphylococcus aureus<br />
D. æµæ„Ÿä½µç™¼ç—‡(influenza) â€“ Streptococcus pneumoniae<br />
<mark>E. æ¥è§¸é³¥ç¦½(birds) â€“ Coxiella burnetii (Q fever)</mark>  </p>
</li>
<li>
<p>ä¸€ä½30æ­²ç”·æ€§ï¼Œå› ç™¼ç”Ÿæ€¥æ€§è…¹ç€‰ä½µæœ‰è¡€ä¾¿(dysentery)è‡³æ€¥è¨ºå°±é†«ï¼Œå…¶å¯èƒ½è‡´ç—…åŸçš„çµ„åˆï¼Œä¸‹åˆ—é¸é …ä½•è€…æœ€ç‚ºé©ç•¶ï¼Ÿ #medicine/GI <br />
(1) Staphylococcus aureus (2) Salmonella typhi (3) Enterotoxigenic E.coli (4) Campylobacter<br />
jejuni (5) Bacillus cereus<br />
A. (1)+(2)+(3)<br />
<mark>B. (2)+(4)</mark><br />
C. (1)+(3)+(5)<br />
D. (2)+(3)<br />
E. (1)+(5)  </p>
</li>
<li>
<p>æœ‰é—œå‹•ç‰©å’¬å‚·èˆ‡æ„ŸæŸ“è‡´ç—…åŸä¹‹é…å°ï¼Œä¸‹åˆ—ä½•è€…æœ€ä¸é©ç•¶ï¼Ÿ #medicine/SSTI <br />
A. ç‹—(Dog)â€“Pasteurella multocida<br />
B. äºº(Human)â€“viridans streptococci<br />
<mark>C. çŒ´(Monkey)â€“Streptobacillus moniliformis</mark>  <code>B virus</code><br />
D. è›‡(Snake)â€“Pseudomonas aeruginosa<br />
E. é¼ (Rodent)â€“Leptospira  </p>
</li>
<li>
<p>æœ‰é—œåœ¨è¡€æ¶²å¹¹ç´°èƒç§»æ¤å¾Œ(Hematopoietic Stem Cell Transplant)æ—©æœŸ(&lt;1å€‹æœˆ)ç™¼ç”Ÿçš„æ„ŸæŸ“ï¼Œä¸‹åˆ—ä½•è€…è‡´ç—…åŸä¹‹é¸é …æœ€ä¸é©ç•¶ï¼Ÿ #medicine/transplant<br />
A. Pseudomonas aeruginosa<br />
B. Herpes simplex virus<br />
<mark>C. Cytomegalovirus (CMV)</mark>  <code>ç§»æ¤å¾Œ1å€‹æœˆè‡³100å¤©</code><br />
D. Candida albicans<br />
E. Clostridium difficile  </p>
</li>
<li>
<p>ä¸‹åˆ—ä¹‹æŠ—ç”Ÿç´ é¸é …ï¼Œä½•è€…ç„¡æ³•æ²»ç™‚ææ–¯ç‰¹èŒ(Listeria monocytogenes)æ„ŸæŸ“ï¼Ÿ #medicine/Listeria <br />
A. Ampicillin<br />
<mark>B. Ceftriaxone</mark><br />
C. Vancomycin <code>é€™å€‹æ ¹æ“šç†±ç—…ä¹Ÿæ˜¯ä¸è¡Œ...</code><br />
D. Linezolid<br />
E. TMP-SMX(Trimethoprim-Sulfamethoxazole)  </p>
</li>
<li>
<p>ä»¥ä¸‹é‡å°çŒ´ç—˜(Monkeypox)çš„æ•˜è¿°ï¼Œä½•è€…æœ€ä¸é©ç•¶? #medicine/EID  #medicine/mpox<br />
A. çŒ´ç—˜ç—…æ¯’å±¬æ–¼ç—˜ç—…æ¯’ç§‘(Poxviridae)ï¼Œæ­£ç—˜ç—…æ¯’å±¬(Orthopoxvirideae)ï¼Œç‚ºé›™è‚¡DNAç—…æ¯’(dsDNA)<br />
B. æ¥ç¨®å¤©èŠ±(smallpox)ç–«è‹—ï¼Œå¯å°çŒ´ç—˜ç”¢ç”Ÿéƒ¨åˆ†å…ç–«åŠ›<br />
C. ä¸»è¦è—‰ç”±é½§é½’é¡å‹•ç‰©åŠéˆé•·é¡å‹•ç‰©å‚³æ’­çµ¦äººï¼Œå±¬äººç•œå…±é€šå‚³æŸ“ç—…(zoonosis)<br />
D. å‰é©…ç—‡ç‹€ï¼Œå¦‚ç™¼ç†±ã€é ­ç—›ã€ç–²å€¦ï¼Œç´„ç¶­æŒ1è‡³4å¤©<br />
<mark>E. ç™¼ç–¹(çš®è†šç—…ç¶)ä¿‚ç”±å››è‚¢å‘è‡‰éƒ¨åŠè»€å¹¹ä¸­å¿ƒè”“å»¶(centripetal)</mark>  <code>é€šå¸¸è‡ªè‡‰éƒ¨è”“å»¶è‡´èº«é«”å…¶ä»–éƒ¨ä½ï¼Œå››è‚¢æ¯”è»€å¹¹æ›´å¸¸è¦‹</code>  </p>
</li>
</ol>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-13 00:00:00">August 13, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              1 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="infections-in-immunocompromised-hosts"><a class="toclink" href="medicine/infections-in-immunocompromised-hosts/">Infections in Immunocompromised Hosts</a></h2>
<p>source: Pocket Medicine, 2022  </p>
<ul>
<li>Many Pts have â‰¥1 risk (eg, DM, ESRD, transplant, extremes of age)  </li>
<li>Accurate dx of opportunistic infections and targeted Rx key in this population  </li>
<li>The following is not an exhaustive list, but a delineation of common or classic etiologies  </li>
</ul>
<table>
<thead>
<tr>
<th><strong>Predisposition</strong></th>
<th><strong>Classic Infectious Etiologies</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Humoral immune dysfunction</strong>Â (eg,Â CVID, myeloma) andÂ <strong>asplenia</strong></td>
<td><strong>Encapsulated bacteria: **<em>S. pneumo</em>,Â <em>H. flu</em>,Â <em>N. meningitidis</em>Â (vaccinate against these 3, ideally prior to splenectomy)<br><br></strong>Other bacteria:<strong><em>E. coli</em>Â and other GNRs,Â <em>Capnocytophaga</em><br><br></strong>Parasites:** _Babesia, Giardia; _*<em>Viruses: *</em>VZV, echovirus, enterovirus</td>
</tr>
<tr>
<td><strong>Granulocytopenia or neutropenia</strong>Â (includesÂ DM,Â ESRDÂ â†’ functional impairment)</td>
<td><strong>Bacteria:</strong> <em>Gram positive</em>: coag âŠ– staph,Â <em>S. aureus</em>, viridans strep,Â <em>S. pneumo</em>, other strep;Â <em>Corynebacterium</em>Â spp.,Â <em>Bacillus</em>Â spp.Â <em>Gram negative</em>:Â <em>E. coli</em>,Â <em>Klebsiella</em>,Â <em>Pseudomonas</em><br><br><strong>Fungi:</strong> <em>Yeast</em>:Â <em>Candida albicans</em>Â and otherÂ <em>Candida</em>Â spp.Â <em>Molds</em>:Â <em>Aspergillus, Mucor</em>Â spp., endemic fungi and others<br><br><strong>Viruses:</strong> VZV, HSV1 and 2,Â CMV</td>
</tr>
<tr>
<td><strong>Impaired cell-mediated immunity (CMI)</strong>Â (eg, HIV/AIDS, chronic steroids, posttransplant,Â DM,Â ESRD, autoimmune dis.)</td>
<td><strong>Bacteria:</strong> <em>Salmonella spp., Campylobacter, Listeria, Yersinia, Legionella</em>(<em>Lancet</em>Â 2016;387:376)<em>, Rhodococcus, Nocardia</em>, TB, non-TB mycobacteria<br><br><strong>Fungi:</strong> <em>Candida, Crypto, Histo, Coccidio, Aspergillus, Pneumocystis, Zygomycetes</em>Â spp. and other molds<br><br><strong>Viruses:</strong> HSV,Â VZV,Â CMV,Â EBV, JC virus, BK virus<br><br><strong>Parasites:</strong> <em>Toxoplasma, Cryptosporidium, Isospora, Microsporidia Babesia; Strongyloides</em></td>
</tr>
<tr>
<td><strong>Organ dysfunction</strong></td>
<td><strong>Liver (esp. cirrhosis):</strong> <em>Vibrio</em>Â spp., encapsulated bacteria<br><br><strong>ESRD:</strong>Â impaired granulocyte fxn and CMI as above<br><br>Iron overload (or deferoxamineÂ Rx):Â <em>Yersinia</em>,Â <em>Zygomycetes</em></td>
</tr>
<tr>
<td><strong>Biologics</strong>Â (eg, TNF inhibitors, anti-B-cellÂ Rx; âœ“ forÂ TBÂ before starting)</td>
<td><strong>Bacteria:</strong>Â sepsis, septic arthritis,Â TB, NTM,Â <em>Listeria</em>,Â <em>Legionella</em><br><br><strong>Fungi:</strong> <em>Pneumocystis, Histo, Coccidio, Aspergillus</em>, endemic fungi<br><br><strong>Viruses:</strong>Â JC virus (PML),Â EBV,Â HSV,Â VZV,Â HBV<br><br><strong>Parasites:</strong> <em>Strongyloides</em>Â reactivation</td>
</tr>
</tbody>
</table>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-12 00:00:00">August 12, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicinetb/" class="md-meta__link">medicine/tb</a></li>
        
        
          
          <li class="md-meta__item">
            
              8 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="tuberculosis"><a class="toclink" href="medicinetb/tuberculosis/">Tuberculosis</a></h2>
<p>source: Pocket Medicine, 2022, å°ç£è‚ºçµæ ¸è¨ºæ²»æŒ‡å¼•ç¬¬ä¸ƒç‰ˆ  </p>
<h3 id="definitions"><a class="toclink" href="medicinetb/tuberculosis/#definitions">Definitions</a></h3>
<ul>
<li>Primary: new Mycobacterium tuberculosis (TB) in a naÃ¯ve host; symptomatic or asymptomatic; 90% of infected normal hosts will never develop clinically evident disease  </li>
<li>Latent: well-controlled infection without clinical or radiographic evidence of active disease; can persist for years to decades  </li>
<li>Reactivated: activation of latent; more likely in the setting of immunosuppression.  </li>
<li>Milliary: disseminated lympho-hematogenous spread due to primary or reactivated TB  </li>
<li>Multidrug-resistant (MDR): resistant to <strong>isoniazid (INH) &amp; rifampin</strong>. Can occur as 1Â° infxn.  </li>
<li>Extensively drug-resistant (XDR): resistant to INH, rifampin (RIF), fluoroquinolones (FQ), and at least one of amikacin, kanamycin, or capreomycin  </li>
</ul>
<h3 id="epidemiology-nejm-20163751081"><a class="toclink" href="medicinetb/tuberculosis/#epidemiology-nejm-20163751081">Epidemiology (NEJM 2016;375:1081)</a></h3>
<ul>
<li>Transmission via aerosols; untreated active dx requires airborne isolation in healthcare facilities and community isolation measures; must involve local public health authorities  </li>
<li>Acquisition: residents/travel in TB-endemic area, IVDU, resident/worker in correctional facility or homeless shelter, close contact w/ active TB  </li>
<li>Reactivation: risk is 5% in first 2 yr, 5-10% overall; â†‘ if HIV âŠ•, immunosupp. (anti-TNF, steroids), ESRD, DM, cancer, transplant, malnourished, smoker, substance use disorder  </li>
<li>åœ¨ç››è¡Œç‡ä½çš„å·²é–‹ç™¼åœ‹å®¶ï¼Œå¦‚æ­ç¾å„åœ‹ï¼Œå…¶çµæ ¸ç—…çš„ç™¼ç”Ÿå¤§éƒ¨åˆ†æ˜¯å…§å› æ€§çš„ï¼ˆendogenousï¼‰ï¼Œå³ç”±èˆŠçš„çº–ç¶­åŒ–æˆ–éˆ£åŒ–ç—…ç¶å†æ´»åŒ–è€Œä¾†ï¼›åä¹‹ï¼Œåœ¨ç››è¡Œç‡é«˜çš„åœ°å€å‰‡ç”±å¤–åœ¨çš„æ„ŸæŸ“è€Œä¾†  </li>
<li>æ ¹æ“šç ”ç©¶å ±å‘Šé¡¯ç¤ºï¼Œå’Œä¸€å€‹é–‹æ”¾æ€§ï¼ˆå‚³æŸ“æ€§ï¼‰è‚ºçµæ ¸ç—…äººè¦ªå¯†æ¥è§¸çš„å®¶äººï¼Œå¤§ç´„æœ‰<strong>30%</strong>çš„æ©Ÿç‡æœƒå—åˆ°æ„ŸæŸ“  <ul>
<li>åˆæ„ŸæŸ“ä¹‹å¾Œï¼Œä¸€èˆ¬äººçµ‚å…¶ä¸€ç”Ÿé«”å…§çµæ ¸èŒå†åº¦æ´»åŒ–è€Œç™¼ç—…ï¼ˆreactivationï¼‰çš„æ©Ÿç‡ç´„ç‚º<strong>5~10ï¼…</strong>ï¼Œå…¶ä¸­ç´„æœ‰ä¸€åŠæ˜¯åœ¨æ„ŸæŸ“å¾Œçš„<strong>å‰5å¹´</strong>ç™¼ç—…ï¼Œè€Œä»¥<strong>ç¬¬1å¹´</strong>çš„å±éšªæ€§æœ€å¤§  </li>
</ul>
</li>
</ul>
<h3 id="screening-for-latent-tb"><a class="toclink" href="medicinetb/tuberculosis/#screening-for-latent-tb">Screening for <a href="../ltbi">latent TB</a></a></h3>
<ul>
<li>Whom to screen: high likelihood of exposure and/or high risk of progression to active disease including HIV âŠ• and prior to immunosuppression (pre-transplant or anti-TNF)  </li>
<li>Relies on host immune system, so limited Se in immunosuppressed individuals  </li>
<li>Nb, testing for host exposure &amp; immune response to TB, not whether TB active (vide infra)  </li>
<li>Screening tests  <ul>
<li>IFN-Î³ release assays (IGRA): preferred test; Ag-stimulated IFN-Î³ release from Pt's T-cells. â†‘ Sp over TST/PPD in BCG vaccinated Pts.  </li>
<li>Tuberculin skin test (TST/ PPD): inject purified protein intradermally, examine for wheal 48-72 hrs later. Interpret based on max diameter of induration, not erythema.  </li>
</ul>
</li>
</ul>
<h3 id="clinical-manifestations-lancet-20163871211"><a class="toclink" href="medicinetb/tuberculosis/#clinical-manifestations-lancet-20163871211">Clinical manifestations (Lancet 2016;387:1211)</a></h3>
<ul>
<li>Constitutional symptoms are common in all manifestations, but may be absent  </li>
<li>Primary TB pneumonia: middle or lower lobe consolidation, Â± effusion, Â± cavitation  <ul>
<li>åˆæ„ŸæŸ“è®ŠåŒ–ç¾¤ä¹‹ä¸€ï¼Œæˆ–å…©è€…éƒ½æ¯”è¼ƒé¡¯è‘—ï¼Œåœ¨è‡¨åºŠä¸Šå¯ä»¥è¨ºæ–·ï¼Œä¾‹å¦‚è‚ºé–€æ·‹å·´çµè…«è„¹ï¼Œé›™æ¥µæ€§æµ¸æ½¤ç­‰  </li>
<li>åˆæ„ŸæŸ“åŸç™¼ç—…ç¶æœ¬èº«åš´é‡å´©æ¯€ï¼Œç™¼ç”Ÿæ”¯æ°£ç®¡å…§æ•£æ’­ï¼Œå½¢æˆæ»²é€æ€§å¾ˆå¼·çš„ç©ºæ´æ€§çµæ ¸ï¼Œå«ä½œ<strong>åŸç™¼è‚ºç™†(primary pthisis)</strong>  </li>
<li>æ·‹å·´çµè…«å¾—å¾ˆå¤§ï¼Œå£“è¿«æˆ–ç ´å£æ”¯æ°£ç®¡å£ï¼Œé€ æˆè‚ºå¡Œé™·ï¼Œæˆ–é˜»å¡æ€§è‚ºæ°£è…«ã€æˆ–é˜»å¡æ€§è‚ºç‚ã€æˆ–ç¶“æ”¯æ°£ç®¡è€Œæ•£æ’­è‡³å…¶ä»–è‚ºé‡ï¼Œé€™ç¨®ç¾è±¡ç¨±ç‚º<strong>ä¸Šçµæ ¸(epituberculosis)</strong>ï¼Œèƒ¸éƒ¨ X å…‰å½±åƒå¯è¦‹æ·‹å·´çµè…«å¤§ä»¥åŠè‚ºæµ¸æ½¤æˆ–é¡ä¼¼å¤§è‘‰æ€§è‚ºç‚çš„é™°å½±ã€‚è‡¨åºŠä¸Šæœ‰æ™‚å¯è¦‹é ¸éƒ¨æ·‹å·´çµè…«å¤§  </li>
<li>å»¶çºŒåˆæ¬¡æ„ŸæŸ“ç—…ç¶ï¼Œè‚ºæœ«æ¢¢éƒ¨ä½å°ç—…ç¶æœ‰æ™‚æœƒå¼•ç™¼<strong>èƒ¸è†œç‚</strong>åŠèƒ¸è…”ç©æ¶²  </li>
<li>æ·‹å·´çµç—…ç¶æŒçºŒé€²å±•ï¼Œçµæ ¸åˆ†ææ¡¿èŒé€²å…¥è¡€æµä¸­è€Œç™¼ç”Ÿ<strong>ç²Ÿç²’çµæ ¸</strong>  </li>
<li>åŒæ¨£ä»¥è¡€è¡Œæ€§æ•£æ’­è‡³è‚ºå¤–å™¨å®˜ï¼Œå¦‚éª¨é«“ã€è‚ã€è…ã€è„¾åŠä¸­æ¨ç¥ç¶“ç³»çµ±ï¼Œå½¢æˆ<strong>è‚ºå¤–çµæ ¸</strong>  </li>
</ul>
</li>
<li>TB pleurisy: pulmonary effusion Â± pericardial and peritoneal effusions secondary to granuloma breakdown and local inflammation; can occur in primary or reactivation  </li>
<li>Reactivation TB pulmonary disease: upper lobe infiltrate Â± volume loss Â± cavitation  <ul>
<li>CXRæ¿ƒæ·¡ä¸ä¸€ï¼Œé‚Šç·£ä¸æ¸…æ¥šï¼Œå¤šç™¼æ€§ï¼Œæœ‰ç©ºæ´ï¼Œ<strong>è‚ºå°–éƒ¨(S1, S2)æˆ–ä¸‹è‚ºè‘‰çš„ä¸Šè‚ºæ®µ(S6)å¤š</strong>  </li>
<li>Endobronchial TB: normal CXR  </li>
</ul>
</li>
<li>Milliary TB: diffuse millet seed-sized lesions, more common in immunosupp.  <ul>
<li>Lung, <strong>liver, spleen (80~100%)Â â†’ kidney (60%)</strong>, bone marrow (25~75%)  </li>
</ul>
</li>
<li>Extrapulmonary TB: lymphadenitis, pericarditis, peritonitis, CNS disease including meningitis, GU tract disease Â± sterile pyuria, osteoarticular disease (vertebral = Pott's disease), granulomatous hepatitis, splenitis, cutaneous disease, å–®ç´”ä¹‹çµæ ¸è‚‹è†œç©æ¶²  <ul>
<li><strong>å–‰é ­çµæ ¸ã€æ”¯æ°£ç®¡çµæ ¸ã€è…¸çµæ ¸</strong>æ˜¯æ”¯æ°£ç®¡æ’­æ•£æ‰€è‡´  </li>
<li>Intestine: terminal ileum &amp; cecumæœ€å¸¸è¦‹  </li>
<li>åœ¨å°ç£ï¼Œè‚ºçµæ ¸èˆ‡è‚ºå¤–çµæ ¸çš„æ¯”ä¾‹æ˜¯9:1  </li>
</ul>
</li>
<li>TB and HIV: HIV âŠ• at â†‘ risk infxn, reactivation (8-10%/yr without ART, higher w/ â†“ CD4), and progressive 1Â° infxn. CXR can be atypical espec. if CD4 â‰¤200 (JAMA 2005;293:2740).  </li>
</ul>
<div class="admonition note">
<p class="admonition-title">Note</p>
<p>ç´„ 50%çš„è‚ºå¤–çµæ ¸ç—…äººåŒæ™‚ç½¹æ‚£è‚ºçµæ ¸<br />
ä¸€å€‹åŒæ™‚ç½¹æ‚£è‚ºçµæ ¸èˆ‡è‚ºå¤–çµæ ¸ä¹‹ç—…äººæ‡‰æ­¸é¡ç‚ºè‚ºçµæ ¸å€‹æ¡ˆ<br />
ç²Ÿç²’æ€§çµæ ¸æœ‰è‚ºä¹‹ç—…ç¶æ­¸é¡ç‚ºè‚ºçµæ ¸<br />
ä¸€å€‹åŒæ™‚ç½¹æ‚£å¤šéƒ¨ä½è‚ºå¤–çµæ ¸ä¹‹ç—…äººå…¶æ­¸é¡ä»¥å…¶æœ€åš´é‡è€…ç‚ºä¸»  </p>
</div>
<h3 id="diagnostics-for-active-tb-cid-20176411"><a class="toclink" href="medicinetb/tuberculosis/#diagnostics-for-active-tb-cid-20176411">Diagnostics for active TB (CID 2017;64:11)</a></h3>
<p><img alt="diagnosis" src="../../assets/images/6f5f04e174c8d5d96ad668cebb8debab_MD5.jpeg" /><br />
[^1] å¿…è¦æ™‚ï¼ŒåŒ…æ‹¬èƒ¸éƒ¨é›»è…¦æ–·å±¤æƒææª¢æŸ¥ã€‚<br />
[^2] é†«å¸«å¾—è¦–ç—…æƒ…ï¼Œæ±ºå®šæ˜¯å¦é€²è¡Œç—°å¡—ç‰‡ã€NAA test åŠåŸ¹é¤Šã€‚ä½†è‹¥è‚ºçµæ ¸çš„å¯èƒ½æ€§ç›¸ç•¶ä½ï¼Œå‰‡ä¸å»ºè­°NAA testã€‚<br />
[^3] ç—°å¡—ç‰‡åŠåŸ¹é¤Šï¼Œå¿…é ˆåŒæ™‚é€²è¡Œ2~3 æ¬¡ã€‚<br />
[^4] åŸ¹é¤Šé™½æ€§æª¢é«”ç¶“é‘‘å®šç‚ºçµæ ¸åˆ†ææ¡¿èŒï¼Œå³å¯ç¢ºè¨ºç‚ºè‚ºçµæ ¸ã€‚<br />
[^5] è‹¥è‚ºçµæ ¸çš„å¯èƒ½æ€§ç›¸ç•¶ä½ï¼Œä¸å»ºè­°NAA testã€‚<br />
[^6] å¡—ç‰‡é™½æ€§ï¼Œè‡¨åºŠé†«å¸«å¯ç›´æ¥ä¸‹è¨ºæ–·ç‚ºè‚ºçµæ ¸ï¼Œä½†å»ºè­°ä»æ‡‰é€²è¡ŒNAA testã€‚<br />
[^7] æŠ—ç”Ÿç´ æ²»ç™‚å¯åœ¨å¾—çŸ¥ç—°å¡—ç‰‡é™°æ€§æˆ–ç—°æª¢é©—çš„åŒæ™‚æŠ•äºˆã€‚<br />
[^8] ä¾æ–‡ä¸­ã€Œæ ¸é…¸å¢å¹…æª¢é©—çš„åˆ¤è®€ã€å»ºè­°é€²è¡Œï¼Œä¸¦ç¶œåˆç—…äººè‡¨åºŠè¡¨ç¾åŠåŸ¹é¤Šçµæœï¼Œä¾†ç¢ºå®šæ˜¯å¦ç‚ºè‚ºçµæ ¸æˆ–å…¶ä»–è¨ºæ–·ã€‚<br />
[^9] ä¾æ–‡ä¸­ã€Œæ ¸é…¸å¢å¹…æª¢é©—çš„åˆ¤è®€ã€å»ºè­°é€²è¡Œï¼Œä¸¦ç¶œåˆç—…äººè‡¨åºŠè¡¨ç¾åŠåŸ¹é¤Šçµæœï¼Œä¾†ç¢ºå®šæ˜¯å¦ç‚ºéçµæ ¸åˆ†ææ¡¿èŒæˆ–å…¶ä»–è¨ºæ–·ã€‚<br />
[^10] è‹¥è‡¨åºŠé†«å¸«æœ‰ç–‘ç¾©æ™‚ï¼Œå¯èˆ‡ç–¾ç—…ç®¡åˆ¶ç½²çš„è½„å€å€ç®¡ä¸­å¿ƒè¯çµ¡ï¼Œä¸¦è«‹å®‰æ’å°ˆå®¶æä¾›å”è©¢ã€‚  </p>
<ul>
<li>Pulmonary TB: common CXR findings discussed above; induced sputum AFB smear &amp; culture (3 samples at least 8 h apart) Â± NAAT/ PCR (GeneXpert); consider bronchoscopy + BAL Â± transbronchial biopsy. GeneXpert can also detect RIF resistance (non-bloody sputum only). Sp 98%/Se 74%, independent of HIV status.  <ul>
<li>AFSå¡—ç‰‡ï¼šæ¯ mL æ¨™æœ¬æœ‰ <strong>5000 è‡³ 10000</strong> éš»ç´°èŒæ–¹èƒ½æª¢æ¸¬å‡º  </li>
<li>åŸ¹é¤Šï¼šæ¯ mL æ¨™æœ¬ <strong>10 è‡³ 100</strong> éš»ç´°èŒå³å¯åµæ¸¬åˆ°  <ul>
<li>å‚³çµ±Lowenstein-Jensen åŸ¹é¤ŠåŸºæˆ–Middlebrook 7H10 æˆ–7H11 ç­‰å›ºé«”åŸ¹é¤ŠåŸºï¼Œéœ€3-8æ˜ŸæœŸæ‰èƒ½åŸ¹é¤Šå‡ºçµæ ¸åˆ†ææ¡¿èŒï¼›è‹¥åŸ¹é¤Šé™°æ€§é ˆç­‰å¾…8 æ˜ŸæœŸæ‰èƒ½ç™¼å‡ºé™°æ€§å ±å‘Šã€‚  </li>
<li>è‡ªå‹•åŒ–æ¶²é«”åŸ¹é¤ŠåŸºç³»çµ±ï¼Œé™½æ€§é€šå¸¸éœ€æ™‚ç´„2è‡³4æ˜ŸæœŸå¾—çŸ¥ï¼›è‹¥åŸ¹é¤Šé™°æ€§é ˆç­‰å¾…6 æ˜ŸæœŸã€‚  </li>
<li>èŒæ ªé‘‘å®šçš„æ–¹å¼å¯ä»¥åˆ†å­ç”Ÿç‰©ã€æŠ—åŸå…ç–«æª¢æ¸¬åŠMALDI-TOFè³ªè­œå„€ç­‰æ–¹æ³•é€²è¡Œã€‚  </li>
<li>Lateral flow immunochromatographic test, ICTï¼šåµæ¸¬æ˜¯å¦å«æœ‰çµæ ¸åˆ†ææ¡¿èŒåˆ†æ³Œçš„ç‰¹å®šMPB64æŠ—åŸï¼Œå¯åœ¨15åˆ†é˜å…§å®Œæˆè©¦é©—åŠåˆ¤è®€ï¼ˆèŒé‡å¤ªå°‘æ™‚å¯èƒ½æœƒæœ‰å½é™°æ€§ï¼Œé ˆä»¥å…¶ä»–æ–¹æ³•è¼”åŠ©åˆ¤å®šï¼‰ã€‚æœ‰äº›çµæ ¸åˆ†ææ¡¿èŒç¾¤ï¼Œä¾‹å¦‚ï¼šç‰›å‹çµæ ¸åˆ†ææ¡¿èŒ(Mycobacterium bovis )ç­‰ï¼Œä¸¦ä¸å…·æœ‰MPB64æŠ—åŸï¼›ç‰¹å®šçµæ ¸åˆ†ææ¡¿èŒå¦‚æœåœ¨MPB64 åŸºå› ç™¼ç”Ÿè®Šç•°ï¼Œä¹Ÿæœ‰å¯èƒ½ç”¢ç”Ÿå½é™°æ€§ã€‚  </li>
</ul>
</li>
</ul>
</li>
<li>NATï¼šåˆ©ç”¨PCRå¯åµæ¸¬è‡¨åºŠæª¢é«”ä¹‹çµæ ¸åˆ†ææ¡¿èŒç´„<strong>10-130</strong>éš»ç´°èŒ  <ul>
<li>å¡—ç‰‡é™½æ€§ï¼šæ•æ„Ÿï¨ 92-100%ï¼Œç‰¹ç•°ï¨&gt;95%ï¼›å¡—ç‰‡é™°æ€§ä½†åŸ¹é¤Šé™½æ€§ï¼šæ•æ„Ÿï¨ä¸‹é™è‡³ 40-93%ï¼Œä½†ç‰¹ç•°ï¨ä»ç¶­æŒåœ¨å¤§æ–¼95%  </li>
<li>è‹¥è‡¨åºŠè¡¨ç¾æˆ–å½±åƒè®ŠåŒ–çš†ä¸åƒè‚ºçµæ ¸ï¼Œä¸å»ºè­°é€²è¡Œå¸¸è¦çš„ NAA æª¢é©—  </li>
<li>å¡—ç‰‡åŠ NAA æª¢é©—çš†å‘ˆé™½æ€§ï¼Œå¯æ¨æ–·ç‚ºç½¹æ‚£çµæ ¸ç—…  </li>
<li>å¡—ç‰‡å‘ˆç¾é™½æ€§ï¼Œä½†æ˜¯ NAAæª¢é©—å‘ˆé™°æ€§ï¼š<mark>å¿…é ˆæª¢æŸ¥æ˜¯å¦å›  PCR åæ‡‰ä¸­å«æœ‰æ ¸é…¸è¤‡è£½çš„æŠ‘åˆ¶ç‰©æ‰€è‡´</mark>ï¼Œè‹¥ç„¡æŠ‘åˆ¶ç‰©çš„å½±éŸ¿ï¼Œå‰‡å¯æ¨æ¸¬ç—…äººä¹‹ç—°ä¸­å­˜åœ¨æœ‰éçµæ ¸åˆ†ææ¡¿èŒè€Œéçµæ ¸èŒ  </li>
<li>å¡—ç‰‡å‘ˆé™°æ€§ï¼Œä½† NAA æª¢æŸ¥å‘ˆé™½æ€§ï¼Œå‰‡å¯ä¾è‡¨åºŠç¶œåˆåˆ¤æ–·æˆ–è€ƒæ…®å†é€²è¡Œå¦ä¸€å¥—æª¢é«”çš„ NAA æª¢é©—ï¼›å¦‚æœä»å¾—åˆ°é™½æ€§çµæœï¼Œå‰‡å¯æ¨è«–æ­¤ç—…äººå¯èƒ½å¾—åˆ°çµæ ¸ç—…  </li>
<li>å…©è€…çš†ç‚ºé™°æ€§ï¼Œå‰‡è¡¨ç¤ºç—°ä¸­æ‡‰ç„¡çµæ ¸åˆ†ææ¡¿èŒå­˜åœ¨<br />
<img alt="NAT" src="../../assets/images/1dfa6fa6e8fbe181119e586a3a6273a9_MD5.jpeg" />  </li>
</ul>
</li>
<li>GeneXpertï¼šå¯åœ¨ä¸€èˆ¬å¯¦é©—å®¤ç’°å¢ƒä½¿ç”¨ä¸¦åœ¨ 2-3 å°æ™‚å³å¾—åˆ°æª¢é©—çµæœï¼Œåœ¨å¡—ç‰‡é™½æ€§æª¢é«”ï¼Œå…¶æ•æ„Ÿï¨é”98%ã€ç‰¹ç•°ï¨é”99%ï¼›è‹¥æª¢é«”ç‚ºå¡—ç‰‡é™°æ€§ï¼Œå…¶æ•æ„Ÿï¨ä¸‹é™è‡³68%ã€ç‰¹ç•°ï¨ç‚º99%  <ul>
<li>ä¹Ÿå¯æ‡‰ç”¨æ–¼ rifampin æŠ—è—¥ä¹‹ç—°æ¶²æª¢æ¸¬ï¼Œå…¶å°æ–¼ rifampin æŠ—è—¥ä¹‹æ•æ„Ÿï¨ç‚º95%è€Œç‰¹ç•°ï¨å¯é”98%ï¼›æƒŸç•¶æª¢æŸ¥å°è±¡çš„ rifampin æŠ—è—¥æ€§ä½æ–¼5%æ™‚ï¼Œå…¶é™½æ€§é æ¸¬å€¼æœƒé™è‡³70%ä»¥ä¸‹ï¼Œæ•…ä»éœ€å‚³çµ±è—¥ç‰©æ„Ÿå—æ€§è©¦é©—çµæœæˆ–å…¶å®ƒåˆ†å­æª¢æ¸¬æ³•å†ç¢ºèªæ˜¯å¦ç‚º rifampin æŠ—è—¥  </li>
</ul>
</li>
<li>Image:  <ul>
<li>æ´»å‹•æ€§è‚ºçµæ ¸å¯è¦‹æ¿ƒæ·¡ä¸å‡ä¸”é‚Šç·£ä¸æ¸…æ¥šçš„è‚ºå¯¦è³ªç—…è®Šã€å£è¼ƒåšçš„ç©ºæ´æ€§ç—…ç¶ã€æ”¯æ°£ç®¡æ€§è‚ºç‚ã€ç²Ÿç²’ç‹€ç—…è®Šã€è‚‹è†œç©æ°´åŠèˆ‡èˆŠç‰‡æ¯”å°æœ‰è‚ºå¯¦è³ªç—…ç¶ä¹‹æ–°è®ŠåŒ–ã€‚  </li>
<li>ä½†è‹¥å±¬è‚ºçµæ ¸ç—Šç™’å¾Œæ‰€éºç•™çš„é™³èˆŠæ€§éæ´»å‹•æ€§è‚ºçµæ ¸ï¼Œå‰‡èƒ¸éƒ¨Xå…‰å½±åƒï¼Œå¸¸è¦‹å¯†é›†çš„ç¡¬çµä¼´éš¨éˆ£åŒ–é»ï¼Œé€™äº›å°ç¡¬çµä¹Ÿå¸¸ä¼´éš¨ä¸åŒç¨‹åº¦ä¹‹çº–ç¶­åŒ–çµç–¤ç—…ç¶ï¼Œåˆ†ä½ˆæ–¼è‚ºä¸Šè‘‰ï¼›åŒæ™‚äº¦å¯è¦‹è‚‹è†œè®Šåšã€‚  </li>
</ul>
</li>
<li>Timing of chest CT: æ‡·ç–‘ç‚ºæ´»å‹•æ€§è‚ºçµæ ¸ä½†èƒ¸éƒ¨Xå…‰è®ŠåŒ–ä¸æ˜é¡¯æˆ–å¤šé‡æŠ—è—¥æ€§çµæ ¸ç—…æ˜¯å¦å­˜åœ¨ç©ºæ´è€Œå¿…é ˆè€ƒæ…®é–‹åˆ€  </li>
<li>Extrapulmonary TB  <ul>
<li>Pleural/pericardial effusions or ascites: fluid sampling for AFB cx/smear, NAAT/ PCR, cell counts. Adenosine deaminase (ADA) can be â†‘, best validated in ascites. Free INFÎ³ can be elevated in pleural/ascitic fluid (not validated in pericardial effusions). Higher diagnostic yield with pleural/pericardial biopsies for disease at these sites.  </li>
<li>CSF: fluid sampling for AFB cx/smear (submit at least 10 mL), NAAT/PCR, cell count (lymphocyte predominanace), glucose (low), protein (high), ADA (high)  </li>
<li>Soft tissue: tissue biopsy with AFB staining, pathology w/ granulomas  </li>
</ul>
</li>
</ul>
<h3 id="patient-isolation"><a class="toclink" href="medicinetb/tuberculosis/#patient-isolation">Patient isolation</a></h3>
<ul>
<li>Decision based on likelihood of active disease. Consider when cough, dyspnea, hemoptysis, â‰¥1 risk factor (HIV âŠ•, foreign born, substance use disorder, homeless, recent incarceration, prior TB or exposure).  </li>
<li>Discontinue if alternative dx and AFB smear neg Ã—3, or TB treated for 2 wk &amp; AFB neg Ã—3  </li>
</ul>
<h3 id="treatment-of-active-tuberculosis-nejm-20153732149-lancet-20163871211"><a class="toclink" href="medicinetb/tuberculosis/#treatment-of-active-tuberculosis-nejm-20153732149-lancet-20163871211">Treatment of active tuberculosis (NEJM 2015;373:2149; Lancet 2016;387:1211)</a></h3>
<ul>
<li>Prior to treatment, consult ID, check LFTs, Cr, HIV &amp; hepatitis A/B/C screen, DM screen, pregnancy screen, vision testing for acuity and color, EtOH use history  </li>
<li>Treatment requires several drugs to prevent resistance (see below)  </li>
<li>Suspect MDRTB if prior TB Rx (esp. if poor adherence), travel to area w/ â†‘ rates of MDR (India, China, Eastern Europe including Russia, South Africa), exposure to person w/ likely MDR-TB (NEJM 2008;359:636)  </li>
<li><mark>â€œParadoxical worseningâ€</mark> of sx can occur after starting Rx. More common w/ extrapulm. TB &amp; more frequent/severe w/ concurrent immune reconstitution (eg, HIV âŠ• Pts started on ART, Pts taken off immunosuppression). Must r/oRx failure (repeat Cx, imaging), consider checking drug levels.  </li>
<li>Duration of treatment varies based on host, clinical manifestation, and improvement/progression on treatment  </li>
</ul>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Adverse Effects^</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (INH)</td>
<td>Hepatitis (avoidÂ EtOH), periph neuropathy (â†“ risk by suppl. vit B6), drug-induced lupus</td>
</tr>
<tr>
<td>Rifampin (RIF)</td>
<td>Orange tint of body fluids, GI upset, hepatitis (avoidÂ EtOH), hypersensitivity, fever, drug interactions</td>
</tr>
<tr>
<td>Pyrazinamide (PZA)</td>
<td>Hepatitis (avoidÂ EtOH), hyperuricemia, arthritis</td>
</tr>
<tr>
<td>Ethambutol (EMB)</td>
<td>Optic neuritis</td>
</tr>
<tr>
<td>Streptomycin (SM)</td>
<td>Ototoxicity, nephrotoxicity</td>
</tr>
<tr>
<td>Amikacin (AMK)</td>
<td>Ototoxicity, nephrotoxicity</td>
</tr>
<tr>
<td>Quinolone (moxifloxacin, levofloxacin)</td>
<td>GI upset, tendinopathy, â†‘ QTc</td>
</tr>
<tr>
<td>^Risk of hepatitis â†‘ w/ pre-existing liver disease. Consult ID, consider holding/replacing PZA or INH.</td>
<td></td>
</tr>
</tbody>
</table>
<div class="admonition warning">
<p class="admonition-title">æ¨™æº–çš„çµæ ¸æ²»ç™‚è™•æ–¹</p>
<p>INH + RMP + PZA + EMB x 60å¤© â†’ INH + RMP + EMB x 120å¤©  </p>
</div>
<ul>
<li>INH å’ŒRMP éƒ½æ•æ„Ÿè€…ï¼Œå¯è€ƒæ…®åœç”¨EMB  </li>
<li>å°æ–¼èƒ¸éƒ¨X å…‰æœ‰å»£æ³›çš„çµæ ¸ä¾µçŠ¯æˆ–æ˜¯é–‹æ´ç—…ç¶ï¼Œæˆ–è€…æ˜¯ç¬¬äºŒå€‹æœˆç—°åŸ¹é¤Šä»ç‚ºé™½æ€§ï¼Œä»¥åŠåŠ å¼·æœŸæ²’æœ‰å…¨ç¨‹ä½¿ç”¨PZA çš„ç—…äººï¼Œæ‡‰è©²å°‡æŒçºŒæœŸå»¶é•·ç‚º7 å€‹æœˆ  </li>
</ul>
<h4 id="_1"><a class="toclink" href="medicinetb/tuberculosis/#_1">è‚ºå¤–çµæ ¸çš„æ²»ç™‚æœŸé–“</a></h4>
<table>
<thead>
<tr>
<th>éƒ¨ä½</th>
<th>æ²»ç™‚æœŸé–“(æœˆ)</th>
<th>é¡å›ºé†‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>ç²’ç²’æ€§çµæ ¸</td>
<td>6-9*</td>
<td></td>
</tr>
<tr>
<td>çµæ ¸æ€§æ·‹å·´è…ºç‚</td>
<td>6-9*</td>
<td></td>
</tr>
<tr>
<td>çµæ ¸æ€§è‚‹è†œç‚</td>
<td>6-9*</td>
<td></td>
</tr>
<tr>
<td>ç”Ÿæ®–æ³Œå°¿é“çµæ ¸</td>
<td>6-9*</td>
<td></td>
</tr>
<tr>
<td>éª¨çµæ ¸</td>
<td>9-12</td>
<td>å¼·çƒˆå»ºè­°</td>
</tr>
<tr>
<td>ä¸­æ¨ç¥ç¶“ç³»çµ±çµæ ¸</td>
<td>12-18</td>
<td>å¼·çƒˆå»ºè­°</td>
</tr>
<tr>
<td>è…¹éƒ¨çµæ ¸</td>
<td>6-9*</td>
<td>éƒ¨åˆ†å»ºè­°</td>
</tr>
<tr>
<td>çµæ ¸æ€§å¿ƒåŒ…è†œç‚</td>
<td>6-9*</td>
<td>å¼·çƒˆå»ºè­°</td>
</tr>
<tr>
<td>[^*] æ—©æœŸæœ‰åŠ ç”¨å…©å€‹æœˆçš„PZAå‰‡å¯æ¡å…­å€‹æœˆçš„ç™‚ç¨‹ï¼Œå¦‚æœç„¡æ³•ä½¿ç”¨PZAå‰‡ç™‚ç¨‹ç‚ºä¹å€‹æœˆï¼›ä¸»æ²»é†«å¸«äº¦å¯è¦–ç—…äººçš„è‡¨åºŠç‹€æ³å»¶é•·æ²»ç™‚ã€‚</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="_2"><a class="toclink" href="medicinetb/tuberculosis/#_2">ç¬¬ä¸€ç·šè™•æ–¹è—¥ç‰©</a></h3>
<h4 id="isoniazid"><a class="toclink" href="medicinetb/tuberculosis/#isoniazid">Isoniazid</a></h4>
<ul>
<li>å¹²æ“¾çµæ ¸åˆ†ææ¡¿èŒmycolic acidåˆæˆï¼ŒæŠ‘åˆ¶<strong>ç´°èƒå£</strong>çš„åˆæˆ â†’ å°<strong>å¿«é€Ÿå¢æ®–</strong>çš„çµæ ¸åˆ†ææ¡¿èŒç‰¹åˆ¥æœ‰æ•ˆï¼Œ<strong>æ—©æœŸæ®ºèŒåŠ›</strong>å¼·ï¼Œä½†æ»…èŒèƒ½åŠ› (sterilizing activity) æ¬¡æ–¼RMPå’ŒPZA  </li>
<li>æŠ—è—¥æ€§åŸºå› ï¼š<strong><em>katG</em>, *inhA</strong>* mutations (3.5x10^-6)  <ul>
<li><strong><em>inhA</em></strong>çªè®Šå¼•èµ·çš„æŠ—è—¥é€šå¸¸æ˜¯<strong>ä½æ¿ƒåº¦</strong>æŠ—è—¥ï¼Œä¸€èˆ¬åŠ‘é‡ 300mg INHæ‰€é”åˆ°çš„è¡€ä¸­æ¿ƒåº¦é è¶…é inhA æŠ—è—¥èŒç¨®çš„æœ€ä½æŠ‘èŒæ¿ƒåº¦ã€‚å¦‚æœç—…äººæ²»ç™‚åæ‡‰è‰¯å¥½ï¼Œç§»é™¤INHæœƒå¼±åŒ–æ²»ç™‚æ–¹æ¡ˆ  </li>
<li><strong><em>katG</em></strong>çªè®Šå¼•èµ·çš„æŠ—è—¥é€šå¸¸æ˜¯<strong>é«˜æ¿ƒåº¦</strong>æŠ—è—¥ï¼Œéœ€è¦è¼ƒé«˜åŠ‘é‡çš„INH  </li>
</ul>
</li>
<li>AE: hepatitis, <strong><code>peripheral neuropathy</code></strong>, rash, drug fever,  </li>
<li><strong>Pyridoxine</strong> (vitamin B6, 50 mg)ï¼šç³–å°¿ç—…ã€è…åŠŸèƒ½ä¸å…¨ã€ç‡Ÿé¤Šä¸è‰¯ã€æ…¢æ€§è‚ç—…ã€é…—é…’ã€æ„ŸæŸ“HIVã€æœ«æ¢¢ç¥ç¶“ç‚ã€æ‡·å­•ã€å“ºä¹³ã€ä½¿ç”¨ cycloserineæˆ–<strong>é«˜åŠ‘é‡</strong> isoniazid (16-20 mg/kg/day) æ²»ç™‚  </li>
</ul>
<h4 id="rifampicin"><a class="toclink" href="medicinetb/tuberculosis/#rifampicin">Rifampicin</a></h4>
<ul>
<li>æŠ‘åˆ¶çµæ ¸åˆ†ææ¡¿èŒ<strong>RNA-polymerase</strong>çš„æ´»æ€§ï¼Œå°åå™¬ç´°èƒå…·è‰¯å¥½çš„ç©¿é€åŠ›ï¼Œèƒ½ç©¿é€è¨±å¤šçµ„ç¹”ä¸”é”åˆ°ç›¸ç•¶é«˜æ¿ƒï¨ï¼Œæ—©æœŸæ®ºèŒåŠ›æ¬¡æ–¼INHï¼Œä½†æœ‰æ¥µå¥½çš„æ»…èŒåŠ› (sterilizing activity)  </li>
<li>æŠ—è—¥æ€§åŸºå› ï¼š<strong><code>*rpoB</code></strong>* mutation (1.2x10^-8)  </li>
<li>AE: hepatitis, <strong><code>orange-colored urine</code></strong>, rash, <strong><code>thrombocytopenia, hemolytic anemia</code></strong>, AKI, é¡æµæ„Ÿç—‡ç‹€, drug fever  </li>
<li>æœƒ<strong>é™ä½</strong>å£æœé¿å­•è—¥æ¿ƒåº¦  </li>
</ul>
<h4 id="pyrazinamide"><a class="toclink" href="medicinetb/tuberculosis/#pyrazinamide">Pyrazinamide</a></h4>
<ul>
<li>Nicotinamide analogs, may inhibit the <strong>fatty acid synthetase I</strong> enzyme of <em>M. tuberculosis</em>ï¼Œå°å·¨å™¬ç´°èƒå…§<strong>é…¸æ€§</strong>ç’°å¢ƒä¸­<strong>ç”Ÿé•·ç·©æ…¢</strong>çš„çµæ ¸åˆ†ææ¡¿èŒæœ€å…·æ®ºèŒåŠ›ï¼Œåœ¨æ²»ç™‚çš„å‰å…©å€‹æœˆä½¿ç”¨æ™‚æ•ˆæœæœ€ä½³ï¼›ç´„30%ç¶“ç”±è‚è‡Ÿä»£è¬ï¼Œä»¥pyrazinoic acidç”±å°¿æ¶²æ’å‡ºï¼Œæœƒå½±éŸ¿å°¿ç´ (renal urate)çš„æ’é™¤ï¼Œé€ æˆé«˜å°¿é…¸è¡€ç—‡  </li>
<li>æŠ—è—¥æ€§åŸºå› ï¼š<em>pncA</em> mutation (1.0x10^-5)  </li>
<li>AE: hepatitisï¼Œç—›é¢¨ï¼Œè…¸èƒƒä¸é©ï¼ˆä¸€ç·šè—¥ç‰©ä¸­æœ€å¸¸è¦‹ï¼‰ï¼Œè¡€ç³–å‡é«˜  </li>
<li>å¡ä»‹è‹—èŒæ ªå°pyrazinamideæœ‰æŠ—è—¥æ€§  </li>
</ul>
<h4 id="ethambutol"><a class="toclink" href="medicinetb/tuberculosis/#ethambutol">Ethambutol</a></h4>
<ul>
<li>æŠ‘åˆ¶çµæ ¸åˆ†ææ¡¿èŒ<strong>ç´°èƒå£</strong>çš„åˆæˆï¼›ä¸€èˆ¬åŠ‘é‡é›–åƒ…æœ‰æŠ‘èŒèƒ½åŠ›ï¼Œè¼ƒé«˜åŠ‘é‡æ™‚early bactericidal activityä¸äºæ–¼rifampicinï¼›ç•¶æœ‰åŸç™¼æ€§INHæŠ—è—¥å­˜åœ¨æ™‚ï¼Œåˆä½µä½¿ç”¨EMBå¯èƒ½å¯ä»¥æ¸›å°‘ç”¢ç”ŸRMPæŠ—è—¥èŒæ ªï¼›CNSç©¿é€åŠ›å·®  </li>
<li>æŠ—è—¥æ€§åŸºå› ï¼šembA, embB (3.1x10^-5)  </li>
<li>AE: <strong>retrobulbar neuritis</strong> (esp. CKD) with è¦–åŠ›æ¨¡ç³Šã€ä¸­å¤®ç›²é»åŠç´…ç¶ è‰²ç›²ï¼Œè…¸èƒƒä¸é©  </li>
<li>ä¸å¯èˆ‡åˆ¶é…¸åŠ‘ (antacids) ä¸€èµ·ä½¿ç”¨  </li>
</ul>
<h4 id="rifabutin"><a class="toclink" href="medicinetb/tuberculosis/#rifabutin">Rifabutin</a></h4>
<ul>
<li>rifamycin çš„ä¸€ç¨®è¡ç”Ÿç‰©ï¼Œä½†RFB åœ¨ä¸å½±éŸ¿æ ¸ç³–æ ¸é…¸(RNA) æˆ–è›‹ç™½è³ªåˆæˆçš„æƒ…å½¢ä¸‹èƒ½æŠ‘åˆ¶èƒ¸è…ºå˜§å•¶æ”å…¥è‡³ç´°èŒçš„å»æ°§æ ¸ç³–æ ¸é…¸(DNA)å…§ï¼Œå…¶ä½œç”¨æ©Ÿè½‰èˆ‡RMP ä¸å®Œå…¨ç›¸åŒ  </li>
<li>é›–ç„¶å®ƒåœ¨è‚å…§ç™¼ç”Ÿä»£è¬ä½œç”¨ï¼Œä½†å°è‚åŠŸèƒ½ç•°å¸¸çš„ç—…äººä»èƒ½æ‡‰ç”¨ï¼Œä¸æœƒåŠ é‡INH å°è‚çš„æ¯’æ€§  </li>
<li>å¸¸è¦‹çš„å‰¯ä½œç”¨å’ŒRMP é¡ä¼¼ï¼Œæœ‰çš®ç–¹/æ”ç™¢ã€è…¸èƒƒä¸é©ã€é—œç¯€ç—›ã€è‚æ¯’æ€§ï¼›é«˜åŠ‘é‡RFB æˆ–èˆ‡clarithromycinã€fluconazole æˆ–protease inhibitors ä½µç”¨æ™‚ï¼Œæ˜“é€ æˆå–®å´æˆ–é›™å´çœ¼è‘¡è„è†œç‚(uveitis, 8%)ï¼Œè‹¥ç«‹å³åœè—¥ï¼Œå¯ç·©è§£  </li>
<li>æ¯”RMP å®¹æ˜“å¼•èµ·åš´é‡çš„ç™½è¡€çƒä½ä¸‹ç—‡ï¼ˆleukopeniaï¼Œ2%ï¼‰ï¼Œä¸”å’ŒRMPå‡ºç¾äº¤å‰æŠ—è—¥çš„å¯èƒ½æ€§æ¥µé«˜ï¼ˆcross resistanceï¼Œè‡ºç£çš„æ•¸æ“šç‚º87%ï¼‰ï¼Œå»ºè­°åªç”¨åœ¨ä¸‹åˆ—å¹¾ç¨®æƒ…å½¢ï¼š  <ul>
<li>ä½¿ç”¨è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ã€éæ ¸è‹·åéŒ„é…¶æŠ‘åˆ¶åŠ‘çš„HIV é™½æ€§ç—…äºº  </li>
<li>è‹¥ç—…äººä½¿ç”¨å£æœæŠ—å‡è¡€åŠ‘ï¼Œä¸è«–æ˜¯warfarin æˆ–æ˜¯æ–°ä¸€ä»£å£æœæŠ—å‡è¡€åŠ‘(novel oral anti-coagulant, NOAC)ï¼Œä½¿ç”¨RMP å‡æœƒå½±éŸ¿å…¶åŠŸèƒ½ï¼Œç›¸è¼ƒæ–¼RMPï¼Œrifabutin å°æŠ—å‡è¡€åŠ‘çš„ä»£è¬å½±éŸ¿ç¨‹åº¦æ¯”è¼ƒä½ï¼Œå¯è€ƒæ…®ä»¥rifabutin å–ä»£ï¼Œä¸¦æŒçºŒè§€å¯Ÿè‡¨åºŠå æ‡‰ï¼Œä¹Ÿæ‡‰æé†’ç—…äººå’Œé–‹ç«‹æŠ—å‡è¡€åŠ‘çš„é†«å¸«ï¼Œæ³¨æ„è¡€æ “å’Œå‡ºè¡€çš„é¢¨éšªã€‚  </li>
<li>ç—…äººç™¼ç”ŸRMP çš„å‰¯ä½œç”¨ï¼Œä¸”æ¸¬è©¦å¾Œç¢ºèª rifabutin å¯ä»¥é¿å…é€™å€‹å‰¯ä½œç”¨  </li>
<li>ç´°èŒå°RMP æŠ—è—¥ï¼Œä¸”DST è­‰å¯¦rifabutin å°å®ƒæœ‰æ•ˆ  </li>
</ul>
</li>
</ul>
<h3 id="_3"><a class="toclink" href="medicinetb/tuberculosis/#_3">æ²»ç™‚åæ‡‰è©•ä¼°åŠçµæœ</a></h3>
<ul>
<li>ç—°æª¢æŸ¥ï¼š  <ul>
<li>è‡³å°‘åœ¨æ²»ç™‚ç´„<strong>å…©å€‹æœˆã€äº”å€‹æœˆä»¥åŠå®Œæ²»æ™‚</strong>æ”¶é›†å…©å¥—ç—°è¿½è¹¤æª¢æŸ¥å¡—ç‰‡è€é…¸æ€§æŸ“è‰²åŠåˆ†ææ¡¿èŒåŸ¹é¤Š  </li>
<li>å°æ–¼æ²»ç™‚å‰èƒ¸éƒ¨Xå…‰é¡¯ç¤ºæœ‰é–‹æ´ç—…ç¶ã€ä¸”æ²»ç™‚å…©å€‹æœˆå¾Œä»æŒçºŒé™½æ€§çš„ç—…äººæ‡‰è©²è€ƒæ…®å°‡æ•´å€‹çµæ ¸ç—…æ²»ç™‚çš„ç™‚ç¨‹å»¶é•·è‡³å°‘<strong>ä¸‰å€‹æœˆ</strong>ï¼ˆç¸½å…±ä¹å€‹æœˆä»¥ä¸Šï¼‰  </li>
<li>å°æ–¼ç—°å¡—ç‰‡æˆ–åŸ¹é¤Šé™½æ€§çš„ç—…äººï¼Œå»ºè­°<strong>æ¯æœˆ</strong>è¿½è¹¤é©—ç—°ç›´è‡³é™°è½‰ç‚ºæ­¢  </li>
</ul>
</li>
<li>
<p>èƒ¸éƒ¨Xå…‰æª¢æŸ¥ï¼š  </p>
<ul>
<li>éå¤šé‡æŠ—è—¥çµæ ¸ç—…çš„ç—…äººï¼Œ æ²»ç™‚å‰ã€æ²»ç™‚å¾Œ1~2å€‹æœˆã€åŠå®Œæ²»æ™‚ï¼Œå»ºè­°è¿½è¹¤èƒ¸éƒ¨â…©å…‰  </li>
<li>å¤šé‡æŠ—è—¥ç—…äººå‰‡å»ºè­°<strong>æ¯ä¸‰å€‹æœˆ</strong>è¿½è¹¤èƒ¸éƒ¨â…©å…‰ï¼Œç‰¹åˆ¥æ˜¯åŠ å¼·æœŸï¼Œä»¥ä½œç‚ºè—¥ç‰©æ²»ç™‚åæ‡‰çš„åƒè€ƒã€‚ä½†æ‡‰é¿å…åªæ ¹æ“šèƒ¸éƒ¨Xå…‰å°±å†’ç„¶æ±ºå®šåœè—¥  </li>
</ul>
</li>
<li>
<p>æ²»ç™‚æ»¿äºŒå€‹æœˆï¼Œç—°å¡—ç‰‡ä»ç„¶é™½æ€§çš„ç—…äººï¼š  </p>
<ul>
<li>å¦‚æœç—…äººçš„ç—‡ç‹€æ”¹å–„ï¼Œç—°å¡—ç‰‡çš„åƒ¹æ•¸é€æ¼¸æ¸›ä½ï¼Œæˆ–æ˜¯ç—°åŸ¹é¤Šç”±é€æª¢åˆ°å›å ±é™½æ€§çš„æ™‚é–“éš¨è‘—æ²»ç™‚è€Œå»¶é•·ï¼Œé‚£å¯èƒ½æ˜¯Nonviable bacteria (NVB)ï¼Œç—°åŸ¹é¤Šæœƒæ˜¯é™°æ€§çš„ï¼Œå¯ä»¥ç¶­æŒç•¶ä¸‹çš„è™•æ–¹ï¼Œå»¶é•·PZA çš„æ²»ç™‚æ™‚ç¨‹ï¼Œä¸¦æŒçºŒè¿½è¹¤ç—…äººçš„ç—‡ç‹€ã€èƒ¸éƒ¨X å…‰å’Œç—°å¡—ç‰‡åŠåŸ¹é¤Šã€‚å¿…è¦æ™‚å¯ä»¥ç¸®çŸ­è¿½è¹¤çš„é–“éš”ï¼Œä¹Ÿå¯ä»¥å°‡ç—°é€ç–¾ç—…ç®¡åˆ¶ç½²ï¼Œé€²è¡ŒINH å’ŒRMP çš„åŸºå› æª¢æ¸¬ï¼Œäº†è§£æ˜¯å¦æœ‰æŠ—è—¥èŒæ ªçš„ç”¢ç”Ÿã€‚  </li>
</ul>
</li>
<li>
<p>çµæ ¸æ²»ç™‚çš„éç¨‹ä¸­ï¼Œä¹Ÿå¯èƒ½åŸ¹é¤Šå‡ºéçµæ ¸åˆ†ææ¡¿èŒï¼ŒNAA test é›–ç„¶èƒ½ç”¨ä¾†åˆ†è¾¦çµæ ¸èŒå’Œéçµæ ¸åˆ†ææ¡¿èŒï¼Œä½†æ˜¯NAA test é™½æ€§ï¼Œä¹Ÿå¯èƒ½æ˜¯NVBï¼Œä½¿å¾—æ±ºç­–æ›´è¤‡é›œã€‚å¦‚æœç—…äººçš„ç—…æƒ…ç©©å®šï¼Œå¯ä»¥éœå¾…åŸ¹é¤Šå’ŒèŒæ ªé‘‘å®šçš„çµæœã€‚  </p>
</li>
<li>
<p>åŠ å¼·æœŸçµæŸæ™‚ï¼Œå¦‚æœç—…äººçš„çš„æ²»ç™‚åæ‡‰ä¸å¦‚é æœŸï¼šè‡¨åºŠç—‡ç‹€å’Œè‚ºéƒ¨ç—…ç¶å½±åƒå­¸è®ŠåŒ–æ²’æœ‰æ”¹å–„ï¼Œæˆ–æ˜¯ç—°æ¶²åŸ¹é¤Šä»ç‚ºé™½æ€§ã€‚éœ€è€ƒæ…®ç—…äººé€™æ™‚èº«ä¸Šçš„ç´°èŒï¼Œå¯èƒ½å·²ç”¢ç”Ÿæ–°çš„æŠ—è—¥ï¼Œä¸èƒ½åªä¾æ“šå…ˆå‰çš„DST çµæœä¾†è¨­è¨ˆè™•æ–¹ï¼ŒåªåŠ å…¥ä¸€ç¨®æ–°è—¥ç‰©ä¼åœ–è£œå¼·ç›®å‰çš„è™•æ–¹æ˜¯å¸¸è¦‹çš„éŒ¯èª¤ï¼Œé€™éº¼åšä¸¦ä¸è¶³ä»¥å»ºç«‹ä¸€å€‹æœ‰æ•ˆçš„è™•æ–¹ï¼Œåè€Œä½¿æ–°åŠ å…¥çš„è—¥ç‰©ä¹Ÿæ›éœ²åœ¨ç”¢ç”Ÿæ–°æŠ—è—¥çš„é¢¨éšªä¸­ï¼Œä½¿æœªä¾†æ²»ç™‚çš„è™•æ–¹è¨­è¨ˆæ›´å›°é›£ã€‚æ‡‰å°‡ç—…äººçš„ç—°æª¢é«”é€é©—RMP çš„æŠ—è—¥åŸºå› ï¼Œåœ¨æœ€çŸ­çš„æ™‚é–“å…§æ’é™¤rifampicin æŠ—è—¥çš„å¯èƒ½æ€§ï¼Œå¦‚æœè¦åŠ å…¥æ–°çš„è—¥ç‰©ä¾†è£œå¼·è™•æ–¹ï¼Œé€šå¸¸éœ€åŒæ™‚åŠ å…¥3 ç¨®é æœŸæœ‰æ„Ÿå—æ€§ä¸”éå»æœªä½¿ç”¨éçš„è—¥ç‰©ï¼Œåœ¨æ›´å‹•è™•æ–¹å‰ï¼Œå»ºè­°æå‡ºç—…ä¾‹å¯©æŸ¥èˆ‡å°ˆå®¶è¨è«–ã€‚  </p>
</li>
<li>
<p>æ²»ç™’ (Cured)ï¼šç´°èŒå­¸ç¢ºè¨ºä¹‹çµæ ¸å€‹æ¡ˆæ–¼æ²»ç™‚éç¨‹ä¸­==<strong>è‡³å°‘ä¸€æ¬¡ç—°åŸ¹é¤Šé™°æ€§</strong>ä¸”<strong>æœ€å¾Œä¸€å€‹æœˆä¹‹æ²»ç™‚æ™‚ç—°åŸ¹é¤Šé™°æ€§</strong>==  </p>
</li>
<li>å®Œæ²» (Treatment completed)ï¼šç—…äººå·²å®Œæˆæ²»ç™‚ä½†å…¶ç—°æª¢é©—ç„¡æ³•æ­¸é¡ç‚ºæ²»ç™’æˆ–æ²»ç™‚å¤±æ•—  <ul>
<li>é–‹å§‹æ²»ç™‚æ™‚ç—°å¡—ç‰‡é™½æ€§çš„ç—…äººï¼Œåœ¨æ²»ç™‚éç¨‹ä¸­è‡³å°‘1æ¬¡<strong>ç—°å¡—ç‰‡é™°æ€§</strong>ä¸”æœ€å¾Œ1å€‹æœˆ<strong>ç—°å¡—ç‰‡é™°æ€§</strong>ã€‚å¡—ç‰‡ç„¡æ³•é™°è½‰çš„ç—…äººå¿…é ˆè­‰æ˜æ˜¯éçµæ ¸åˆ†ææ¡¿èŒæˆ–æ­»èŒ  </li>
<li>é–‹å§‹æ²»ç™‚æ™‚ç—°åŸ¹é¤Šé™½æ€§çš„ç—…äººï¼Œåœ¨æ²»ç™‚éç¨‹ä¸­è‡³å°‘ 1 æ¬¡ç—°<strong>åŸ¹é¤Šé™°æ€§</strong>ã€‚åŸ¹é¤Šç„¡æ³•é™°è½‰çš„ç—…äººå¿…é ˆé‘‘å®šæ˜¯<strong>éçµæ ¸åˆ†ææ¡¿èŒ</strong>  </li>
<li>æ²»ç™‚å…¨ç¨‹ç—°å¡—ç‰‡åŸ¹é¤Šéƒ½é™°æ€§çš„ç—…äººï¼Œåœ¨æ²»ç™‚éç¨‹ä¸­<strong>èƒ¸éƒ¨â…©å…‰é€²æ­¥æˆ–ç©©å®š</strong>  </li>
<li>å®Œæˆæ²»ç™‚å¾Œçš„ç›£æ¸¬ï¼šç›®å‰çš„è­‰æ“šé¡¯ç¤ºï¼Œå®Œæˆæ²»ç™‚å¾Œçš„çµæ ¸ç—…äººï¼Œæ¯”ä¸€èˆ¬äººæœ‰æ›´é«˜çš„æ©Ÿæœƒå†å¾—çµæ ¸ç—…ã€‚å®Œæ²»å¾Œçš„ç¬¬ä¸€å¹´å»ºè­°æ¯åŠå¹´è¿½è¹¤ä¸€æ¬¡ï¼Œæ­¤å¾Œæ¯å¹´è¿½è¹¤ä¸€æ¬¡ã€‚è¿½è¹¤æ™‚ï¼Œå»ºè­°å®‰æ’èƒ¸éƒ¨â…©å…‰æª¢æŸ¥ï¼Œè‹¥æœ‰å‘¼å¸é“ç—‡ç‹€ï¼Œä¹Ÿæ‡‰è€ƒæ…®é©—ç—°ã€‚  </li>
</ul>
</li>
<li>æ²»ç™‚æˆåŠŸ (Treatment success)ï¼šæ²»ç™’+å®Œæ²»  </li>
<li>æ²»ç™‚å¤±æ•—ï¼šæ²»ç™‚æ»¿å››å€‹æœˆå¾Œç—°åŸ¹é¤Šä»ç„¶é™½æ€§ï¼Œæˆ–æ˜¯æ²»ç™‚å‰ç—°åŸ¹é¤Šé™°æ€§ï¼Œä½†åœ¨æ²»ç™‚äºŒå€‹æœˆå¾ŒåŸ¹é¤Šè®Šç‚ºé™½æ€§  </li>
</ul>
<h3 id="_4"><a class="toclink" href="medicinetb/tuberculosis/#_4">å‰¯ä½œç”¨</a></h3>
<ul>
<li>çµæ ¸ç—…äººåœ¨<strong>æ²»ç™‚å‰</strong>ä»¥åŠé–‹å§‹æ²»ç™‚å¾Œçš„ç¬¬<strong>2ã€4ã€8é€±</strong>ï¼Œæ‡‰è€ƒæ…®å®‰æ’<strong>CBC/DC, BUN/Cr, AST/ALT/bil-T, uric acid</strong>ç­‰  </li>
<li>ä½¿ç”¨EMBè€…==<strong>æ¯æœˆ</strong>==æª¢æŸ¥è¦–åŠ›åŠè¾¨è‰²åŠ›ï¼Œè‹¥ç—…äººæœ‰è¼ƒé«˜çš„é¢¨éšªç™¼ç”Ÿè¦–ç¥ç¶“ç‚ï¼Œåœ¨ç¢ºå®šç‚ºè—¥ç‰©å…¨æ•æ„Ÿä¹‹çµæ ¸ç—…å¾Œï¼Œå¯è€ƒæ…®åœæ­¢ä½¿ç”¨EMB  </li>
<li>ä½¿ç”¨aminoglycosideæˆ–polypeptideé¡è—¥ç‰©çš„çµæ ¸ç—…äººå®œæ³¨æ„è¿½è¹¤è½åŠ›åŠå¹³è¡¡èƒ½åŠ›  </li>
<li>ç—…äººè‹¥æœ‰ä»¥ä¸‹ä»»ä½•ä¸€ç¨®æƒ…æ³ï¼Œå®œè€ƒæ…®åœ¨ä¸è‰¯åæ‡‰å°šæœªç·©è§£ä¹‹å‰é¸æ“‡å…¶ä»–æŠ—çµæ ¸è—¥ç‰©æ²»ç™‚ï¼š  <ol>
<li>çµæ ¸ç—…æƒ…åš´é‡ï¼Œå¯èƒ½å±åŠç”Ÿå‘½æˆ–é€ æˆç„¡æ³•å¾©åŸä¹‹å‚·å®³ï¼Œä¾‹å¦‚çµæ ¸ç—…ä½µç™¼<strong>æˆäººå‘¼å¸çª˜è¿«ç—‡ã€çµæ ¸æ€§è…¦è†œç‚</strong>ç­‰  </li>
<li>ç—…äººå…·æœ‰é«˜å‚³æŸ“åŠ›ä¸”ç„¡æ³•é©ç•¶éš”é›¢  </li>
</ol>
</li>
</ul>
<h4 id="_5"><a class="toclink" href="medicinetb/tuberculosis/#_5">è‚ç‚</a></h4>
<ul>
<li>å°ç£çµæ ¸ç—…äººçš„å¹´é½¡å±¤åé«˜ï¼ŒåŒæ™‚ç—…æ¯’æ€§è‚ç‚ç››è¡Œï¼Œå†åŠ ä¸Šè¼ƒå¤šçš„N-acetyltransferase 2çš„slowacetylatorï¼Œå› æ­¤ç”¢ç”Ÿè‚ç‚çš„æ©Ÿæœƒé«˜æ–¼å¤§éƒ¨åˆ†çµæ ¸ç—…ç››è¡Œåœ°å€  </li>
<li>åœè—¥æ¢ä»¶ï¼šæœ‰è‚ç‚ç—‡ç‹€è€ŒAST/ALTè¶…éæ­£å¸¸ä¸Šé™çš„ä¸‰å€ï¼›æˆ–ç„¡è‚ç‚ç—‡ç‹€ä½†AST/ALTè¶…éæ­£å¸¸ä¸Šé™çš„==<strong>äº”å€</strong>==  </li>
<li>è‹¥è‚ç‚ç™¼ç”Ÿæ™‚ï¼Œè‡¨åºŠåˆ¤æ–·å¿…é ˆç¹¼çºŒæŠ—çµæ ¸è—¥ç‰©æ²»ç™‚ï¼Œè€ƒæ…®ä»¥ä¸€ç¨®é‡åŠ‘ã€EMBã€åŠ ä¸Šä¸€ç¨®FQ é¡è—¥ç‰©æ²»ç™‚  <ul>
<li>ç”±æ–¼FQ é¡è—¥ç‰©ä¹Ÿå¯èƒ½é€ æˆè‚ç‚ï¼Œå› æ­¤æ²»ç™‚éç¨‹ä¸­ä»é ˆæŒçºŒè¿½è¹¤è‚åŠŸèƒ½  </li>
</ul>
</li>
<li>å¦‚æœæš«æ™‚æ²’æœ‰å¿…è¦ç¹¼çºŒæŠ—çµæ ¸è—¥ç‰©æ²»ç™‚ï¼Œå»ºè­°ç­‰å¾…è‚åŠŸèƒ½æ¢å¾©æˆ–ä¸‹é™è‡³æ­£å¸¸ä¸Šé™çš„ä¸‰å€ä»¥ä¸‹å¾Œï¼Œä¾INHâ†’RMPâ†’PZA é †åºï¼Œå†é‡æ–°é€²è¡Œæ¼¸é€²å¼çµ¦è—¥è©¦é©—ï¼Œé€ä¸€åŠ å…¥å…¶ä»–ä¸€ç·šè—¥ç‰©  <ol>
<li>ï»¿ï»¿ï»¿åœ¨æ‰€æœ‰ç¬¬ä¸€ç·šæŠ—çµæ ¸è—¥ç‰©ç•¶ä¸­ï¼ŒINHå…·æœ‰æœ€é«˜çš„æ—©æœŸæ®ºèŒåŠ›ï¼Œå¯ä»¥è¿…é€Ÿæ¸›å°‘ç—…äººé«”å…§çµæ ¸åˆ†ææ¡¿èŒé‡ï¼Œæ”¹å–„è‡¨åºŠç—‡ç‹€åŠé™ä½å‚³æŸ“åŠ›  </li>
<li>ï»¿ï»¿ï»¿é€ä¸€åŠ è—¥æ™‚ï¼Œç”±æ–¼ä½¿ç”¨çš„è—¥ç‰©ç¨®é¡å¾€å¾€ä¸è¶³ï¼Œå› æ­¤æœ€å…ˆä½¿ç”¨çš„è—¥ç‰©ï¼Œæœ€æœ‰å¯èƒ½ç”¢ç”ŸæŠ—è—¥æ€§ã€‚åŸºæ–¼ä¿è­·RMPï¼Œå„ªå…ˆåŠ å…¥INH  </li>
</ol>
</li>
<li>é€ä¸€åŠ è—¥çš„éç¨‹ä¸­ï¼Œå¯ä»¥åŒæ™‚ä½¿ç”¨è¶³å¤ åŠ‘é‡çš„EMBã€‚ä¿ŸæˆåŠŸåŠ ä¸Šè¶³å¤ æœ‰æ•ˆè—¥ç‰©å¾Œï¼Œå¯ä»¥åœæ­¢é‡åŠ‘  </li>
<li>è‹¥ç—…äººä¹‹è—¥ç‰©æ€§è‚ç‚åš´é‡æˆ–åˆä½µæœ‰é»ƒç–¸ï¼Œåœ¨æˆåŠŸåœ°é‡æ–°ä½¿ç”¨ä¸ŠINH åŠRMPä¹‹å¾Œï¼Œä¸å»ºè­°å˜—è©¦åŠ å…¥PZA<br />
<img alt="hepatits_flowchart" src="../../assets/images/eb9c6714ed9a2bd4f2e3862fe0c6477f_MD5.jpeg" /><br />
<img alt="hepatitis_challenge" src="../../assets/images/70b2c6f4f5838a906dedac0d22900aea_MD5.jpeg" />  </li>
</ul>
<h4 id="_6"><a class="toclink" href="medicinetb/tuberculosis/#_6">å°¿é…¸</a></h4>
<ul>
<li>ï»¿ï»¿Creatinineä¸Šå‡è¶…é0.5mg/dL  </li>
<li>ï»¿ï»¿åš´é‡ç„¡æ³•ç·©è§£ä¹‹ç—›é¢¨ç—‡ç‹€ã€æˆ–å·²ç¶“æ”å–è¶³å¤ æ°´åˆ†ä¸”æ¥å—ä½æ™®æ—é£²é£Ÿä¹‹å¾Œè¡€æ¸…å°¿é…¸å€¼ä»é«˜æ–¼13 mg/dLã€æˆ–é«˜å°¿é…¸è¡€ç—‡ä½µæ€¥æ€§è…åŠŸèƒ½æƒ¡åŒ–â†’åœç”¨PZA  </li>
<li>ä¸å»ºè­°ä½¿ç”¨allopurinolï¼ˆèˆ‡PZA æœ‰è—¥ç‰©äº¤äº’ä½œç”¨ï¼‰ï¼Œå¯è€ƒæ…®æ¡ç”¨é™å°¿é…¸è—¥benzbromarone  </li>
</ul>
<h4 id="_7"><a class="toclink" href="medicinetb/tuberculosis/#_7">çš®ç–¹</a></h4>
<ul>
<li>åš´é‡ç„¡æ³•ç·©è§£ä¹‹çš®ç–¹ã€æ”ç™¢ã€æˆ–ä½µç™¼toxic epidermal necrolysis, Stevens-Johnson syndrome  <ul>
<li>INH-RMP-EMBâ†’PZA de-sensitization<br />
<img alt="rash_challenge" src="../../assets/images/b3d2f56abc296d9dc6b97219bea1bada_MD5.jpeg" />  </li>
</ul>
</li>
</ul>
<h4 id="_8"><a class="toclink" href="medicinetb/tuberculosis/#_8">è…¸èƒƒä¸é©</a></h4>
<ul>
<li>ç¬¬ä¸€ç·šè—¥ç‰©ä¸­ï¼ŒPZA æ˜¯æœ€å¸¸å¼•èµ·è…¸èƒƒä¸é©çš„è—¥ç‰©ã€‚å¦å¤–ï¼Œé£¯å‰æœç”¨INH èˆ‡RMPï¼Œè¡€ä¸­è—¥ç‰©æ¿ƒåº¦æœƒæ¯”é£¯å¾Œæœç”¨ç¨é«˜ï¼Œä½†è…¸èƒƒé“çš„ä¸è‰¯åæ‡‰ä¹Ÿå› æ­¤è€Œé¡¯è‘—æé«˜ã€‚  </li>
<li>è™•ç†æ–¹å¼ï¼šå…©é€±å…§æœƒè‡ªè¡Œæ¸›ç·©æˆ–æ¶ˆå¤±ï¼Œç—‡ç‹€è¼ƒåš´é‡è€…ï¼Œå¯ä»¥å»ºè­°ç—…äººé£¯å¾Œæˆ–èˆ‡é£Ÿç‰©ä¸€èµ·æœç”¨ï¼Œæˆ–åœ¨ç¡å‰çµ¦è—¥ã€‚ä½†è‹¥ç—‡ç‹€åš´é‡ï¼Œæ‡‰ç«‹å³åœæ­¢æ‰€æœ‰æŠ—çµæ ¸è—¥ç‰©ï¼Œå¾…ç—‡ç‹€æ”¹å–„å¾Œï¼Œä¾ç…§INHâ†’RMPâ†’EMBâ†’PZA çš„é †åºé€ä¸€åŠ å…¥è¶³å¤ ä¹‹æŠ—çµæ ¸è—¥ç‰©ã€‚  </li>
</ul>
<h4 id="_9"><a class="toclink" href="medicinetb/tuberculosis/#_9">è¦–ç¥ç¶“ç‚</a></h4>
<ul>
<li>è¦–åŠ›é™ä½ã€ç´…ç¶ è‰²ç›²ï¼ˆdyschromatopsiaï¼‰ã€ä¸­å¤®ç›²é»ï¼ˆcentral scotomaï¼‰ï¼Œé€šå¸¸å…©çœ¼ä¸€èµ·ç™¼ç”Ÿ  </li>
<li>ç”±æ–¼è‡ºç£åœ°å€çµæ ¸ç—…äººçš„å¹´é½¡å±¤åé«˜ï¼Œæœ‰è¼ƒå¤šçš„ç—…äººåŒæ™‚ç½¹æ‚£ç³–å°¿ç—…æˆ–è…è‡Ÿç–¾ç—…ï¼Œè¦–ç¥ç¶“ç‚çš„æ©ŸæœƒåŒæ¨£é«˜æ–¼å¤§éƒ¨åˆ†çµæ ¸ç—…ç››è¡Œåœ°å€ï¼Œä¸”è¼ƒå¯èƒ½ç”¢ç”Ÿç„¡æ³•æ¢å¾©çš„è¦–åŠ›å‚·å®³  </li>
<li>EMB æ˜¯æœ€å¸¸è¦‹é€ æˆè¦–ç¥ç¶“ç‚çš„è—¥ç‰©ï¼Œåœ¨å»ºè­°çš„åŠ‘é‡ä¸‹ï¼ˆ15â€“20mg/kgï¼‰ï¼Œè¦–ç¥ç¶“ç‚ç™¼ç”Ÿæ©Ÿç‡å¤§ç´„ä»‹æ–¼1â€“2%ï¼Œæ°¸ä¹…è¦–åŠ›ç¼ºæçš„ç™¼ç”Ÿç‡å‰‡å°æ–¼1%  </li>
<li>å…¶ä»–æŠ—çµæ ¸è—¥ç‰©åŒ…æ‹¬INHã€rifabutinã€ethionamideã€ä»¥åŠclofazimineã€linezolid ç­‰ç­‰ï¼Œä¹Ÿéƒ½è¢«å ±å‘Šæœ‰è¦–åŠ›å‚·å®³çš„å¯èƒ½  </li>
<li>ç™¼ç”Ÿåš´é‡çš„è¦–åŠ›å‚·å®³æ™‚ï¼Œæ‡‰ç«‹å³åœæ­¢å¯èƒ½ç”¢ç”Ÿè¦–ç¥ç¶“æ¯’æ€§çš„è—¥ç‰©ï¼ŒåŒ…æ‹¬ä¸Šåˆ—æ‰€æœ‰è—¥ç‰©ï¼›å”¯æ­¤æ™‚æ‡‰ç‰¹åˆ¥æ³¨æ„è™•æ–¹æ˜¯å¦æœ‰è—¥ç‰©ç¨®é¡ä¸è¶³çš„å•é¡Œ  </li>
<li>è¼•å¾®çš„è¦–åŠ›æ¨¡ç³Šæ™‚ï¼Œå¯ä»¥å…ˆåœæ­¢EMBï¼Œä¹‹å¾Œå¯†åˆ‡è§€å¯Ÿï¼Œç…§æœƒçœ¼ç§‘é†«å¸«  </li>
</ul>
<h4 id="_10"><a class="toclink" href="medicinetb/tuberculosis/#_10">éª¨é«“æŠ‘åˆ¶</a></h4>
<ul>
<li>åš´é‡ä¹‹è²§è¡€ã€è¡€å°æ¿ä¸‹é™ã€ç´«æ–‘ã€ç™½è¡€çƒä½ä¸‹ã€æˆ–ç”šè‡³æ³›è¡€çƒå¯¡å°‘ç—‡  </li>
<li>æœ€å¸¸è¦‹çš„å¼•ç™¼è—¥ç‰©ç‚º rifabutinå’ŒRMP  </li>
<li>INHä¹Ÿæœƒç”¢ç”Ÿhemolytic anemia, agranulocytosis  </li>
<li>EMBå’ŒPZAä¹Ÿæœ‰å°è‡´è²§è¡€çš„å ±å‘Š  </li>
<li>ç•¶ç—…äººç™¼ç”Ÿåš´é‡çš„è¡€çƒç´°èƒæ¸›å°‘æ™‚ï¼Œæ‡‰ç«‹å³åœæ­¢æ‰€æœ‰æŠ—çµæ ¸è—¥ç‰©ï¼Œå¾…è¡€çƒæ¢å¾©å¾Œï¼Œä¾ INHâ†’EMBâ†’PZA çš„é †åºï¼Œé€²è¡Œæ¼¸é€²å¼çµ¦è—¥è©¦é©—ï¼Œé€ä¸€åŠ å…¥å…¶ä»–ä¸€ç·šè—¥ç‰©  </li>
</ul>
<h4 id="_11"><a class="toclink" href="medicinetb/tuberculosis/#_11">è…åŠŸèƒ½æƒ¡åŒ–</a></h4>
<ul>
<li>é«˜å°¿é…¸é€ æˆcrystal uropathy  </li>
<li>RMP å°è‡´interstitial nephritis  </li>
<li>å…¶ä»–èº«é«”ç‹€æ³æ”¹è®Šå°è‡´æ€¥æ€§è…æå‚·  </li>
<li>ä¸€æ—¦ç™¼ç¾è…åŠŸèƒ½æƒ¡åŒ–ï¼Œé™¤äº†åœæ­¢æŠ—çµæ ¸è—¥ç‰©æ²»ç™‚ä»¥å¤–ï¼Œä¹Ÿæ‡‰è©²å®‰æ’é€²ä¸€æ­¥æª¢æŸ¥æˆ–ç…§æœƒè…è‡Ÿç§‘é†«å¸«é‘‘åˆ¥è¨ºæ–·ã€‚ä¹‹å¾Œå¾…è…åŠŸèƒ½æ¢å¾©æˆ–ç©©å®šå¾Œï¼Œå†é€ä¸€ä¸Šè—¥  </li>
</ul>
<h4 id="_12"><a class="toclink" href="medicinetb/tuberculosis/#_12">ç”¢ç”Ÿä¸è‰¯åæ‡‰ä¹‹å¾Œè™•ç†èª¿æ•´çš„å»ºè­°</a></h4>
<p><img alt="regimen_adjust" src="../../assets/images/5820fcb1f443750d420fb2328167d274_MD5.jpeg" /></p>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicineabx/" class="md-meta__link">medicine/abx</a></li>
        
        
          
          <li class="md-meta__item">
            
              8 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="antibiotics"><a class="toclink" href="medicineabx/antibiotics/">Antibiotics</a></h2>
<h3 id="_1"><a class="toclink" href="medicineabx/antibiotics/#_1">ä½œç”¨æ©Ÿåˆ¶</a></h3>
<p><img alt="mechanism" src="../../assets/images/d5cd1072950af118968f9283c66a7d7c_MD5.jpeg" />  </p>
<table>
<thead>
<tr>
<th>ANTIBACTERIAL AGENT(S)</th>
<th>MAJOR TARGET</th>
<th>MECHANISM(S) OF ACTION</th>
<th>MECHANISM(S) OF RESISTANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Î²-Lactams (penicillins, cephalosporins, monobactams, carbapenems)</td>
<td>Cell-wall synthesis</td>
<td>Bind cell-wall cross-linking enzymes (PBPs, <strong>transpeptidases</strong>)</td>
<td>1. Drug inactivation by Î²-lactamases<br>    <br>2. Altered PBP targets<br>    <br>3. Reduced diffusion through porin channels<br>    <br>4. Altered iron uptake proteins (cefiderocol)</td>
</tr>
<tr>
<td>Glycopeptides and lipoglycopeptides (vancomycin, teicoplanin, telavancin, dalbavancin, oritavancin)</td>
<td>Cell-wall synthesis</td>
<td>Block cell wall glycosyltransferases by binding D-Ala-D-Ala stem-peptide terminus<br><br>Teicoplanin, telavancin, dalbavancin, and oritavancin: affect membrane function</td>
<td>1. Altered D-Ala-D-Ala target (D-Ala-D-Lac)<br>    <br>2. Increased D-Ala-D-Ala target binding at sites distant from cell wall synthesis enzymes</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>Cell-wall synthesis</td>
<td>Blocks lipid carrier of cell wall precursors</td>
<td>Active drug efflux</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>Cell-wall synthesis</td>
<td>Blocks linkage of stem peptide to NAG by enoyltransferase</td>
<td>1. Target enzyme overexpression<br>    <br>2. Drug-modifying enzymes</td>
</tr>
<tr>
<td>Aminoglycosides (gentamicin, tobramycin, amikacin, plazomicin)</td>
<td>Protein synthesis</td>
<td>Bind 30S ribosomal subunit<br><br>Block translocation of peptide chain<br><br>Cause misreading of mRNA</td>
<td>1. Drug-modifying enzymes<br>    <br>2. Methylation at ribosome binding site<br>    <br>3. Decreased permeation to target due to active efflux</td>
</tr>
<tr>
<td>Tetracyclines (tetracycline, doxycycline, minocycline)</td>
<td>Protein synthesis</td>
<td>Bind 30S ribosomal subunit<br><br>Inhibit peptide elongation</td>
<td>1. Active drug efflux<br>    <br>2. Ribosomal protection proteins</td>
</tr>
<tr>
<td>Tigecycline, eravacyclin, omadacycline</td>
<td>Protein synthesis</td>
<td>Same as tetracyclines</td>
<td>Active drug efflux (pumps different from those affecting tetracyclines)</td>
</tr>
<tr>
<td>Macrolides (erythromycin, clarithromycin, azithromycin) and the ketolide telithromycin</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Block peptide chain exit</td>
<td>1. Methylation at ribosome binding site<br>    <br>2. Active drug efflux</td>
</tr>
<tr>
<td>Lincosamides (clindamycin)</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Block peptide bond formation</td>
<td>Methylation at ribosome binding site</td>
</tr>
<tr>
<td>Streptogramins (quinupristin, dalfopristin)</td>
<td>Protein synthesis</td>
<td>Same as macrolides</td>
<td>1. Same as macrolides<br>    <br>2. Drug-modifying enzymes</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>Protein synthesis</td>
<td>Binds 50S ribosomal subunit<br><br>Blocks aminoacyl tRNA positioning</td>
<td>Drug-modifying enzymes</td>
</tr>
<tr>
<td>Oxazolidinones (linezolid, tedizolid)</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Inhibit initiation of peptide synthesis</td>
<td>1. Altered rRNA binding site<br>    <br>2. Methylation of ribosome binding site</td>
</tr>
<tr>
<td>Pleuromutilins (lefamulin)</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Blocks peptidyl transferase center</td>
<td>1. Altered L3 and L4 protein binding site<br>    <br>2. Methylation of ribosome binding site</td>
</tr>
<tr>
<td>Mupirocin</td>
<td>Protein synthesis</td>
<td>Blocks isoleucyl tRNA synthetase</td>
<td>1. Acquired resistant tRNA synthetase (drug bypass)<br>    <br>2. Altered native tRNA synthetase target</td>
</tr>
<tr>
<td>Sulfonamides (sulfadiazine, sulfisoxazole, and sulfamethoxazole)</td>
<td>Folate synthesis</td>
<td>Inhibit dihydropteroate synthetase</td>
<td>Acquired resistant dihydropteroate synthetase (drug bypass)</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>Folate synthesis</td>
<td>Inhibits dihydrofolate reductase</td>
<td>Acquired resistant dihydrofolate reductase (drug bypass)</td>
</tr>
<tr>
<td>Quinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin, delafloxacin)</td>
<td>DNA synthesis</td>
<td>Inhibit DNA gyrase and DNA topoisomerase IV<br><br>Enzymeâ€“DNAâ€“drug complex: blocks DNA replication apparatus</td>
<td>1. Altered target(s)<br>    <br>2. Active efflux<br>    <br>3. Protection of target from drug<br>    <br>4. Drug-modifying enzyme (ciprofloxacin)</td>
</tr>
<tr>
<td>Rifamycins (rifampin, rifabutin, rifapentine)</td>
<td>RNA synthesis</td>
<td>Inhibit RNA polymerase</td>
<td>Altered target</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Nucleic acid synthesis</td>
<td>Reduces reactive drug derivatives that damage DNA</td>
<td>Altered drug-activating enzymes</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Nucleic acid synthesis</td>
<td>Reduces reactive drug derivatives that damage DNA</td>
<td>1. Altered drug-activating enzyme<br>    <br>2. Acquired detoxifying enzymes<br>    <br>3. Active efflux</td>
</tr>
<tr>
<td>Polymyxins (polymyxin B and polymyxin E [colistin])</td>
<td>Cell membrane</td>
<td>Bind LPS and disrupt both outer and cytoplasmic membranes</td>
<td>Altered cell-membrane charge with reduced drug binding</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>Cell membrane</td>
<td>Produces membrane channel and membrane leakage</td>
<td>Altered cell-membrane charge with reduced drug binding</td>
</tr>
</tbody>
</table>
<h4 id="_2"><a class="toclink" href="medicineabx/antibiotics/#_2">æŠ—è—¥æ€§æ©Ÿè½‰</a></h4>
<p><img alt="resistance_zh" src="../../assets/images/be7c385cf6d7376b54c4de4794df94d7_MD5.jpeg" /><br />
<img alt="resistance_en" src="../../assets/images/64e57133364b2f9716df1ac514b4d418_MD5.jpeg" />  </p>
<h4 id="_3"><a class="toclink" href="medicineabx/antibiotics/#_3">è—¥ç‰©å‹•åŠ›å­¸</a></h4>
<ul>
<li>è—¥ç‰©å‹•åŠ›å­¸ï¼šæè¿°è—¥ç‰©åœ¨é«”å…§çš„åˆ†å¸ƒæƒ…æ³  </li>
<li>è—¥æ•ˆå‹•åŠ›å­¸ï¼šæè¿°è—¥ç‰©ä½œç”¨æ–¼ç—…åŸé«”çš„æ±ºå®šå› ç´ ï¼Œä¸¦èˆ‡è—¥ç‰©å‹•åŠ›å­¸å› ç´ ç›¸é—œ  </li>
</ul>
<h5 id="_4"><a class="toclink" href="medicineabx/antibiotics/#_4">æ¿ƒåº¦ä¾è³´å‹æŠ—ç”Ÿç´ </a></h5>
<p>é€™é¡æŠ—ç”Ÿç´ å¤šç‚ºæŠ‘åˆ¶ç´°èŒè›‹ç™½è³ªæˆ–æ ¸é…¸åˆæˆçš„æŠ—ç”Ÿç´ ï¼Œå¦‚aminoglycosidesã€fluoroquinolonesï¼Œå› å…¶æ®ºèŒä½œç”¨èˆ‡è¡€ä¸­æ¿ƒåº¦å‘ˆæ­£æ¯”ï¼Œç‚ºé”æœ€å¤§ä¹‹æ®ºèŒä½œç”¨ï¼Œå»ºè­°æŠ—ç”Ÿç´ ä¹‹Cmaxé ˆé«˜æ–¼MIC 4å€ä»¥ä¸Šï¼Œä¸”å› å…¶æœ‰æŠ—ç”Ÿç´ å¾Œæ•ˆæ‡‰ (Post-antibiotic effect,PAE) çš„ç‰¹æ€§ï¼Œå³ä¾¿è¡€ä¸­è—¥ç‰©æ¿ƒåº¦åœ¨çµ¦è—¥é–“éš”æœŸé–“å…§ä½æ–¼MICï¼Œä»å¯ç¶­æŒä¸€å®šçš„æŠ—èŒä½œç”¨ã€‚å› æ­¤æ¡é«˜åŠ‘é‡ã€å»¶é•·çµ¦è—¥é–“éš”çš„æ–¹å¼æŠ•äºˆæ˜¯æ¯”è¼ƒç†æƒ³çš„æ–¹å¼ï¼Œonce-daily<br />
aminoglycosideçš„çµ¦è—¥æ¨¡å¼å³ä»¥æ­¤ç†å¿µæ‰€ç™¼å±•ã€‚  </p>
<h5 id="_5"><a class="toclink" href="medicineabx/antibiotics/#_5">æ™‚é–“ä¾è³´å‹æŠ—ç”Ÿç´ </a></h5>
<p>é€™é¡æŠ—ç”Ÿç´ å¤šç‚ºbeta-lactamsé¡ï¼Œå¦‚penicillinã€cephalosporinsã€‚å°penicillinå’Œcephalosporinsè€Œè¨€ï¼Œè¡€ä¸­è—¥ç‰©æ¿ƒåº¦&gt;MICçš„æ™‚é–“è¶Šé•·è¶Šèƒ½æ»²é€é«”å…§çµ„ç¹”ï¼Œå»ºè­°æ²»ç™‚æœŸé–“çš„è¡€ä¸­æ¿ƒåº¦æœ‰50%ä»¥ä¸Šçš„æ™‚é–“é«˜æ–¼MICï¼Œä»¥é”ç™‚æ•ˆæœ€å¤§åŒ–ã€æŠ—ç”Ÿç´ è€è—¥æ€§æœ€å°åŒ–çš„ç›®æ¨™ã€‚æ­¤é¡è—¥å“ä»¥é€£çºŒè¼¸æ³¨æˆ–å»¶é•·è¼¸æ³¨æ™‚é–“çš„æ–¹å¼çµ¦è—¥ï¼Œé™¤äº†å¯ç©©å®šæŠ—ç”Ÿç´ è¡€ä¸­æ¿ƒ<br />
åº¦çš„è®ŠåŒ–ã€ä¸å¢åŠ é‡ç—‡æ‚£è€…AKIçš„ç™¼ç”Ÿç‡å¤–ï¼Œå°æ•´é«”çš„é†«ç™‚ç…§è­·æ”¯å‡ºè²»ç”¨ä¹Ÿå¯é¡¯è‘—é™ä½ã€‚  </p>
<h5 id="_6"><a class="toclink" href="medicineabx/antibiotics/#_6">æ›²ç·šä¸‹é¢ç©/æœ€ä½æŠ‘èŒæ¿ƒåº¦ç›¸é—œ</a></h5>
<p>å¦‚vancomycinï¼Œå»ºè­°è¡€ä¸­è—¥ç‰©æ¿ƒåº¦ä¹‹æ›²ç·šä¸‹é¢ç© (AUC) èˆ‡MICæ¯”å€¼é”åˆ°400-600<br />
mg Ã— h/Lçš„ç›®æ¨™ï¼ˆå‡è¨­MICç‚º1ï¼‰ï¼Œå¯ç¢ºä¿æŠ—ç”Ÿç´ ç™‚æ•ˆèˆ‡å®‰å…¨æ€§ã€‚  </p>
<h4 id="penetrationtissue-concentration"><a class="toclink" href="medicineabx/antibiotics/#penetrationtissue-concentration">Penetration/Tissue concentration</a></h4>
<ul>
<li>éBBB: penicillin, ampicillin, oxacillin, 3rd-4th cephalosporins, moxifloxacin, vancomycin, chloramphenicol, rifampin, imipenem, meropenem, trimethoprim-sulfamethoxazole  </li>
<li>Prostatitis/epididymo-orchitis: ceftriaxone, doxycycline, fluoroquinolones, trimethoprim-sulfamethoxazole  </li>
<li>Endophthalmitis: 3rd cepha, vancomycin  </li>
</ul>
<h3 id="_7"><a class="toclink" href="medicineabx/antibiotics/#_7">æœ¬é™¢æœ‰çš„æŠ—ç”Ÿç´ </a></h3>
<h4 id="cephalosporins"><a class="toclink" href="medicineabx/antibiotics/#cephalosporins">Cephalosporins</a></h4>
<p>ç¬¬ä¸€ä»£ï¼šCefazolin, cephalexin (PO)<br />
ç¬¬äºŒä»£ï¼šCefuroxime (IV, PO)<br />
ç¬¬ä¸‰ä»£ï¼šCeftriaxone, ceftazidime, cefoperazone/sulbactam, ceftazidime/avibactam, cefixime (PO)<br />
ç¬¬å››ä»£ï¼šCefepime<br />
ç¬¬äº”ä»£ï¼šCeftaroline  </p>
<h4 id="penicillins"><a class="toclink" href="medicineabx/antibiotics/#penicillins">Penicillins</a></h4>
<p>Penicillin G, penicillin benzathine (IM)<br />
Oxacillin, dicloxacillin (PO)<br />
Ampicillin, ampicillin/sulbactam<br />
Amoxicillin, amoxicillin/clavulanic acid (PO)<br />
Piperacillin, piperacillin/tazobactam  </p>
<h4 id="carbapenems"><a class="toclink" href="medicineabx/antibiotics/#carbapenems">Carbapenems</a></h4>
<p>Ertapenem, imipenem/cilastatin, meropenem  </p>
<h4 id="aminoglycosides"><a class="toclink" href="medicineabx/antibiotics/#aminoglycosides">Aminoglycosides</a></h4>
<p>Gentamicin, amikacin  </p>
<h4 id="fluoroquinolones"><a class="toclink" href="medicineabx/antibiotics/#fluoroquinolones">Fluoroquinolones</a></h4>
<p>Moxifloxacin, ciprofloxacin, levofloxacin (IV, PO)  </p>
<h4 id="tetracyclines"><a class="toclink" href="medicineabx/antibiotics/#tetracyclines">Tetracyclines</a></h4>
<p>Tetracycline (PO), doxycycline (PO), tigecycline, minocycline  </p>
<h4 id="macrolides"><a class="toclink" href="medicineabx/antibiotics/#macrolides">Macrolides</a></h4>
<p>Azithromycin (PO), clarithromycin (PO), erythromycin  </p>
<h4 id="glycopeptides-lipoglycopeptides-daptomycin-oxazolidinones"><a class="toclink" href="medicineabx/antibiotics/#glycopeptides-lipoglycopeptides-daptomycin-oxazolidinones">Glycopeptides, lipoglycopeptides, daptomycin, oxazolidinones</a></h4>
<p>Vancomycin, teicoplanin, daptomycin, linezolid (IV, PO)  </p>
<h4 id="other-anti-bacterials"><a class="toclink" href="medicineabx/antibiotics/#other-anti-bacterials">Other anti-bacterials</a></h4>
<p>Clindamycin (PO)<br />
Fosfomycin (IV, PO)<br />
Trimethoprim-sulfamethoxazole (PO)<br />
Colistin<br />
Metronidazole (IV, PO)<br />
Rifampin, isoniazid, ethambutol, pyrazinamide (PO)  </p>
<h4 id="anti-fungals"><a class="toclink" href="medicineabx/antibiotics/#anti-fungals">Anti-fungals</a></h4>
<p>Fluconazole (IV, PO): å°<em>Aspergillus spp., Candida krusei</em>ç„¡æ•ˆ; <em>Candida glabrata, Candida tropicalis</em>ä¹Ÿå¯èƒ½æ²’æ•ˆ<br />
Voriconazole (IV, PO)<br />
Isavuconazole<br />
Anidulafungin<br />
Amphotericin B liposome  </p>
<h3 id="_8"><a class="toclink" href="medicineabx/antibiotics/#_8">æŠ—èŒç¯„åœ</a></h3>
<p><img alt="../assets/images/7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg|7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg" src="../../assets/images/7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg|7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg" /><br />
<a href="http://charliekuo.com/?p=3114">Source</a>  </p>
<h4 id="anfi-fungals"><a class="toclink" href="medicineabx/antibiotics/#anfi-fungals">Anfi-fungals</a></h4>
<table>
<thead>
<tr>
<th>Organism</th>
<th>AmB</th>
<th>Fluconazole</th>
<th>Vori</th>
<th>Isavu</th>
<th>Anidulafungin</th>
<th>5FC</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Candida albicans</em></td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><em>C. parapsilosis</em></td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><em>C. tropicalis</em></td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><em>C. glabrata</em></td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td><em>C. krusei</em></td>
<td>+</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td><em>Cryptococcus</em> spp.</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>++</td>
</tr>
<tr>
<td><em>Aspergillus fumigatus</em></td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><em>A. flavus</em></td>
<td>+-</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><em>A. terreus</em></td>
<td>-</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><em>A. nigger</em></td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Mucorales</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><em>Fusarium spp.</em></td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<h4 id="mdro"><a class="toclink" href="medicineabx/antibiotics/#mdro">MDRO</a></h4>
<table>
<thead>
<tr>
<th>æŠ—è—¥æ€§ç´°èŒ</th>
<th>å¯æ²»ç™‚è—¥ç‰©ï¼ˆç²—é«”å­—ç‚ºé¦–é¸ï¼‰</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amp-C Î²-lactamase GNB</td>
<td>cefepime, <strong>carbapenems</strong>, fluoroquinolones, tigecycline</td>
</tr>
<tr>
<td>ESBL</td>
<td><strong>carbapenems</strong>, (ceftazidime, piperacillin/tazobactam, fluoroquinolone, trimethoprim-sulfamethoxazole, tigecycline, fosfomycin)</td>
</tr>
<tr>
<td>MRSA</td>
<td><strong>vancomycin</strong>, teicoplanin, daptomyxin, linezolid, tigecycline, ceftaroline, (trimethoprim-sulfamethoxazole, clindamycin, doxycycline)</td>
</tr>
<tr>
<td>PsA</td>
<td>pip/tazo, ceftazidime, cefoperazone, cefepime, ceftazidime/avibactam, meropenem, imipenem, doripenem, ciprofloxacin, levofloxacin, aminoglycosides, cefiderocol, aztreonam</td>
</tr>
<tr>
<td>MDRAB</td>
<td>carbapenem, <strong>sulbactam</strong>, colistin, tigecycline, minocycline, cefiderocol</td>
</tr>
<tr>
<td>CRE</td>
<td>ceftazidime/avibactam, aminoglycosides, colistin, tigecycline, minocycline, cefidericol, aztreonam</td>
</tr>
<tr>
<td>VRE</td>
<td><strong>linezolid</strong>, daptomycin, tigecycline, fosfomycin</td>
</tr>
<tr>
<td>PRSP</td>
<td>ceftriaxone, vancomycin, teicoplanin, tigecycline</td>
</tr>
</tbody>
</table>
<h4 id="_9"><a class="toclink" href="medicineabx/antibiotics/#_9">ç‰¹æ®Šç´°èŒ</a></h4>
<ul>
<li>Enterococcus: <strong>ampicillin</strong>; cephalosporinsæ²’æœ‰æ•ˆ  </li>
<li>Listeria monocytogenes: <strong>ampicillin</strong>; linezolid, trimethoprim-sulfamethoxazole, penicillin, gentamicin  </li>
<li>Clostridioides difficile: metronidazole, vancomycin, fidaxomicin  </li>
<li>Pasteurella multocida: <strong>amoxicillin/clavulanic acid</strong>, penicillin, amoxicillin, cefuroxime, levofloxacin, moxifloxacin, doxycycline, trimethoprim-sulfamethoxazole  </li>
<li>Neisseria gonorrhoeae: <strong>ceftriaxone</strong>  </li>
<li>Neisseria meningitides: <strong>penicillin</strong>; ceftriaxone  </li>
<li>Salmonella spp.: <strong>ceftriaxone</strong>, fluoroquinolone  </li>
<li>Vibrio: tetracyclines, fluoroquinolone, trimethoprim-sulfamethoxazole  </li>
<li>Stenotrophomonas maltophila: <strong>trimethoprim-sulfamethoxazole</strong>; levofloxacin, minocycline, colistin  </li>
<li>Burkholderia pseudomallei: ceftazidime, meropenem, imipenem  </li>
<li>Legionella: azithromycin or quinolone  </li>
<li>Treponema pallidum: penicillin; ceftriaxone, doxycycline  </li>
<li>Mycoplasma pneumoniae: tetracyclines, erythromycin  </li>
<li>Chlamydia spp.: tetracyclines, azithromycin  </li>
<li>Anaerobes: <strong>metronidazole</strong>, amp/sulb, pip/tazo, cephamycin, carbapenems, clindamycin, moxifloxacin, tigecycline  </li>
</ul>
<h4 id="drugs-of-choices"><a class="toclink" href="medicineabx/antibiotics/#drugs-of-choices">Drugs of choices</a></h4>
<table>
<thead>
<tr>
<th>ANTIMICROBIAL(S)</th>
<th>INFECTIONS</th>
<th>COMMON PATHOGENS (% SUSCEPTIBLE); RESISTANCE AS NOTED[^a]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin G</td>
<td>æ¢…æ¯’ï¼›yawsï¼›é‰¤ç«¯èºæ—‹é«”ç—…ï¼›éˆçƒèŒæ„ŸæŸ“ï¼›è‚ºç‚éˆçƒèŒæ„ŸæŸ“ï¼›æ”¾ç·šèŒç—…ï¼›å£è…”å’Œç‰™å‘¨æ„ŸæŸ“ï¼›æµè¡Œæ€§è…¦è†œç‚åŠè…¦è†œç‚é›™çƒèŒè¡€ç—‡ï¼›è‰ç¶ è‰²éˆçƒèŒå¿ƒå…§è†œç‚ï¼›æ¢­ç‹€èŠ½å­¢æ¡¿èŒæ€§è‚Œå£æ­»ï¼›ç ´å‚·é¢¨ï¼›é¼ å’¬ç†±ï¼›Pasteurella multocida æ„ŸæŸ“ï¼›ä¸¹æ¯’ï¼ˆErysipelothrix rhusiopathiaeï¼‰</td>
<td><em>Neisseria meningitidis</em>; viridans streptococci (69%); <em>Streptococcus pneumoniae</em> (97% nonmeningitis; 75% meningitis)</td>
</tr>
<tr>
<td>Ampicillin, amoxicillin</td>
<td>Salmonellosis; æ€¥æ€§ä¸­è€³ç‚; <em>Haemophilus influenzae</em> è…¦è†œç‚å’Œæœƒå­ç‚ ; <strong><em>Listeria monocytogenes</em> è…¦è†œç‚; <em>Enterococcus faecalis</em> UTI</strong></td>
<td><em>Escherichia coli</em> (51%); <em>H. influenzae</em> (70%); <em>Salmonella</em> spp. (85%)</td>
</tr>
<tr>
<td>Nafcillin, oxacillin</td>
<td><strong>MSSA</strong>èŒè¡€ç—‡å’Œå¿ƒå…§è†œç‚</td>
<td><em>Staphylococcus aureus</em> (70%); coagulase-negative staphylococci (50%)</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>è…¹è…”å…§æ„ŸæŸ“ï¼ˆå…¼æ€§è…¸é“é©è˜­æ°é™°æ€§æ¡¿èŒå’Œçµ•å°å­æ°§èŒï¼‰ï¼›æ··åˆèŒå¢å¼•èµ·çš„æ„ŸæŸ“ï¼ˆå¸å…¥æ€§è‚ºç‚ã€ç³–å°¿ç—…è¶³æ½°ç˜ï¼‰ï¼›ç”± Pseudomonas aeruginosa å¼•èµ·çš„æ„ŸæŸ“</td>
<td><em>P. aeruginosa</em> (82%)</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>E. coli UTIï¼›æ‰‹è¡“é é˜²ï¼›MSSA èŒè¡€ç—‡å’Œå¿ƒå…§è†œç‚</td>
<td><em>E. coli</em> (82%)</td>
</tr>
<tr>
<td>Cefoxitin, cefotetan</td>
<td>è…¹è…”å…§æ„ŸæŸ“å’Œéª¨ç›†ç‚æ€§ç–¾ç—…</td>
<td><em>Bacteroides fragilis</em> (60%)[^b]</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>æ·‹ç—…ï¼›è‚ºç‚éˆçƒèŒè…¦è†œç‚ï¼›è‰ç¶ è‰²éˆçƒèŒå¿ƒå…§è†œç‚ï¼›æ²™é–€æ°èŒç—…å’Œå‚·å¯’ï¼›ç”±é<em>Pseudomonas aeruginosa</em>å¼•èµ·çš„é™¢å…§æ„ŸæŸ“</td>
<td><em>S. pneumoniae</em> (91% meningitis; 99% nonmeningitis); <em>E. coli</em> (90%); <em>Klebsiella pneumoniae</em> (88%)</td>
</tr>
<tr>
<td>Ceftazidime, cefepime</td>
<td>ç”±å…¼æ€§é©è˜­æ°é™°æ€§æ¡¿èŒå’Œ <em>Pseudomonas</em> spp. å¼•èµ·çš„é™¢å…§æ„ŸæŸ“</td>
<td><em>P. aeruginosa</em> (86%)</td>
</tr>
<tr>
<td>Ceftaroline</td>
<td><em>S. pneumoniae</em>, MSSA, <em>H. influenzae, K. pneumoniae, Klebsiella oxytoca, E. coli</em>å¼•èµ·çš„CAPï¼›ç”± MSSA, MRSA, <em>Streptococcus pyogenes, Streptococcus agalactiae, E. coli, K. pneumoniae, K. oxytoca</em> å¼•èµ·çš„æ€¥æ€§ç´°èŒæ€§çš®è†šåŠçš®è†šçµæ§‹æ„ŸæŸ“</td>
<td>å¤§å¤šæ•¸å° Ceftaroline æ•æ„Ÿï¼›ä¾†è‡ªå–®ä¸€å¸Œè‡˜é†«é™¢çš„å››æ ª MRSA åˆ†é›¢æ ªå° Ceftaroline çš„ MIC &gt;4 Î¼g/mL[^c]ï¼›å…¶ä»–å€‹æ¡ˆå ±å‘Šï¼ŒåŒ…æ‹¬åœ¨æœªæ›¾æ¥è§¸ ceftaroline çš„æ‚£è€…[^d,e]</td>
</tr>
<tr>
<td>Ceftazidime-avibactam, meropenem-vaborbactam</td>
<td>ç”±æŠ—è—¥æ€§é©è˜­æ°é™°æ€§èŒï¼ˆåŒ…æ‹¬ <em>Pseudomonas</em> å’Œä¸€äº›å­æ°§èŒï¼‰å¼•èµ·çš„è¤‡é›œæ€§å°¿è·¯æ„ŸæŸ“å’Œè¤‡é›œæ€§è…¹è…”å…§æ„ŸæŸ“ï¼ˆceftazidime-avibactam èˆ‡ metronidazole ä½µç”¨ï¼‰</td>
<td><em>P. aeruginosa</em> (84â€“97%)[^f]<br><br>MDR Enterobacterales, including carbapenem-resistant Enterobacterales that produce KPCs<br><br>No activity against metallo-Î²-lactamases (e.g., NDM)</td>
</tr>
<tr>
<td>Imipenem, meropenem</td>
<td>ç”± <em>Enterobacter</em> spp. å’Œç”¢ç”Ÿ ESBL çš„é©è˜­æ°é™°æ€§æ¡¿èŒå¼•èµ·çš„è…¹è…”å…§æ„ŸæŸ“</td>
<td><em>P. aeruginosa</em> (84%); <em>Acinetobacter calcoaceticus-baumannii</em> complex (85%) (meropenem susceptibilities reported)</td>
</tr>
<tr>
<td>Ertapenem</td>
<td>CAPï¼›è¤‡é›œæ€§å°¿è·¯æ„ŸæŸ“ï¼ŒåŒ…æ‹¬è…ç›‚è…ç‚ï¼›æ€¥æ€§éª¨ç›†æ„ŸæŸ“ï¼›è¤‡é›œæ€§è…¹è…”å…§æ„ŸæŸ“ï¼›è¤‡é›œæ€§çš®è†šå’Œçš®è†šçµæ§‹æ„ŸæŸ“ï¼Œä¸åŒ…æ‹¬ä¼´æœ‰éª¨é«“ç‚æˆ–ç”± <em>P. aeruginosa</em> å¼•èµ·çš„ç³–å°¿ç—…è¶³æ„ŸæŸ“</td>
<td><em>Enterobacter cloacae</em> (90%); <em>K. pneumoniae</em> (98%)</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>å°penicillinéæ•æ‚£è€…ç”±å…¼æ€§é©è˜­æ°é™°æ€§æ¡¿èŒå’Œ <em>Pseudomonas</em> å¼•èµ·çš„æ„ŸæŸ“</td>
<td><em>P. aeruginosa</em> (69%)</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>ç”± MRSA å¼•èµ·çš„èŒè¡€ç—‡ã€å¿ƒå…§è†œç‚å’Œå…¶ä»–ä¾µè¥²æ€§ç–¾ç—…ï¼›è‚ºç‚éˆçƒèŒè…¦è†œç‚ï¼›å£æœè£½åŠ‘ç”¨æ–¼ CDAD</td>
<td><em>S. aureus</em> (100%); <em>E. faecalis</em> (96%); <em>E. faecium</em> (34%)</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>VRE æ„ŸæŸ“ï¼›MRSA èŒè¡€ç—‡</td>
<td><em>E. faecalis</em> (99.9%)[^i]; <em>E. faecium</em> (99.7%)[^i]; <em>S. aureus</em> (99.9%)[^g]</td>
</tr>
<tr>
<td>Gentamicin, amikacin, streptomycin, tobramycin</td>
<td>èˆ‡penicillinä½µç”¨æ²»ç™‚è‘¡è„çƒèŒã€è…¸çƒèŒæˆ–éˆçƒèŒå¿ƒå…§è†œç‚ï¼›èˆ‡ Î²-lactamé¡ä½µç”¨æ²»ç™‚é©è˜­æ°é™°æ€§èŒè¡€ç—‡ï¼›è…ç›‚è…ç‚</td>
<td><em>E. coli</em> (gentamicin, 91%); <em>P. aeruginosa</em> (amikacin, 82%; gentamicin, 84%); <em>A. calcoaceticus-baumannii</em> complex (gentamicin, 89%)</td>
</tr>
<tr>
<td>Azithromycin, clarithromycin, erythromycin</td>
<td><em>Legionella, Campylobacter</em>, <em>Mycoplasma</em> æ„ŸæŸ“ï¼›CAPï¼›å°penicillinéæ•æ‚£è€…çš„Aå‹éˆçƒèŒå’½å–‰ç‚ï¼›ç´°èŒæ€§è¡€ç®¡ç˜¤ç—…ï¼›<em>Helicobacter pylori</em>ï¼›é³¥å‹åˆ†ææ¡¿èŒæ„ŸæŸ“</td>
<td><em>S. pneumoniae</em> (60%); group A streptococci (82%); <em>H. pylori</em> (75%)j</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>åš´é‡ã€ä¾µè¥²æ€§çš„Aå‹éˆçƒèŒæ„ŸæŸ“ï¼ˆèˆ‡ Î²-lactamåˆç”¨ï¼‰ï¼›ç”±çµ•å°å­æ°§èŒå¼•èµ·çš„æ„ŸæŸ“ï¼›ç”±æ•æ„Ÿçš„è‘¡è„çƒèŒå¼•èµ·çš„æ„ŸæŸ“</td>
<td><em>S. aureus</em> (70%)</td>
</tr>
<tr>
<td>Doxycycline, minocycline</td>
<td>æ…¢æ€§æ”¯æ°£ç®¡ç‚çš„æ€¥æ€§ç´°èŒæ€§åŠ é‡ï¼›è¼•åº¦CAPï¼›MRSAçš®è†šå’Œè»Ÿçµ„ç¹”æ„ŸæŸ“ï¼›<em>Vibrio vulnificus</em> æ„ŸæŸ“ï¼›æŠ«è¡£èŒ (doxycycline)ï¼›Rickettsiaæ„ŸæŸ“ï¼ˆæ™èŸ²ç—…ã€æ–‘ç–¹å‚·å¯’ï¼‰ï¼›penicillinéæ•è€…æ²»ç™‚æ”¾ç·šèŒæ„ŸæŸ“ï¼›<strong>é‰¤ç«¯èºæ—‹é«”æ„ŸæŸ“ï¼›æ¢…æ¯’ï¼›é¡é¼»ç–½</strong>ï¼›é¼»ç–½ï¼›é¼ ç–«ï¼›å¸ƒé­¯æ°èŒç—…ï¼ˆèˆ‡streptomycinåˆç”¨ï¼‰ï¼›å…”ç†±ç—…ï¼›èŠå§†ç—… (doxycycline)ï¼›è…¹è‚¡æºè‚‰èŠ½è…«<br><br> <strong><em>Stenotrophomonas, Mycobacterium marinum</em></strong>æ„ŸæŸ“ (minocycline)<br><mark>å¥ä¿çµ¦ä»˜åƒ…é™å°CRAB</mark></td>
<td><em>S. pneumoniae</em> (63%); <em>S. aureus</em> (97%)</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>ç”± <em>S. pneumoniae, H. influenzae</em>, or <em>Legionella pneumophila</em> å¼•èµ·çš„CAPï¼›ç”± <em>E. coli</em>, vancomycin-susceptible <em>E. faecalis, Citrobacter freundii, E. cloacae, K. pneumoniae, K. oxytoca, Bacteroides</em> spp., <em>Clostridium perfringens</em>, and <em>Peptostreptococcus</em> spp.å¤šé‡æŠ—è—¥é©è˜­æ°é™°æ€§èŒå’Œå­æ°§èŒå¼•èµ·çš„è¤‡é›œæ€§è…¹è…”å…§æ„ŸæŸ“ï¼›ç”± <em>E. coli</em>, MRSA, MSSA, <em>S. pyogenes, Streptococcus anginosus, S. agalactiae, B. fragilis</em> å¼•èµ·çš„è¤‡é›œæ€§çš®è†šå’Œè»Ÿçµ„ç¹”æ„ŸæŸ“</td>
<td>Mostly susceptible, although case reports of resistance in <em>A. baumannii</em> and <em>K. pneumoniae</em></td>
</tr>
<tr>
<td>TMP-SMX</td>
<td>ç¤¾å€æ€§UTIå’Œç¤¾å€æ€§MRSAçš®è†šå’Œè»Ÿçµ„ç¹”æ„ŸæŸ“</td>
<td><em>E. coli</em> (73%); <em>S. aureus</em> (95%)</td>
</tr>
<tr>
<td>Ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin</td>
<td>CAP (levofloxacin and moxifloxacin); UTI; <em>Pseudomonas</em> infections (ciprofloxacin and levofloxacin)ï¼›é†«é™¢ç²å¾—æ€§é©è˜­æ°é™°æ€§è…¸é“æ„ŸæŸ“ï¼›ç´°èŒæ€§è…¸èƒƒç‚</td>
<td><em>S. pneumoniae</em> (99% levofloxacin); <em>E. coli</em> (79% for ciprofloxacin and levofloxacin); <em>P. aeruginosa</em> (ciprofloxacin, 76%; levofloxacin, 70%); <strong><em>Salmonella</em> spp.</strong> (72% for ciprofloxacin and levofloxacin)</td>
</tr>
<tr>
<td>Rifampin</td>
<td><strong>è‘¡è„çƒèŒç•°ç‰©æ„ŸæŸ“ï¼ˆèˆ‡å…¶ä»–æŠ—è‘¡è„çƒèŒè—¥ç‰©è¯åˆä½¿ç”¨ï¼‰; <em>Legionella</em> pneumonia</strong>; <em>Mycobacterium tuberculosis</em>; atypical nontuberculous mycobacterial infection</td>
<td><em>S. aureus</em> (99%), although staphylococci rapidly develop resistance with monotherapy</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>çµ•å°å­æ°§é©è˜­æ°é™°æ€§èŒï¼ˆå¦‚ Bacteroides spp.ï¼‰ï¼›è‚ºã€è…¦æˆ–è…¹éƒ¨è†¿ç˜ï¼›ç´°èŒæ€§é™°é“ç‚ï¼›CDAD</td>
<td>Mostly susceptible; resistance very rare</td>
</tr>
<tr>
<td>Linezolid, tedizolid</td>
<td>VRE; ç”± MSSA å’Œ MRSA å¼•èµ·çš„çš®è†šåŠè»Ÿçµ„ç¹”æ„ŸæŸ“ï¼›ä¼´æœ‰èŒè¡€ç—‡çš„CAPï¼›HAP</td>
<td>Mostly susceptible; resistance occasionally seen in VRE</td>
</tr>
<tr>
<td>Colistin</td>
<td>ç”±å°å…¶ä»–æ‰€æœ‰æ²»ç™‚æ–¹æ¡ˆè€è—¥çš„é©è˜­æ°é™°æ€§æ¡¿èŒå¼•èµ·çš„æ„ŸæŸ“ (å¦‚ <em>P. aeruginosa, Acinetobacter</em> spp., and <em>Stenotrophomonas maltophilia</em>)</td>
<td><em>P. aeruginosa</em> (case reports, outbreaks)</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>å¤§å¤šæ•¸é©è˜­æ°é™°æ€§æ¡¿èŒå’Œä¸€äº›é©è˜­æ°é™½æ€§èŒå¼•èµ·çš„UTIï¼›åå¾©æ€§è†€èƒ±ç‚çš„é é˜²</td>
<td><em>E. coli</em> (95%); <em>E. faecalis</em> (99%)</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>å¤§å¤šæ•¸é©è˜­æ°é™°æ€§æ¡¿èŒå’Œä¸€äº›é©è˜­æ°é™½æ€§èŒå¼•èµ·çš„å°¿è·¯æ„ŸæŸ“ï¼›åå¾©æ€§è†€èƒ±ç‚çš„é é˜²</td>
<td>è¢«èªç‚ºæ˜¯ä½æŠ—è—¥æ€§</td>
</tr>
<tr>
<td>Cefiderocol</td>
<td>ç”±å¤šé‡æŠ—è—¥é©è˜­æ°é™°æ€§èŒå¼•èµ·çš„è¤‡é›œæ€§å°¿è·¯æ„ŸæŸ“å’Œ/æˆ–è…ç›‚è…ç‚ï¼ŒåŒ…æ‹¬ç”¢ç”ŸESBLæˆ–carbapenemaseçš„ç´°èŒä»¥åŠå¤šé‡æŠ—è—¥æ€§<em>Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Burkholderia cepacia complex</em></td>
<td>åˆæ­¥ç ”ç©¶ä¸­é¡¯ç¤ºæŠ—è—¥æ©Ÿç‡éå¸¸ä½</td>
</tr>
</tbody>
</table>
<h3 id="_10"><a class="toclink" href="medicineabx/antibiotics/#_10">å­•å©¦</a></h3>
<ul>
<li>ä¸å»ºè­°ä½¿ç”¨aminoglycosides, tetracyclines  </li>
<li>Metronidazole, trimethoprim-sulfamethoxazoleç¬¬ä¸€å­•æœŸç¦ç”¨  </li>
</ul>
<h3 id="_11"><a class="toclink" href="medicineabx/antibiotics/#_11">å¸¸è¦‹å‰¯ä½œç”¨</a></h3>
<h4 id="ampicillinsulbactam"><a class="toclink" href="medicineabx/antibiotics/#ampicillinsulbactam">Ampicillin/sulbactam</a></h4>
<ul>
<li>è…¹ç€‰  </li>
<li>å½è†œæ€§è…¸ç‚  </li>
</ul>
<h4 id="piperacillintazobactam"><a class="toclink" href="medicineabx/antibiotics/#piperacillintazobactam">Piperacillin/tazobactam</a></h4>
<ul>
<li>è…æ¯’æ€§  </li>
<li>è…¸é“èŒç¾¤å¤±è¡¡ï¼ˆå¯èƒ½å°è‡´å½è†œæ€§è…¸ç‚ï¼‰  </li>
<li>è¡€å°æ¿æ¸›å°‘ç—‡  </li>
</ul>
<h4 id="ceftriaxone"><a class="toclink" href="medicineabx/antibiotics/#ceftriaxone">Ceftriaxone</a></h4>
<ul>
<li>è‚æ¯’æ€§ã€é»ƒç–¸  </li>
<li>ä¸å¯åŠ å…¥å«éˆ£ä¹‹é»æ»´æ³¨å°„æ¶²  </li>
</ul>
<h4 id="cefepime"><a class="toclink" href="medicineabx/antibiotics/#cefepime"><strong>Cefepime</strong></a></h4>
<ul>
<li>ç¥ç¶“æ¯’æ€§ï¼ˆå°¤å…¶æ˜¯åœ¨è…åŠŸèƒ½å—æçš„ç—…äººä¸­ï¼Œå¯èƒ½å¼•èµ·ç™²ç™‡ï¼‰  </li>
</ul>
<h4 id="carbapenems_1"><a class="toclink" href="medicineabx/antibiotics/#carbapenems_1">Carbapenems</a></h4>
<ul>
<li>ç¥ç¶“æ¯’æ€§ï¼ˆç‰¹åˆ¥æ˜¯åœ¨é«˜åŠ‘é‡æˆ–è…åŠŸèƒ½ä¸å…¨æ™‚ï¼‰  </li>
</ul>
<h4 id="aminoglycosides-gentamicin"><a class="toclink" href="medicineabx/antibiotics/#aminoglycosides-gentamicin">Aminoglycosides (Gentamicin)</a></h4>
<ul>
<li>è…æ¯’æ€§ï¼špreexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration  </li>
<li>è€³æ¯’æ€§ï¼ˆå¯èƒ½å¼•èµ·è½åŠ›æå¤±æˆ–å¹³è¡¡éšœç¤™ï¼‰ï¼šproportional to the amount of drug given and the duration of treatment; tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage  </li>
<li>ç¥ç¶“è‚Œè‚‰é˜»ç¤™ã€å‘¼å¸è¡°ç«­  </li>
</ul>
<h4 id="sulfamethoxazoletrimethoprim-tmp-smx"><a class="toclink" href="medicineabx/antibiotics/#sulfamethoxazoletrimethoprim-tmp-smx">Sulfamethoxazole/Trimethoprim (TMP-SMX)</a></h4>
<ul>
<li>é«˜è¡€é‰€  </li>
<li>è…æ¯’æ€§  </li>
<li>è‚æ¯’æ€§  </li>
<li>éæ•åæ‡‰  </li>
<li>éª¨é«“æŠ‘åˆ¶ï¼ˆå¯èƒ½å¼•èµ·è²§è¡€ã€ç™½è¡€çƒæ¸›å°‘ã€è¡€å°æ¿æ¸›å°‘ï¼‰  </li>
</ul>
<h4 id="vancomycin"><a class="toclink" href="medicineabx/antibiotics/#vancomycin">Vancomycin</a></h4>
<ul>
<li>è…æ¯’æ€§  </li>
<li>è€³æ¯’æ€§  </li>
<li>å—œä¸­æ€§çƒä½ä¸‹ã€ç™½è¡€çƒæ¸›å°‘ã€è¡€å°æ¿æ¸›å°‘  </li>
<li><mark><strong>Red man syndrome</strong></mark>ï¼šèˆ‡vancomycinçš„åŠ‘é‡æœ‰æ‰€é—œè¯ï¼Œç‰¹åˆ¥æ˜¯ç™¼ç”Ÿåœ¨åŠ‘é‡è¼ƒå¤§ä¸”å¿«é€Ÿæ»´æ³¨æ™‚ã€‚ä¸»è¦æ˜¯ç”±çš®è†šã€è‚ºã€è…¸èƒƒé“ã€å¿ƒè‚ŒåŠè¡€ç®¡ç³»çµ±ä¸­çš„<strong>è‚¥å¤§ç´°èƒ</strong>åŠå—œé¹¼æ€§ç™½è¡€çƒé‡‹å‡º<strong>çµ„ç¹”èƒº</strong>æ‰€å°è‡´çš„ã€‚æ­¤ç¾è±¡é€šå¸¸ç™¼ç”Ÿåœ¨é¦–æ¬¡çš„çµ¦äºˆåŠ‘é‡ï¼Œä½†ä¹Ÿå¯èƒ½æœƒç™¼ç”Ÿåœ¨ä»»ä½•ä¸€å€‹çµ¦è—¥æ™‚é–“ã€‚ä¸€èˆ¬å¸¸è¦‹çš„å…¸å‹çš„ç—‡ç‹€ç‚º<strong>ä¸ŠåŠèº«è»€å¹¹</strong>æœ‰æ½®ç´…ã€ç´…ç–¹ã€è•éº»ç–¹åŠæ”ç™¢ä¹‹ç¾è±¡ï¼Œåœ¨å¹¾å€‹æ¯”è¼ƒåš´é‡çš„æ¡ˆä¾‹ä¸­æ›¾ç™¼ç¾ä½è¡€å£“ã€èƒ¸ç—›åŠå‘¼å¸çª˜è¿«ä¹‹ç—‡ç‹€ã€‚  </li>
<li>å…¨èº«æ€§éæ•åæ‡‰ï¼šæ˜¯ä¸€ç¨®æ€¥æ€§ä¸”å±åŠç”Ÿå‘½çš„å…ç–«åæ‡‰ï¼Œä¸€èˆ¬ç™¼ç”Ÿéå¸¸è¿…é€Ÿï¼Œé€šå¸¸åœ¨çµ¦è—¥å¾Œä¹‹5-30åˆ†é˜ä»¥å…§ç™¼ä½œã€‚é¦–å…ˆç—…äººæœƒå°vancomycinæ•æ„Ÿè€Œåœ¨é«”å…§ç”¢ç”Ÿvancomycinç‰¹ç•°æ€§çš„IgEï¼ˆvancomycin-specific IgEï¼‰ã€‚è‹¥å°ç”¢ç”Ÿéæ•ä¹‹ç—…äººé‡è¤‡æŠ•äºˆvancomycinæœƒé€ æˆæ•æ„Ÿæ€§è‚¥å¤§ç´°èƒä¸Šçš„IgEæ¥å—å™¨ç”¢ç”Ÿäº¤å‰é€£çµåæ‡‰ï¼Œè€Œå¼•èµ·è¡€ç®¡æ´»åŒ–èª¿ç¯€ç‰©è³ªçš„é‡‹å‡ºï¼Œé€™äº›ç‰©è³ªä¾‹å¦‚æœ‰çµ„ç¹”èƒºã€ç™½ä¸‰ç¨€ç´ C4ï¼ˆleukotriene C4ï¼‰ã€å‰åˆ—è…ºç´ ï¼ˆprostaglandin D2ï¼‰åŠç´°èƒä»‹è³ªç´ ï¼Œä¾‹å¦‚ï¼šè…«ç˜¤å£æ­»å› å­ï¼ˆTNF-aï¼‰åŠinterleukin 4, 5, 6, 7, 8åŠ13ã€‚å› ç‚ºé€™äº›ç‰©è³ªä¹‹é‡‹å‡ºè€Œæ“´å¤§vancomycinä¹‹éæ•åæ‡‰é€²è€Œç”¢ç”Ÿè¡€ç®¡æ“´å¼µä½œç”¨å¼•èµ·å…¨èº«æ€§çš®è†šç´…ç–¹ã€æ”ç™¢ã€è•éº»ç–¹ã€æ”¯æ°£ç®¡æ”¶ç¸®ã€è…¸é“éåº¦è •å‹•ã€ä½è¡€å£“æˆ–å¿ƒå¾‹ä¸æ•´ã€‚  </li>
</ul>
<h4 id="daptomycin"><a class="toclink" href="medicineabx/antibiotics/#daptomycin">Daptomycin</a></h4>
<ul>
<li>è‚Œè‚‰ç—…è®Šï¼ˆmyopathyï¼‰  </li>
<li>Drug-induced eosinophilic pneumoniaï¼ˆå°‘è¦‹ï¼‰  </li>
<li>Do not use for primary pneumonia: inactivated by pulmonary surfactant  </li>
</ul>
<h4 id="linezolid"><a class="toclink" href="medicineabx/antibiotics/#linezolid">Linezolid</a></h4>
<ul>
<li>è‚æ¯’æ€§  </li>
<li>è¡€çƒä½ä¸‹ï¼ˆä½¿ç”¨å…©å‘¨ä»¥ä¸Šï¼‰  </li>
<li>ä¸å¯èˆ‡å–®èƒºæ°§åŒ–é…¶æŠ‘åˆ¶åŠ‘(monoamine oxidase inhibitor)æˆ–selective serotonin re-uptake inhibitorå…±åŒä½¿ç”¨ï¼ˆserotonin syndromeï¼‰  </li>
<li>è¦–ç¥ç¶“ç—…è®Š  </li>
<li>ä¹³é…¸ä¸­æ¯’ï¼ˆå°‘è¦‹ï¼‰  </li>
</ul>
<h4 id="clindamycin"><a class="toclink" href="medicineabx/antibiotics/#clindamycin">Clindamycin</a></h4>
<ul>
<li>è…¹ç€‰  </li>
<li>å½è†œæ€§è…¸ç‚ï¼ˆç”±å›°é›£æ¢­ç‹€æ¡¿èŒå¼•èµ·ï¼‰  </li>
<li>çš®ç–¹  </li>
<li>è‚æ¯’æ€§  </li>
</ul>
<h4 id="tetracyclines-doxycycline-minocycline"><a class="toclink" href="medicineabx/antibiotics/#tetracyclines-doxycycline-minocycline">Tetracyclines (å¦‚doxycycline, minocycline)</a></h4>
<ul>
<li>å…‰æ„Ÿå—æ€§  </li>
<li>èƒƒè…¸ä¸é©  </li>
<li>éª¨éª¼å’Œç‰™é½’ç™¼è‚²éšœç¤™ï¼ˆç‰¹åˆ¥æ˜¯åœ¨å…’ç«¥ä¸­ï¼‰  </li>
<li>è‚æ¯’æ€§  </li>
<li>ä½µç”¨WarfarinæœƒåŠ å¼·WarfarinæŠ—å‡è¡€åŠŸèƒ½å¢åŠ å‡ºè¡€çš„é¢¨éšª  </li>
</ul>
<h4 id="fluoroquinolones_1"><a class="toclink" href="medicineabx/antibiotics/#fluoroquinolones_1">Fluoroquinolones</a></h4>
<ul>
<li>QTc å»¶é•·  </li>
<li>è‚Œè…±ç‚åŠè‚Œè…±æ–·è£‚ã€é—œç¯€ç—…è®Šï¼ˆå…’ç«¥ä¸é©åˆä½¿ç”¨ï¼Œè€å¹´äººå’ŒåŒæ™‚ç”¨steroidçš„äººä½¿ç”¨fluoroquinoloneæœƒå¢åŠ æ­¤å‰¯ä½œç”¨ä¹‹é¢¨éšªï¼‰  </li>
<li>è¡€ç³–ç•°å¸¸ï¼ˆé«˜è¡€ç³–æˆ–ä½è¡€ç³–ï¼‰  </li>
<li>èˆ‡aortic aneurysm or dissectionå¯èƒ½æœ‰é—œ  </li>
</ul>
<h4 id="macrolides_1"><a class="toclink" href="medicineabx/antibiotics/#macrolides_1">Macrolides</a></h4>
<ul>
<li>èƒƒè…¸é“ä¸é©ï¼ˆå¦‚è…¹ç€‰ã€å™å¿ƒï¼‰  </li>
<li>QTc å»¶é•·  </li>
<li>è‚æ¯’æ€§  </li>
</ul>
<h4 id="metronidazole"><a class="toclink" href="medicineabx/antibiotics/#metronidazole">Metronidazole</a></h4>
<ul>
<li>è…¸èƒƒä¸é©ï¼ˆå¦‚å™å¿ƒã€å˜”åï¼‰  </li>
<li>å‘¨é‚Šç¥ç¶“ç—…è®Šï¼ˆé•·æœŸä½¿ç”¨ï¼‰  </li>
<li>å£è…”é‡‘å±¬å‘³  </li>
<li>é…’ç²¾ä¸è€å—åæ‡‰  </li>
</ul>
<h4 id="fluconazole"><a class="toclink" href="medicineabx/antibiotics/#fluconazole">Fluconazole</a></h4>
<ul>
<li>QTc å»¶é•·  </li>
<li>è‚æ¯’æ€§  </li>
</ul>
<h4 id="amphotericin-b"><a class="toclink" href="medicineabx/antibiotics/#amphotericin-b">Amphotericin B</a></h4>
<ul>
<li>è…æ¯’æ€§  </li>
<li>ä½è¡€é‰€  </li>
<li>è¼¸æ³¨åæ‡‰ï¼šç™¼ç‡’ã€å¯’é¡«ã€é ­ç—›ã€å¿ƒæéé€Ÿ  </li>
</ul>
<h3 id="_12"><a class="toclink" href="medicineabx/antibiotics/#_12">è€ƒå¤é¡Œ</a></h3>
<h4 id="_13"><a class="toclink" href="medicineabx/antibiotics/#_13">å°ˆå¸«</a></h4>
<h4 id="_14"><a class="toclink" href="medicineabx/antibiotics/#_14">å…§ç§‘é†«å¸«</a></h4>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              3 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="cns-infection"><a class="toclink" href="medicine/cns-infection/">CNS Infection</a></h2>
<p>source:: Pocket Medicine, 2022  </p>
<h3 id="_1"><a class="toclink" href="medicine/cns-infection/#_1">æ€¥æ€§ç´°èŒæ€§è…¦è†œç‚</a></h3>
<h4 id="_2"><a class="toclink" href="medicine/cns-infection/#_2">å®šç¾©</a></h4>
<ul>
<li>è…¦/è„Šé«“å‘¨åœçµ„ç¹”çš„ç™¼ç‚  </li>
<li>é€šå¸¸èµ·æºæ–¼é¼»å’½éƒ¨ï¼ˆè¡€è¡Œæ’­æ•£ï¼‰ã€èŒè¡€ç—‡æˆ–ç›´æ¥æ¥ç¨®ï¼ˆæ‰‹è¡“ã€é„°è¿‘æ„ŸæŸ“ã€å‰µå‚·ã€ç•°ç‰©ï¼»å¦‚è…¦è„Šæ¶²åˆ†æµç®¡ï¼½ï¼‰  </li>
</ul>
<h5 id="nejm-20113642016"><a class="toclink" href="medicine/cns-infection/#nejm-20113642016"><strong>ç´°èŒæ€§è…¦è†œç‚ä¸­çš„å¾®ç”Ÿç‰©å­¸</strong> (<em>NEJM</em> 2011;364:2016)</a></h5>
<table>
<thead>
<tr>
<th>ç—…åŸé«”</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Streptococcus pneumoniae</em> (30-60%)</td>
<td>å¸¸è¦‹æ–¼æœ‰å‰é©…æ„ŸæŸ“ï¼ˆèŒè¡€ç—‡ã€è‚ºç‚ã€å¿ƒå…§è†œç‚ï¼‰æ‚£è€…<br><br>æŠ—è—¥æ€§_S. pneumoniae_:<br> - ç´„40%å°PCNæŠ—è—¥ï¼ˆå³ä½¿æ˜¯ä¸­åº¦æŠ—è—¥ä¹Ÿå¾ˆéº»ç…©ï¼‰<br>- ç´„10%å°ç¬¬ä¸‰ä»£é ­å­¢èŒç´ æŠ—è—¥</td>
</tr>
<tr>
<td><em>Neisseria meningitidis</em> (10-35%)</td>
<td>ä¸»è¦è¦‹æ–¼å¹´é½¡å°æ–¼30æ­²çš„æ‚£è€…ï¼Œå¸¸ä¼´æœ‰ç˜€é»æˆ–ç´«æ–‘<br><br>åœ¨ç„¡è„¾ç—‡ã€è£œé«”ç¼ºä¹ã€HIVã€SCTã€æœªæ¥ç¨®ç–«è‹—è€…ä¸­é¢¨éšªå¢åŠ <br><br>å»ºè­°æ‰€æœ‰11-18æ­²çš„é’å°‘å¹´ã€HIVæ„ŸæŸ“è€…ã€ç„¡è„¾ç—‡è€…ã€C5-9ç¼ºä¹è€…æ¥ç¨®ç–«è‹—</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> (&lt;5%)</td>
<td>ç„¡è„¾ç—‡ã€è£œé«”ç¼ºä¹ã€HIVã€SCTã€æœªæ¥ç¨®ç–«è‹—ã€è…¦è„Šæ¶²æ¼ã€å‰µå‚·/æ‰‹è¡“ã€ä¹³çªç‚æ‚£è€…ä¸­é¢¨éšªå¢åŠ <br><br>å»ºè­°æ‰€æœ‰å…’ç«¥æ¥ç¨®ç–«è‹—ï¼›ç™¼ç—…ç‡é¡¯è‘—é™ä½</td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em> (5-10%)</td>
<td>åœ¨å…ç–«æŠ‘åˆ¶ï¼ˆé¡å›ºé†‡ä½¿ç”¨ã€ç§»æ¤ï¼‰ã€è€å¹´äººã€æƒ¡æ€§è…«ç˜¤ã€å­•å©¦ã€è‚ç¡¬åŒ–æ‚£è€…ä¸­å¢åŠ <br>çˆ†ç™¼å¸¸èˆ‡å—æ±¡æŸ“çš„ä¹³è£½å“å’Œç”Ÿè”¬èœæœ‰é—œ</td>
</tr>
<tr>
<td>GNBs (1-10%)</td>
<td>åœ¨èˆ‡é†«ç™‚ä¿å¥ç›¸é—œçš„è…¦è†œç‚ä¸­è¼ƒå¸¸è¦‹ï¼ˆå¦‚_Escherichia coli_ã€<em>Klebsiella</em>ã€<em>Pseudomonas aeruginosa</em>ï¼‰</td>
</tr>
<tr>
<td><em>Staphylococci</em> (5%)</td>
<td>å‰é©…æ„ŸæŸ“ï¼ˆå¿ƒå…§è†œç‚ã€èŒè¡€ç—‡ï¼‰ã€CNSæ‰‹è¡“å¾Œã€ç•°ç‰©ï¼ˆè…¦è„Šæ¶²åˆ†æµç®¡ã€ç¡¬è†œä¸‹å¹«æµ¦ï¼‰ç›¸é—œ</td>
</tr>
<tr>
<td>æ··åˆæ„ŸæŸ“</td>
<td>æ‡‰æ‡·ç–‘é¡±æ—æ„ŸæŸ“ç¶æˆ–è…¦è„Šæ¶²æ¼ã€CNSæ‰‹è¡“å¾Œæ„ŸæŸ“</td>
</tr>
</tbody>
</table>
<h4 id="lancet-201633916"><a class="toclink" href="medicine/cns-infection/#lancet-201633916">è‡¨åºŠè¡¨ç¾ (Lancet 2016;339:16)</a></h4>
<ul>
<li>é ­ç—› (84%)ã€ç™¼ç‡’ (74%)ã€é ¸éƒ¨åƒµç¡¬ (74%)ã€ç•å…‰ã€GCS &lt;14 (71%)ã€å™å¿ƒ (62%)ã€ç™²ç™‡ç™¼ä½œ (23%)ï¼›95%æ‚£è€…æœ‰ä»¥ä¸‹4ç¨®ç—‡ç‹€ä¸­çš„2ç¨®ï¼šé ­ç—›ã€ç™¼ç‡’ã€é ¸éƒ¨åƒµç¡¬ã€æ„è­˜æ”¹è®Š  </li>
<li>è€å¹´äººå’Œå…ç–«æŠ‘åˆ¶æ‚£è€…çš„è¡¨ç¾å¯èƒ½ä¸å…¸å‹ï¼ˆå¦‚æ²’æœ‰ç™¼ç‡’çš„å—œç¡ï¼‰  </li>
</ul>
<h4 id="cid-20023546-am-j-emerg-med-2013311601"><a class="toclink" href="medicine/cns-infection/#cid-20023546-am-j-emerg-med-2013311601">é«”æª¢ (CID 2002;35:46; Am J Emerg Med 2013;31:1601)</a></h4>
<ul>
<li>é ¸éƒ¨åƒµç¡¬ï¼ˆéˆæ•åº¦ 30%ï¼Œç‰¹ç•°æ€§ 68%ï¼‰ã€Kernigâ€™s signï¼ˆéˆæ•åº¦ 5%ï¼Œç‰¹ç•°æ€§ 95%ï¼‰ã€Brudzinskâ€™s signï¼ˆéˆæ•åº¦ 5%ï¼Œç‰¹ç•°æ€§ 95%ï¼‰ã€Joltâ€™s signï¼ˆé ­ç—›éš¨æ°´å¹³è½‰å‹•æƒ¡åŒ–ï¼‰ï¼ˆéˆæ•åº¦ 64%ï¼Œç‰¹ç•°æ€§ 43%ï¼‰  </li>
<li>Â± å±€éƒ¨ç¥ç¶“ç—…å­¸ç™¼ç¾ï¼ˆç´„30%ï¼›åç™±ã€å¤±èªç—‡ã€è¦–é‡ç¼ºæã€é¡±ç¥ç¶“éº»ç—ºï¼‰  </li>
<li>Â± é ­é ¸è€³é¼»å–‰ç™¼ç¾ï¼šé¼»ç«‡å£“ç—›ã€æ¸…æ¾ˆé¼»æ¼ï¼ˆè…¦è„Šæ¶²æ¼ï¼‰  </li>
<li>Â± çš®è†šå’Œé—œç¯€ç™¼ç¾ï¼šç˜€é»ç–¹ï¼ˆ<em>N. meningitidis</em>ï¼‰ã€ç”Ÿæ®–å™¨æˆ–å£è…”æ½°ç˜ï¼ˆHSVï¼‰ã€ä¼´éš¨é—œç¯€ç©æ¶²çš„é—œç¯€ç‚ï¼ˆ<em>N. meningitidis</em>ï¼‰  </li>
</ul>
<h4 id="_3"><a class="toclink" href="medicine/cns-infection/#_3">ç´°èŒæ€§è…¦è†œç‚çš„é †åºç®¡ç†</a></h4>
<ul>
<li>è¡€æ¶²åŸ¹é¤Šï¼Œé–‹å§‹ç¶“é©—æ€§æŠ—ç”Ÿç´ ï¼Œè€ƒæ…®ä½¿ç”¨é¡å›ºé†‡ï¼ˆè¦‹ä¸‹æ–‡ï¼‰  </li>
<li>å¦‚æœ‰é©æ‡‰ç—‡ï¼Œé€²è¡Œé ­éƒ¨CTæª¢æŸ¥ï¼ˆè¦‹ä¸‹æ–‡ï¼‰  </li>
<li>å„˜å¿«é€²è¡Œè…°æ¤ç©¿åˆºï¼ˆå¦‚æœæ²’æœ‰ç¦å¿Œç—‡ï¼‰ï¼›å¦‚æœåœ¨é–‹å§‹æŠ—ç”Ÿç´ å¾Œç´„4å°æ™‚å…§ç²å¾—è…¦è„Šæ¶²åŸ¹é¤Šï¼Œçµæœä¸å¤ªå¯èƒ½æœƒæ”¹è®Š  </li>
</ul>
<h4 id="nejm-20173883036"><a class="toclink" href="medicine/cns-infection/#nejm-20173883036">è¨ºæ–·ç ”ç©¶ (NEJM 2017;388:3036)</a></h4>
<ul>
<li>åœ¨ä½¿ç”¨æŠ—ç”Ÿç´ å‰é€²è¡Œ2æ¬¡è¡€æ¶²åŸ¹é¤Š  </li>
<li>åœ¨å¥åº·å®¿ä¸»çš„ç´°èŒæ€§è…¦è†œç‚ä¸­ï¼Œç™½è¡€çƒè¨ˆæ•¸ &gt;10,000 çš„æ©Ÿç‡è¶…é90%  </li>
<li>å¦‚æœæœ‰1å€‹ä»¥ä¸Šçš„é«˜é¢¨éšªå› ç´ ï¼Œå¦‚å…ç–«æŠ‘åˆ¶ã€CNSç–¾ç—…å²ã€æ–°ç™¼ç™²ç™‡ç™¼ä½œã€å±€éƒ¨ç¥ç¶“å­¸ç™¼ç¾ã€ä¹³é ­æ°´è…«ã€GCS &lt;15ï¼Œå‰‡éœ€åœ¨è…°æ¤ç©¿åˆºå‰é€²è¡Œé ­éƒ¨CTä»¥æ’é™¤è…«ç˜¤æ•ˆæ‡‰ (CID 2004;39:1267)  </li>
<li>è…°æ¤ç©¿åˆºä¸¦æ¸¬é‡å‰å£“ (NEJM 2006;355:e12)  </li>
<li>å°‡è…¦è„Šæ¶²é€æª¢é€²è¡Œç´°èƒè¨ˆæ•¸å’Œåˆ†é¡ã€è‘¡è„ç³–ã€è›‹ç™½è³ªã€é©è˜­æ°æŸ“è‰²ã€ç´°èŒåŸ¹é¤Š  </li>
<li>æ ¹æ“šè‡¨åºŠæ‡·ç–‘é€²è¡Œé¡å¤–çš„è…¦è„Šæ¶²ç ”ç©¶ï¼šæŠ—é…¸æ¡¿èŒæŸ“è‰²/åŸ¹é¤Šï¼ˆæˆ–MTb PCRï¼‰ã€éš±çƒèŒæŠ—åŸã€çœŸèŒåŸ¹é¤Šã€VDRLã€PCRï¼ˆHSVã€VZVã€è…¸é“ç—…æ¯’ï¼‰ã€ç´°èƒå­¸  </li>
<li>è…¦è„Šæ¶²é©è˜­æ°æŸ“è‰²çš„éˆæ•åº¦ç‚º30-90%ï¼›å¦‚æœè…°æ¤ç©¿åˆºåœ¨ä½¿ç”¨æŠ—ç”Ÿç´ å‰é€²è¡Œï¼ŒåŸ¹é¤Šçš„éˆæ•åº¦ç‚º80-90%ï¼Œä½†å¦‚æœæ‡·ç–‘ç‚ºç´°èŒæ€§è…¦è†œç‚ï¼ŒæŠ—ç”Ÿç´ æ‡‰ä¸å»¶é²ä½¿ç”¨  </li>
<li>2çš„è¦å‰‡ï¼š<strong>è…¦è„Šæ¶²ç™½è¡€çƒ&gt;2000ã€è‘¡è„ç³–&lt;20ã€è›‹ç™½è³ª&gt;200</strong>ï¼Œå°ç´°èŒæ€§è…¦è†œç‚çš„ç‰¹ç•°æ€§è¶…é98%  </li>
<li>å¦‚é©ç•¶æŠ—ç”Ÿç´ æ²»ç™‚48å°æ™‚å¾Œç„¡è‡¨åºŠåæ‡‰æˆ–è…¦è„Šæ¶²åˆ†æµï¼Œå‰‡éœ€é‡è¤‡è…°æ¤ç©¿åˆº  </li>
<li>æ¬¡ä¸–ä»£å®šåºæŠ€è¡“å¯æé«˜è¨ºæ–·ç‡ (NEJM 2019;380:2327)  </li>
</ul>
<h5 id="_4"><a class="toclink" href="medicine/cns-infection/#_4">è…¦è†œç‚ä¸­å…¸å‹çš„è…¦è„Šæ¶²ç™¼ç¾</a></h5>
<table>
<thead>
<tr>
<th><strong>é¡å‹</strong></th>
<th><strong>å¤–è§€</strong></th>
<th><strong>å£“åŠ›ï¼ˆcm H2Oï¼‰</strong></th>
<th><strong>WBC/mmÂ³Â <em>ä¸»å°é¡å‹</em></strong></th>
<th><strong>Glcï¼ˆmg/dLï¼‰</strong></th>
<th><strong>TPÂ (mg/dL)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>æ­£å¸¸</strong></td>
<td>æ¸…æ¾ˆ</td>
<td>9-18</td>
<td>0-5Â <em>æ·‹å·´ç´°èƒ</em></td>
<td>50-75</td>
<td>15-40</td>
</tr>
<tr>
<td><strong>ç´°èŒæ€§</strong></td>
<td>æ¸¾æ¿</td>
<td>18-30</td>
<td>100-10,000Â <em>å¤šå½¢æ ¸ç´°èƒ</em></td>
<td>&lt;45</td>
<td>100-1000</td>
</tr>
<tr>
<td><strong>çµæ ¸æ€§</strong></td>
<td>æ¸¾æ¿</td>
<td>18-30</td>
<td>&lt;500Â <em>æ·‹å·´ç´°èƒ</em></td>
<td>&lt;45</td>
<td>100-200</td>
</tr>
<tr>
<td><strong>çœŸèŒæ€§</strong></td>
<td>æ¸¾æ¿</td>
<td>18-30</td>
<td>&lt;300Â <em>æ·‹å·´ç´°èƒ</em></td>
<td>&lt;45</td>
<td>40-300</td>
</tr>
<tr>
<td><strong>ç„¡èŒæ€§</strong></td>
<td>æ¸…æ¾ˆ</td>
<td>9-18</td>
<td>&lt;300Â <em>å¤šå½¢æ ¸ç´°èƒ</em> â†’Â <em>æ·‹å·´ç´°èƒ</em></td>
<td>50-100</td>
<td>50-100</td>
</tr>
</tbody>
</table>
<h4 id="lancet-20123801693"><a class="toclink" href="medicine/cns-infection/#lancet-20123801693">ç´°èŒæ€§è…¦è†œç‚çš„ç¶“é©—æ€§æ²»ç™‚ (<em>Lancet</em> 2012;380:1693)</a></h4>
<table>
<thead>
<tr>
<th><strong>50æ­²ä»¥ä¸‹æˆäºº</strong></th>
<th>Ceftriaxone + vancomycinï¼ˆæ¿ƒåº¦15-20ï¼‰ï¼Œè€ƒæ…®éœè„ˆæ³¨å°„acyclovir</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>50æ­²ä»¥ä¸Šæˆäºº</strong></td>
<td>Ceftriaxone + vancomycin + ampicillinï¼Œè€ƒæ…®éœè„ˆæ³¨å°„acyclovir</td>
</tr>
<tr>
<td><strong>å…ç–«æŠ‘åˆ¶è€…</strong></td>
<td>[Cefepimeæˆ–meropenem] + vancomycin Â± ampicillinï¼ˆå¦‚æœå·²ä½¿ç”¨meropenemï¼Œå‰‡ä¸éœ€è¦ampicillinï¼‰ï¼Œè€ƒæ…®éœè„ˆæ³¨å°„acyclovirå’ŒçœŸèŒè¦†è“‹</td>
</tr>
<tr>
<td><strong>é†«ç™‚ç›¸é—œæ„ŸæŸ“ï¼ˆå¦‚æ‰‹è¡“ã€è…¦è„Šæ¶²åˆ†æµç®¡ï¼‰</strong></td>
<td>[Cefepimeæˆ–meropenemæˆ–ceftazidime] + vancomycin</td>
</tr>
</tbody>
</table>
<ul>
<li>å¯èƒ½çš„è©±ï¼Œæ‡‰æ ¹æ“šæ•æ„Ÿæ€§æˆ–ç•¶åœ°çš„æŠ—è—¥æ¨¡å¼ä½¿ç”¨é‡å°ç—…åŸé«”çš„æ²»ç™‚  </li>
<li>ç¢ºèªé©ç•¶çš„åŠ‘é‡ï¼Œå› ç‚ºè…¦è†œç‚ä¸­é€šå¸¸éœ€è¦æ›´é«˜çš„åŠ‘é‡ï¼ˆä½†å¯èƒ½éœ€è¦æ ¹æ“šè…åŠŸèƒ½é€²è¡Œèª¿æ•´ï¼‰  </li>
<li><strong>é¡å›ºé†‡</strong>ï¼šå¦‚æœç—…åŸé«”æœªçŸ¥ï¼Œå»ºè­°åœ¨é–‹å§‹æŠ—ç”Ÿç´ å‰æˆ–èˆ‡å…¶åŒæ™‚ä½¿ç”¨dexamethasoneéœè„ˆæ³¨å°„10æ¯«å…‹ï¼Œæ¯6å°æ™‚ä¸€æ¬¡ï¼Œé€£çºŒ4å¤©ã€‚å°æ–¼<strong><em>S. pneumoniae</em>å’ŒGCS 8-11</strong>çš„æ‚£è€…æœ‰æœ€å¤§çš„ç›Šè™•ï¼ˆç¥ç¶“æ®˜ç–¾å’Œæ­»äº¡ç‡é™ä½ç´„50%ï¼‰ã€‚<mark>é¿å…ä½¿ç”¨æ–¼éš±çƒèŒæ„ŸæŸ“</mark>ï¼ˆNEJM 2016;374:542ï¼‰ã€‚  </li>
<li>é é˜²æ€§æªæ–½ï¼šå°æ–¼<em>N. meningitidis</em>çš„å¯†åˆ‡æ¥è§¸è€…ï¼Œä½¿ç”¨rifampinï¼ˆ600 mgå£æœï¼Œæ¯æ—¥å…©æ¬¡ï¼ŒæŒçºŒ2å¤©ï¼‰æˆ–ciprofloxacinï¼ˆ500 mgå£æœï¼Œä¸€æ¬¡ï¼‰æˆ–ceftriaxoneï¼ˆ250 mgè‚Œè‚‰æ³¨å°„ï¼Œä¸€æ¬¡ï¼‰  </li>
<li>é é˜²æªæ–½ï¼šåœ¨æ’é™¤<em>N. meningitidis</em>ä¹‹å‰ï¼Œæ¡å–é£›æ²«éš”é›¢æªæ–½  </li>
</ul>
<h3 id="_5"><a class="toclink" href="medicine/cns-infection/#_5">ç„¡èŒæ€§è…¦è†œç‚</a></h3>
<h4 id="_6"><a class="toclink" href="medicine/cns-infection/#_6">å®šç¾©</a></h4>
<ul>
<li>è‡¨åºŠ/å¯¦é©—å®¤è­‰æ“šé¡¯ç¤ºè…¦è†œç™¼ç‚ï¼Œä½†ç´°èŒåŸ¹é¤Šï¼ˆè…¦è„Šæ¶²åŠè¡€æ¶²ï¼‰çµæœç‚ºé™°æ€§  </li>
</ul>
<h4 id="neurology-20066675"><a class="toclink" href="medicine/cns-infection/#neurology-20066675">ç—…å› å­¸ (Neurology 2006;66:75)</a></h4>
<ul>
<li>ç—…æ¯’æ€§ï¼šè…¸ç—…æ¯’æ˜¯æœ€å¸¸è¦‹çš„åŸå› ï¼ˆå¤å­£/ç§‹å­£ï¼›çš®ç–¹ã€è…¸èƒƒé“ç—‡ç‹€ã€ä¸Šå‘¼å¸é“æ„ŸæŸ“ç—‡ç‹€ï¼‰ï¼ŒHIVã€HSVã€VZVã€è…®è…ºç‚ã€æ·‹å·´ç´°èƒæ€§è„ˆçµ¡è…¦è†œç‚ç—…æ¯’ï¼ˆèˆ‡é½§é½’å‹•ç‰©æ¥è§¸ï¼‰ã€è…¦ç‚ç—…æ¯’ã€è…ºç—…æ¯’ã€å°å…’éº»ç—¹ç—…æ¯’ã€CMVã€EBVã€è¥¿å°¼ç¾…æ²³ç—…æ¯’  </li>
<li>å±€éƒ¨ç´°èŒæ„ŸæŸ“ï¼šè…¦/ç¡¬è†œå¤–/ç¡¬è†œä¸‹è†¿ç˜ï¼Œä¸­æ¨ç¥ç¶“ç³»çµ±æ•—è¡€æ€§è¡€æ “éœè„ˆç‚  </li>
<li>æ²»ç™‚éçš„ç´°èŒæ€§è…¦è†œç‚  </li>
<li>å…¶ä»–æ„ŸæŸ“ï¼šçµæ ¸ã€çœŸèŒï¼ˆéš±çƒèŒã€çƒé»´èŒï¼‰ã€èŠå§†ç—…ã€æ¢…æ¯’ã€éˆç«¯èºæ—‹é«”ç—…  </li>
<li>è…«ç˜¤ï¼šé¡±å…§è…«ç˜¤ï¼ˆæˆ–å›Šè…«ï¼‰ã€æ·‹å·´ç˜¤æ€§æˆ–ç™Œæ€§è…¦è†œç‚  </li>
<li>è—¥ç‰©å¼•èµ·çš„è…¦è†œç‚ï¼šNSAIDsã€éœè„ˆæ³¨å°„å…ç–«çƒè›‹ç™½ã€æŠ—ç”Ÿç´ ï¼ˆTMP-SMXã€penicillinï¼‰ã€æŠ—ç™²ç™‡è—¥  </li>
<li>ç³»çµ±æ€§è‡ªé«”å…ç–«ç–¾ç—…ï¼šSLEã€é¡è‚‰ç˜¤ã€è²è³½ç‰¹æ°ç—…ã€ä¹¾ç‡¥ç¶œåˆç—‡ã€é¡é¢¨æ¿•æ€§é—œç¯€ç‚  </li>
<li>Mollaret'sï¼šåè¦†æ€§æ·‹å·´ç´°èƒæ€§è…¦è†œç‚ï¼Œæœƒè‡ªå·±ç·©è§£ï¼ˆé€šå¸¸ç‚ºHSV-2ï¼‰  </li>
</ul>
<h4 id="_7"><a class="toclink" href="medicine/cns-infection/#_7">è¨ºæ–·</a></h4>
<ul>
<li>é€²è¡Œè…°æ¤ç©¿åˆºä»¥é€²è¡Œè…¦è„Šæ¶²åˆ†æï¼šç—…æ¯’æ€§ç—…å› ä¸­å¸¸è¦‹æ·‹å·´ç´°èƒå¢å¤šç—‡ï¼ˆè¦‹ä¸Šæ–¹è…¦è†œç‚ä¸­çš„å…¸å‹è…¦è„Šæ¶²ç™¼ç¾è¡¨æ ¼ï¼‰  </li>
<li>è€ƒæ…®è…¦è„Šæ¶²ç´°èƒå­¸å’Œè…¦éƒ¨/è„Šé«“MRIä»¥è©•ä¼°æ˜¯å¦æœ‰æƒ¡æ€§è…«ç˜¤  </li>
<li>å¦‚æœè…¦è„Šæ¶²æª¢æŸ¥ç„¡æ‰€ç™¼ç¾ä¸”ç¶“é©—æ€§æ²»ç™‚ç„¡æ”¹å–„ï¼Œåœ¨é©ç•¶æƒ…æ³ä¸‹è€ƒæ…®é€²è¡Œè¡€æ¸…è‡ªé«”å…ç–«åŠç—…æ¯’æª¢æ¸¬  </li>
</ul>
<h4 id="_8"><a class="toclink" href="medicine/cns-infection/#_8">ç¶“é©—æ€§æ²»ç™‚</a></h4>
<ul>
<li>æ‡·ç–‘ç‚ºç´°èŒæ€§è…¦è†œç‚ï¼šåƒè¦‹ä¸Šæ–¹ç´°èŒæ€§è…¦è†œç‚çš„ç¶“é©—æ€§æ²»ç™‚  </li>
<li>æ‡·ç–‘ç‚ºç—…æ¯’æ€§è…¦è†œç‚ï¼šå¦‚æœæ‡·ç–‘ç‚ºHSVè…¦è†œè…¦ç‚ â†’ éœè„ˆæ³¨å°„acyclovir  </li>
<li>ç—…å› ä¸æ˜ï¼šè€ƒæ…®é–‹å§‹ç¶“é©—æ€§ç´°èŒæ€§è…¦è†œç‚æ²»ç™‚ï¼ŒåŒæ™‚è§€å¯Ÿä¸¦ç­‰å¾…è…¦è„Šæ¶²æª¢æŸ¥çµæœ  </li>
</ul>
<h3 id="nejm-2018379557"><a class="toclink" href="medicine/cns-infection/#nejm-2018379557">è…¦ç‚ (NEJM 2018;379:557)</a></h3>
<h4 id="_9"><a class="toclink" href="medicine/cns-infection/#_9">å®šç¾©</a></h4>
<ul>
<li>è…¦å¯¦è³ªç™¼ç‚ï¼Œç‰¹å¾µç‚ºè…¦åŠŸèƒ½å—æï¼ˆæ„è­˜æ”¹è®Šã€ç¥ç¶“ç¼ºæï¼‰ï¼Œé€šå¸¸ç”±åŸç™¼æ€§ç—…æ¯’æ„ŸæŸ“æˆ–ç—…æ¯’æ„ŸæŸ“å¾Œç™¼ç‚å¼•èµ·  </li>
</ul>
<h4 id="20-neurology-20066675-cid-200847303"><a class="toclink" href="medicine/cns-infection/#20-neurology-20066675-cid-200847303">ç—…å› å­¸ (ç‰¹å®šç—…å› åœ¨&lt;20%çš„ç—…ä¾‹ä¸­æ‰¾åˆ°; Neurology 2006;66:75; CID 2008;47:303)</a></h4>
<ul>
<li><strong>HSV-1</strong>ï¼šæ‰€æœ‰å¹´é½¡/å­£ç¯€ã€‚å¦‚æœæ²»ç™‚å¾Œç—‡ç‹€å¾©ç™¼ï¼Œè€ƒæ…®ç‚ºç—…æ¯’å¾©ç™¼æˆ–è‡ªé«”å…ç–«æ€§è…¦ç‚ï¼Œå› ç‚ºæ•¸é€±å¾Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç—…ç‡å¾ˆé«˜ (Lancet Neurol 2018;17:760)  </li>
<li>VZVåŸç™¼æ€§æ„ŸæŸ“æˆ–å†æ´»åŒ–ï¼šÂ± æ°´æ³¡ç–¹ï¼›æ‰€æœ‰å¹´é½¡ï¼ˆåå‘è€å¹´äººï¼‰ï¼Œæ‰€æœ‰å­£ç¯€  </li>
<li>èŸ²åª’ç—…æ¯’ï¼šè©•ä¼°ç—…åª’èšŠ/åœ°ç†æš´éœ²ã€‚èšŠå­ï¼šæ—¥æœ¬è…¦ç‚ã€è¥¿å°¼ç¾…æ²³ç—…æ¯’ã€‚  </li>
<li>è…¸ç—…æ¯’ï¼ˆcoxsackie, echoï¼‰ï¼šä¸Šå‘¼å¸é“æ„ŸæŸ“/è…¸èƒƒé“ç—‡ç‹€å‰é©…ï¼›å¤æœ«/ç§‹åˆé”é«˜å³°  </li>
<li>å…¶ä»–æ„ŸæŸ“ï¼šCMVã€EBVã€HIVã€JCç—…æ¯’ã€éº»ç–¹ã€è…®è…ºç‚ã€ç‹‚çŠ¬ç—…ã€è…ºç—…æ¯’ã€æµæ„Ÿç—…æ¯’ã€èŠå§†ç—…  </li>
<li>éæ„ŸæŸ“æ€§ï¼šè‡ªé«”å…ç–«/å‰¯è…«ç˜¤ï¼ˆæŠ—NMDARã€æŠ—Huã€æŠ—Ma2ã€æŠ—CRMP5ã€æŠ—mGluR5ï¼‰ï¼Œæ„ŸæŸ“å¾Œè„«é«“é˜ï¼ˆä¾‹å¦‚ï¼ŒADEMï¼‰  </li>
</ul>
<h4 id="_10"><a class="toclink" href="medicine/cns-infection/#_10">è‡¨åºŠè¡¨ç¾</a></h4>
<ul>
<li>ç™¼ç‡’ + æ„è­˜ç‹€æ…‹æ”¹è®Šï¼ˆè¼•å¾®è‡³åš´é‡ï¼‰ã€ç™²ç™‡ç™¼ä½œã€å±€éƒ¨ç¥ç¶“ç¼ºæã€è…¦è†œè…¦ç‚ä¸­çš„é ­ç—›  </li>
</ul>
<h4 id="cid-2013571114"><a class="toclink" href="medicine/cns-infection/#cid-2013571114">è¨ºæ–·ç ”ç©¶ (CID 2013;57:1114)</a></h4>
<ul>
<li>è…¦è„Šæ¶²åˆ†æï¼šæ·‹å·´ç´°èƒå¢å¤šç—‡ï¼›HSVï¼ˆ95% æ•æ„Ÿåº¦å’Œç‰¹ç•°åº¦ï¼‰ã€VZVçš„PCRï¼›æ ¹æ“šé¢¨éšªå› ç´ è€ƒæ…®å…¶ä»–PCRæª¢æŸ¥ï¼ˆCMV/EBVã€HIVã€JCç—…æ¯’ã€è…ºç—…æ¯’/è…¸ç—…æ¯’ã€è¥¿å°¼ç¾…æ²³ç—…æ¯’ï¼‰  </li>
<li>å¦‚æœè…¦è„Šæ¶²æª¢æŸ¥ç„¡æ‰€ç™¼ç¾ä¸”ç¶“é©—æ€§HSV/VZVæ²»ç™‚ç„¡æ”¹å–„ï¼Œåœ¨é©ç•¶æƒ…æ³ä¸‹è€ƒæ…®æª¢æ¸¬è‡ªé«”å…ç–«ç—…å› åŠè¡€æ¸…ç—…æ¯’æª¢æ¸¬  </li>
<li>MRIï¼ˆå¦‚æœç„¡æ³•é€²è¡Œå‰‡ä½¿ç”¨CTï¼‰ï¼›HSVï¼šé¡³è‘‰ï¼›è¥¿å°¼ç¾…æ²³ç—…æ¯’å’ŒPowassanç—…æ¯’ï¼šä¸˜è…¦é«˜ä¿¡è™Ÿ  </li>
<li>EEGæ’é™¤ç™²ç™‡ï¼›è…¦ç‚ä¸­çš„ç™¼ç¾éç‰¹ç•°æ€§ï¼ˆHSVçš„é¡³è‘‰é‡é»ï¼‰  </li>
</ul>
<h4 id="_11"><a class="toclink" href="medicine/cns-infection/#_11">æ²»ç™‚</a></h4>
<ul>
<li>HSV/VZVï¼šAcyclovir 10 mg/kg éœè„ˆæ³¨å°„ï¼Œæ¯8å°æ™‚ä¸€æ¬¡ï¼›è€ƒæ…®ç¶“é©—æ€§æ²»ç™‚ï¼Œå› ç‚ºæ©Ÿç‡è¼ƒé«˜  </li>
</ul>
<p><a href="../../../CNS">Original</a>  </p>
<h3 id="_12"><a class="toclink" href="medicine/cns-infection/#_12">è€ƒå¤é¡Œ</a></h3>
<h4 id="_13"><a class="toclink" href="medicine/cns-infection/#_13">å°ˆå¸«</a></h4>
<h4 id="_14"><a class="toclink" href="medicine/cns-infection/#_14">å…§ç§‘é†«å¸«</a></h4>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              3 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="coronavirus-disease-2019-covid-19-sars-cov-2-infection"><a class="toclink" href="medicine/covid-19/">CORONAVIRUS DISEASE 2019 (COVID-19) / SARS-COV-2 INFECTION</a></h2>
<p>source: Pocket Medicine, 2022; å°ç£è¨ºæ²»æŒ‡å¼•  </p>
<h3 id="_1"><a class="toclink" href="medicine/covid-19/#_1">å¾®ç”Ÿç‰©å­¸èˆ‡æµè¡Œç—…å­¸</a></h3>
<ul>
<li>é€éå‘¼å¸é“é¡†ç²’åœ¨äººèˆ‡äººä¹‹é–“å‚³æ’­ï¼›ç„¡ç—‡ç‹€èˆ‡ç—‡ç‹€å‰çš„å‚³æ’­å¯èƒ½ç™¼ç”Ÿ    </li>
<li>æ½›ä¼æœŸï¼šæœ€é•·å¯é”14å¤©ï¼Œå¾æš´éœ²åˆ°ç—‡ç‹€å‡ºç¾çš„ä¸­ä½æ™‚é–“ç‚º4-5å¤©  </li>
<li>ç¢ºè¨ºç—…äººç™¼ç—…==<strong>å‰2å¤©</strong>==å³å¯èƒ½å…·å‚³æŸ“åŠ›  </li>
<li>ç¢ºè¨ºç—…äººä¸Šå‘¼å¸é“æª¢é«”å¯æŒçºŒæª¢æ¸¬SARS-CoV-2æ ¸é…¸é™½æ€§å¹³å‡é”==<strong>å…©é€±</strong>==ä»¥ä¸Šï¼Œä¸”ä¸‹å‘¼å¸é“æª¢é«”æª¢å‡ºç—…æ¯’çš„æ™‚é–“å¯èƒ½æ›´ä¹…  </li>
<li>è¼•ç—‡å€‹æ¡ˆåœ¨ç™¼ç—…==<strong>10æ—¥å¾Œ</strong>==å³ç„¡æ³•å¾ä¸Šå‘¼å¸é“æª¢é«”æˆåŠŸåŸ¹é¤Šå‡ºç—…æ¯’ï¼ˆéƒ¨åˆ†é‡ç—‡å€‹æ¡ˆæˆ–å…ç–«ä¸å…¨è€…å¯èƒ½å»¶é•·è‡³20æ—¥ï¼‰ï¼Œæ­¤æ™‚é€™äº›å€‹æ¡ˆçš„ç—…æ¯’é‡å‡å¾ˆä½ï¼ˆ Realtime PCR Ct å€¼é«˜ï¼‰ï¼Œç›®å‰ä¹Ÿæ²’æœ‰è­‰æ“šé¡¯ç¤ºæ­¤æ™‚é€™äº›å€‹æ¡ˆèƒ½å‚³æ’­ç–¾ç—…  </li>
</ul>
<h3 id="_2"><a class="toclink" href="medicine/covid-19/#_2">è‡¨åºŠè¡¨ç¾</a></h3>
<ul>
<li>ç¯„åœå¾ç„¡ç—‡ç‹€åˆ°é‡ç—…ï¼Œå‡ºç¾ç—‡ç‹€çš„æ‚£è€…ä¸­ï¼Œ81%ç‚ºè¼•è‡³ä¸­åº¦ï¼Œ<strong>14%ç‚ºé‡ç—‡</strong>ï¼ˆç¼ºæ°§ï¼‰ï¼Œ<strong>5%ç‚ºå±é‡</strong>ï¼ˆARDSã€ä¼‘å…‹ã€å¤šé‡å™¨å®˜è¡°ç«­ï¼‰(<em>JAMA</em> 2020:323;13)  </li>
<li>å¸¸è¦‹ç—‡ç‹€ï¼šç™¼ç‡’ã€å¯’é¡«ã€å’³å—½ã€å‘¼å¸å›°é›£ï¼ˆç´„ä¸‰åˆ†ä¹‹ä¸€ï¼‰ã€è‚Œè‚‰ç—›ã€é ­ç—›ã€å™å¿ƒã€å˜”åã€è…¹ç€‰ã€å–ªå¤±å—…è¦º/å‘³è¦º  </li>
<li>Omicron è®Šç•°æ ªç›¸è¼ƒæ–¼å…¶ä»–è®Šç•°æ ªä¹‹ç—‡ç‹€è¼ƒè¼•å¾®ï¼Œç„¡ç—‡ç‹€è€…çš„æ¯”ä¾‹ä¹Ÿè¼ƒé«˜  </li>
<li>é‡ç—‡çš„å±éšªå› ç´ ï¼š<strong>å¹´é½¡â‰¥65æ­²ã€å¿ƒè¡€ç®¡ç–¾ç—…ã€ç³–å°¿ç—…ã€ä¸­é¢¨ã€è‚ºç—…ã€æ…¢æ€§è…ç—…ã€è‚¥èƒ–</strong>  </li>
<li>å…’ç«¥æ„ŸæŸ“ SARS-CoV-2 å¯èƒ½å‡ºç¾ multisystem inflammatory syndromeï¼ˆMIS-Cï¼‰ ï¼Œå…¶è‡¨åºŠè¡¨ç¾é¡ä¼¼å·å´ç—‡æˆ–æ¯’æ€§ä¼‘å…‹ç—‡å€™ç¾¤ï¼Œç—‡ç‹€åŒ…æ‹¬å‡ºç–¹ã€çµè†œç‚ã€ä¼‘å…‹ã€å¿ƒè‚Œæå‚·æˆ–å† ç‹€å‹•è„ˆè¡€ç®¡ç˜¤ç­‰  </li>
<li>ç™½è¡€çƒç¸½æ•¸ä¸€èˆ¬ä¸é«˜æˆ–ï¨‰ä½ï¼Œï§µå·´çƒæ¸›å°‘  </li>
<li>å€‹æ¡ˆç—…æ³å¯èƒ½åœ¨ç™¼ç—…å¾Œç¬¬äºŒå‘¨æƒ¡åŒ–ï¼›ä¸€åŠçš„æ‚£è€…åœ¨ç™¼ç—…å¾Œ8å¤©ï¼ˆç¯„åœï¼š5-13 å¤©ï¼‰å‡ºç¾å‘¼å¸æ€¥ä¿ƒï¼Œç´„æœ‰ä¸‰åˆ†ä¹‹ä¸€çš„å€‹æ¡ˆé€²å±•ç‚ºARDS ï¼Œç´„æœ‰äºŒè‡³ä¸‰æˆå€‹æ¡ˆéœ€è¦åŠ è­·ç—…æˆ¿æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯æœ‰æ…¢æ€§ç–¾ç—…å¦‚ç³–å°¿ç—…ã€é«˜è¡€å£“ã€åŠå¿ƒè¡€ç®¡ç–¾ç—…çš„æ‚£è€…  </li>
<li>åœ¨è‚ºç‚ä½é™¢çš„æ‚£è€…ä¸­ï¼Œç–¾ç—…è‡´æ­»ç‡å¯é«˜é”ä¸€æˆ  </li>
<li>å¯¦é©—å®¤æª¢æŸ¥æ·‹å·´çƒæ¸›å°‘(lymphopenia)åˆä½µD-dimerå‡é«˜èˆ‡æ­»äº¡ç‡å‘ˆæ­£ç›¸é—œ  </li>
<li>éƒ¨åˆ† SARS-CoV-2 æ‚£è€…åœ¨æ€¥æ€§æœŸåº·å¾©å¾Œï¼Œæœƒæœ‰æŒçºŒæ€§æˆ–æ–°å‡ºç¾çš„ç—‡ç‹€ï¼Œç¨±ç‚º COVID-19 æ€¥æ€§æ„ŸæŸ“å¾Œå¾µå€™ç¾¤ (post-COVID condition)ï¼Œé€šå¸¸åœ¨ç™¼ç—…ä¸‰å€‹æœˆå¾Œç™¼ç”Ÿï¼Œç—‡ç‹€éœ€è‡³å°‘æŒçºŒå…©å€‹æœˆä»¥ä¸Šï¼Œä¸”ç„¡æ³•ä»¥å…¶ä»–ç—…å› è§£é‡‹ã€‚æµè¡Œç—…å­¸ç ”ç©¶é¡¯ç¤ºç™¼ç”Ÿç‡ä»‹æ–¼ä¸€æˆè‡³äºŒæˆä¹‹é–“ï¼Œä¸»è¦ç—‡ç‹€åŒ…æ‹¬ç–²å€¦ã€å‘¼å¸å›°é›£ã€èªçŸ¥åŠŸèƒ½èˆ‡ç¡çœ éšœç¤™ã€å—…å‘³è¦ºæ”¹è®Šç­‰ï¼Œä½†å„å™¨å®˜ç³»çµ±å‡å¯èƒ½å‡ºç¾ç›¸é—œç—‡ç‹€ï¼Œä¸¦å¸¸æœƒå½±éŸ¿æ‚£è€…æ—¥å¸¸ç”Ÿæ´»åŠŸèƒ½ã€‚  </li>
</ul>
<h3 id="_3"><a class="toclink" href="medicine/covid-19/#_3">åš´é‡åº¦åˆ†é¡</a></h3>
<h4 id="_4"><a class="toclink" href="medicine/covid-19/#_4">è¼•åº¦ï¼šç„¡ä½µç™¼ç—‡ä¹‹è¼•ç—‡</a></h4>
<p>æ²’æœ‰ä»»ä½•ä½µç™¼ç—‡çš„ä¸Šå‘¼å¸é“ç—…æ¯’æ€§æ„ŸæŸ“æ‚£è€…  </p>
<h4 id="_5"><a class="toclink" href="medicine/covid-19/#_5">ä¸­åº¦ï¼šè‚ºç‚</a></h4>
<p>æ²’æœ‰åš´é‡è‚ºç‚å¾µå€™çš„è‚ºç‚æ‚£è€…ï¼Œç„¡æ°§æ°£è¨­å‚™è¼”åŠ©ï¼ˆroom airï¼‰ä¸‹è¡€æ°§é£½å’Œåº¦&gt;94%  </p>
<h4 id="_6"><a class="toclink" href="medicine/covid-19/#_6">é‡åº¦ï¼šåš´é‡è‚ºç‚</a></h4>
<p>é’å°‘å¹´æˆ–æˆäººï¼šç™¼ç‡’æˆ–å‘¼å¸é“æ„ŸæŸ“ï¼Œåˆä½µä¸‹åˆ—ä»»ä¸€é …ï¼š<br />
- å‘¼å¸é€Ÿç‡ &gt; 30 ä¸‹/åˆ†é˜<br />
- åš´é‡å‘¼å¸çª˜è¿«ï¼ˆsevere respiratory distressï¼‰PaO2/FiO2 &lt;300<br />
- ç„¡æ°§æ°£è¨­å‚™è¼”åŠ©ï¼ˆroom airï¼‰ä¸‹è¡€æ°§é£½å’Œåº¦â‰¦ 94%<br />
- æˆ–è‚ºæµ¸æ½¤(infiltration) &gt; 50%  </p>
<h4 id="ards"><a class="toclink" href="medicine/covid-19/#ards">æ¥µé‡åº¦ï¼šæ€¥æ€§å‘¼å¸çª˜è¿«ç—‡å€™ç¾¤ï¼ˆARDSï¼‰</a></h4>
<p>æ™‚åºï¼šåœ¨å·²çŸ¥è‡¨åºŠç—…å› ä¹‹ä¸€å‘¨å…§ï¼Œæ–°ç™¼ç”Ÿå‘¼å¸é“ç—‡ç‹€ï¼Œæˆ–åŸæœ‰ä¹‹å‘¼å¸é“ç—‡ç‹€åŠ åŠ‡ã€‚<br />
èƒ¸éƒ¨å½±åƒï¼ˆ<strong>X</strong> å…‰ã€é›»è…¦æ–·å±¤ã€è‚ºéƒ¨è¶…éŸ³æ³¢ç­‰ï¼‰ ï¼šé›™å´è‚ºéƒ¨æ–‘å¡Šï¼ˆopacitiesï¼‰ ï¼Œä¸”ç„¡æ³•åªä»¥è‚‹è†œç©æ°´ã€è‚ºè‘‰å¡Œé™·ã€æˆ–çµç¯€è§£é‡‹ã€‚<br />
è‚ºæ°´è…«åŸå› ï¼ˆ<strong>origin of edema</strong>ï¼‰ ï¼šç„¡æ³•å®Œå…¨ä»¥å¿ƒè‡Ÿè¡°ç«­æˆ–é«”æ¶²å®¹ç©éé‡ï¼ˆfluid overloadï¼‰è§£é‡‹ä¹‹å‘¼å¸è¡°ç«­ï¼Œä¸”é ˆå®¢è§€ä¹‹è©•ä¼°è­‰æ“šï¼Œä»¥æ’é™¤éœæ°´æ€§è‚ºæ°´è…«ï¼ˆhydrostaticï¼‰ã€‚  </p>
<p>æ°§åˆåº¦ï¼ˆæˆäººï¼‰ï¼š<br />
* è¼•åº¦ ARDSï¼š200mmHg &lt; PaO2/FiO2 â‰¤300mmHgï¼ˆåˆä½µ PEEP æˆ– CPAP â‰¥ 5 cmH2Oï¼Œæˆ–æœªæ¥å—æ©Ÿæ¢°å¼å‘¼å¸è¼”åŠ©ï¼‰ã€‚<br />
* ä¸­åº¦ ARDSï¼š100mmHg &lt; PaO2/FiO2 â‰¤200mmHgï¼ˆåˆä½µ PEEP â‰¥ 5 cmH2Oï¼Œæˆ–æœªæ¥å—æ©Ÿæ¢°å¼å‘¼å¸è¼”åŠ©ï¼‰ã€‚<br />
* é‡åº¦ ARDSï¼šPaO2/FiO2 â‰¤ 100mmHgï¼ˆåˆä½µPEEP â‰¥ 5 cmH2Oï¼Œæˆ–æœªæ¥å—æ©Ÿæ¢°å¼å‘¼å¸è¼”åŠ©ï¼‰ã€‚<br />
* ç•¶ç„¡ PaO2 ä¹‹æ•¸å€¼æ™‚ï¼ŒSpO2/FiO2 â‰¤ 315 å¯èªç‚ºæœ‰ ARDSï¼ˆå³ä¾¿æ‚£è€…æœªæ¥å—æ©Ÿæ¢°å¼å‘¼å¸è¼”åŠ©ï¼‰ã€‚  </p>
<h3 id="_7"><a class="toclink" href="medicine/covid-19/#_7">è¨ºæ–·</a></h3>
<ul>
<li>é¼»å’½ã€ä¸‹å‘¼å¸é“æˆ–å‰é¼»è…”çš„RT-PCRæª¢æ¸¬  </li>
<li>å‰é¼»è…”çš„å¿«é€ŸæŠ—åŸæª¢æ¸¬ï¼ˆæ•æ„Ÿåº¦ä½æ–¼PCRï¼‰  </li>
<li>èƒ¸éƒ¨Xå…‰ï¼šé€šå¸¸é¡¯ç¤ºé›™å´ä¸é€æ˜å½±ï¼ˆç‰¹åˆ¥æ˜¯å¤–åœï¼‰ï¼Œæ—©æœŸå¯èƒ½æ­£å¸¸ï¼›è‹¥è¨ºæ–·ä¸æ˜å¯è€ƒæ…®CT  </li>
<li>CTè®ŠåŒ–ä¸å…·ç‰¹ç•°æ€§ï¼Œå¯èƒ½åŒ…æ‹¬ GGOã€è‚ºå¯¦è³ªåŒ–ï¼ˆconsolidationï¼‰ç­‰ã€‚é›–ç—…ç¨‹å¾ŒæœŸå‡ºç¾é–“è³ªæ€§è®ŠåŒ–ï¼ˆinterstitial changeï¼‰ ï¼Œä½†ç›®å‰ä»ç„¡æ³•ç¢ºå®šæ˜¯å¦æœƒæœ‰è‚ºçº–ç¶­åŒ–ï¼ˆfibrosisï¼‰ä¹‹å¾Œéºç—‡  </li>
</ul>
<h3 id="_8"><a class="toclink" href="medicine/covid-19/#_8">æ²»ç™‚</a></h3>
<ul>
<li>Nirmatrelvir/ritonavir (Paxlovid)ï¼šèƒ½é˜»æ­¢ç—…æ¯’è›‹ç™½é…¶ï¼ˆproteaseï¼‰è¤‡è£½ï¼Œritonaviræ˜¯cytochrome P450 3A4 (CYP3A4)çš„å¼·æŠ‘åˆ¶åŠ‘ï¼Œå¯æ¸›ç·©nirmatrelvirè¢«è‚è‡Ÿcytochrome P450åˆ†è§£ä»£è¬çš„é€Ÿåº¦ï¼Œè€Œå¢å¼·å…¶æ•ˆæœ  </li>
<li>Molnupiravirï¼šè—‰ç”±å…¶æˆä»½çš„æ ¸è‹·é¡ä¼¼ç‰©ï¼Œè®“ç—…æ¯’çš„è¤‡è£½é…¶åœ¨RNAè¤‡è£½æ™‚ä¸æ–·ç´¯ç©çªè®Šï¼Œå°è‡´ç„¡æ³•å®Œå…¨è¤‡è£½è€Œè‡ªè¡Œæ¶ˆå¤±ã€‚å› æœ‰åŸºå› çªè®Šç­‰è€ƒé‡ï¼Œä¸å»ºè­°ä½¿ç”¨æ–¼å­•å©¦ã€‚  </li>
<li>Remdesivirï¼šæŠ‘åˆ¶ç—…æ¯’èšåˆé…¶ï¼ˆRNA polymeraseï¼‰  </li>
<li>Nirmatrelvir/ritonavir (Paxlovid)ï¼šèƒ½é˜»æ­¢ç—…æ¯’è›‹ç™½é…¶ï¼ˆproteaseï¼‰è¤‡è£½ï¼Œritonaviræ˜¯cytochrome P450 3A4 (CYP3A4)çš„å¼·æŠ‘åˆ¶åŠ‘ï¼Œå¯æ¸›ç·©Nirmatrelvirè¢«è‚è‡Ÿcytochrome P450åˆ†è§£ä»£è¬çš„é€Ÿåº¦ï¼Œè€Œå¢å¼·å…¶æ•ˆæœ  </li>
<li>Molnupiravirï¼šè—‰ç”±å…¶æˆä»½çš„æ ¸è‹·é¡ä¼¼ç‰©ï¼Œè®“ç—…æ¯’çš„è¤‡è£½é…¶åœ¨RNAè¤‡è£½æ™‚ç”¢ç”Ÿæœ‰ç¼ºé™·çš„RNAï¼Œå› æœ‰åŸºå› çªè®Šç­‰è€ƒé‡ï¼Œä¸å»ºè­°ä½¿ç”¨æ–¼å­•å©¦  </li>
<li>Remdesivirï¼šæŠ‘åˆ¶ç—…æ¯’èšåˆé…¶ï¼ˆRNA polymeraseï¼‰  </li>
</ul>
<p><img alt="treatment" src="../../assets/images/6e358234a9fbbbf988a503a1c478ac37_MD5.jpeg" />  </p>
<ul>
<li>é‡ç—‡é¢¨éšªå› å­ï¼šâ‰§65 æ­²ã€æ°£å–˜ã€ç™Œç—‡ã€ç³–å°¿ç—…ã€æ…¢æ€§è…ç—…ã€å¿ƒè¡€ç®¡ç–¾ç—…ï¼ˆä¸å«é«˜è¡€å£“ï¼‰ã€æ…¢æ€§è‚ºç–¾ï¼ˆé–“è³ªæ€§è‚ºç—…ã€è‚ºæ “å¡ã€è‚ºé«˜å£“ã€æ°£ç®¡æ“´å¼µã€æ…¢æ€§é˜»å¡æ€§è‚ºç—…ï¼‰ã€çµæ ¸ç—…ã€æ…¢æ€§è‚ç—…ï¼ˆè‚ç¡¬åŒ–ã€éé…’ç²¾æ€§è„‚è‚ªæ€§è‚ç‚ã€é…’ç²¾æ€§è‚ç—…èˆ‡å…ç–«æ€§è‚ç‚ï¼‰ã€å¤±èƒ½ï¼ˆæ³¨æ„åŠ›ä¸è¶³åŠéå‹•ç—‡ã€è…¦æ€§éº»ç—ºã€å…ˆå¤©æ€§ç¼ºé™·ã€ç™¼å±•æˆ–å­¸ç¿’éšœç¤™ã€è„Šé«“æå‚·ï¼‰ã€ç²¾ç¥ç–¾ç—…ï¼ˆæƒ…ç·’éšœç¤™ã€æ€è¦ºå¤±èª¿ç—‡ï¼‰ã€å¤±æ™ºç—‡ã€å¸è¸ï¼ˆæˆ–å·²æˆ’è¸è€…ï¼‰ã€BMI â‰§ 30ã€æ‡·å­•ï¼ˆæˆ–ç”¢å¾Œå…­å‘¨å…§ï¼‰ã€å½±éŸ¿å…ç–«åŠŸèƒ½ä¹‹ç–¾ç—…ï¼ˆHIV æ„ŸæŸ“ã€å…ˆå¤©æ€§å…ç–«ä¸å…¨ã€å¯¦é«”å™¨å®˜æˆ–è¡€æ¶²å¹¹ç´°èƒç§»æ¤ã€ä½¿ç”¨é¡å›ºé†‡æˆ–å…¶ä»–å…ç–«æŠ‘åˆ¶åŠ‘  </li>
<li>ä¸éœ€ä½¿ç”¨æ°§æ°£ï¼šè‹¥æœ‰é‡ç—‡é¢¨éšªå› å­ï¼Œç™¼ç—…äº”å¤©å…§å¯æœç”¨Paxlovidå’ŒMolnupiravirï¼ˆé™ç”¨æ–¼ç„¡æ³•ä½¿ç”¨å…¶ä»–å»ºè­°è—¥ç‰©è€…ï¼‰ï¼Œæˆ–ç™¼ç—…ä¸ƒå¤©å…§å¯çµ¦äºˆç‘å¾·è¥¿éŸ‹<strong>ä¸‰å¤©</strong>  </li>
<li>ä½é™¢ä¸”éœ€è¦è¼”åŠ©æ°§æ°£çš„æ‚£è€…ï¼š<mark><strong>dexamethasone</strong></mark> 6mg QD æœ€å¤š10å¤© Â± ç‘å¾·è¥¿éŸ‹<strong>äº”å¤©</strong>ï¼ˆæŠ‘åˆ¶ç—…æ¯’RNAèšåˆé…¶ï¼‰  </li>
<li>ä½é™¢ä¸”æ’ç®¡æˆ–ä½¿ç”¨ECMOçš„æ‚£è€…ï¼šdexamethasone + tocilizumabï¼ˆæŠ—IL-6ï¼‰æˆ–baricitinib/tofacitinibï¼ˆJAK inhibitorï¼‰  </li>
<li>è¡€æ “ç™¼ç”Ÿç‡éš¨ç–¾ç—…åš´é‡ç¨‹åº¦ä¸Šå‡ã€‚å»ºè­°è¦–å€‹æ¡ˆè‡¨åºŠåš´é‡ç¨‹åº¦èˆ‡ç›¸é—œæª¢é©—æ•¸æ“š(å¦‚ï¼ŒD-dimerã€fibrinogen ç­‰)ï¼Œè€ƒæ…®å°åš´é‡è‚ºç‚ä»¥ä¸Šç¨‹åº¦æ‚£è€…çµ¦äºˆé é˜²æ€§åŠ‘é‡æŠ—å‡è¡€åŠ‘  </li>
<li>è‹¥æ‚£è€…ç„¡ä¼‘å…‹è­‰æ“šï¼Œå‰‡æ¡å–ä¿å®ˆæ€§çš„è¼¸æ¶²æ²»ç™‚  </li>
<li>å°åš´é‡è‚ºç‚ä»¥ä¸Šç¨‹åº¦ä¹‹SARS-CoV-2æ‚£è€…ï¼Œè€ƒæ…®çµ¦äºˆç¶“é©—æ€§æŠ—ç”Ÿç´ /æŠ—ç—…æ¯’è—¥ç‰©ä»¥æ²»ç™‚å…¶ä»–å¯èƒ½çš„ç´°èŒ/ç—…æ¯’æ„ŸæŸ“  </li>
</ul>
<h3 id="_9"><a class="toclink" href="medicine/covid-19/#_9">é é˜²</a></h3>
<ul>
<li>é‡å°åˆºçªè›‹ç™½çš„ç–«è‹—éå¸¸æœ‰æ•ˆã€‚é›–ç„¶å¯èƒ½æœƒæ„ŸæŸ“ï¼Œä½†ç—…æƒ…æœƒè¼•å¾—å¤šã€‚  </li>
</ul>
<h4 id="ttsvitt"><a class="toclink" href="medicine/covid-19/#ttsvitt">TTS/VITT</a></h4>
<ul>
<li>The term thrombosis and thrombocytopenia syndrome (TTS) refers to all thrombocytopenia and thrombotic complications after vaccination.   </li>
<li>Based on clinical similarities to â€œautoimmuneâ€ or â€œspontaneousâ€ heparin-induced thrombocytopenia, Immunoglobulin G (IgG) antibodies cross-reacting with â€œunboundâ€ platelet factor 4 (PF4) in assays for heparin-induced thrombocytopenia (HIT) were soon identified in a subgroup of patients with TTS, termed vaccine-induced immune thrombotic thrombocytopenia (VITT).  </li>
<li>The term thrombosis and thrombocytopenia syndrome (TTS) refers to all thrombocytopenia and thrombotic complications after vaccination.   </li>
<li>Based on clinical similarities to â€œautoimmuneâ€ or â€œspontaneousâ€ heparin-induced thrombocytopenia, Immunoglobulin G (IgG) antibodies cross-reacting with â€œunboundâ€ platelet factor 4 (PF4) in assays for heparin-induced thrombocytopenia (HIT) were soon identified in a subgroup of patients with TTS, termed vaccine-induced immune thrombotic thrombocytopenia (VITT).  </li>
<li>ç™¼ç”Ÿç‡ï¼š&lt; 20 cases / million doses  </li>
</ul>
<h5 id="case-definition-criteria"><a class="toclink" href="medicine/covid-19/#case-definition-criteria">Case definition criteria</a></h5>
<ul>
<li>Onset of symptoms 5-30 days after COVID-19 vaccine (or up to 42 days if isolated DVT/PE)   </li>
<li>Presence of thrombosis   </li>
<li>Thrombocytopenia (platelet count &lt;150 Ã— 10<sup>9</sup>/L)   </li>
<li>D-dimer &gt;4000 Î¼g/mL (FEU)   </li>
<li>Positive anti-PF4 Abs ELISA   </li>
</ul>
<h5 id="definite-vitt"><a class="toclink" href="medicine/covid-19/#definite-vitt">Definite VITT</a></h5>
<ul>
<li>Meets all 5 criteria   </li>
</ul>
<h5 id="probable"><a class="toclink" href="medicine/covid-19/#probable">Probable</a></h5>
<ul>
<li>D-dimer &gt;4000 FEU but one criterion not fulfilled (timing, thrombosis, thrombocytopenia, anti-PF4 Abs), or   </li>
<li>D-dimer unknown or 2000-4000 FEU with all other criteria present   </li>
</ul>
<h5 id="possible"><a class="toclink" href="medicine/covid-19/#possible">Possible</a></h5>
<ul>
<li>D-dimer unknown or 2000-4000 FEU with one other criterion not fulfilled, or   </li>
<li>Two other criteria not fulfilled (timing, thrombosis, thrombocytopenia, anti-PF4 Abs)   </li>
</ul>
<h5 id="unlikely"><a class="toclink" href="medicine/covid-19/#unlikely">Unlikely</a></h5>
<ul>
<li>Platelet count &lt;150 Ã— 10<sup>9</sup>/L without thrombosis with D-dimer &lt;2000 FEU, or   </li>
<li>Thrombosis with platelet count &gt;150 Ã— 10<sup>9</sup>/L and D-dimer &lt;2000 FEU, regardless of anti-PF4 Ab result, and/or   </li>
</ul>
<h3 id="_10"><a class="toclink" href="medicine/covid-19/#_10">è€ƒå¤é¡Œ</a></h3>
<h4 id="_11"><a class="toclink" href="medicine/covid-19/#_11">å°ˆå¸«</a></h4>
<h4 id="_12"><a class="toclink" href="medicine/covid-19/#_12">å…§ç§‘é†«å¸«</a></h4>
<div class="footnote">
<hr />
<ol>
<li id="fn:3">
<p>å°Omicronè®Šç•°æ ªæ•ˆæœä¸ä½³&#160;<a class="footnote-backref" href="medicine/covid-19/#fnref:3" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
</ol>
</div>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="category/medicinehiv/" class="md-meta__link">medicine/hiv</a></li>
        
        
          
          <li class="md-meta__item">
            
              5 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="hivaids"><a class="toclink" href="medicinehiv/hivaids/">HIV/AIDS</a></h2>
<p>source: Pocket Medicine, 2022  </p>
<h3 id="_1"><a class="toclink" href="medicinehiv/hivaids/#_1">å®šç¾©èˆ‡è‡¨åºŠè¡¨ç¾</a></h3>
<ul>
<li>æ€¥æ€§HIVï¼šçš®ç–¹ã€æ·‹å·´çµè…«å¤§ã€ç™¼ç‡’ã€å£è…”æ½°ç˜ã€å’½å–‰ç‚ã€è‚Œè‚‰ç–¼ç—›ã€è…¹ç€‰  <ul>
<li>ä¸€èˆ¬åœ¨æ¥è§¸å¾Œç´„2-6é€±å‡ºç¾ï¼›ä¸¦éæ‰€æœ‰HIVæ„ŸæŸ“è€…æœƒå‡ºç¾æ€¥æ€§HIVçš„ç—‡ç‹€  </li>
</ul>
</li>
<li>æ„›æ»‹ç—…ï¼ˆAIDSï¼‰ï¼šHIV + CD4 &lt;200/mmÂ³ æˆ–å‡ºç¾AIDSå®šç¾©çš„ä¼ºæ©Ÿæ€§æ„ŸæŸ“ï¼ˆOIï¼‰æˆ–æƒ¡æ€§è…«ç˜¤  </li>
</ul>
<h4 id="aids-defining-opportunistic-illnesses-in-hiv-infection"><a class="toclink" href="medicinehiv/hivaids/#aids-defining-opportunistic-illnesses-in-hiv-infection">AIDS-Defining Opportunistic Illnesses in HIV Infection</a></h4>
<ul>
<li>Encephalopathy attributed to HIV  </li>
<li>Progressive multifocal leukoencephalopathy  </li>
<li>Bacterial infections, multiple or recurrent (only among children aged &lt;6 years.)  </li>
<li>Salmonella septicemia, recurrent  </li>
<li>Pneumonia, recurrent (only among adults, adolescents, and children aged â‰¥6 years)  </li>
<li>Candidiasis of bronchi, trachea, or lungs  </li>
<li>Candidiasis of esophagus  </li>
<li>Coccidioidomycosis, disseminated or extrapulmonary  </li>
<li>Cryptococcosis, extrapulmonary  </li>
<li>Histoplasmosis, disseminated or extrapulmonary  </li>
<li>Pneumocystis jirovecii (previously known as "Pneumocystis carinii") pneumonia  </li>
<li>Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age &gt;1 month  </li>
<li>Cytomegalovirus retinitis (with loss of vision)  </li>
<li>Herpes simplex: chronic ulcers (&gt;1 month's duration) or bronchitis, pneumonitis, or esophagitis (onset at age &gt;1 month)  </li>
<li>Mycobacterium avium complex or Mycobacterium kansasii, disseminated or extrapulmonary  </li>
<li>Mycobacterium tuberculosis of any site, pulmonary (only among adults, adolescents, and children aged â‰¥6 years), disseminated, or extrapulmonary  </li>
<li>Mycobacterium, other species or unidentified species, disseminated or extrapulmonary  </li>
<li>Cervical cancer, invasive (only among adults, adolescents, and children aged â‰¥6 years)  </li>
<li>Kaposi sarcoma  </li>
<li>Lymphoma, Burkitt (or equivalent term)  </li>
<li>Lymphoma, immunoblastic (or equivalent term)  </li>
<li>Lymphoma, primary, of brain  </li>
<li>Wasting syndrome attributed to HIV  </li>
<li>Cryptosporidiosis, chronic intestinal (&gt;1 month's duration)  </li>
<li>Isosporiasis, chronic intestinal (&gt;1 month's duration)  </li>
<li>Toxoplasmosis of brain, onset at age &gt;1 month  </li>
</ul>
<h3 id="_2"><a class="toclink" href="medicinehiv/hivaids/#_2">æµè¡Œç—…å­¸</a></h3>
<ul>
<li>ç´„æœ‰120è¬ç¾åœ‹äººèˆ‡HIVæ„ŸæŸ“å…±å­˜ï¼ˆ13% ä¸çŸ¥é“è‡ªå·±æ„ŸæŸ“ï¼‰ï¼›å…¨çƒç´„3700è¬  </li>
<li>é«˜é¢¨éšªç¾¤é«”ï¼šç”·æ€§åŒæ€§æˆ€è€…ã€è®Šæ€§å¥³æ€§ã€éœè„ˆæ³¨å°„æ¯’å“è€…ã€æ€§å·¥ä½œè€…ã€é«˜é¢¨éšªæ‚£è€…çš„ä¼´ä¾¶  </li>
<li>å‚³æ’­é€”å¾‘ï¼šæ€§è¡Œç‚ºï¼ˆç„¡æŠ—ç—…æ¯’è—¥ç‰©æ™‚é¢¨éšªç‚º0.1-1%ï¼‰ã€é‡æ‰ï¼ˆè·æ¥­æˆ–éœè„ˆæ³¨å°„æ¯’å“ï¼‰ã€å‚ç›´å‚³æ’­ï¼ˆç„¡æŠ—ç—…æ¯’è—¥ç‰©æ™‚é¢¨éšªç‚º15-40%ï¼‰ã€è¼¸è¡€ã€å™¨å®˜ç§»æ¤ï¼ˆåœ¨ç¾åœ‹ä¸å¸¸è¦‹ï¼‰  </li>
</ul>
<h3 id="nejm-20153732237-lancet-201638753-j-infect-dis-201821816-cdc-2021"><a class="toclink" href="medicinehiv/hivaids/#nejm-20153732237-lancet-201638753-j-infect-dis-201821816-cdc-2021">é é˜² (NEJM 2015;373:2237; Lancet 2016;387:53; J Infect Dis 2018;218:16; CDC 2021)</a></h3>
<ul>
<li>æš´éœ²å‰é é˜²ï¼ˆPrEPï¼‰ï¼šæ¯æ—¥æœç”¨TDF/FTCï¼Œè‹¥éµå®ˆç™‚ç¨‹å¯æ¸›å°‘è¶…é90%çš„å‚³æ’­é¢¨éšªã€‚è€ƒæ…®ç”¨æ–¼HIVé™°æ€§ä¼´ä¾¶ã€ç„¡å®‰å…¨å¥—æ€§è¡Œç‚ºçš„é«˜é¢¨éšªç¾¤é«”ã€6å€‹æœˆå…§æœ‰æ€§å‚³æ’­æ„ŸæŸ“å²ã€éœè„ˆæ³¨å°„æ¯’å“ä¸”å…±ç”¨é‡é ­è€…ã€‚é–‹å§‹ä¹‹å‰éœ€æ’é™¤HIVï¼Œä¸¦æ¯3å€‹æœˆæª¢æŸ¥è…åŠŸèƒ½ã€æ€§ç—…åŠHIVã€‚  </li>
<li>æš´éœ²å¾Œé é˜²ï¼ˆPEPï¼‰ï¼šåœ¨é«˜é¢¨éšªæš´éœ²å¾Œç›¡å¿«ï¼ˆ72å°æ™‚å…§ï¼‰é–‹å§‹ï¼ˆå¦‚æœHIVç‹€æ…‹ä¸æ˜å‰‡éœ€è¦å€‹åˆ¥æ±ºå®šï¼‰ã€‚æª¢æŸ¥åŸºç¤HIVã€æ€§ç—…ã€HBVã€HCVã€‚æ²»ç™‚ï¼š2ç¨®NRTIï¼ˆé€šå¸¸æ˜¯TDF/FTCï¼‰+ RALæˆ–DTG Ã— 4é€±ã€‚è€ƒæ…®å¾ŒçºŒé–‹å§‹PrEPã€‚  </li>
</ul>
<h3 id="jama-2018320379"><a class="toclink" href="medicinehiv/hivaids/#jama-2018320379">ç¯©æª¢èˆ‡è¨ºæ–· (JAMA 2018;320:379)</a></h3>
<ul>
<li>æ‰€æœ‰13-64æ­²äººç¾¤è‡³å°‘ç¯©æª¢ä¸€æ¬¡ï¼Œæ¯æ¬¡æ‡·å­•æ™‚ã€è‹¥æœ‰æ–°æ€§ç—…æ„ŸæŸ“è¨ºæ–·æ™‚ç¯©æª¢ï¼›é«˜é¢¨éšªè€…æ¯å¹´ç¯©æª¢  </li>
<li>HIVæŠ—é«”/p24æŠ—åŸï¼ˆELISAæª¢æ¸¬ï¼‰ï¼šæ„ŸæŸ“å¾Œ1-12é€±é™½æ€§ï¼›éˆæ•åº¦è¶…é99%ï¼›ç‚ºä¸»è¦ç¯©æª¢æ¸¬è©¦  </li>
<li>å¦‚æœçµæœç‚ºé™½æ€§ï¼ŒæŠ—é«”åˆ†å‹æª¢æ¸¬å¯ç¢ºèªä¸¦å€åˆ†HIV-1èˆ‡HIV-2ï¼ˆMMWR 2013;62:489ï¼‰  </li>
<li>è¡€æ¼¿HIV RNA PCRç—…æ¯’é‡ï¼ˆVLï¼‰ï¼šæª¢æ¸¬ç¯„åœç‚º20-1000è¬æ‹·è²/mLï¼›å½é™½æ€§å¯èƒ½ç™¼ç”Ÿï¼Œä½†é€šå¸¸æ‹·è²æ•¸é‡è¼ƒå°‘ï¼›ç›¸æ¯”ä¹‹ä¸‹ï¼ŒåˆæœŸæ„ŸæŸ“ç—…æ¯’é‡æ‡‰è©²è¼ƒé«˜ï¼ˆ&gt;75è¬ï¼‰  </li>
<li>CD4è¨ˆæ•¸ï¼šä¸æ˜¯è¨ºæ–·æ¸¬è©¦ï¼Œå› ç‚ºå¯èƒ½HIVé™½æ€§ä½†CD4æ­£å¸¸ï¼Œæˆ–HIVé™°æ€§ä½†CD4ä½  </li>
</ul>
<h3 id="hiv-cid-202073e3572"><a class="toclink" href="medicinehiv/hivaids/#hiv-cid-202073e3572">å°æ–°è¨ºæ–·HIVé™½æ€§æ‚£è€…çš„è™•ç† (CID 2020;73:e3572)</a></h3>
<ul>
<li>è«®è©¢é—œæ–¼è‹¥æœè—¥éµå¾æ€§é«˜å‰‡æ²»ç™‚é å¾Œè‰¯å¥½ã€æ²»ç™‚é¸æ“‡åŠç—…æƒ…æŠ«éœ²  </li>
<li>å¯¦é©—å®¤è©•ä¼°ï¼šCD4è¨ˆæ•¸ã€HIVç—…æ¯’é‡åŠåŸºå› å‹ã€CBC/DCã€åŸºç¤ç”ŸåŒ–ã€è‚åŠŸèƒ½ã€HbA1cã€è¡€è„‚è‚ªã€å°¿æ¶²åˆ†æã€PPD/IGRAã€æ¢…æ¯’æŠ—é«”ã€æŠ«è¡£èŒèˆ‡æ·‹ç—…ï¼ˆ3éƒ¨ä½ï¼‰ã€A/B/Cå‹è‚ç‚ã€G6PDï¼ˆå¦‚æœæ˜¯é«˜é¢¨éšªæ—ç¾¤ï¼‰ã€æ‡·å­•ç¯©æª¢ã€è‹¥ä½¿ç”¨abacavirå‰‡æª¢æŸ¥HLA-Bï¼Š5701  <ul>
<li>å¦‚æœæ˜¯AIDSï¼šCMV IgGã€Toxo IgGã€‚  </li>
</ul>
</li>
<li>ç¢ºèªæ‰€æœ‰ç–«è‹—ï¼ˆåŒ…æ‹¬æ¯å¹´æµæ„Ÿç–«è‹—ï¼‰éƒ½æ˜¯æœ€æ–°çš„ï¼Œè‹¥CD4 â‰¤200å‰‡é¿å…ä½¿ç”¨æ´»èŒç–«è‹—  </li>
<li>åŠæ—©é–‹å§‹æŠ—ç—…æ¯’è—¥ç‰©ï¼ˆæœ€å¥½åœ¨å¯¦é©—å®¤æª¢æŸ¥å’ŒåŸºå› å‹çµæœå¾Œï¼ŒåŒæ™‚å¾—åˆ°HIVå°ˆå®¶æŒ‡å°ï¼‰ï¼Œä¸è«–CD4æ•¸å€¼å¦‚ä½•ï¼Œå› ç‚ºå¯ä»¥é™ä½æ­»äº¡ç‡ï¼ˆNEJM 2015;373:795ï¼‰  </li>
<li>æ²»ç™‚å¯ä»¥é é˜²å°ä¼´ä¾¶çš„å‚³æ’­ã€‚ç•¶ç—…æ¯’é‡æª¢æ¸¬ä¸åˆ°è¶…é6å€‹æœˆæ™‚ï¼Œç„¡ä¿è­·æ€§è¡Œç‚ºçš„å‚³æ’­é¢¨éšªç´„ç‚º0%ï¼ˆJAMA 2016;316:171ï¼›Lancet HIV 2018;5:e438ï¼‰ã€‚  </li>
<li>æ²»ç™‚æ–¹æ¡ˆåŒ…æ‹¬ï¼š2ç¨®NRTIï¼ˆå¦‚TAF + FTCï¼‰+ INSTIæˆ–åŠ å¼·å‹PIï¼ˆå¦‚DRV/rï¼‰  </li>
<li>é–‹å§‹æŠ—ç—…æ¯’æ²»ç™‚å¯èƒ½æœƒå› å…ç–«é‡å»ºç™¼ç‚ç—‡å€™ç¾¤ï¼ˆIRISï¼‰æš«æ™‚åŠ é‡ç¾æœ‰çš„ä¼ºæ©Ÿæ€§æ„ŸæŸ“ï¼ˆTBã€MACã€CMVç­‰ï¼‰ã€‚åœ¨æŠ—ç—…æ¯’æ²»ç™‚çš„å‰4é€±ä½¿ç”¨é¡å›ºé†‡å¯é™ä½TBç›¸é—œIRISçš„é¢¨éšªï¼Œä½†ä¸å»ºè­°å¸¸è¦ä½¿ç”¨ï¼ˆNEJM 2018;379:1915ï¼‰ã€‚  </li>
<li>å¦‚æœæ“”å¿ƒæœ‰<strong>éš±çƒèŒæˆ–TBè…¦è†œç‚</strong>ï¼Œä¸æ‡‰ç«‹å³é–‹å§‹æŠ—ç—…æ¯’æ²»ç™‚  </li>
<li>é–‹å§‹æŠ—ç—…æ¯’æ²»ç™‚å¾Œï¼Œéœ€æ¯4é€±æª¢æŸ¥ä¸€æ¬¡ç—…æ¯’ç›´åˆ°é”åˆ°ä¸å¯æª¢æ¸¬ï¼Œä¹‹å¾Œæ¯3-4å€‹æœˆç›£æ¸¬ä¸€æ¬¡  </li>
</ul>
<h3 id="hiv"><a class="toclink" href="medicinehiv/hivaids/#hiv">å°ä¹‹å‰å·²çŸ¥HIVé™½æ€§æ‚£è€…çš„è™•ç†</a></h3>
<ul>
<li>ç—…å²èˆ‡é«”æª¢ï¼ˆé»è†œçš®è†šã€ç¥ç¶“èªçŸ¥ã€ä¼ºæ©Ÿæ€§æ„ŸæŸ“ã€æƒ¡æ€§è…«ç˜¤ã€æ€§ç—…ï¼‰ï¼›è—¥ç‰©åŠä¾å¾æ€§  </li>
<li>å›é¡§æŠ—ç—…æ¯’è—¥ç‰©ï¼ˆéå»å’Œç¾åœ¨ï¼‰ï¼›å¦‚æœä½é™¢ï¼Œé€šå¸¸ç¹¼çºŒä½¿ç”¨æŠ—ç—…æ¯’è—¥ç‰©ï¼Œå¦‚æœå¿…é ˆåœç”¨ï¼Œå‰‡å…¨éƒ¨åœæ­¢ä»¥é™ä½æŠ—è—¥æ€§é¢¨éšª  </li>
<li>æ²»ç™‚å¤±æ•—ï¼šåœ¨ä½¿ç”¨æŠ—ç—…æ¯’è—¥ç‰©å¹¾å€‹æœˆå¾Œç„¡æ³•é”åˆ°ä¸å¯æª¢æ¸¬VLã€ç—…æ¯’åå½ˆï¼ˆåœ¨ä¹‹å‰çš„æŠ‘åˆ¶å¾ŒVL &gt;200æ‹·è²/mL Ã—2æ¬¡ï¼‰ã€CD4è¨ˆæ•¸ä¸‹é™æˆ–è‡¨åºŠæƒ¡åŒ–  </li>
</ul>
<h4 id="_3"><a class="toclink" href="medicinehiv/hivaids/#_3">æ©Ÿæœƒæ€§æ„ŸæŸ“é é˜²</a></h4>
<table>
<thead>
<tr>
<th><strong>æ„ŸæŸ“</strong></th>
<th><strong>æŒ‡å¾µ</strong></th>
<th><strong>åˆç´šé é˜²</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>çµæ ¸</td>
<td>PPDé™½æ€§ï¼ˆâ‰¥5 mmï¼‰ã€IGRAæˆ–é«˜é¢¨éšªæš´éœ²</td>
<td>åƒè¦‹æ½›ä¼çµæ ¸çš„æ²»ç™‚</td>
</tr>
<tr>
<td>è‚ºå›ŠèŸ²è‚ºç‚_Pneumocystis jiroveci_ (PCP)</td>
<td>CD4 &lt;200/mm æˆ– CD4 <strong>&lt;14%</strong> æˆ– <strong>å£è…”å¿µç èŒæ„ŸæŸ“</strong></td>
<td>TMP-SMXï¼ˆé¦–é¸ï¼‰æˆ–dapsoneæˆ–atovaquoneæˆ–å¸å…¥pentamidine</td>
</tr>
<tr>
<td>éš±çƒèŒ</td>
<td>CD4 &lt;150/mm ä¸”æœ‰åœ°æ–¹æµè¡Œ/æš´éœ²å²</td>
<td>Itraconazole</td>
</tr>
<tr>
<td>å¼“å½¢èŸ²</td>
<td>CD4 &lt;100/mmÂ³ ä¸”Toxo IgGé™½æ€§</td>
<td>TMP-SMXæˆ–dapsone 50 mg + pyrimethamine + leucovorin</td>
</tr>
<tr>
<td>MAC</td>
<td>è‹¥å·²é–‹å§‹æœ‰æ•ˆæŠ—ç—…æ¯’è—¥ç‰©å‰‡ä¸å†å»ºè­°é é˜²</td>
<td></td>
</tr>
<tr>
<td>åœæ­¢é é˜²çš„æ™‚é–“ï¼šè‹¥CD4 &gt;200 Ã— 3å€‹æœˆå‰‡åœæ­¢PCPå’Œå¼“å½¢èŸ²çš„é é˜²</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="hivaids_1"><a class="toclink" href="medicinehiv/hivaids/#hivaids_1">HIV/AIDSçš„ä½µç™¼ç—‡</a></h3>
<table>
<thead>
<tr>
<th><strong>CD4 è¨ˆæ•¸</strong></th>
<th><strong>ä½µç™¼ç—‡</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ä»»ä½•</strong></td>
<td><em>S. pneumonia</em>ã€TBã€VZVã€HPVä½µç™¼ç—‡ã€å¡æ³¢è¥¿æ°è‚‰ç˜¤ã€æ·‹å·´ç˜¤ã€å¿ƒè¡€ç®¡ç–¾ç—…é¢¨éšªå¢åŠ ã€éª¨å¯†åº¦é™ä½</td>
</tr>
<tr>
<td><strong>&lt;500</strong></td>
<td>å…¨èº«ç—‡ç‹€ã€‚é»è†œçš®è†šï¼šè„‚æ¼æ€§çš®è†šç‚ï¼›ç‰›çš®ç™¬ï¼›å£è…”æ¯›ç‹€ç™½æ–‘ï¼›HSVã€‚åè¦†çš„ç´°èŒæ„ŸæŸ“</td>
</tr>
<tr>
<td><strong>&lt;200</strong></td>
<td>è‚ºå›ŠèŸ²è‚ºç‚ã€å¼“å½¢èŸ²ã€é€²è¡Œæ€§å¤šç¶æ€§ç™½è³ªè…¦ç—…ï¼ˆPMLï¼‰ã€éš±çƒèŒã€å¿µç èŒã€çƒé»´èŒã€çµ„ç¹”èƒæ¼¿èŒ</td>
</tr>
<tr>
<td><strong>&lt;50-100</strong></td>
<td>å·¨ç´°èƒç—…æ¯’ï¼ˆCMVï¼‰ã€é³¥å‹çµæ ¸èŒï¼ˆMACï¼‰ã€ä¸­æ¨ç¥ç¶“ç³»çµ±æ·‹å·´ç˜¤ã€ä¾µè¥²æ€§éº´èŒç—…ã€æ¡¿èŒè¡€ç®¡ç˜¤ï¼ˆæ’­æ•£æ€§_Bartonella_æ„ŸæŸ“ï¼‰ã€æ­»äº¡ï¼ˆ&lt;50 æ˜¯é†«ç™‚æ€¥ç—‡ï¼‰</td>
</tr>
</tbody>
</table>
<h4 id="hivaids_2"><a class="toclink" href="medicinehiv/hivaids/#hivaids_2">HIV/AIDSæ‚£è€…çš„ç™¼ç‡’æª¢æŸ¥</a></h4>
<h5 id="infect-dis-clin-north-am-2007211013"><a class="toclink" href="medicinehiv/hivaids/#infect-dis-clin-north-am-2007211013">ç—…å›  (Infect Dis Clin North Am 2007;21:1013)</a></h5>
<ul>
<li>æ„ŸæŸ“ (82-90%)ï¼šé³¥å‹çµæ ¸èŒï¼ˆMACï¼‰ã€TBã€å·¨ç´°èƒç—…æ¯’ï¼ˆCMVï¼‰ã€æ—©æœŸ è‚ºå›ŠèŸ²è‚ºç‚ï¼ˆPCPï¼‰ã€çµ„ç¹”èƒæ¼¿èŒï¼ˆHistoplasmosisï¼‰ã€éš±çƒèŒï¼ˆCryptococcosisï¼‰ã€çƒé»´èŒï¼ˆCoccidioidomycosisï¼‰ã€å¼“å½¢èŸ²ï¼ˆToxoplasmosisï¼‰ã€å¿ƒå…§è†œç‚  </li>
<li>éæ„ŸæŸ“æ€§ï¼šæ·‹å·´ç˜¤ã€è—¥ç‰©åæ‡‰  </li>
<li>éæ€¥æ€§HIVæ„ŸæŸ“æœ¬èº«å¾ˆå°‘ (&lt;5%) æ˜¯ç™¼ç‡’çš„ä¸»è¦åŸå›   </li>
</ul>
<h5 id="cd4"><a class="toclink" href="medicinehiv/hivaids/#cd4">æª¢æŸ¥ï¼šæ ¹æ“š CD4 è¨ˆæ•¸ã€ç—‡ç‹€ã€æµè¡Œç—…å­¸åŠæš´éœ²æƒ…æ³é€²è¡Œ</a></h5>
<ul>
<li>CBCã€åŸºç¤ç”ŸåŒ–ã€è‚åŠŸèƒ½æª¢æŸ¥ã€è¡€æ¶²åŸ¹é¤Šã€èƒ¸éƒ¨ X å…‰ã€å°¿æ¶²åˆ†æã€åˆ†ææ¡¿èŒåŠçœŸèŒåŸ¹é¤Šã€æª¢æŸ¥è—¥ç‰©ã€å¿…è¦æ™‚æª¢æŸ¥èƒ¸éƒ¨åŠè…¹éƒ¨ CT  </li>
<li>CD4 &lt;100-200 â†’ è¡€æ¸…éš±çƒèŒæŠ—åŸã€å°¿æ¶²çµ„ç¹”èƒæ¼¿èŒæŠ—åŸã€CMV PCR  </li>
<li>å‘¼å¸ç³»çµ±ç—‡ç‹€ â†’ èƒ¸éƒ¨ X å…‰ï¼›å‹•è„ˆè¡€æ°§åˆ†æï¼›ç—°æ¶²ç´°èŒåŸ¹é¤Šã€PJæŸ“è‰²ã€æŠ—é…¸æ¡¿èŒæª¢æŸ¥ï¼›æ”¯æ°£ç®¡é¡æª¢æŸ¥  </li>
<li>è…¹ç€‰ â†’ ç³ä¾¿åŸ¹é¤Šã€åµèŸ²æª¢æŸ¥ã€æŠ—é…¸æ¡¿èŒæª¢æŸ¥ï¼›å¦‚æœ‰å¿…è¦ï¼Œé€²è¡Œçµè…¸é¡æª¢æŸ¥ä»¥ç›´æ¥è§€å¯Ÿå’Œå–æ¨£  </li>
<li>è¡€æ¶²å­¸ç•°å¸¸ â†’ éª¨é«“åˆ‡ç‰‡ä»¥é€²è¡Œç—…ç†æª¢æŸ¥åŠåŸ¹é¤Šï¼ŒåŒ…æ‹¬åˆ†ææ¡¿èŒåŠçœŸèŒçš„æª¢æŸ¥  </li>
<li>é ­ç—›/è¦–åŠ›è®ŠåŒ– â†’ è…°æ¤ç©¿åˆºï¼›å°‡è…¦è„Šé«“æ¶²é€å»ç´°èŒ/çœŸèŒåŸ¹é¤Šã€éš±çƒèŒæŠ—åŸã€å¿…è¦æ™‚çµæ ¸èŒPCRï¼›å¾è¡€æ¸…ä¸­æª¢æŸ¥CMV PCRï¼›çœ¼ç§‘æ•£ç³æª¢æŸ¥  </li>
</ul>
<h5 id="_4"><a class="toclink" href="medicinehiv/hivaids/#_4">çš®è†š</a></h5>
<ul>
<li>å—œé…¸æ€§æ¯›å›Šç‚ï¼›ç–£ï¼ˆHPVï¼‰ï¼›HSVåŠVZVï¼›MRSAè»Ÿçµ„ç¹”æ„ŸæŸ“ï¼›ç–¥ç˜¡ï¼›å¿µç èŒæ„ŸæŸ“ï¼›æ¿•ç–¹ï¼›çµç¯€æ€§ç˜™ç™¢ç—‡ï¼›ç‰›çš®ç™¬ï¼›è—¥ç‰©çš®ç–¹ï¼›æŒ‡ç”²ä¸‹çœŸèŒç—…  </li>
<li>è»Ÿç–£ï¼ˆpoxvirusï¼‰ï¼š2-5 mm çš„çç ç‹€ä¸˜ç–¹ï¼Œä¸­å¤®æœ‰å‡¹é™·  </li>
<li>å¡æ³¢è¥¿æ°è‚‰ç˜¤ï¼ˆKSHVæˆ–HHV8ï¼‰ï¼šç´…ç´«è‰²éè¤ªè‰²çµç¯€æ€§ç—…è®Š  </li>
<li>æ¡¿èŒè¡€ç®¡ç˜¤ï¼ˆæ’­æ•£æ€§Bartonellaï¼‰ï¼šè„†å¼±çš„ç´«è—è‰²è¡€ç®¡ä¸˜ç–¹  </li>
</ul>
<h5 id="_5"><a class="toclink" href="medicinehiv/hivaids/#_5">å£è…”</a></h5>
<ul>
<li>éµå£ç˜¡ï¼›KSï¼›å£è…”å¿µç èŒç—…ï¼ˆå‡ä¹³ç‹€æ–‘å¡Šï¼Œé€šå¸¸ç„¡ç—›ï¼‰  </li>
<li>å£è…”æ¯›ç‹€ç™½æ–‘ï¼šç„¡ç—›çš„ä¹³é ­ç‹€å¢ç”Ÿï¼Œé™„æœ‰ç™½è‰²å¡—å±¤ï¼Œé€šå¸¸åœ¨èˆŒé ­å´é¢ï¼Œç”±EBVå¼•èµ·ï¼Œä½†ä¸æ˜¯ç™Œå‰ç—…è®Š  </li>
</ul>
<h5 id="_6"><a class="toclink" href="medicinehiv/hivaids/#_6">çœ¼ç§‘</a></h5>
<ul>
<li>CMVè¦–ç¶²è†œç‚ï¼ˆCD4é€šå¸¸&lt;50ï¼‰ï¼›æ²»ç™‚ï¼šgancicloviræˆ–valganciclovirã€foscarnetæˆ–cidofovir  </li>
<li>HZVã€VZVã€æ¢…æ¯’ï¼ˆä»»ä½•CD4è¨ˆæ•¸ï¼Œè¦–ç‚ºç¥ç¶“æ¢…æ¯’ï¼‰æˆ–å¼“å½¢èŸ²æ„ŸæŸ“ï¼ˆCD4é€šå¸¸&lt;100ï¼‰  </li>
</ul>
<h5 id="_7"><a class="toclink" href="medicinehiv/hivaids/#_7">å…§åˆ†æ³Œ/ä»£è¬</a></h5>
<ul>
<li>æ€§è…ºåŠŸèƒ½æ¸›é€€ï¼›è…ä¸Šè…ºåŠŸèƒ½ä¸è¶³ï¼ˆCMVã€MACã€TBã€HIVæˆ–è—¥ç‰©ç›¸é—œï¼‰ï¼›è‚Œè‚‰èç¸®ï¼›éª¨è³ªç–é¬†/è„†æ€§éª¨æŠ˜ï¼ˆæ‰€æœ‰CD4è¨ˆæ•¸ï¼‰  </li>
<li>è„‚è‚ªé‡åˆ†ä½ˆç—‡ï¼šä¸­å¤®è‚¥èƒ–ã€å¤–å‘¨è„‚è‚ªèç¸®ã€è¡€è„‚ç•°å¸¸ã€é«˜è¡€ç³–  </li>
</ul>
<h5 id="jacc-201361511"><a class="toclink" href="medicinehiv/hivaids/#jacc-201361511">å¿ƒè¡€ç®¡ (JACC 2013;61:511)</a></h5>
<ul>
<li>å† ç‹€å‹•è„ˆç–¾ç—…ã€ä¸­é¢¨ã€éœè„ˆè¡€æ “æ “å¡ã€æ“´å¼µæ€§å¿ƒè‚Œç—…ï¼›è‚ºå‹•è„ˆé«˜å£“ï¼›å¿ƒåŒ…ç‚/å¿ƒåŒ…ç©æ¶²  </li>
</ul>
<h5 id="_8"><a class="toclink" href="medicinehiv/hivaids/#_8">å‘¼å¸ç³»çµ±</a></h5>
<table>
<thead>
<tr>
<th><strong>å½±åƒå­¸æ¨¡å¼</strong></th>
<th><strong>å¸¸è¦‹åŸå› </strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>æ­£å¸¸</td>
<td>æ—©æœŸ PCP</td>
</tr>
<tr>
<td>æ“´æ•£æ€§é–“è³ªæµ¸æ½¤</td>
<td>PCPã€TBã€ç—…æ¯’æ„ŸæŸ“ï¼Œæˆ–æ’­æ•£æ€§çœŸèŒæ„ŸæŸ“</td>
</tr>
<tr>
<td>ç„¦é»æ€§å¯¦è®Šæˆ–è…«å¡Š</td>
<td>ç´°èŒæˆ–çœŸèŒæ„ŸæŸ“ã€TBã€KS</td>
</tr>
<tr>
<td>ç©ºæ´æ€§ç—…è®Š</td>
<td>TBã€NTMã€éº´èŒæ„ŸæŸ“ã€å…¶ä»–çœŸèŒæ„ŸæŸ“ã€ç´°èŒæ„ŸæŸ“ï¼ˆåŒ…æ‹¬_Staph aureus_ã€<em>Nocardia</em>ã€<em>Rhodococcus</em>ï¼‰</td>
</tr>
<tr>
<td>èƒ¸è…”ç©æ¶²</td>
<td>TBã€ç´°èŒæˆ–çœŸèŒæ„ŸæŸ“ã€KSã€æ·‹å·´ç˜¤</td>
</tr>
</tbody>
</table>
<h6 id="pneumocystis-jiroveci-pcp-nejm-19903231444"><a class="toclink" href="medicinehiv/hivaids/#pneumocystis-jiroveci-pcp-nejm-19903231444">Pneumocystis jiroveci (PCP) è‚ºå›ŠèŸ²è‚ºç‚ (NEJM 1990;323:1444)</a></h6>
<ul>
<li>CD4 &lt;200  </li>
<li>ç™¼ç‡’ã€å¤œé–“ç›œæ±—ã€é‹å‹•å¾Œå‘¼å¸å›°é›£ã€ä¹¾å’³  </li>
<li>èƒ¸éƒ¨ X å…‰é¡¯ç¤ºé–“è³ªæ¨¡å¼ï¼ŒPaO2 ä¸‹é™ï¼ŒA-aæ¢¯åº¦ä¸Šå‡ï¼ŒLDH ä¸Šå‡ï¼Œç—°æ¶² PCP æŸ“è‰²é™½æ€§ï¼ŒÎ²-glucan é™½æ€§  </li>
<li>å¦‚æœ PaO2 &gt;70ï¼šTMP-SMX 15-20 mg/kgï¼Œåˆ†ä¸‰æ¬¡å£æœ  </li>
<li>å¦‚æœ PaO2 &lt;70 æˆ– A-aæ¢¯åº¦ &gt;35ï¼šåœ¨æŠ—ç”Ÿç´ æ²»ç™‚ä¹‹å‰ä½¿ç”¨ prednisoneï¼ˆ40 mg å£æœå…©æ¬¡ï¼Œ5 å¤©å¾Œæ¸›å°‘ï¼‰  </li>
</ul>
<h6 id="hiv-jama-20171771613"><a class="toclink" href="medicinehiv/hivaids/#hiv-jama-20171771613">HIV âŠ• å¸ç…™è€…æ›´å¯èƒ½æ­»æ–¼è‚ºç™Œè€Œéä¼ºæ©Ÿæ€§æ„ŸæŸ“ (JAMA 2017;177:1613)</a></h6>
<h5 id="_9"><a class="toclink" href="medicinehiv/hivaids/#_9">èƒƒè…¸åŠè‚è†½ç³»çµ±</a></h5>
<ul>
<li>é£Ÿé“ç‚ï¼šå¿µç èŒã€CMVï¼ˆå–®ä¸€ã€å¤§è›‡è¡Œï¼‰ã€HSVï¼ˆå¤šç™¼ã€å°è€Œæ·ºï¼‰ã€å·¨å¤§éµå£ç˜¡ã€è—¥ç‰©å¼•èµ·ï¼›å¦‚æœæ²’æœ‰å¿µç èŒæ„ŸæŸ“æˆ–å°ç¶“é©—æ€§æŠ—çœŸèŒæ²»ç™‚ç„¡åæ‡‰å‰‡å®‰æ’èƒƒé¡  </li>
<li>è…¸ç‚ï¼šç´°èŒæ€§ï¼ˆå°¤å…¶æ˜¯æ€¥æ€§ï¼šå¿—è³€æ°èŒã€æ²™é–€æ°èŒã€å›°é›£æ¢­ç‹€æ¡¿èŒ ï¼‰ï¼›åŸèŸ²æ€§ï¼ˆå°¤å…¶æ˜¯æ…¢æ€§ï¼šGiardiaã€Isosporaã€Cryptosporidiumã€Cyclosporaã€Microsporidiumã€Entamoebaï¼‰ï¼›ç—…æ¯’æ€§ï¼ˆCMVã€è…ºç—…æ¯’ï¼‰ï¼›çœŸèŒæ€§ï¼ˆHistoplasmosisï¼‰ï¼›MACï¼›AIDS è…¸ç—…ï¼›TB è…¸ç‚  </li>
<li>è…¸èƒƒé“å‡ºè¡€ï¼šCMVã€å¡æ³¢è¥¿æ°è‚‰ç˜¤ã€æ·‹å·´ç˜¤ã€Histoplasmosisï¼›ç›´è…¸ç‚ï¼šHSVã€CMVã€LGVã€æ·‹ç—…  </li>
<li>è‚ç‚ï¼šHBVã€HCVã€CMVã€MACã€TBã€Histoplasmosisã€è—¥ç‰©èª˜ç™¼  </li>
<li>AIDSè†½ç®¡ç—…ï¼šé€šå¸¸èˆ‡ CMV æˆ– Cryptosporidium æˆ– Microsporidiumï¼ˆCD4 ä¸‹é™æ™‚ï¼‰ç›¸é—œ  </li>
</ul>
<h5 id="_10"><a class="toclink" href="medicinehiv/hivaids/#_10">è…è‡Ÿ</a></h5>
<ul>
<li>HIV ç›¸é—œè…ç—…ï¼ˆå¡Œé™·æ€§ FSGSï¼‰ï¼›è…æ¯’æ€§è—¥ç‰©ï¼ˆå¦‚ TDF â†’ è¿‘æ›²å°ç®¡åŠŸèƒ½éšœç¤™ï¼‰  </li>
</ul>
<h5 id="nejm-20183781029"><a class="toclink" href="medicinehiv/hivaids/#nejm-20183781029">è¡€æ¶²å­¸/è…«ç˜¤å­¸ (NEJM 2018;378:1029)</a></h5>
<ul>
<li>è¡€æ¶²å­¸ç•°å¸¸ï¼šACDã€è…«ç˜¤/æ„ŸæŸ“ï¼ˆå¦‚ MAC/TBï¼‰å°éª¨é«“çš„æµ¸æ½¤ã€è—¥ç‰©æ¯’æ€§ã€æº¶è¡€ã€å…ç–«æ€§è¡€å°æ¿æ¸›å°‘ç—‡  </li>
<li>éä½•æ°é‡‘æ·‹å·´ç˜¤ï¼šä»»ä½• CD4 è¨ˆæ•¸é »ç‡å¢åŠ ï¼Œä½†éš¨è‘— CD4 æ¸›å°‘è€Œå¢åŠ   </li>
<li>ä½•æ°é‡‘æ·‹å·´ç˜¤ï¼ˆä»»ä½• CD4ï¼›ART çš„å½±éŸ¿å°šä¸æ˜ç¢ºï¼‰  </li>
<li>ä¸­æ¨ç¥ç¶“ç³»çµ±æ·‹å·´ç˜¤: CD4 è¨ˆæ•¸ &lt;50ï¼Œèˆ‡ EBV ç›¸é—œ  </li>
<li><strong>å¡æ³¢è¥¿æ°è‚‰ç˜¤KSï¼ˆHHV-8ï¼‰</strong>: åœ¨ä»»ä½• CD4 è¨ˆæ•¸ä¸‹ï¼Œç™¼ç—…ç‡å›  CD4 æ¸›å°‘è€Œå¢åŠ ï¼Œé€šå¸¸ç‚ºç”·ç”·æ€§è¡Œç‚ºè€…ï¼ˆMSMï¼‰ï¼›é»è†œçš®è†šï¼ˆç´«è‰²ç—…è®Šï¼‰ï¼›è‚ºéƒ¨ï¼ˆçµç¯€ã€æµ¸æ½¤ã€æ·‹å·´çµæ“´å¤§ï¼‰ï¼›èƒƒè…¸é“ï¼ˆå‡ºè¡€ã€é˜»å¡ï¼‰  </li>
<li><strong>å­å®®é ¸/è‚›é–€ç™Œï¼ˆHPV é«˜é¢¨éšªï¼Œç‰¹åˆ¥æ˜¯åœ¨ MSM ä¸­ï¼‰</strong>  </li>
<li><strong>è‚ç™Œï¼ˆèˆ‡ HBV/HCV ç›¸é—œï¼‰</strong>ã€<strong>èƒƒç™Œ</strong>  </li>
</ul>
<h5 id="_11"><a class="toclink" href="medicinehiv/hivaids/#_11">ç¥ç¶“å­¸/å¿ƒç†å­¸</a></h5>
<ul>
<li><strong>è…¦è†œç‚</strong>ï¼šéš±çƒèŒï¼ˆä½¿ç”¨è…¦è„Šé«“æ¶²è¨ºæ–·ï¼›è¡€æ¸…æŠ—åŸæ•æ„Ÿåº¦ 90%ï¼‰ã€ç´°èŒæ€§ï¼ˆåŒ…æ‹¬ææ–¯ç‰¹èŒï¼‰ã€ç—…æ¯’æ€§ï¼ˆHSVã€CMVã€åŸç™¼ HIVï¼‰ã€TBã€Histoplasmosisã€Coccidioidomycosisã€æ·‹å·´ç˜¤ï¼›ç¥ç¶“æ¢…æ¯’ï¼ˆé¡±ç¥ç¶“éº»ç—ºï¼‰  </li>
<li><strong>å ä½æ€§ç—…è®Š</strong>ï¼šå¯èƒ½è¡¨ç¾ç‚ºé ­ç—›ã€å±€éƒ¨ç¥ç¶“å­¸ç¼ºææˆ–æ„è­˜æ”¹è®Šã€‚æª¢æŸ¥ï¼šMRIï¼Œè…¦éƒ¨åˆ‡ç‰‡åƒ…åœ¨æ‡·ç–‘éå¼“å½¢èŸ²ç—…ç—…å› ï¼ˆå¼“å½¢èŸ²è¡€æ¸…å­¸é™°æ€§ï¼‰æˆ–å°2é€±ç¶“é©—æ€§æŠ—å¼“å½¢èŸ²æ²»ç™‚ç„¡åæ‡‰æ™‚é€²è¡Œï¼ˆå¼“å½¢èŸ²æ„ŸæŸ“<strong>50% æ–¼ç¬¬ 3 å¤©æ²»ç™‚æœ‰åæ‡‰ï¼Œ91% æ–¼ç¬¬ 14 å¤©</strong>ï¼›NEJM 1993;329:995ï¼‰  </li>
</ul>
<table>
<thead>
<tr>
<th><strong>ç—…å› </strong></th>
<th><strong>å½±åƒå­¸è¡¨ç¾</strong></th>
<th><strong>è¨ºæ–·ç ”ç©¶</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>å¼“å½¢èŸ²æ„ŸæŸ“</strong></td>
<td>å¢å¼·ç—…è®Šï¼Œé€šå¸¸åœ¨åŸºåº•ç¥ç¶“ç¯€ï¼ˆå¯ä»¥æ˜¯å¤šç™¼æ€§ï¼‰</td>
<td>âŠ•Â å¼“å½¢èŸ²è¡€æ¸…å­¸ï¼ˆæ•æ„Ÿåº¦ç´„ 85%ï¼‰</td>
</tr>
<tr>
<td><strong>ä¸­æ¨ç¥ç¶“ç³»çµ±æ·‹å·´ç˜¤</strong></td>
<td>å¢å¼·ç’°ç‹€ç—…è®Šï¼ˆå–®ç™¼æ€§ 60%ï¼‰</td>
<td>âŠ• CSF PCR æª¢æŸ¥ EBV  <br>  <br>âŠ• SPECT æˆ– PET æƒæ</td>
</tr>
<tr>
<td><strong>é€²è¡Œæ€§å¤šç¶æ€§ç™½è³ªè…¦ç—…ï¼ˆPMLï¼‰</strong></td>
<td>ç™½è³ªä¸­å¤šç™¼æ€§éå¢å¼·ç—…è®Š</td>
<td>âŠ• CSF PCR æª¢æŸ¥ JC ç—…æ¯’</td>
</tr>
<tr>
<td>å…¶ä»–ï¼šè†¿ç˜ã€åˆ†ææ¡¿èŒæ„ŸæŸ“ã€éš±çƒèŒæ„ŸæŸ“ã€TBã€CMVã€HIV</td>
<td>ä¸ä¸€å®š</td>
<td>åˆ‡ç‰‡</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>HIV ç›¸é—œç™¡å‘†ç—‡</strong>ï¼šæŠ‘é¬±ç—‡ç‹€ã€æ³¨æ„åŠ›/é›†ä¸­åŠ›å—æã€ç²¾ç¥é‹å‹•é²ç·©  </li>
<li><strong>æŠ‘é¬±ç—‡</strong>ï¼šè‡ªæ®º/æŠ‘é¬±ç—‡ç™¼ç—…ç‡å¢åŠ   </li>
<li><strong>è„Šé«“ç—…è®Š</strong>ï¼šæ„ŸæŸ“ï¼ˆCMVã€HSVï¼‰ã€è„Šé«“å£“è¿«ï¼ˆç¡¬è†œå¤–è†¿ç˜ã€æ·‹å·´ç˜¤ï¼‰  </li>
<li><strong>å‘¨é‚Šç¥ç¶“ç—…è®Š</strong>ï¼šè—¥ç‰©ï¼ˆå°¤å…¶æ˜¯ç¬¬ä¸€ä»£NRTIsï¼‰ã€CMVã€ç³–å°¿ç—…  </li>
</ul>
<h5 id="dmac"><a class="toclink" href="medicinehiv/hivaids/#dmac">å…¨èº«æ€§é³¥å‹åˆ†ææ¡¿èŒæ„ŸæŸ“ï¼ˆDMACï¼‰</a></h5>
<ul>
<li>ç™¼ç‡’ã€å¤œé–“ç›œæ±—ã€é«”é‡æ¸›è¼•ã€è…¹ç—›ã€è…¹ç€‰ã€å…¨è¡€çƒæ¸›å°‘ã€‚å¯å¼•èµ·å±€éƒ¨æ·‹å·´çµç‚  </li>
<li>æ²»ç™‚ï¼šclarithro/azithro + ethambutol Â± rifampin/rifabutin  </li>
</ul>
<h5 id="cmv"><a class="toclink" href="medicinehiv/hivaids/#cmv">å·¨ç´°èƒç—…æ¯’ï¼ˆCMVï¼‰</a></h5>
<ul>
<li>è¦–ç¶²è†œç‚ã€é£Ÿé“ç‚ã€çµè…¸ç‚ã€è‚ç‚ã€ç¥ç¶“ç—…è®Šã€è…¦ç‚  </li>
<li>CMV ç—…æ¯’é‡å¯èƒ½ç‚ºé™°æ€§  </li>
<li>è€ƒæ…®çµ„ç¹”åˆ‡ç‰‡  </li>
<li>æ²»ç™‚ï¼šganciclovirã€valganciclovirã€foscarnet æˆ– cidofovir  </li>
</ul>
<p>Original: <a href="../../../HIV">HIV</a><br />
<a href="../hiv-long-acting">hiv-long-acting</a>  </p>
<h3 id="_12"><a class="toclink" href="medicinehiv/hivaids/#_12">è€ƒå¤é¡Œ</a></h3>
<h4 id="_13"><a class="toclink" href="medicinehiv/hivaids/#_13">å°ˆå¸«</a></h4>
<h4 id="_14"><a class="toclink" href="medicinehiv/hivaids/#_14">å…§ç§‘é†«å¸«</a></h4>
    
  </div>
</article>
      
      
        
          



<nav class="md-pagination">
  <span class="md-pagination__current">1</span> <a class="md-pagination__link" href="page/2/">2</a> <a class="md-pagination__link" href="page/3/">3</a>
</nav>
        
      
    </div>
  </div>

          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
    
      
      <nav class="md-footer__inner md-grid" aria-label="Footer" >
        
        
          
          <a href="category/medicine/" class="md-footer__link md-footer__link--next" aria-label="Next: medicine">
            <div class="md-footer__title">
              <span class="md-footer__direction">
                Next
              </span>
              <div class="md-ellipsis">
                medicine
              </div>
            </div>
            <div class="md-footer__button md-icon">
              
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M4 11v2h12l-5.5 5.5 1.42 1.42L19.84 12l-7.92-7.92L10.5 5.5 16 11H4Z"/></svg>
            </div>
          </a>
        
      </nav>
    
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": ".", "features": ["navigation.path", "navigation.footer"], "search": "assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    
      <script src="assets/javascripts/bundle.af256bd8.min.js"></script>
      
        <script src="js/timeago.min.js"></script>
      
        <script src="js/timeago_mkdocs_material.js"></script>
      
        <script src="javascripts/mathjax.js"></script>
      
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
      
        <script src="https://cdn.jsdelivr.net/gh/ObsidianPublisher/assets@main/dist/javascript.js"></script>
      
    
  </body>
</html>